var images_info;if (!images_info) images_info =[]; images_info["88"]={"88021":{"type":"graphic_picture","displayName":"Pathologic findings in GAE","title":"Pathologic findings in granulomatous amebic encephalitis (GAE)","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Pathologic findings in granulomatous amebic encephalitis (GAE)</div><div class=\"cntnt\"><img style=\"width:513px; height:176px;\" src=\"images/ID/88021_Pathologic_find_GAE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) A case of GAE, showing numerous trophozoites surrounding a blood vessel. Notice the prominent karyosome in most organisms and the cytoplasmic vacuole in a few parasites. Hematoxylin and eosin, x160.<br />(Panel B) Multiple amebic trophozoites surrounding a blood vessel in a case of GAE caused by <EM>Balamuthia mandrillaris</EM>. Periodic acid-Schiff, x160.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Parasitic Disorders: Pathology, Diagnosis, and Management, 2nd edition. Baltimore: Lippincott Williams &amp; Wilkins, 1999. Copyright © 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 88021 Version 2.0</div></div></div>"},"88023":{"type":"graphic_diagnosticimage","displayName":"Diabetic macular edema","title":"Diabetic macular edema: appearance on optical coherence tomography","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Diabetic macular edema: appearance on optical coherence tomography</div><div class=\"cntnt\"><img style=\"width:513px; height:137px;\" src=\"images/ENDO/88023_Diabetic_macular_edema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Optical coherence tomography (OCT) of diabetic macular edema. There are numerous large cysts visible within the macula (arrows), and the retinal thickness is increased.<br />(B) OCT of normal macula (for comparison) showing typical foveal contour.</div><div id=\"graphicVersion\">Graphic 88023 Version 1.0</div></div></div>"},"88026":{"type":"graphic_picture","displayName":"Phototherapy unit 1","title":"Stand-up full body phototherapy unit","html":"<div class=\"graphic\"><div style=\"width: 741px\" class=\"figure\"><div class=\"ttl\">Stand-up full body&nbsp;phototherapy unit</div><div class=\"cntnt\"><img style=\"width:721px; height:452px;\" src=\"images/DERM/88026_Phototherapy_unit_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 Herbert Waldmann GmbH &amp; Co. KG.</div><div id=\"graphicVersion\">Graphic 88026 Version 1.0</div></div></div>"},"88027":{"type":"graphic_picture","displayName":"Phototherapy unit 2","title":"Partial/full-body phototherapy unit","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Partial/full-body phototherapy unit</div><div class=\"cntnt\"><img style=\"width:725px; height:278px;\" src=\"images/DERM/88027_Phototherapy_unit_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 Herbert Waldmann GmbH &amp; Co. KG.</div><div id=\"graphicVersion\">Graphic 88027 Version 1.0</div></div></div>"},"88028":{"type":"graphic_picture","displayName":"Phototherapy unit 3","title":"Phototherapy unit for localized treatment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Phototherapy unit for localized treatment</div><div class=\"cntnt\"><img style=\"width:358px; height:724px;\" src=\"images/DERM/88028_Phototherapy_unit_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 Herbert Waldmann GmbH &amp; Co. KG.</div><div id=\"graphicVersion\">Graphic 88028 Version 1.0</div></div></div>"},"88039":{"type":"graphic_table","displayName":"Essential equipment for REBOA placement","title":"Essential equipment for REBOA placement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Essential equipment for REBOA placement</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Essential equipment for REBOA placement</td> </tr> <tr> <td class=\"indent1\">5 Fr micropuncture, or 18 gauge arterial line set</td> </tr> <tr> <td class=\"indent1\">Ultrasound (linear probe) with cover</td> </tr> <tr> <td class=\"indent1\">Sterile drapes to cover to one foot beyond patient's feet</td> </tr> <tr> <td class=\"indent1\">Surgical set for groin access</td> </tr> <tr> <td class=\"indent1\">Long working wires (J-wire [0.035 in, 180 cm], Rosen [0.035, 180 cm], Amplatz Super Stiff [0.035, 260 cm])</td> </tr> <tr> <td class=\"indent1\">Sheath with dilator (12 to 14 Fr, 30 to 45 cm)</td> </tr> <tr> <td class=\"indent1\">Coda balloon catheter (32 mm diameter, 120 cm)</td> </tr> <tr> <td class=\"indent1\">2 to 30 mL Luer lock syringes</td> </tr> <tr> <td class=\"indent1\">3-way stopcock</td> </tr> <tr> <td class=\"indent1\">100 mL injectable saline</td> </tr> <tr> <td class=\"indent1\">Omnipaque contrast (mix 10 mL in 20 mL injectable saline for balloon)</td> </tr> <tr> <td class=\"indent1\">Sterile basin</td> </tr> <tr> <td class=\"indent1\">Scalpel (#11 or #15)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">REBOA: resuscitative endovascular balloon occlusion.</div><div id=\"graphicVersion\">Graphic 88039 Version 2.0</div></div></div>"},"88059":{"type":"graphic_picture","displayName":"Balamuthia skin lesions ","title":"Spectrum of skin lesions in patients infected with <EM>Balamuthia mandrillaris</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spectrum of skin lesions in patients infected with <EM>Balamuthia mandrillaris</EM></div><div class=\"cntnt\"><img style=\"width:443px; height:439px;\" src=\"images/ID/88059_Balamuthia_skin_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) A young boy with a classical plaque lesion on the central face.<br />(Panel B) An adult female with a similar lesion over the nose.<br />(Panel C) An older patient with a plaque over the nose.<br />(Panel D) A young boy with an annular plaque behind the knee (after the face, the second most common location).</div><div id=\"graphicVersion\">Graphic 88059 Version 2.0</div></div></div>"},"88061":{"type":"graphic_table","displayName":"Atypical antidepressants - Pharmacokinetics","title":"Atypical antidepressants: Pharmacokinetics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Atypical antidepressants: Pharmacokinetics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Bioavailability<br /> (percent)</td> <td class=\"subtitle1\">Time to peak plasma concentration<br /> (hours)</td> <td class=\"subtitle1\">Primary metabolism*</td> <td class=\"subtitle1\">Active metabolite(s)</td> <td class=\"subtitle1\">Elimination half-life<br /> (hours)</td> <td class=\"subtitle1\">Effect on drug metabolism<br /> (significant)*</td> <td class=\"subtitle1\">Clearance</td> </tr> <tr class=\"divider_bottom\"> <td>Agomelatine<sup>&#182;</sup></td> <td> <p>&#60;5</p> Wide inter-individual variation; unaffected by food</td> <td>1 to 2</td> <td> <p>CYP1A2</p> Avoid use with moderate or strong inhibitors of CYP1A2</td> <td>No</td> <td>1 to 2</td> <td>None</td> <td>Hepatic; avoid use in setting of hepatic impairment or active liver disease</td> </tr> <tr class=\"divider_bottom\"> <td>Bupropion</td> <td>Not available; modestly increased by food</td> <td> <p>Immediate release: 2</p> <p>Sustained release: 3</p> Extended release: 5</td> <td> <p>CYP2B6</p> UGT glucuronidation</td> <td>Yes (hydroxybupropion and others)</td> <td> <p>14 (parent, immediate release)</p> <p>20 (parent, extended release)</p> 21-51 (active metabolites)</td> <td>Inhibits CYP2D6</td> <td>Hepatic and renal; dose adjustment may be needed in setting of renal or hepatic insufficiency</td> </tr> <tr> <td>Mirtazapine</td> <td> <p>50</p> Unaffected by food</td> <td>2</td> <td> <p>CYP1A2</p> <p>CYP2D6</p> CYP3A4</td> <td>Yes (<em>N</em>-desmethyl mirtazapine)</td> <td> <p>20 to 40 (parent)</p> <p>25 (active metabolite)</p> T &#189; and serum concentrations are increased in female and older subjects</td> <td>None</td> <td>Hepatic and renal; dose adjustment may be needed in setting of renal or hepatic insufficiency</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CYP: cytochrome P450; UGT: uridine diphosphate glucuronosyltransferase.<br />* Drug interactions and management suggestions may be determined by use of Lexi-Interact, the drug interactions program included with UpToDate.<br />&para; Not available in the United States.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Spina E, Trifir&ograve; G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012; 26:39.</li>&#xD;&#xA;    <li>Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther 2005; 27:1685.</li>&#xD;&#xA;    <li>McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol 2010; 25:95.</li>&#xD;&#xA;    <li>Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs 2009; 23:427.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 88061 Version 5.0</div></div></div>"},"88062":{"type":"graphic_table","displayName":"Serotonin modulator antidepressants - Pharmacokinetics","title":"Serotonin modulator antidepressants: Pharmacokinetics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Serotonin modulator antidepressants: Pharmacokinetics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Bioavailability<br /> (percent)</td> <td class=\"subtitle1\">Time to peak plasma concentration<br /> (hours)</td> <td class=\"subtitle1\">Primary metabolism*</td> <td class=\"subtitle1\">Active metabolite(s)</td> <td class=\"subtitle1\">Elimination half-life<br /> (hours)</td> <td class=\"subtitle1\">Effect(s) on drug metabolism<br /> (significant)*</td> <td class=\"subtitle1\">Clearance</td> </tr> <tr> <td>Nefazodone<sup>&#182;</sup></td> <td>20 (modestly decreased by food)</td> <td>0.5 to 2 (delayed by food)</td> <td> <p>CYP3A4</p> <p>CYP2D6</p> </td> <td>Yes<br /> (triazoledione, hydroxynefazodone, and <em>m</em>-chlorophenylpiperazine [mCPP])</td> <td> <p>2-5 (parent)</p> <p>2-33 (active metabolites)</p> </td> <td>Potent inhibitor of CYP 3A4 and P-gp inducer; can cause numerous dose-dependent drug interactions</td> <td>Hepatic; avoid in hepatic disease or in setting of elevated transaminases (complicates monitoring); half-life and serum concentrations increased in hepatic insufficiency</td> </tr> <tr> <td colspan=\"8\">Trazodone</td> </tr> <tr> <td class=\"indent1\">Immediate release</td> <td>65</td> <td rowspan=\"2\"> <p>1 (unfed)</p> <p>2 (fed)</p> 9 (unfed)</td> <td rowspan=\"2\">CYP3A4</td> <td rowspan=\"2\">Yes<br /> (<em>m</em>-chlorophenylpiperazine)</td> <td>5 to 9</td> <td rowspan=\"2\">P-gp inducer</td> <td rowspan=\"2\">Hepatic</td> </tr> <tr> <td class=\"indent1\">Extended release</td> <td>87 (preferably taken on empty stomach)</td> <td>10</td> </tr> <tr> <td>Vilazodone</td> <td>72 (preferably taken with meal)</td> <td>4 to 5</td> <td>CYP3A4; dose decrease needed with potent inhibitors of CYP3A4</td> <td>No</td> <td>25</td> <td>None</td> <td>Hepatic</td> </tr> <tr> <td>Vortioxetine</td> <td>75 (not affected by food)</td> <td>7 to 11</td> <td>CYP2D6; dose decrease needed with potent inhibitors of CYP2D6</td> <td>No</td> <td>66</td> <td>None</td> <td>Hepatic</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CYP: cytochrome P450; Pgp: P-glycoprotein efflux transporter.<br />* Drug interactions and management suggestions may be determined by use of Lexi-Interact, the drug interactions program included with UpToDate.<br />¶ Not a first or second line choice. Rare reports of fatal hepatotoxicity lead to market withdrawal in many countries.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012; 26:39.</LI>&#xD;&#xA;<LI>Frampton JE. Vilazodone: in major depressive disorder. CNS Drugs 2011; 25:615.</LI>&#xD;&#xA;<LI>Zhang J, Mathis MV, Sellers JW, et al. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine. J Clin Psychiatry 2015; 76:8.</LI></OL></div><div id=\"graphicVersion\">Graphic 88062 Version 6.0</div></div></div>"},"88063":{"type":"graphic_table","displayName":"SNRI antidepressants - Pharmacokinetics","title":"Serotonin-norepinephrine reuptake inhibitor antidepressants: Pharmacokinetics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Serotonin-norepinephrine reuptake inhibitor antidepressants: Pharmacokinetics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Bioavailability<br /> (percent)</td> <td class=\"subtitle1\">Time to peak plasma concentration<br /> (hours)</td> <td class=\"subtitle1\">Primary metabolism*</td> <td class=\"subtitle1\">Active metabolite(s)</td> <td class=\"subtitle1\">Effect(s) on drug metabolism<br /> (significant)*</td> <td class=\"subtitle1\">Elimination half-life<br /> (hours)</td> <td class=\"subtitle1\">Clearance</td> </tr> <tr> <td>Desvenlafaxine</td> <td> <p>80</p> Unaffected by food</td> <td>7.5</td> <td>UGT glucuronidation</td> <td>No</td> <td>None</td> <td> <p>9 to 11</p> Prolonged in renal or hepatic impairment</td> <td> <p>Hepatic and renal; 45% excreted unchanged</p> <p>Dose adjustment needed in renal or hepatic impairment</p> </td> </tr> <tr> <td>Duloxetine</td> <td> <p>50</p> Wide interindividual variation (30 to 80); minimally affected by food</td> <td> <p>6 (unfed)</p> 10 (fed)</td> <td> <p>CYP1A2, CYP2D6</p> </td> <td>No</td> <td>Inhibits CYP2D6</td> <td> <p>10 to 12</p> Prolonged in hepatic impairment</td> <td> <p>Hepatic and renal; avoid in hepatic insufficiency (any degree), liver disease, or substantial alcohol use</p> <p>Dose adjustment needed in renal impairment</p> </td> </tr> <tr> <td>Levomilnacipran ER</td> <td> <p>&#62;90</p> <p>Unaffected by food</p> </td> <td> <p>6 to 8</p> <p>Avoid concurrent administration with alcohol which can accelerate release of levomilnacipran from the extended-release preparation</p> </td> <td>Primarily CYP3A4</td> <td>No</td> <td>None</td> <td> <p>12</p> <p>Prolonged in moderate to severe renal impairment</p> </td> <td> <p>Hepatic and renal; 58% excreted unchanged</p> <p>Dose adjustment needed renal impairment</p> </td> </tr> <tr> <td>Milnacipran</td> <td> <p>85 to 90</p> Unaffected by food</td> <td>2 to 4</td> <td>Glucuronidation</td> <td>No</td> <td>None</td> <td> <p>8 to 10</p> Prolonged in moderate to severe renal impairment and&nbsp;severe hepatic impairment </td> <td> <p>Renal and hepatic; 55% excreted unchanged</p> <p>Dose adjustment needed in renal impairment</p> </td> </tr> <tr> <td colspan=\"8\">Venlafaxine</td> </tr> <tr> <td>&nbsp; Immediate release</td> <td> <p>13<sup><span style=\"font-size: 13px;\">&#182;</span></sup></p> Unaffected by food</td> <td>1 to 2</td> <td rowspan=\"2\"> <p>CYP2D6, CYP3A4</p> </td> <td rowspan=\"2\">Yes (desvenlafaxine)</td> <td rowspan=\"2\">None</td> <td rowspan=\"2\">5 (parent) <p>11 (active metabolite)</p> Prolonged in renal or hepatic impairment</td> <td rowspan=\"2\"> <p>Renal and hepatic; 87% excreted unchanged</p> <p>Dose adjustment needed in renal or hepatic impairment</p> </td> </tr> <tr> <td>&nbsp;&nbsp;Extended release</td> <td> <p>45<sup><span style=\"font-size: 13px;\">&#182;</span></sup></p> Unaffected by food</td> <td>5.5</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CYP: cytochrome P450; UGT: uridine diphosphate glucuronosyltransferase.<br />* Drug interactions and management suggestions may be determined by use of Lexi-Interact, the drug interactions program included with UpToDate.<br />¶ Oral bioavailability is increased by&nbsp;two- to threefold in mild to moderate hepatic impairment.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012; 26:39.</LI>&#xD;&#xA;<LI>Yang LP, Plosker GL. Desvenlafaxine extended release. CNS Drugs 2008; 22:1061. </LI>&#xD;&#xA;<LI>Thase ME, Sloan DM. Venlafaxine and desvenlafaxine. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 4th ed, Schatzberg AF, Nemeroff CB. (Eds), American Psychiatric Publishing, Inc., Washington, DC 2009. p.439.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 88063 Version 7.0</div></div></div>"},"88072":{"type":"graphic_table","displayName":"Immunohistochemical markers dx ATC","title":"Immunohistochemical markers useful for the diagnosis of anaplastic thyroid cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunohistochemical markers useful for the diagnosis of anaplastic thyroid cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"5\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Immunohistochemical marker</td> <td class=\"subtitle1\">DTC</td> <td class=\"subtitle1\">MTC</td> <td class=\"subtitle1\">ATC</td> <td class=\"subtitle1\">SCC</td> <td class=\"subtitle1\">Lymphoma</td> </tr> <tr> <td>Pankeratin (AE1/AE3)</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;*</td> </tr> <tr> <td>High molecular weight keratins</td> <td class=\"centered\">+ (PTC)<br /> &ndash; (FTC)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>TTF-1</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>PAX8</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+/&ndash;<sup>&#182;</sup></td> </tr> <tr> <td>Thyroglobulin</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Synaptophysin</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Chromogranin</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Calcitonin</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>CEA</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>P53</td> <td class=\"centered\">&ndash; (rare +)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">+/&ndash;</td> </tr> <tr> <td>E-cadherin</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>B-catenin</td> <td class=\"centered\">Membranous</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Nuclear or &ndash;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+/&ndash; (nuclear)</td> </tr> <tr> <td>CD45</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ATC: anaplastic thyroid carcinoma; CD45: protein tyrosine phosphatase receptor type C; CEA: carcinoembryonic antigen; DTC: differentiated thyroid carcinoma; FTC: follicular thyroid carcinoma; MTC: medullary thyroid carcinoma; P53: cellular tumor antigen p53 or tumor protein p53; PAX8: paired box protein Pax 8 or paired box 8; PTC: papillary thyroid carcinoma; SCC: squamous cell carcinoma; TTF-1: thyroid transcription factor 1; +: positive; –: negative; +/–: usually positive, often negative; –/+: usually negative, may be positive.<br />* Plasmablastic lymphoma, anaplastic large cell lymphoma, and very rarely some diffuse large B cell lymphomas can express cytokeratin that is detected by AE1/AE3 cytokeratin monoclonal antibodies.<br />¶ PAX8 was detected by immunohistochemistry in normal B cells, but was not studied in lymphoma. It is very likely that various lymphomas express PAX8.</div><div class=\"graphic_reference\">Reproduced with permission from: Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012: 22:1104. Copyright &copy; 2012 Mary Ann Liebert, Inc.</div><div id=\"graphicVersion\">Graphic 88072 Version 3.0</div></div></div>"},"88073":{"type":"graphic_table","displayName":"ICAR-MEDCOM hypothermia scale","title":"ICAR-MEDCOM hypothermia (HT) scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ICAR-MEDCOM hypothermia (HT) scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">International Commission for Mountain Emergency Medicine hypothermia scale</td> </tr> <tr> <td class=\"subtitle2\">Hypothermia (HT) stage</td> <td class=\"subtitle2\">Clinical assessment</td> <td class=\"subtitle2\">Expected core temperature, C&#176; (F&#176;)*</td> </tr> <tr> <td class=\"centered\">HT I</td> <td>Clear consciousness with shivering</td> <td class=\"centered\">35-32 (95-89.6)</td> </tr> <tr> <td class=\"centered\">HT II</td> <td>Impaired consciousness without shivering</td> <td class=\"centered\">32-28 (89.6-82.4)</td> </tr> <tr> <td class=\"centered\">HT III</td> <td>Unconsciousness</td> <td class=\"centered\">28-24 (82.4-75.2)</td> </tr> <tr> <td class=\"centered\">HT IV</td> <td>Apparent death</td> <td class=\"centered\">&#60;24-13.7 (&#60;75.2-56.7)<sup>&#182;</sup></td> </tr> <tr> <td class=\"centered\">HT V</td> <td>Death due to irreversible hypothermia</td> <td class=\"centered\">&#60;13.7-9 (56.7-48.2)<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Clinical assessment may be used to stage hypothermia when core temperature measurement in the field is not available, but be aware that clinical findings can vary substantially.<br />¶ The core temperature at which irreversible hypothermia with death occurs is <STRONG>not</STRONG> well defined. Please refer to UpToDate topics on hypothermia for discussions regarding prehospital declaration of death and withdrawal of resuscitation.</div><div class=\"graphic_reference\">Modified with permission from: Durrer B, Brugger H, Syme D, and the International Commission for Mountain Emergency Medicine. The medical on-site treatment of hypothermia: ICAR-MEDCOM recommendation. High Alt Med Biol 2003; 4:99. Copyright &copy; 2003 Mary Ann Liebert, Inc.</div><div id=\"graphicVersion\">Graphic 88073 Version 7.0</div></div></div>"},"88074":{"type":"graphic_figure","displayName":"Tubular field deficit","title":"Tubular field deficit","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Tubular field deficit</div><div class=\"cntnt\"><img style=\"width:554px; height:467px;\" src=\"images/PSYCH/88074_Tubular_field_deficit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A \"tubular\" field deficit is inconsistent with the laws of optics and eye physiology.</div><div class=\"graphic_reference\">Reproduced with permission from: Stone J, Carson A, Sharpe M. Functional symptoms and signs in neurology: Assessment and diagnosis. J Neurol Neurosurg Psychiatry 2005; 76:i2. BMJ Publishing Group Ltd. Copyright &copy; 2005.</div><div id=\"graphicVersion\">Graphic 88074 Version 2.0</div></div></div>"},"88075":{"type":"graphic_picture","displayName":"Hoovers sign for psychogenic leg weakness","title":"Hoovers sign for psychogenic leg weakness","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Hoovers sign for psychogenic leg weakness</div><div class=\"cntnt\"><img style=\"width:513px; height:341px;\" src=\"images/PSYCH/88075_Hoovers_psych_leg_weak.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Stone J. The bare essentials: Functional symptoms in neurology. Pract Neurol 2009; 9:179. BMJ Publishing Group Ltd. Copyright &copy; 2009.</div><div id=\"graphicVersion\">Graphic 88075 Version 1.0</div></div></div>"},"88076":{"type":"graphic_figure","displayName":"Hoover's sign for functional leg weakness","title":"Hoover's sign for functional leg weakness","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Hoover's sign for functional leg weakness</div><div class=\"cntnt\"><img style=\"width:600px; height:462px;\" src=\"images/PSYCH/88076_Hoovers_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Hip extension is weak when tested directly.<br />(B) Hip extension is normal when the patient is asked to flex the opposite hip.</div><div class=\"graphic_reference\">Reproduced with permission from: Stone J, Zeman A, Sharpe M. Functional weakness and sensory disturbance. J Neurol Neurosurg Psychiatry 2002; 73:241. BMJ Publishing Group Ltd. Copyright &copy; 2002.</div><div id=\"graphicVersion\">Graphic 88076 Version 2.0</div></div></div>"},"88077":{"type":"graphic_figure","displayName":"Psychogenic hemisensory disturbance","title":"Psychogenic hemisensory disturbance","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Psychogenic hemisensory disturbance</div><div class=\"cntnt\"><img style=\"width:528px; height:604px;\" src=\"images/PSYCH/88077_Psychogenic_hemisensory_disturbance.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Charcot JM. Clinical lectures on diseases of the nervous system. Vol 3. London: New Sydenham Society, 1889.</div><div id=\"graphicVersion\">Graphic 88077 Version 1.0</div></div></div>"},"88078":{"type":"graphic_figure","displayName":"Using a graph for patient history with functional symptoms","title":"Using a graph to take a history from a patient with functional symptoms","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Using a graph to take a history from a patient with functional symptoms</div><div class=\"cntnt\"><img style=\"width:539px; height:402px;\" src=\"images/PSYCH/88078_Us_graph_patien_hist_sympt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Stone J, Carson A, Sharpe M. Functional symptoms and signs in neurology: Assessment and diagnosis. J Neurol Neurosurg Psychiatry 2005; 76:i2. BMJ Publishing Group Ltd. Copyright &copy; 2005.</div><div id=\"graphicVersion\">Graphic 88078 Version 1.0</div></div></div>"},"88079":{"type":"graphic_table","displayName":"Aetiological factors in patients with functional symptoms","title":"A range of potential aetiological factors in patients with functional symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">A range of potential aetiological factors in patients with functional symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Factors</td> <td class=\"subtitle1\">Biological</td> <td class=\"subtitle1\">Psychological</td> <td class=\"subtitle1\">Social</td> </tr> <tr class=\"divider_bottom\"> <td>Acting at all stages</td> <td> <p>Organic disease</p> History of previous functional symptoms</td> <td> <p>Emotional disorder</p> Personality disorder</td> <td> <p>Socioeconomic/deprivation</p> Life events and difficulties</td> </tr> <tr class=\"divider_bottom\"> <td>Predisposing</td> <td> <p>Genetic factors affecting personality</p> Biological vulnerabilities in the nervous system?</td> <td> <p>Perception of childhood experience as adverse</p> <p>Personality traits</p> Poor attachment/coping style</td> <td> <p>Childhood neglect/abuse</p> <p>Poor family functioning</p> Symptom modelling (via media or personal contact)</td> </tr> <tr class=\"divider_bottom\"> <td>Precipitating</td> <td> <p>Abnormal physiological event or state (eg, hyperventilation, sleep deprivation, sleep paralysis)</p> Physical injury/pain</td> <td> <p>Perception of life event as negative, unexpected</p> Acute dissociative episode/panic attack</td> <td>&nbsp;</td> </tr> <tr> <td>Perpetuating</td> <td> <p>Plasticity in CNS motor and sensory (including pain) pathways</p> <p>Deconditioning</p> Neuroendocrine and immunological abnormalities similar to those seen in depression and anxiety</td> <td> <p>Illness beliefs (patient and family)</p> <p>Perception of symptoms as being due to disease/damage/outwith the scope of self-help</p> <p>Not feeling believed</p> Avoidance of symptom provocation (eg, by learned conditioning)</td> <td> <p>The presence of a welfare system</p> <p>Social benefits of being ill</p> <p>Availability of legal compensation</p> <p>Stigma of \"mental illness\" in society and from medical profession</p> Ongoing medical investigations and uncertainty</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Stone J. The bare essentials: Functional symptoms in neurology. Pract Neurol 2009; 9:179. BMJ Publishing Group Ltd. Copyright &copy; 2009.</div><div id=\"graphicVersion\">Graphic 88079 Version 1.0</div></div></div>"},"88080":{"type":"graphic_table","displayName":"Treating conversion disorder with cognitive-behavioral therapy","title":"Treating conversion disorder with cognitive-behavioral therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treating conversion disorder with cognitive-behavioral therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td><strong>Accept the problem</strong></td> <td>Clinicians start by stating that they accept the reality of the patients' problem and want to work with them to improve it</td> </tr> <tr> <td><strong>Agree to a shared understanding</strong></td> <td>A shared understanding of the problem is an essential foundation for treatment. Explore the degree of confidence and understanding that patients have in their diagnosis. Improve that confidence by addressing doubts and reiterating the positive basis for the diagnosis and a rehabilitative approach to treatment. Ideally, therapists should be able to show the physical signs (eg, Hoover's sign or distractible tremor) to patients in order to improve their confidence.</td> </tr> <tr> <td><strong>Agree treatment goals</strong></td> <td>Ascertain what patients want and agree on specific practical goals (eg, walking to stores)</td> </tr> <tr> <td><strong>Identify unhelpful cognitions</strong></td> <td>Explore the patient's thoughts and beliefs about their symptoms. As an example, patients with a left hemiparesis may believe that they have had a stroke. Other common thoughts are that the disability is fixed or that doing more will make symptoms worse (or cause bodily \"damage\"). Diaries of thoughts and behaviors in specific situations may be helpful.</td> </tr> <tr> <td><strong>Identify unhelpful behaviors</strong></td> <td>The most common are forms of avoidance. As an example, patients with leg paralysis may be reluctant to move because walking is tiring, painful, or socially embarrassing. Patients with nonepileptic seizures may fear the consequences of an attack and thus avoid crowded situations.</td> </tr> <tr> <td><strong>Challenge unhelpful behaviors</strong></td> <td>It is often helpful to work on behavior first. Behavioral change requires the gradual reduction of avoidance behavior and other maladaptive behavioral responses to symptoms. Goals must be specific, attainable, and valuable to the patient. It may be helpful to work with a physical therapist.</td> </tr> <tr> <td><strong>Challenge unhelpful cognitions</strong></td> <td>Evidence for and against beliefs can be reviewed. As an example, the experience of behavior change can be used to challenge cognitions about the impairment being fixed.</td> </tr> <tr> <td><strong>Involve the family</strong></td> <td>Key family members may be invited to attend treatment sessions so that they understand the rationale for the diagnosis and treatment plan. In addition, they need practical advice about how they should respond to symptoms. As an example, a nonepileptic seizure should be handled like a panic attack in a calm and reassuring way, not with drugs and a phone call for an ambulance.</td> </tr> <tr> <td><strong>Encourage practice</strong></td> <td>Improvement is usually gradual. The desired behavior is practiced daily until it is mastered, and then the next goal is undertaken. As an example, patients with functional paralysis who ultimately want to walk to stores may have to start by walking round their home, until they feel progressively less tired as a consequence.</td> </tr> <tr> <td><strong>Anticipate fluctuations</strong></td> <td>It is unusual for patients with conversion disorder to improve continuously without any setbacks. Symptoms typically improve then relapse, or attacks resolve and then recur in a cluster.</td> </tr> <tr> <td><strong>Consider teaching relaxation and distraction techniques</strong></td> <td>Relaxation techniques (eg, progressive muscle relaxation or breathing retraining) can aid coping with unpleasant symptoms. Distraction techniques such as those used in panic disorder (eg, speaking to someone or mental arithmetic) may help generate a sense of control over attacks or exacerbations of symptoms.</td> </tr> <tr> <td><strong>Encourage patients to consider a psychological etiology, but do not insist upon this</strong></td> <td>Although many patients can eventually realize the relationship between their symptoms and psychological problems, it is not always necessary for a successful outcome. As an example, patients may come to appreciate that their dissociative experiences and lack of bodily control arises from childhood abuse. Ensuring that such links are actually present and are elicited in a way that is helpful rather than harmful to the patient requires time and experience. Patients should dictate the speed with which these links are made, not the therapist.</td> </tr> <tr> <td><strong>Use problem solving to address practical problems</strong></td> <td>Problem solving can be used to help patients address obstacles to recovery, such as difficulties with relationships, work, finances, and legal issues</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 88080 Version 2.0</div></div></div>"},"88081":{"type":"graphic_picture","displayName":"Minimal erythema dose MED","title":"Minimal erythema dose (MED)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Minimal erythema dose (MED)</div><div class=\"cntnt\"><img style=\"width:393px; height:185px;\" src=\"images/DERM/88081_Min_erythema_dose_MED.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The MED is the smallest dose of UVB required to induce a barely perceptible erythema 24 hours after irradiation. The minimal erythema dose (MED) for this patient is shown in the bordered square.</div><div id=\"graphicVersion\">Graphic 88081 Version 1.0</div></div></div>"},"88082":{"type":"graphic_picture","displayName":"Sunburn chest","title":"Sunburn","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Sunburn</div><div class=\"cntnt\"><img style=\"width:598px; height:243px;\" src=\"images/DERM/88082_Sunburn_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A severe sunburn in a boy who had been sleeping in the sun. Note the sparing of the chest areas covered by the folded arms.</div><div class=\"graphic_reference\">Reproduced from: Lautenschlager S, Wulf HC, Pittelkow MR. Photoprotection. Lancet 2007; 370:528. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88082 Version 1.0</div></div></div>"},"88085":{"type":"graphic_table","displayName":"Guidelines for teaching mindfulness based cognitive therapy","title":"Training guidelines for teaching mindfulness based cognitive therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Training guidelines for teaching mindfulness based cognitive therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">The typical minimal requirements for teaching mindfulness based cognitive therapy for mood disorders include:</td> </tr> <tr> <td class=\"indent1\">1. An ongoing commitment to a personal daily mindfulness practice.</td> </tr> <tr> <td class=\"indent1\">2. Professional qualification in clinical practice and training in mental health that includes the use of structured, evidence based psychotherapies for mood disorders (eg, cognitive-behavior therapy, interpersonal psychotherapy, and behavioral activation). </td> </tr> <tr> <td class=\"indent1\">3. Knowledge about and experience in treating mood disorders within a group and individual format.</td> </tr> <tr> <td class=\"indent1\">4. Completion of a rigorous mindfulness based teacher training program or \"supervised pathway\" with a minimum duration of 12 months. (A supervised pathway might include attending three, eight-week courses, the first as a participant, the second as trainee, the third as co-teacher, as well as attending workshops on theoretical and practical aspects of teaching the core practices and curriculum).</td> </tr> <tr> <td class=\"indent1\">5. Ongoing adherence to ethical conduct as outlined within the clinician's profession. </td> </tr> <tr> <td class=\"indent1\">6. On-going peer supervision with an experienced <em>mindfulness </em><em>based</em> <em>teacher</em>, which includes receiving periodic (eg, annual) feedback on teaching through video recordings, a supervisor sitting in on teaching sessions, or co-teaching with planned feedback sessions.</td> </tr> <tr> <td class=\"subtitle1_single\">For the purposes of continuing professional development, we recommend:</td> </tr> <tr> <td class=\"indent1\">1. Participation in residential teacher-led mindfulness meditation retreats.</td> </tr> <tr> <td class=\"indent1\">2. Ongoing peer supervision with mindfulness-based <em>colleagues</em>, developed and maintained as a means to share experiences and learn collaboratively.</td> </tr> <tr> <td class=\"indent1\">3. Additional training to develop skills in delivering mindfulness-based approaches, as well as maintaining one's knowledge of the current evidence for mindfulness based treatment.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Segal ZV, Williams JMG, Teasdale JD. Mindfulness Based Cognitive Therapy for Depression. New York: Guilford Press, 2013.</div><div id=\"graphicVersion\">Graphic 88085 Version 1.0</div></div></div>"},"88088":{"type":"graphic_table","displayName":"Conditions causing hypothermia in children","title":"Conditions causing hypothermia in children by physiologic mechanism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions causing hypothermia in children by physiologic mechanism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Substrate deficiency</td> </tr> <tr> <td class=\"indent1\">Hypoglycemia</td> </tr> <tr> <td class=\"subtitle1_single\">Central nervous system conditions that disrupt hypothalamic and autonomic temperature regulation</td> </tr> <tr> <td class=\"indent1\">Traumatic brain or spinal cord injury (including neurosurgical procedures)</td> </tr> <tr> <td class=\"indent1\">Intracranial hemorrhage</td> </tr> <tr> <td class=\"indent1\">Stroke</td> </tr> <tr> <td class=\"indent1\">Brain tumors (eg, craniopharyngioma or astrocytoma)</td> </tr> <tr> <td class=\"indent1\">Congenital brain malformations (eg, anencephaly or absence of the corpus callosum)</td> </tr> <tr> <td class=\"indent1\">Familial dysautonomia</td> </tr> <tr> <td class=\"subtitle1_single\">Generalized infection*</td> </tr> <tr> <td class=\"indent1\">Sepsis</td> </tr> <tr> <td class=\"indent1\">Meningitis</td> </tr> <tr> <td class=\"indent1\">Encephalitis</td> </tr> <tr> <td class=\"subtitle1_single\">Drug overdose with agents that cause central nervous system depression and vasodilation</td> </tr> <tr> <td class=\"indent1\">Ethanol</td> </tr> <tr> <td class=\"indent1\">Opioids</td> </tr> <tr> <td class=\"indent1\">Clonidine</td> </tr> <tr> <td class=\"indent1\">Benzodiazepines</td> </tr> <tr> <td class=\"indent1\">Barbiturates</td> </tr> <tr> <td class=\"indent1\">Antipsychotic agents (eg, chlorpromazine)</td> </tr> <tr> <td class=\"indent1\">Antidepressants (eg, amitriptyline)</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine or metabolic diseases that impair energy utilization or basal metabolic rate</td> </tr> <tr> <td class=\"indent1\">Adrenal insufficiency</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> </tr> <tr> <td class=\"indent1\">Hypoparathyroidism</td> </tr> <tr> <td class=\"indent1\">Hypopituitarism</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Menkes disease (Menkes kinky hair syndrome)</td> </tr> <tr> <td class=\"indent1\">Organic acidemias</td> </tr> <tr> <td class=\"indent1\">Aminoacidemias</td> </tr> <tr> <td class=\"subtitle1_single\">Increased insensible losses due to disruption of skin</td> </tr> <tr> <td class=\"indent1\">Burns</td> </tr> <tr> <td class=\"indent1\">Epidermolysis bullosa and other weeping dermatoses</td> </tr> <tr> <td class=\"subtitle1_single\">Decreased calorie intake with decreased energy production and loss of insulating subcutaneous fat</td> </tr> <tr> <td class=\"indent1\">Malnutrition</td> </tr> <tr> <td class=\"indent1\">Anorexia nervosa</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Hyponatremia (eg, water intoxication)</td> </tr> <tr> <td class=\"indent1\">Episodic spontaneous hypothermia with hyperhidrosis<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Child abuse and maltreatment</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Hypothermia is most frequently described in septic young infants or neonates and in patients with Gram negative sepsis.<br />&para; Episodic spontaneous hypothermia with hyperhidrosis is a rare syndrome that is notable for hypothermia, diaphoresis, absence of shivering, and pallor without evidence of central nervous system abnormality or endocrinopathy. In addition to supportive care, episodes may respond to or be prevented by cyproheptadine.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Corneli HM. Accidental hypothermia. J Pediatr 1992; 120:671.</li>&#xD;&#xA;    <li>Tunnessen WW, Roberts KB. Hypothermia. In: Signs and Symptoms in Pediatrics, 3rd edition, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.8.</li>&#xD;&#xA;    <li>Greenberg RA, Rittichier KK. Pediatric nonenvironmental hypothermia presenting to the emergency department: Episodic spontaneous hypothermia with hyperhidrosis. Pediatr Emerg Care 2003; 19:32.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 88088 Version 3.0</div></div></div>"},"88090":{"type":"graphic_table","displayName":"Cytogenetic abnormalities AML","title":"Cytogenetic abnormalities in acute myeloid leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytogenetic abnormalities in acute myeloid leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cytogenetic finding</td> <td class=\"subtitle1\">Affected genes</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Prognosis</td> <td class=\"subtitle1\">Approximate incidence in de novo AML</td> </tr> <tr> <td>t(8;21)</td> <td><em>RUNX1/RUNX1T1</em></td> <td> <p>Younger adults (average age 30 years)</p> <p>AML with maturation (FAB M2)</p> <p>Auer rods usually present</p> </td> <td>Favorable</td> <td>5 to 7%</td> </tr> <tr> <td>t(15;17)</td> <td><em>PML/RARA</em></td> <td> <p>Younger adults (average age 40 years)</p> <p>Atypical promyelocytes with bilobed nucleus and granules (APL, FAB M3)</p> Disseminated intravascular coagulation common </td> <td>Favorable; high cure rate with all-trans retinoic acid-based therapy</td> <td>5 to 8%</td> </tr> <tr> <td>t(11;17)</td> <td><em>ZBTB16/RARA</em></td> <td>Similar to APL but with sparser granules and absence of the typical bilobed nucleus</td> <td>Poor response to all-trans retinoic acid-based treatment</td> <td>&#60;1%</td> </tr> <tr> <td>abn(16q22) </td> <td><em>CBFB/MYH11</em> </td> <td> <p>Younger adults (average age 35 to 40 years)</p> Acute myelomonocytic leukemia (FAB M4) with eosinophilia</td> <td>Favorable; high reinduction rate post relapse</td> <td>5%</td> </tr> <tr> <td>abn(11q23) </td> <td><em>MLL</em> and many partners</td> <td> <p>Older adults (average age &#62;50 years)</p> <p>Acute monoblastic and monocytic leukemia (FAB M5)</p> Hyperleukocytosis and extramedullary disease common</td> <td>Poor, except t(9;11)</td> <td>3%</td> </tr> <tr> <td>+8</td> <td>&nbsp;</td> <td> <p>Older adults (average age &#62;60 years)</p> <p>Varied morphology</p> Often associated with other chromosomal additions and deletions</td> <td>Poor</td> <td>3 to 10%</td> </tr> <tr> <td>del 5, del 7, 5q-, 7q-, or combinations</td> <td>&nbsp;</td> <td> <p>Older adults (average age &#62;60 years)</p> <p>Varied morphology, common in acute erythroid leukemia (FAB M6)</p> Common in patients with secondary AML and prior MDS</td> <td>Poor</td> <td>15 to 20%</td> </tr> <tr> <td>Inv 3</td> <td><em>RPN1/MECOM</em></td> <td> <p>Morphologically abnormal megakaryocytes; increased platelet count</p> Other abnormalities common (del 5,7)</td> <td>Poor</td> <td>&#60;1%</td> </tr> <tr> <td>abn(p17)</td> <td><em>TP53</em></td> <td> <p>Younger adults (average age &#60;60 years)</p> <p>Varied morphology</p> Other abnormalities common (del 5,7, complex karyotype)</td> <td>Poor</td> <td>5%</td> </tr> <tr> <td>+13</td> <td>&nbsp;</td> <td> <p>Older adults (average age &#62;60 years)</p> Varied morphology, sometimes undifferentiated, high frequency of hybrid features</td> <td>Poor</td> <td>Approximately 1 to 2%</td> </tr> <tr> <td>t(6;9)(p2;q34)</td> <td><em>DEK/NUP214</em></td> <td>AML with maturation (FAB M2)/Acute myelomonocytic leukemia (FAB M4) with prominent basophilia</td> <td>Poor</td> <td>&#60;1 to 2%</td> </tr> <tr> <td>t(9;22)</td> <td><em>BCR/ABL1</em></td> <td> <p>Older adults (average age &#62;50 years)</p> Usually AML with minimal differentiation (FAB M1), prominent splenomegaly, possible transformation of unrecognized CML</td> <td>Poor</td> <td>Approximately 1%</td> </tr> <tr> <td>t(1;22)</td> <td><em>RBM15/MKL1 </em></td> <td> <p>Infants (aged 0 to&nbsp;3 years)</p> Often acute megakaryoblastic leukemia (FAB M7), prominent organomegaly </td> <td>Poor</td> <td>&#60;1%</td> </tr> <tr> <td>t(8;16)</td> <td><em>KAT6A/CREBBP</em></td> <td>Acute myelomonocytic leukemia (FAB M4) and acute monoblastic and monocytic leukemia (FAB M5), erythrophagocytosis</td> <td>Poor</td> <td>&#60;1%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AML: acute myeloid leukemia; APL: acute promyelocytic leukemia; FAB: French American British classification system; MDS: myelodysplastic syndrome; CML: chronic myeloid leukemia.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed, Swerdlow SH, Campo E, Harris NL, et al (Eds), IARC: Lyon, 2008.</li>&#xD;&#xA;    <li>Mehta AB, Bain BJ, Fitchett M, et al. Trisomy 13 and myeloid malignancy--characteristic blast cell morphology: a United Kingdom Cancer Cytogenetics Group survey. Br J Haematol 1998; 101:749.</li>&#xD;&#xA;    <li>Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116:354.</li>&#xD;&#xA;    <li>P&eacute;rot C, Huret JL. t(8;16)(p11;p13). Atlas Genet Cytogenet Oncol Haematol 1999; 3:36.</li>&#xD;&#xA;    <li>Schiffer C, Stone RM. Acute myeloid leukemia in adults: mast cell leukemia and other mast cell neoplasms. In Hong WK, Bast RC, Hait WN, et al (Eds), Holland-Frei Cancer Medicine, 8th Ed, Shelton: PMPH USA, 2010.</li>&#xD;&#xA;    <li>Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet 2013; 381:484.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 88090 Version 2.0</div></div></div>"},"88091":{"type":"graphic_table","displayName":"Molecular markers in AML","title":"Molecular markers in acute myeloid leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Molecular markers in acute myeloid leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"5\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Approximate frequency in de-novo AML</td> <td class=\"subtitle1\">Frequency in CN AML</td> <td class=\"subtitle1\">Strong associations</td> <td class=\"subtitle1\">Not recorded with</td> <td class=\"subtitle1\">Outlook</td> </tr> <tr> <td><em><strong>NPM1</strong></em></td> <td>35 percent</td> <td>50 percent</td> <td>CN AML, <em>FLT3</em>-ITD, <em>FLT3</em>-TKD, <em>DNMT3A</em>, <em>IDH1</em>, <em>IDH2</em></td> <td><em>CEBPA</em> double mutant</td> <td>Favorable in patients with CN AML and in elderly patients</td> </tr> <tr> <td><em><strong>CEBPA</strong></em></td> <td>7 percent</td> <td>8 to 19 percent</td> <td>CN AML, <em>FLT3</em>-ITD</td> <td><em>NPM1</em></td> <td>Favorable in patients with CN AML (if biallelic)</td> </tr> <tr> <td><strong><em>FLT3</em>-ITD</strong></td> <td>20 to 25 percent</td> <td>30 to 35 percent</td> <td>CN AML, APL, t(6;9), <em>NPM1</em></td> <td>&nbsp;</td> <td>Adverse in patients with CN AML; could vary with allelic burden; no clear effect in patients with APL</td> </tr> <tr> <td><strong><em>FLT3</em>-TKD</strong></td> <td>5 percent</td> <td>14 percent</td> <td>CN AML, <em>NPM1</em></td> <td>&nbsp;</td> <td>Controversial</td> </tr> <tr> <td><em><strong>KIT</strong></em></td> <td>&nbsp;</td> <td>25 percent</td> <td>Core binding factor leukemias</td> <td>Most other karyotypes</td> <td>Adverse in adult patients with core binding factor leukemias</td> </tr> <tr> <td><strong>TET2</strong></td> <td>8 to 12 percent</td> <td>23 percent</td> <td>Possibly CN AML</td> <td><em>IDH1</em>, <em>IDH2</em></td> <td>Controversial</td> </tr> <tr> <td><em><strong>DNMT3A</strong></em></td> <td>14 to 22 percent</td> <td>20 to 33 percent</td> <td>CN AML, <em>NPM1</em>, <em>FLT3</em></td> <td>Core binding factor leukemias, <em>CEBPA</em>, <em>MLL</em> translocations</td> <td>Possibly adverse in patients with CN AML</td> </tr> <tr> <td><strong><em>IDH1</em>, <em>IDH2</em></strong></td> <td>8 to 16 percent</td> <td>30 percent</td> <td>CN AML, <em>NPM1</em>, <em>FLT3</em></td> <td><em>TET2</em>, <em>WT1</em></td> <td>Controversial</td> </tr> <tr> <td><em><strong>ASXL1</strong></em></td> <td>5 to 30 percent</td> <td>About 10 percent</td> <td>Uncommon with <em>NPM1</em> and <em>FLT3</em></td> <td>Possibly <em>CEBPA</em></td> <td>Adverse in patients with CN AML and older patients; more common in older patients</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Changes of miRNAs 15, 16, 155, and 181 among others, have been reported. The prognostic effect varies and studies are needed to assess the individual miRNA families and their interactions with other mutations. Some studies have shown that overexpression of BAALC, MN1, and ERG genes is associated with poorer outcomes, but needs confirmation.</div><div class=\"graphic_footnotes\">AML: acute myeloid leukemia; CN AML: cytogenetically normal acute myeloid leukemia; ITD: internal tandem duplication; TKD: tyrosine kinase domain; APL: acute promyelocytic leukemia.</div><div class=\"graphic_reference\">Reproduced from: Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet 2013; 381:484. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88091 Version 2.0</div></div></div>"},"88092":{"type":"graphic_table","displayName":"Frequency of extraintestinal manifestations of pediatric IBD","title":"Frequency of extraintestinal manifestations in pediatric patients with inflammatory bowel disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of extraintestinal manifestations in pediatric patients with inflammatory bowel disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Total<br /> n (percent)</td> <td class=\"subtitle1\">Crohn disease<br /> n (percent)</td> <td class=\"subtitle1\">Ulcerative colitis<br /> n (percent)</td> </tr> <tr> <td><strong>Total</strong></td> <td>1009</td> <td>728</td> <td>281</td> </tr> <tr> <td><strong>Any extraintestinal manifestation</strong>*</td> <td>285 (28.2%)</td> <td>218 (29.9%)</td> <td>67 (23.8%)</td> </tr> <tr> <td><strong>Arthralgia</strong></td> <td>166 (16.5%)</td> <td>124 (17%)</td> <td>42 (14.9%)</td> </tr> <tr> <td><strong>Aphthous stomatitis</strong></td> <td>81 (8%)</td> <td>72 (9.9%)<sup>&#182;</sup></td> <td>9 (3.2%)<sup>&#182;</sup></td> </tr> <tr> <td><strong>Arthritis</strong></td> <td>37 (3.7%)</td> <td>32 (4.4%)</td> <td>5 (1.8%)</td> </tr> <tr> <td><strong>Erythema nodosum</strong></td> <td>28 (2.8%)</td> <td>26 (3.6%)<sup>&#916;</sup></td> <td>2 (0.71%)<sup>&#916;</sup></td> </tr> <tr> <td><strong>Primary sclerosing cholangitis</strong></td> <td>15 (1.5%)</td> <td>7 (1%)<sup>&#9674;</sup></td> <td>8 (2.8%)<sup>&#9674;</sup><sup>&#167;</sup></td> </tr> <tr> <td><strong>Pancreatitis</strong></td> <td>9 (0.9%)</td> <td>5 (0.7%)</td> <td>4 (1.4%)</td> </tr> <tr> <td><strong>Chronic active hepatitis</strong></td> <td>6 (0.6%)</td> <td>2 (0.3%)</td> <td>4 (1.4%)</td> </tr> <tr> <td><strong>Iritis or uveitis</strong></td> <td>7 (0.7%)</td> <td>6 (0.8%)</td> <td>1 (0.4%)</td> </tr> <tr> <td><strong>Ankylosing spondylitis</strong></td> <td>4 (0.4%)</td> <td>4 (0.5%)</td> <td>0</td> </tr> <tr> <td><strong>Pyoderma gangrenosum</strong></td> <td>3 (0.3%)</td> <td>3 (0.4%)</td> <td>0</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Number of individual subjects with one or more extraintestinal manifestations.<br />¶ p&lt;0.001 for Crohn disease (CD) versus ulcerative colitis (UC).<br />Δ p&lt;0.01 for CD versus UC.<br /><FONT class=lozenge>◊</FONT> p = 0.039 for CD versus UC.<br />§ The prevalence of primary sclerosing cholangitis may be as high as 10 percent among pediatric patients with ulcerative colitis, according to a study using rigorous case-finding methods.<SUP>[1]</SUP></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Deneau M, Jensen MK, Holmen J, et al. Primary sclerosing cholangitis, autoimmune hepatitis and overlap in Utah children: Epidemiology and natural history. Hepatology 2013.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Dotson JL, Hyams JS, Markowitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr 2010; 51:140. DOI: <a href=\"http://journals.lww.com/jpgn/Fulltext/2010/08000/Extraintestinal_Manifestations_of_Pediatric.5.aspx\" target=\"_blank\">10.1097/MPG.0b013e3181ca4db4</a>. Copyright &copy; 2010 ESPGHAN and NASPGHAN. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 88092 Version 11.0</div></div></div>"},"88130":{"type":"graphic_algorithm","displayName":"Evaluation algorithm for chronic constipation","title":"Evaluation algorithm for chronic constipation","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Evaluation algorithm for chronic constipation</div><div class=\"cntnt\"><img style=\"width:451px; height:394px;\" src=\"images/GAST/88130_Treat_algo_chron_constip.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MR: magnetic resonance.<br />* Because anorectal manometry, rectal balloon expulsion test may not be available in all practice settings, it is acceptable in such circumstances to proceed to assessing colonic transit with the understanding that delayed colonic transit does not exclude a defecatory disorder.</div><div class=\"graphic_reference\">Reproduced from: Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association Medical Position Statement on Constipation. Gastroenterology 2013; 144:211. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88130 Version 1.0</div></div></div>"},"88131":{"type":"graphic_algorithm","displayName":"Treatment algorithm for normal or slow transit constipation","title":"Treatment algorithm for normal or slow transit constipation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Treatment algorithm for normal or slow transit constipation</div><div class=\"cntnt\"><img style=\"width:446px; height:604px;\" src=\"images/GAST/88131_Treat_algo_norm_slow_const.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PEG: polyethylene glycol; MOM: milk of magnesia; GI: gastrointestinal.</div><div class=\"graphic_reference\">Reproduced from: Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association Medical Position Statement on Constipation. Gastroenterology 2013; 144:211. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88131 Version 1.0</div></div></div>"},"88134":{"type":"graphic_algorithm","displayName":"Treatment algorithm for defecating disorders","title":"Treatment algorithm for defecating disorders","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Treatment algorithm for defecating disorders</div><div class=\"cntnt\"><img style=\"width:444px; height:510px;\" src=\"images/GAST/88134_Treat_algo_defecating_dis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MR: magnetic resonance; p.r.n.: as needed.</div><div class=\"graphic_reference\">Reproduced from: Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association Medical Position Statement on Constipation. Gastroenterology 2013; 144:211. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88134 Version 1.0</div></div></div>"},"88228":{"type":"graphic_table","displayName":"UVB initial dose by phototype","title":"UVB phototherapy: Recommended initial doses according to skin phototype","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">UVB phototherapy: Recommended initial doses according to skin phototype</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Skin phototype</td> <td class=\"subtitle1\">Initial BB-UVB dose<br /> (mJ/cm<sup>2</sup>)</td> <td class=\"subtitle1\">Initial NB-UVB dose<br /> (mJ/cm<sup>2</sup>)</td> </tr> <tr> <td class=\"centered\">I</td> <td class=\"centered\">20</td> <td class=\"centered\">130</td> </tr> <tr> <td class=\"centered\">II</td> <td class=\"centered\">25</td> <td class=\"centered\">220</td> </tr> <tr> <td class=\"centered\">III</td> <td class=\"centered\">30</td> <td class=\"centered\">260</td> </tr> <tr> <td class=\"centered\">IV</td> <td class=\"centered\">40</td> <td class=\"centered\">330</td> </tr> <tr> <td class=\"centered\">V</td> <td class=\"centered\">50</td> <td class=\"centered\">350</td> </tr> <tr> <td class=\"centered\">VI</td> <td class=\"centered\">60</td> <td class=\"centered\">400</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 88228 Version 1.0</div></div></div>"},"88235":{"type":"graphic_figure","displayName":"Pennington Forceps","title":"Pennington (Duval) Forceps","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pennington (Duval) Forceps</div><div class=\"cntnt\"><img style=\"width:400px; height:559px;\" src=\"images/SURG/88235_Pennington_forceps.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 88235 Version 1.0</div></div></div>"},"88237":{"type":"graphic_figure","displayName":"DeBakey forceps","title":"DeBakey forceps ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">DeBakey forceps </div><div class=\"cntnt\"><img style=\"width:428px; height:490px;\" src=\"images/SURG/88237_DeBakey_forceps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">DeBakey forceps are used in open thoracotomies and in minimally invasive thoracic procedures.</div><div id=\"graphicVersion\">Graphic 88237 Version 2.0</div></div></div>"},"88240":{"type":"graphic_figure","displayName":"Atraumatic thoracoscopic tissue grasper","title":"Atraumatic thoracoscopic tissue grasper","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Atraumatic thoracoscopic tissue grasper</div><div class=\"cntnt\"><img style=\"width:505px; height:672px;\" src=\"images/HEME/88240_Double_action_mechanism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A conventional grasper (A) will widen the port site when attempting to grasp tissue. By comparison, a thoracoscopic instrument with a double-action mechanism (B) allows grasping of the lung tissue without traumatizing the port site.</div><div id=\"graphicVersion\">Graphic 88240 Version 3.0</div></div></div>"},"88248":{"type":"graphic_figure","displayName":"Scissors for video-assisted thoracoscopic surgery","title":"Scissors for video-assisted thoracoscopic surgery","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Scissors for video-assisted thoracoscopic surgery</div><div class=\"cntnt\"><img style=\"width:504px; height:395px;\" src=\"images/SURG/88248_Scissors_for_VATS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure A depicts specially designed scissors that open at the level of the target tissue.<br />Figure B depicts Metzenbaum scissors that can pass through a small thoracic incision or port but may limit insertion of additional instruments through the same port.</div><div id=\"graphicVersion\">Graphic 88248 Version 4.0</div></div></div>"},"88249":{"type":"graphic_diagnosticimage","displayName":"Renal tuberculosis ","title":"Renal tuberculosis ","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Renal tuberculosis </div><div class=\"cntnt\"><img style=\"width:498px; height:331px;\" src=\"images/ID/88249_Renal_TB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A small, nonfunctioning right kidney containing calcific debris is present.</div><div class=\"graphic_reference\">Reproduced with permission from: Daffner RH. Clinical Radiology: The Essentials, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 88249 Version 1.0</div></div></div>"},"88251":{"type":"graphic_figure","displayName":"Needle drivers for video-assisted thoracic surgery ","title":"Needle drivers for video-assisted thoracic surgery ","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Needle drivers for video-assisted thoracic surgery </div><div class=\"cntnt\"><img style=\"width:508px; height:607px;\" src=\"images/SURG/88251_Needle_drivers_for_VATS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure A and Figure B depict a spring-style handle design needle driver. Figure C depicts the conventional ring handle needle driver.</div><div id=\"graphicVersion\">Graphic 88251 Version 4.0</div></div></div>"},"88252":{"type":"graphic_figure","displayName":"Knot pusher for extracorporeal knot tying ","title":"Knot pusher for extracorporeal knot tying ","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Knot pusher for extracorporeal knot tying </div><div class=\"cntnt\"><img style=\"width:475px; height:666px;\" src=\"images/SURG/88252_Knot_pusher_for_VATS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These figures depict a knot pusher that&nbsp;enables the tie to be made extracorporeally and then pushed to secure the tissue.</div><div id=\"graphicVersion\">Graphic 88252 Version 2.0</div></div></div>"},"88253":{"type":"graphic_figure","displayName":"Straight shafted suture passer","title":"Straight shafted suture passer","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Straight shafted suture passer</div><div class=\"cntnt\"><img style=\"width:488px; height:518px;\" src=\"images/SURG/88253_Suture_passer.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 88253 Version 2.0</div></div></div>"},"88268":{"type":"graphic_table","displayName":"PLD for soft tissue sarcoma","title":"Pegylated liposomal doxorubicin chemotherapy for advanced or metastatic soft tissue sarcomas<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pegylated liposomal doxorubicin chemotherapy for advanced or metastatic soft tissue sarcomas<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 4 weeks.<br /> Duration of therapy: 6 cycles.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Pegylated liposomal doxorubicin</strong>* <strong>(PLD)</strong></td> <td>50 mg/m<sup>2</sup> IV<sup>&#916;</sup></td> <td>Dilute<sup>&#9674;</sup> in 250 mL or 500 mL 5 percent dextrose in water (D5W)<sup>&#167;</sup> and administer at an initial rate of 1 mg/min to minimize infusion reactions. Subsequent doses can be given over 60 minutes.</td> <td>Day 1</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Vesicant/irritant properties:</strong> PLD is an irritant but it can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> There is no standard premedication regimen. For flank pain, flushing, shortness of breath, and/or chest tightness, stop the infusion immediately; after resolution, restart treatment at 50 percent of the original infusion rate<sup>[1]</sup>. If the reaction occurs again, discontinue PLD; however, most patients are able to tolerate a rechallenge. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with granulocyte colony stimulating factors is not indicated (no febrile neutropenia events were observed in the initial study<sup>[1]</sup>). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> A lower starting dose of PLD may be needed for patients with preexisting liver impairment. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiac issues:</strong> Doxorubicin is associated with dose-dependent cardiomyopathy, the incidence of which is related to cumulative dose. PLD causes significant cardiomyopathy, but the risk of developing clinical and subclinical cardiotoxicity is less than with native doxorubicin<sup>[2]</sup>. Assess baseline LVEF prior to initiating therapy. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for infusion reactions, which may affect as many as 10 to 20 percent of patients.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for palmar-plantar erythrodysesthesia and stomatitis.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor cumulative PLD dose. Reassess LVEF periodically during PLD therapy as clinically indicated. In clinical practice, PLD appears to have significantly less cardiotoxicity than unencapsulated anthracyclines, but this does not preclude the need to monitor cardiac function.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential should be done at least prior to each dose of PLD and may be needed weekly.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess liver function prior to each new cycle of treatment.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Myelotoxicity is uncommon with PLD. Withhold a new cycle of treatment until ANC &#8805;1500 cells/microL and platelet count &#8805;75,000/microL<sup>[3]</sup>. The original trial required a 25 percent decrease in PLD dose (to 37.5 mg/m<sup>2</sup>) for grade 4 neutropenia lasting for &#8805;7 days, and a 50 percent dose reduction (to 25 mg/m<sup>2</sup>) for patients with grade 4 neutropenia lasting for &#8805;7 days plus febrile neutropenia and grade 4 thrombocytopenia<sup>[1]</sup>. The manufacturer suggests a 25 percent dose reduction for ANC nadir &#60;500 cells/microL or platelet nadir &#60;25,000/microL, after recovery to ANC &#8805;1500 cells/microL and platelet count &#8805;75,000/microL<sup>[3]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiotoxicity:</strong> No formal guidelines exist for PLD discontinuation based upon LVEF function, but guidelines exist for other anthracyclines. The manufacturer recommends that the benefit of continued therapy be carefully weighed against the risk of producing irreversible cardiac damage if test results indicate deterioration in cardiac function during PLD therapy<sup>[3]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cutaneous toxicity:</strong> Delay new treatment cycle until palmar-plantar erythrodysesthesia is resolved to grade 0 or 1. In the original protocol, for grade 2 toxicity, treatment was delayed by at least one week, and if toxicity persisted for two weeks, the dose was reduced by 25 percent. For persistent grade 3 or 4 toxicity after two weeks, treatment was discontinued<sup>[1]</sup>. The United States Prescribing Information suggests a 25 percent dose reduction for PLD in case of grade 3 or 4 cutaneous toxicity, if it resolves to grade 0 or 1 within two weeks, and treatment discontinuation for grade 2 to 4 cutaneous toxicity that does not resolve after two weeks<sup>[3]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Gastrointestinal toxicity:</strong> Delay new treatment cycle until stomatitis resolved to grade 0 or 1. In this study, dose reductions were allowed for grade 3 or worse mucositis<sup>[1]</sup>. The United States Prescribing Information suggests a 25 percent dose reduction for PLD in case of grade 3 or 4 stomatitis, if it resolves to grade 0 or 1 within two weeks, and treatment discontinuation for grade 2 to 4 stomatitis that does not resolve after two weeks<sup>[3]</sup>.</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count; ANC: absolute neutrophil count.<br />* Liposomal formulations of doxorubicin should NOT be substituted for conventional doxorubicin hydrochloride on a mg-per-mg basis.<br />&Delta; Although this was the dose that was used in the randomized trial<sup>[1]</sup>, many sarcoma experts consider that 50 mg/m<sup>2</sup> is too high, at least for the first dose, and would begin therapy at 40 mg/m<sup>2</sup>, adjusting the dose as tolerated every four weeks.<br /><span class=\"lozenge\">&loz;</span> PLD doses up to 90 mg must be diluted in 250 mL of 5 percent dextrose injection, USP prior to administration. Doses exceeding 90 mg should be diluted in 500 mL of 5 percent dextrose injection, USP prior to administration<sup>[3]</sup>.<br />&sect; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies). Do not use with any diluent other than 5 percent dextrose injection. Do not use with in-line filters. Do not mix with other drugs. Do not use any bacteriostatic agent, such as benzyl alcohol<sup>[3]</sup>.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Judson J, et al. Eur J Cancer 2001; 37:870.</LI>&#xD;&#xA;<LI>Smith LA, et al. BMC Cancer 2010; 10:337.</LI>&#xD;&#xA;<LI>Doxorubicin hydrochloride injection.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed June 8, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 88268 Version 6.0</div></div></div>"},"88273":{"type":"graphic_picture","displayName":"Aspiration and drainage of an auricular hematoma","title":"Aspiration and drainage of an auricular hematoma","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Aspiration and drainage of an auricular hematoma</div><div class=\"cntnt\"><img style=\"width:597px; height:448px;\" src=\"images/EM/88273_Aspirdrainauricuhematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Instillation of 1 percent lidocaine for local analgesia. (B) Aspiration of hematoma using 18-gauge angiocatheter and 10-mL syringe. Syringe is removed (C) and angiocatheter is clipped leaving approximately 1 cm external to the hematoma for drainage (D).</div><div class=\"graphic_reference\">Reproduced with permission from: Brickman K, Adams DZ, Akpunonu P, et al. Acute Management of Auricular Hematoma: A Novel Approach and Retrospective Review. Clin J Sport Med 2013; 23:321. DOI: <a href=\"http://journals.lww.com/cjsportsmed/Abstract/2013/07000/Acute_Management_of_Auricular_Hematoma___A_Novel.14.aspx\" target=\"_blank\">10.1097/JSM.0b013e31825c4623</a>. Copyright &copy; 2013 Wolters Kluwer Health, Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 88273 Version 6.0</div></div></div>"},"88275":{"type":"graphic_table","displayName":"DDx HCL path","title":"Differential diagnosis of hairy cell leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of hairy cell leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Entity</td> <td class=\"subtitle1\">Histology</td> <td class=\"subtitle1\">Immunophenotype</td> <td class=\"subtitle1\">Genetic features/other</td> </tr> <tr> <td>Hairy cell leukemia</td> <td>The HCL cell is mononuclear and one to two times the size of a mature lymphocyte. The nuclei are often eccentric, lack prominent nucleoli, and have a reticular chromatin pattern. The cytoplasm is often abundant and pale blue to blue-gray in color. The cytoplasmic outline is indistinct with varying numbers of projections. Characteristically infiltrates the marrow in an interstitial or diffuse pattern; nodular aggregates are absent.</td> <td>Most cases of HCL express CD20, CD22, CD11c, CD103, CD123, and CD25. Expression of cyclin D1 and annexin A1 is variable. Expression of CD20 and surface immunoglobulin is bright. Rare cases express CD5 or CD10.</td> <td>Virtually all have BRAF V600E mutation</td> </tr> <tr> <td>Hairy cell leukemia variant</td> <td>Variant has circulating tumor cells with morphology intermediate between hairy cells and prolymphocytes. Nucleoli are prominent.</td> <td>Express CD20, CD22, CD11c, and CD103. Expression of CD123 is dim or negative. Do not express annexin A1 or CD25. Expression of CD20 and surface immunoglobulin is bright.</td> <td>HCL variants usually lack the BRAF V600E mutation, but are associated with mutations in MAP2K1. Often associated with IGH4-34 rearrangements.</td> </tr> <tr> <td>Chronic lymphocytic leukemia/small lymphocytic lymphoma</td> <td>\"Typical\" CLL cells are small, mature appearing lymphocytes with a dense nucleus, partially aggregated chromatin; no discernible nucleoli; and a narrow border of clear to slightly basophilic cytoplasm. Often involves the marrow as nodular aggregates, sometimes with proliferation centers.</td> <td>Typically express CD5 and CD23. Expression of CD20 and surface immunoglobulin is dim. Do not express annexin A1.</td> <td>Trisomy 12, deletions of 6q, 11q, 13q, and 17p. Distinct mutational profile without BRAF mutations.</td> </tr> <tr> <td>B cell prolymphocytic leukemia</td> <td> <p>&#62;55 percent (and usually &#62;90 percent) of circulating white cells are \"prolymphocytes\": medium-sized cells with moderately abundant, slightly basophilic cytoplasm; a round or oval nucleus with moderately condensed chromatin; and a single, prominent nucleolus</p> The bone marrow is infiltrated in an interstitial or nodular pattern by similar cells</td> <td> <p>Express bright surface IgM +/&ndash; IgD and bright CD20 as well as other B cell antigens (CD19, CD22, CD79a, FMC7)</p> CD5 and CD23 expression is usually weak or absent. CD11c, CD103, CD10, CD25, and cyclin D1 are not expressed. Do not express annexin A1.</td> <td>&nbsp;</td> </tr> <tr> <td>Splenic marginal zone lymphoma</td> <td>Splenic MZL cells usually have short polar villi. Both white and red pulp of the spleen are involved. Nodular pattern of marrow involvement.</td> <td>Do not express CD103 or annexin A1. Expression of CD20 and surface immunoglobulin is bright.</td> <td>Often associated with deletions of 7q. Distinct mutational profile without BRAF mutations.</td> </tr> <tr> <td>Splenic diffuse red pulp small B cell lymphoma&nbsp;</td> <td>Diffuse infiltration of the bone marrow, peripheral blood, and splenic red pulp by small monomorphous lymphocytes, usually with villous projections.&nbsp;</td> <td>Typically&nbsp;negative for annexin A1, CD25, CD103, CD123, and CD11c&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Mantle cell lymphoma</td> <td>Can have a leukemic phase</td> <td>Typically positive for IgM, IgD, CD20 and CD5 and negative for CD23. Express cyclin D1.</td> <td>t(11;14)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HCL: hairy cell leukemia; CLL: chronic lymphocytic leukemia; MZL: marginal zone lymphoma.</div><div id=\"graphicVersion\">Graphic 88275 Version 6.0</div></div></div>"},"88276":{"type":"graphic_figure","displayName":"Mechanisms of glucocorticoid insensitivity in severe asthma","title":"Mechanisms implicated in glucocorticoid insensitivity in severe asthma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mechanisms implicated in glucocorticoid insensitivity in severe asthma</div><div class=\"cntnt\"><img style=\"width:390px; height:224px;\" src=\"images/PULM/88276_Mech_gluco_insens_sev_asth.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A number of factors including infection, oxidative stress (either directly or indirectly from cigarette smoking), allergen exposure (leading to Th2 cytokine expression), inflammation (eg, IL-17 production from Th17 and other cells), and a lack of vitamin D3 can modulate glucocorticoid function and have been shown to be important in patients with glucocorticoid resistant asthma. Drugs that target these abnormal processes or signalling pathways may prove of benefit in severe asthma.</div><div class=\"graphic_footnotes\">IL: interleukin; LPS: lipopolysaccharide; ROS: reactive oxygen species; TH17: IL-17-producing T helper lymphocytes.</div><div id=\"graphicVersion\">Graphic 88276 Version 1.0</div></div></div>"},"88283":{"type":"graphic_diagnosticimage","displayName":"Bronchiolitis radiograph","title":"Bronchiolitis radiographs","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Bronchiolitis radiographs</div><div class=\"cntnt\"><img style=\"width:515px; height:270px;\" src=\"images/PEDS/88283_Bronchiolitis_radiogr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The above radiographs demonstrate the following findings that are consistent with bronchiolitis:<br />1) Patchy atelectasis, in particular of the right middle lobe<br />2) Bilateral peribronchial infiltrations with air bronchograms<br />3) Hyper-inflation of the lungs with flattening of the diaphragms</div><div id=\"graphicVersion\">Graphic 88283 Version 1.0</div></div></div>"},"88293":{"type":"graphic_table","displayName":"Drugs involved in pemphigus","title":"Drugs involved in pemphigus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs involved in pemphigus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">SH drugs</td> </tr> <tr> <td class=\"subtitle2_single\">SH drugs</td> </tr> <tr> <td class=\"indent1\">Bucillamine</td> </tr> <tr> <td class=\"indent1\">Captopril</td> </tr> <tr> <td class=\"indent1\">D-penicillamine</td> </tr> <tr> <td class=\"indent1\">Gold sodium thiomalate</td> </tr> <tr> <td class=\"indent1\">Pyritinol</td> </tr> <tr> <td class=\"indent1\">Thiopronine</td> </tr> <tr> <td class=\"subtitle2_single\">Drugs with SH metabolites</td> </tr> <tr> <td class=\"indent1\">Carbimazole</td> </tr> <tr> <td class=\"indent1\">Penicillin</td> </tr> <tr> <td class=\"indent1\">Piroxicam</td> </tr> <tr> <td class=\"subtitle1_single\">Non-SH drugs</td> </tr> <tr> <td class=\"subtitle2_single\">Antibiotics</td> </tr> <tr> <td class=\"indent1\">Cephalosporins</td> </tr> <tr> <td class=\"indent1\">Ethambutol</td> </tr> <tr> <td class=\"indent1\">Isoniazid</td> </tr> <tr> <td class=\"indent1\">Pentachlorophenol</td> </tr> <tr> <td class=\"indent1\">Rifampicin</td> </tr> <tr> <td class=\"subtitle2_single\">Pyrazol drugs</td> </tr> <tr> <td class=\"indent1\">Aminophenazone</td> </tr> <tr> <td class=\"indent1\">Aminopyrine</td> </tr> <tr> <td class=\"indent1\">Azapropazone</td> </tr> <tr> <td class=\"indent1\">Noramidopyrine</td> </tr> <tr> <td class=\"indent1\">Phenylbutazone</td> </tr> <tr> <td class=\"subtitle2_single\">Other drugs</td> </tr> <tr> <td class=\"indent1\">Acenocoumarol</td> </tr> <tr> <td class=\"indent1\">Enalapril</td> </tr> <tr> <td class=\"indent1\">Heroin</td> </tr> <tr> <td class=\"indent1\">Hydantoin</td> </tr> <tr> <td class=\"indent1\">Imiquimod</td> </tr> <tr> <td class=\"indent1\">Immunomodulators: interleukin-2, interferon alpha, interferon beta, isosorbide trinitrate</td> </tr> <tr> <td class=\"indent1\">Isotretinoin</td> </tr> <tr> <td class=\"indent1\">Levodopa</td> </tr> <tr> <td class=\"indent1\">Lysine acetylsalicylate</td> </tr> <tr> <td class=\"indent1\">Phenobarbital</td> </tr> <tr> <td class=\"indent1\">Progesterone</td> </tr> <tr> <td class=\"indent1\">Propranolol</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SH: sulfhydryl group.</div><div class=\"graphic_reference\">Reproduced with permission from: Maruani A, Machet MC, Carlotti A, et al. Immunostaining with antibodies to desmoglein provides the diagnosis of drug-induced pemphigus and allows prediction of outcome. Am J Clin Pathol 2008; 130:369. Copyright &copy; 2008-2013 American Society for Clinical Pathology.</div><div id=\"graphicVersion\">Graphic 88293 Version 2.0</div></div></div>"},"88295":{"type":"graphic_figure","displayName":"Incision sites for VATS","title":"Incision sites for video-assisted thoracoscopic surgery ","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Incision sites for video-assisted thoracoscopic surgery </div><div class=\"cntnt\"><img style=\"width:526px; height:470px;\" src=\"images/SURG/88295_IncisionsitesforVATS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incisions are&nbsp;placed according to the position of the patient's ribs, arm, diaphragm, and scapula.</div><div class=\"graphic_footnotes\">VATS: video-assisted thoracoscopic surgery. </div><div id=\"graphicVersion\">Graphic 88295 Version 8.0</div></div></div>"},"88297":{"type":"graphic_figure","displayName":"Incidence of diabetes in youth by age group","title":"Incidence of diabetes mellitus in youth by age group","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Incidence of diabetes mellitus in youth by age group</div><div class=\"cntnt\"><img style=\"width:454px; height:318px;\" src=\"images/PEDS/88297_Incidenc_diabete_youth_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incidence of type 1 and type 2 diabetes mellitus in youth in the United States, from the SEARCH for Diabetes in Youth Study Group, 2002-2003. For type 1 diabetes, there are&nbsp;two peaks in incidence,&nbsp;in mid-childhood&nbsp;and&nbsp;early puberty;&nbsp;this bimodal distribution is not evident from the age categories used for this figure.&nbsp;</div><div class=\"graphic_reference\">Data from: Writing Group for the SEARCH for Diabetes in Youth Study Group, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States. JAMA 2007; 297:2716.</div><div id=\"graphicVersion\">Graphic 88297 Version 2.0</div></div></div>"},"88298":{"type":"graphic_diagnosticimage","displayName":"Trapezoid fracture radiograph","title":"Trapezoid fracture radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trapezoid fracture radiograph</div><div class=\"cntnt\"><img style=\"width:341px; height:600px;\" src=\"images/RADIOL/88298_Trapez_fracture_x_ray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examination of the left wrist in the AP (A), oblique (B), and lateral (C) projections reveal a nondisplaced fracture of the trapezoid (arrows) with overlying soft tissue swelling best appreciated in the lateral examination (arrowhead).</div><div id=\"graphicVersion\">Graphic 88298 Version 3.0</div></div></div>"},"88299":{"type":"graphic_diagnosticimage","displayName":"Lymphoma with extensive bony metastases PET scan","title":"Lymphoma with extensive bony metastases PET scan","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Lymphoma with extensive bony metastases PET scan</div><div class=\"cntnt\"><img style=\"width:597px; height:442px;\" src=\"images/RADIOL/88299_Lymphom_metas_PET_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">55-year-old female patient with widely metastatic, PET scan positive diffuse large B cell lymphoma shown in the whole body view (A), and in an axial view through the pelvis (B). The corresponding CT scan (C) is almost normal.</div><div class=\"graphic_footnotes\">PET: positron emission tomography; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 88299 Version 2.0</div></div></div>"},"88300":{"type":"graphic_picture","displayName":"Pulmonary vascular lesions in MCTD","title":"Pulmonary vascular lesions in mixed connective tissue disease","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Pulmonary vascular lesions in mixed connective tissue disease</div><div class=\"cntnt\"><img style=\"width:596px; height:436px;\" src=\"images/RHEUM/88300_Pulm_vascular_lesions_MCTD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary vascular lesions in MCTD.<BR>(Panel A) Severe intimal fibrosis almost occluding the vascular lumen (Elasitica-Goldner stain).<BR>(Panel B) Organized thrombus in medium-sized artery (Elasitica-Goldner stain).<BR>(Panel C) Plexogenic arteriopathy sometimes occured (Elasitica-Goldner stain).<BR>(Panel D) Vasculitis of small vessels with inflammatory infiltration around vessels almost composed of lymphocytes (Elastica-Goldner stain).<BR>MCTD cases with PH also show the interstitial type, vascular type, and mixed type with both lesions; however, the mixed type is very rare. Further, the vascular type of MCTD shows similar lesions to SSc, such as fibrous thickening, and to SLE, such as plexogenic arteriopathy.</div><div class=\"graphic_footnotes\">MCTD: mixed connective tissue disease; PH: pulmonary hypertension; SSc: systemic sclerosis (scleroderma); SLE: systemic lupus erythematosus.</div><div class=\"graphic_reference\">Reproduced with permission from: Sasaki N, Kamataki A, Sawai T. A histopathological study of pulmonary hypertension in connective tissue disease. Allergol Int 2011; 60:411. Copyright &copy; 2013 Japanese Society of Allergology.</div><div id=\"graphicVersion\">Graphic 88300 Version 1.0</div></div></div>"},"88304":{"type":"graphic_figure","displayName":"Mediastinal mass anatomic compartments","title":"Common diagnostic possibilities of mediastinal masses","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Common diagnostic possibilities of mediastinal masses</div><div class=\"cntnt\"><img style=\"width:352px; height:558px;\" src=\"images/HEME/88304_Mediast_mass_anatomic_comp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The differential diagnosis of a mediastinal mass depends upon the anatomic compartment in which it arises.</div><div class=\"graphic_reference\">Redrawn from: Baue AE, Geha AS, Hammond GL, et al. Glenn's Thoracic and Cardiovascular Surgery, 5th ed, Appleton &amp; Lange, Norwalk, CT 1991.</div><div id=\"graphicVersion\">Graphic 88304 Version 2.0</div></div></div>"},"88305":{"type":"graphic_figure","displayName":"Histological features of medulloblastoma","title":"Histological features of medulloblastoma","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Histological features of medulloblastoma</div><div class=\"cntnt\"><img style=\"width:515px; height:385px;\" src=\"images/ONC/88305_Hist_feat_medulloblas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin staining of (A) classic medulloblastoma, with sheets of small round blue cells with scant cytoplasm; (B) desmoplastic medulloblastoma, characterized by nodular areas of densely packed, reticulin-rich cells, which show features of neuronal differentiation when stained with synaptophysin (not shown); <br />(C) large cell&nbsp;and (D)&nbsp;anaplastic medulloblastoma, with prominent and pleomorphic nuclei with large areas of necrosis and high mitotic rate.<br /><br />Of note, because nearly all large cell&nbsp;tumors also demonstrate&nbsp;an anaplastic component and both large cell and anaplastic tumors are associated with poor prognosis, large cell/anaplastic variant is&nbsp;a single combined category in the World Health&nbsp;Organization (WHO)&nbsp;classification system<SUP> [1]</SUP>.</div><div class=\"graphic_reference\">Reproduced from: Crawford J, MacDonald T, Packer R. Medulloblastoma in childhood: new biological advances. Lancet Neurol 2007; 6:1073. Illustration used with the permission of Elsevier Inc. All rights reserved.<br /><br />[1] WHO Classification of Tumours of the Central Nervous System, 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016.</div><div id=\"graphicVersion\">Graphic 88305 Version 2.0</div></div></div>"},"88332":{"type":"graphic_figure","displayName":"Incisions for lateral neck dissection","title":"Incisions for lateral neck dissection ","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Incisions for lateral neck dissection </div><div class=\"cntnt\"><img style=\"width:541px; height:558px;\" src=\"images/SURG/88332_Incisions_lateral_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Levels III and IV can usually be reached through a standard thyroidectomy incision or a slight extension of that traditional incision to the side of the neck dissection (A). For a more comprehensive neck dissection, the incision must be extended into the lateral neck, either along a skin crease (B) or with a superior \"hockey-stick\" extension either anterior or posterior to the sternocleidomastoid (C).&nbsp;Instead of using the superior extension of the main incision, some surgeons advocate using incision A and making a second counter incision high within the neck (also within a neck crease) in order to access level II adequately (D).&nbsp;</div><div id=\"graphicVersion\">Graphic 88332 Version 2.0</div></div></div>"},"88334":{"type":"graphic_movie","displayName":"Endoscopic ureterocele decompression","title":"Endoscopic ureterocele decompression of a right sided ureterocele with drainage of frank purulent material","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic ureterocele decompression of a right sided ureterocele with drainage of frank purulent material</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/88334_Endoureterocedecompvideo.mp4\" style=\"width:368px;height:224px\"></div><img style=\"width:313px; height:227px;\" src=\"images/PEDS/88334_Endoureterocedecompimg.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 88334 Version 1.0</div></div></div>"},"88346":{"type":"graphic_table","displayName":"Nonscarring alopecias","title":"Nonscarring alopecias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonscarring alopecias</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Epidemiology</td> <td class=\"subtitle1\">Clinical features on scalp</td> <td class=\"subtitle1\">Nonscalp involvement</td> <td class=\"subtitle1\">Pathology</td> <td class=\"subtitle1\">Hair pull test</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Focal hair loss</td> </tr> <tr> <td class=\"indent1\">Alopecia areata*</td> <td>Onset most common in childhood or young adulthood</td> <td>Round patches of nonscarring&nbsp;alopecia with exclamation point hairs; may extend to total hair loss on scalp (alopecia totalis) or loss of all body hair (alopecia universalis); uncommon is a diffuse hair loss presentation</td> <td>Other hair-bearing sites may be affected, nail pitting, trachyonychia</td> <td>Increased catagen/telogen hair follicles; peribulbar lymphocytic infiltrate resembling \"swarm of bees\" around anagen follicles&nbsp;in some cases; multiple miniaturized hair follicles; trichomalacia and pigment casts</td> <td>Positive hair pull test, telogen hairs and dystrophic anagen hairs</td> </tr> <tr> <td class=\"indent1\">Traction alopecia</td> <td>Individuals with chronic use of traction-inducing hairstyles</td> <td>Loss of terminal hairs in areas of traction; prolonged traction may lead to cicatricial alopecia</td> <td>N/A</td> <td> <p>Acute: increased catagen/telogen hairs, occasional pigment casts</p> Chronic: reduction in terminal hairs, occasional fibrous tracts, retained sebaceous glands</td> <td>Normal or positive with broken hair fibers</td> </tr> <tr> <td class=\"indent1\">Alopecia syphilitica</td> <td>Most common in young adults; occurs due to secondary syphilis</td> <td>Patchy hair loss, \"moth-eaten\" appearance</td> <td>Other mucocutaneous manifestations of secondary syphilis</td> <td>Increase in catagen/telogen follicles, perifollicular inflammation with plasma cells</td> <td>Positive for telogen hairs</td> </tr> <tr> <td class=\"indent1\">Temporal triangular alopecia</td> <td>Lifelong, usually detected in infancy or childhood</td> <td>Triangular or oval area with absent terminal hair in temporal region that is a few centimeters in diameter; vellus hairs visible on close inspection</td> <td>N/A</td> <td>Predominance of vellus hairs</td> <td>Normal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pressure-induced (postoperative) alopecia</td> <td>Most commonly seen in surgical patients</td> <td>Hair loss localized to area of prolonged pressure, such as the posterior scalp after prolonged general anesthesia</td> <td>N/A</td> <td>Nearly all hairs in catagen/telogen phase, trichomalacia<sup>&#182;</sup>, melanin in the collapsed outer root sheath, thrombosis, necrosis</td> <td>Normal or positive</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Patterned hair loss</td> </tr> <tr> <td class=\"indent1\">Male pattern hair loss (androgenetic alopecia in men)</td> <td>Most common in adult men, prevalence increases with age</td> <td>Slow, progressive terminal hair loss on the frontal, temporal, and/or vertex scalp</td> <td>N/A</td> <td>Marked variation in follicular size, increased proportion of vellus follicles, slight increase in telogen follicles, fibrous streamers beneath miniaturized hairs</td> <td>Generally normal; may be positive in areas of active hair loss</td> </tr> <tr> <td class=\"indent1\">Female pattern hair loss*</td> <td>Most common in adult women, prevalence increases with age</td> <td>Slow, progressive terminal hair loss and thinning on the crown of the scalp; frontal hairline is often relatively spared</td> <td>If related to hyperandrogenism, signs of hirsutism or virilization may be present</td> <td>Same as in male pattern hair loss</td> <td>Generally normal; may be positive in areas of active hair loss</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trichotillomania</td> <td>May occur in children and adults</td> <td>Broken hairs often distributed in a bizarre pattern</td> <td>May be associated with ingestion of hair and risk for trichobezoar</td> <td>Follicular distortion, pigment casts, trichomalacia<sup>&#182;</sup>, melanin pigment in collapsed root sheaths, fractured hairs, follicular hemorrhage</td> <td>Normal</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Diffuse hair loss*</td> </tr> <tr> <td class=\"indent1\">Telogen effluvium</td> <td>Women more likely to present for evaluation than men</td> <td>Acute or chronic diffuse hair thinning</td> <td>Findings associated with underlying cause may be present</td> <td>Increase in the proportion of telogen follicles (20 to 50% of follicles are in telogen)</td> <td>Positive in active phase; telogen hairs</td> </tr> <tr> <td class=\"indent1\">Anagen effluvium</td> <td>Seen in association with chemotherapy, radiation, toxins</td> <td>Acute loss of hair</td> <td>Findings associated with underlying cause may be present; hair loss in other sites</td> <td>Increased proportion of telogen follicles, dystrophic anagen hairs; rare cases of permanent hair loss may demonstrate linear basaloid structures</td> <td>Positive in active phase, dystrophic anagen hairs or broom-shaped anagen hairs with a pigmented bulb</td> </tr> <tr> <td class=\"indent1\">Loose anagen syndrome</td> <td>Affects children; most common in girls; often those with&nbsp;blond hair</td> <td>Hair is easily dislodged from follicles without pain; hair density appears normal or reduced</td> <td>May be solitary or associated with developmental defects</td> <td>Dystrophic anagen hairs</td> <td>Very positive; majority of hairs are anagen hairs with a ruffled cuticle and absent inner root sheath</td> </tr> <tr> <td class=\"indent1\">Atrichia with papular lesions</td> <td>Autosomal dominant disorder, presents in infancy</td> <td>Hair normal at birth, hair loss in infancy due to abnormality in first hair cycle (defect in catagen phase); papular follicular cysts develop later</td> <td>Hair loss and follicular cysts in other sites</td> <td>Absence of mature hair follicles, cysts present</td> <td>Normal; may be positive in initial stages</td> </tr> <tr> <td class=\"indent1\">Hypotrichosis simplex</td> <td>Group of hypotrichosis disorders; usually autosomal dominant</td> <td>Usually progressive loss of scalp hair during childhood</td> <td>May or may not have involvement of other hair-bearing sites</td> <td>Reduced number of follicles, follicular miniaturization</td> <td>Normal</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Alopecia areata and female pattern hair loss occasionally present with diffuse hair loss.<br />¶ Trichomalacia is a histologic finding of distortion of the hair shaft and extruded pigment that results from repeated hair plucking or other injury.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Otberg N, Shapiro J. Hair growth disorders. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al. (Eds), McGraw Hill 2012.</li>&#xD;&#xA;    <li>Childs JM, Sperling LC. Histopathology of scarring and nonscarring hair loss. Dermatol Clin 2013; 31:43.</li>&#xD;&#xA;    <li>Michailidis E, Theos A, Zlotogorski A, et al. Atrichia with papular lesions resulting from novel compound heterozygous mutations in the human hairless gene. Pediatr Dermatol 2007; 24:E79.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 88346 Version 5.0</div></div></div>"},"88347":{"type":"graphic_table","displayName":"Cicatricial alopecias","title":"Cicatricial (scarring) alopecias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cicatricial (scarring) alopecias</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Epidemiology</td> <td class=\"subtitle1\">Clinical features on scalp</td> <td class=\"subtitle1\">Nonscalp involvement</td> <td class=\"subtitle1\">Pathology</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Lymphocytic primary cicatricial alopecias</td> </tr> <tr> <td class=\"indent1\">Discoid lupus erythematosus</td> <td>Onset usually in young adulthood; more common in women than men; may occur independently or in patients with SLE</td> <td>Erythematous, atrophic plaques with follicular plugging present centrally, hyperpigmentation, and/or hypopigmentation</td> <td>Face, ears, and other sites may be affected; a minority of cases are associated with SLE</td> <td>Interface dermatitis, epidermal atrophy, follicular plugging, basement membrane thickening, perifollicular superficial and deep lymphoplasmacytic infiltrate; DIF shows IgG, IgM, and C3 at the BMZ</td> </tr> <tr> <td class=\"indent1\">Lichen planopilaris</td> <td>Most common in Caucasian and East Indian women</td> <td>Areas of scarring and follicles with erythema and scale; itching and pain may be severe</td> <td>May be accompanied by cutaneous, nail, or mucous membrane lichen planus</td> <td>Lichenoid infiltrate around the isthmus and infundibulum, interface dermatitis, concentric lamellar fibroplasia</td> </tr> <tr> <td class=\"indent1\">Frontal fibrosing alopecia</td> <td>Mostly postmenopausal women</td> <td>Perifollicular erythema, follicular hyperkeratosis, band-like frontal alopecia</td> <td>Loss of eyebrows common, papules on face</td> <td>Lichenoid infiltrate around the isthmus and infundibulum, apoptotic keratinocytes in outer root sheath, concentric lamellar fibroplasia</td> </tr> <tr> <td class=\"indent1\">Classic pseudopelade of Brocq</td> <td>Most common in middle-aged women</td> <td>Skin-colored scarred plaques resembling \"footprints in the snow\"</td> <td>N/A</td> <td>Lymphocytic infiltrate around infundibulum, concentric lamellar fibroplasia around follicles in later lesions</td> </tr> <tr> <td class=\"indent1\">Central centrifugal cicatricial alopecia</td> <td>Most common in women of African origin</td> <td>Patch of scarring alopecia on crown of scalp that progresses centrifugally</td> <td>N/A</td> <td>Premature desquamation of the inner root sheath, loss of sebaceous glands, variable perifollicular chronic inflammation at isthmus and infundibulum, concentric lamellar fibroplasia</td> </tr> <tr> <td class=\"indent1\">Alopecia mucinosa</td> <td>May be associated with mycosis fungoides or CTCL</td> <td>Erythematous or skin-colored indurated plaques with alopecia, follicular papules</td> <td>Eyebrow involvement may be present</td> <td>Mucin deposits in outer root sheath, eventual replacement of follicles by mucin, lymphocytic infiltrate</td> </tr> <tr> <td class=\"indent1\">Keratosis folliculars spinulosa decalvans</td> <td>X-linked inheritance of mutation in the <em>MBTPS2</em> gene; less commonly autosomal dominant transmission</td> <td>Noninflammatory, hyperkeratotic follicular papules and progressive hair loss</td> <td>Eyebrow and eyelash involvement may be present, photophobia</td> <td>Follicular plugging and hypergranulosis, primarily lymphocytic perifollicular infiltrate, fibrosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Neutrophilic primary cicatricial alopecias</td> </tr> <tr> <td class=\"indent1\">Dissecting cellulitis of the scalp</td> <td>Most common in young black men</td> <td>Inflammatory papules, pustules, fluctuant nodules, abscesses; may also have keloidal scarring</td> <td>May be associated with hidradenitis suppurativa and acne conglobata</td> <td>Follicular occlusion, intrafollicular and perifollicular neutrophilic and lymphoplasmacytic&nbsp;infiltrate; follicular perforation, deep abscesses and sinus tracts in later stages</td> </tr> <tr> <td class=\"indent1\">Folliculitis decalvans</td> <td>Most common in young and middle-aged adults, particularly men</td> <td>Patches of alopecia, erythematous follicular papules, pustules, follicular hyperkeratosis, tufted folliculitis</td> <td>N/A</td> <td>Interfollicular and perifollicular neutrophilic infiltrate; mixed infiltrate, granulomas, and fibrosis in later lesions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Mixed primary cicatricial alopecias</td> </tr> <tr> <td class=\"indent1\">Acne keloidalis nuchae</td> <td>Most common in young black men</td> <td>Dome-shaped papules and pustules on the occipital scalp and nape of the neck; keloids may develop</td> <td>N/A</td> <td>Neutrophilic or lymphoplasmacytic inflammatory infiltrate around the isthmus and infundibulum; granulomatous infiltrate may also be present; marked fibrosis</td> </tr> <tr> <td class=\"indent1\">Acne necrotica</td> <td>Usually occurs in adults</td> <td>Umbilicated, pruritic, painful papules that undergo central necrosis and resolve with varioliform scars</td> <td>N/A</td> <td>Infundibular folliculitis with necrosis, lymphocytic or mixed inflammatory infiltrate</td> </tr> <tr> <td class=\"indent1\">Erosive pustular dermatosis of the scalp</td> <td>Most common in older adults, particularly women</td> <td>Pustules, erosions, and crusted plaques</td> <td>N/A</td> <td>Nonspecific early findings; older lesions with a chronic mixed inflammatory infiltrate and fibrosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Other</td> </tr> <tr> <td class=\"indent1\">Tinea capitis</td> <td>Usually affects children</td> <td>Scaly patches or plaques; kerion may develop</td> <td>Tinea corporis may be present</td> <td>Perifollicular inflammation and fungal elements within or around the hair shaft</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SLE: systemic lupus erythematosus; DIF: direct immunofluorescence; IgG: immunoglobulin G; IgM: immunoglobulin M; BMZ: basement membrane zone; CTCL: cutaneous T cell lymphoma.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Otberg N, Shapiro J. Hair growth disorders. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al. (Eds), McGraw Hill 2012.</li>&#xD;&#xA;    <li>Childs JM, Sperling LC. Histopathology of scarring and nonscarring hair loss. Dermatol Clin 2013; 31:43.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 88347 Version 4.0</div></div></div>"},"88371":{"type":"graphic_table","displayName":"Indications for clozapine in major guidelines","title":"Indications for clozapine in major guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for clozapine in major guidelines</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Guidelines</td> <td class=\"subtitle1\">Use for treatment refractoriness</td> <td class=\"subtitle1\">Specific clinical features</td> </tr> <tr class=\"divider_bottom\"> <td>American Psychiatric Association<sup>[1]</sup></td> <td>Persistent psychotic symptoms after 2 antipsychotic trials - \"<em>should be given strong consideration</em>\"</td> <td> <p>Persistent hostility, aggressive behavior</p> <p>Persistent suicidal ideation</p> Tardive dyskinesia</td> </tr> <tr class=\"divider_bottom\"> <td>Schizophrenia Patient Outcomes Research Team<sup>[2]</sup></td> <td>Persistent and clinically significant positive symptoms after &#8805;2 antipsychotic trials (including &#8805;1 second-generation antipsychotic) - \"<em>should be used</em>\"</td> <td> <p>Persistent hostility/violent behaviors - \"<em>should be used</em>\"</p> <p>Marked and persistent suicidal ideation/behaviors - \"<em>should be offered</em>\"</p> Neuroleptic malignant syndrome, persistent dystonia/severe or very distressing tardive dyskinesia - \"<em>should be offered</em>\"</td> </tr> <tr class=\"divider_bottom\"> <td>Texas Medication Algorithm Project<sup>[3]</sup></td> <td>No-response or partial response to 2 antipsychotic trials (including &#8805;1 second-generation antipsychotic)</td> <td> <p>History of recurrent suicidality, violence or comorbid substance abuse - \"<em>consider earlier trial</em>\"</p> <p>Persistent positive symptoms &#62;2 years - \"<em>warrants</em>\"</p> Persistent positive symptoms &#62;5 years - \"<em>requires</em>\" clozapine trial independent of number of AP trials</td> </tr> <tr class=\"divider_bottom\"> <td>Canadian Psychiatric Association<sup>[4]</sup></td> <td>No response to antipsychotic trials from 2 classes</td> <td> <p>Persistent suicidal ideation/behaviors - \"<em>should be considered</em>\"</p> Persistent aggressivity - \"<em>may be helped by</em>\"</td> </tr> <tr> <td>National Institute for Health and Clinical Excellence (NICE)<sup>[5]</sup></td> <td>Sequential use of &#8805;2 antipsychotics (including &#8805;1 second-generation antipsychotic)</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161:1.</LI>&#xD;&#xA;<LI>Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophr Bull 2010; 36:71.</LI>&#xD;&#xA;<LI>Argo TR, Crismon ML, Miller AL, et al. Texas Medication Algorithm Project Procedural Manual: Schizophrenia Algorithm. Austin, Texas: Texas Department of State Health Services; 2008.</LI>&#xD;&#xA;<LI>Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 2005; 50:7S.</LI>&#xD;&#xA;<LI>National Institute for Health and Clinical Excellence. Schizophrenia: Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care, 2009 [accessed 2012 August 15th 2012]. Available from: <A href=\"https://www.nice.org.uk/guidance/cg82/documents/schizophrenia-update-draft-nice-guideline-for-consultation2\">https://www.nice.org.uk/guidance/cg82/documents/schizophrenia-update-draft-nice-guideline-for-consultation2</A>.</LI></OL></div><div id=\"graphicVersion\">Graphic 88371 Version 6.0</div></div></div>"},"88376":{"type":"graphic_table","displayName":"Factors used to calculate KDPI","title":"Factors used to calculate the kidney donor profile index (KDPI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors used to calculate the kidney donor profile index (KDPI)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Donor age</td> </tr> <tr> <td>Donor race/ethnicity</td> </tr> <tr> <td>Hypertension in donor</td> </tr> <tr> <td>Diabetes in donor</td> </tr> <tr> <td>Donor height and weight</td> </tr> <tr> <td>Donor serum creatinine</td> </tr> <tr> <td>Cause of death of donor</td> </tr> <tr> <td>HBV or HCV in donor</td> </tr> <tr> <td>Donation after cardiac death</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of John Vella, MD, FACP, FRCP, FASN.</div><div id=\"graphicVersion\">Graphic 88376 Version 1.0</div></div></div>"},"88377":{"type":"graphic_figure","displayName":"Balloon valvuloplasty in pulmonic stenosis","title":"Balloon valvuloplasty in pulmonic stenosis","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Balloon valvuloplasty in pulmonic stenosis</div><div class=\"cntnt\"><img style=\"width:492px; height:590px;\" src=\"images/CARD/88377_Balloo_valvul_pulm_stenos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Percutaneous balloon valvuloplasty for typical pulmonic valvular stenosis is an effective and safe procedure for those with moderate to severe stenosis. A balloon cathether is shown positioned across the stenotic pulmonic valve. The balloon is inflated to dilate the pulmonic valve opening. The cross-sectional image on the left shows obstruction of the pulmonic valve orifice prior to the valvuloplasty.</div><div class=\"graphic_reference\">Reproduced with permission from: LifeART. Copyright © 2013 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88377 Version 1.0</div></div></div>"},"88379":{"type":"graphic_picture","displayName":"Nexplanon PI","title":"Nexplanon implant","html":"<div class=\"graphic\"><div style=\"width: 638px\" class=\"figure\"><div class=\"ttl\">Nexplanon implant</div><div class=\"cntnt\"><img style=\"width:618px; height:447px;\" src=\"images/PI/88379_Nexplanon_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nexplanon is one brand of birth control implant. It is implanted into the arm. While there it delivers hormones into the body that help prevent pregnancy.</div><div class=\"graphic_reference\">NEXPLANON&reg; image reproduced with permission of Merck Sharp &amp; Dohme B.V., a subsidiary of Merck &amp; Co., Inc., Whitehouse Station, New Jersey, USA. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88379 Version 2.0</div></div></div>"},"88386":{"type":"graphic_picture","displayName":"Ardnt wire-guided endobronchial blocker","title":"Ardnt wire-guided endobronchial blocker","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Ardnt wire-guided endobronchial blocker</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/ANEST/88386_Arndt_wire_endo_blocker.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Ardnt bronchial blocker has a loop extending out of the distal end of the blocker which is passed over a fiberoptic bronchoscope to guide endobronchial placement.</div><div class=\"graphic_reference\">Permission for use granted by Cook Medical Incorporated, Bloomington, Indiana.</div><div id=\"graphicVersion\">Graphic 88386 Version 1.0</div></div></div>"},"88387":{"type":"graphic_picture","displayName":"Cohen tip-deflecting endobronchial blocker","title":"Cohen tip-deflecting endobronchial blocker","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Cohen tip-deflecting endobronchial blocker</div><div class=\"cntnt\"><img style=\"width:576px; height:576px;\" src=\"images/ANEST/88387_Cohen_tip_endobron_bl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Cohen tip-deflecting bronchial blocker (Cook Critical Care, Bloomington, IN). This blocker has a wheel on the proximal end of the blocker (lower arrow) that is <SPAN style=\"COLOR: black\">turned</SPAN> to cause the distal tip of the blocker (upper arrow) to deflect and aid in bronchial placement.</div><div class=\"graphic_reference\">Permission for use granted by Cook Medical Incorporated, Bloomington, Indiana.</div><div id=\"graphicVersion\">Graphic 88387 Version 2.0</div></div></div>"},"88388":{"type":"graphic_picture","displayName":"Fuji Univent","title":"Fuji Univent","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fuji Univent</div><div class=\"cntnt\"><img style=\"width:504px; height:461px;\" src=\"images/ANEST/88388_Fujiunivent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Univent bronchial blocker (Fuji Systems, Tokyo, Japan). This endotracheal tube has an internal channel which contains a bronchial blocker.</div><div id=\"graphicVersion\">Graphic 88388 Version 2.0</div></div></div>"},"88389":{"type":"graphic_picture","displayName":"Fuji Uniblocker","title":"Fuji Uniblocker","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fuji Uniblocker</div><div class=\"cntnt\"><img style=\"width:504px; height:442px;\" src=\"images/ANEST/88389_Fuji_uniblocker.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Uniblocker bronchial blocker (Fuji Systems, Tokyo, Japan). This blocker is similar to the blocker of the Univent tube but it is designed to be placed through a standard single-lumen endotracheal tube. It has a fixed \"hockey-stick\" bend on the distal lumen that can be rotated to advance the blocker into the desired mainstem bronchus. The proximal end of the blocker is seen passing through the connector which is connected to the anesthetic circuit and has a port for a fiberoptic bronchoscope to aid positioning.</div><div id=\"graphicVersion\">Graphic 88389 Version 1.0</div></div></div>"},"88390":{"type":"graphic_picture","displayName":"Rusch EZ-Blocker","title":"Rusch EZ-Blocker","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Rusch EZ-Blocker</div><div class=\"cntnt\"><img style=\"width:586px; height:244px;\" src=\"images/ANEST/88390_Rusch_EZ_Blocker.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Rusch EZ-Blocker is a bifurcated blocker that is positioned with one cuff in each mainstem bronchus.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright © 2013 Teleflex Incorporated.</div><div id=\"graphicVersion\">Graphic 88390 Version 1.0</div></div></div>"},"88391":{"type":"graphic_picture","displayName":"Single lumen endobronchial tube","title":"Single lumen endobronchial tube","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Single lumen endobronchial tube</div><div class=\"cntnt\"><img style=\"width:514px; height:199px;\" src=\"images/ANEST/88391_Singl_lum_endobron_tube.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph of the Phycon single-lumen endotracheal/endobronchial tube, above a standard endotracheal tube (Fuji Systems, Tokyo, Japan) (A).&nbsp;To the right, a photograph of&nbsp;the distal end of the tube with a 12 cc syringe for comparison (B). This long (36 cm) single-lumen tube has a short cuff and does not have a Murphy eye. This increases the margin of safety when these tubes are positioned in the mainstem bronchus for one-lung ventilation. The cuff can be inflated to function as an endotracheal tube&nbsp;or&nbsp;advanced over a fiberoptic bronchoscope into the mainstem bronchus as needed.</div><div id=\"graphicVersion\">Graphic 88391 Version 1.0</div></div></div>"},"88393":{"type":"graphic_table","displayName":"ROHHADNET syndrome","title":"Clinical manifestations of ROHHADNET syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of ROHHADNET syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Percent of cases<sup>[1-3]</sup></td> <td class=\"subtitle1\">Typical age of onset<sup>[2]</sup>&nbsp;</td> </tr> <tr> <td colspan=\"2\"><strong>Hypothalamic endocrine manifestations</strong></td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Early and rapid onset obesity</td> <td class=\"centered\"><strong>100</strong></td> <td class=\"centered\">3 to 7&nbsp;years</td> </tr> <tr> <td class=\"indent1\">Deceleration of growth rate</td> <td class=\"centered\">38</td> <td class=\"centered\">5 to 14 years&nbsp;</td> </tr> <tr> <td class=\"indent1\">Failed growth hormone stimulation test</td> <td class=\"centered\"><strong>62</strong></td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Adrenal insufficiency</td> <td class=\"centered\">29</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Cushing's syndrome</td> <td class=\"centered\">5</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Hypernatremia*</td> <td class=\"centered\"><strong>62</strong></td> <td class=\"centered\">2 to 12 years&nbsp;&nbsp;</td> </tr> <tr> <td class=\"indent1\">Diabetes insipidus</td> <td class=\"centered\">24</td> <td class=\"centered\">2 to 12 years&nbsp;&nbsp;</td> </tr> <tr> <td class=\"indent1\">Hyperprolactinemia</td> <td class=\"centered\">52</td> <td class=\"centered\">4 to 12 years&nbsp;</td> </tr> <tr> <td class=\"indent1\">Hypogonadotropic hypogonadism</td> <td class=\"centered\">43</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Precocious puberty</td> <td class=\"centered\">10</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Respiratory manifestations</strong><sup>&#182;</sup></td> <td class=\"centered\"><strong>100</strong></td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cardiorespiratory arrest</td> <td class=\"centered\">57</td> <td class=\"centered\">3 to 8&nbsp;years&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Autonomic dysregulation<sup>&#916;</sup></strong></td> <td class=\"centered\">52</td> <td class=\"centered\">3&nbsp;to&nbsp;13 years&nbsp;</td> </tr> <tr> <td><strong>Tumors of neural crest origin</strong></td> <td class=\"centered\">52</td> <td class=\"centered\">3&nbsp;to 7 years&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Adrenal ganglioneuroma</td> <td class=\"centered\">29</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Neurobehavioral disorders</strong></td> <td class=\"centered\">48</td> <td class=\"centered\">median 4.8 years&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ROHHADNET: rapid onset obesity, hypothalamic dysfunction, hypoventilation, autonomic dysregulation, and neural crest tumors; SD: standard deviations.<br />* In this case, hypernatremia was defined as consistent blood sodium concentrations of &gt;145 mEq/L (which is &gt;2 SD for age). Paradoxically, some patients have hyponatremia.<br />¶ Respiratory manifestations typically consist of hypercarbia and hypoxemia during wakefulness, sometimes associated with cyanotic episodes.<br />Δ Symptoms of autonomic dysfunction may include episodes of hypo- or hyperthermia (which may be life-threatening), or bradycardia.<SUP>[3]</SUP> </div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Bougneres P, Pantalone L, Linglart A, et al. Endocrine manifestations of the rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, and neural tumor syndrome in childhood. J Clin Endocrinol Metab 2008; 93 (10):3971-3980.</LI>&#xD;&#xA;<LI>Ize-Ludlow D, Gray JA, Sperling MA, et al. Rapid onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation presenting in childhood. Pediatrics 2007; 120:e179.</LI>&#xD;&#xA;<LI>Chow C, Fortier MV, Das L, et al. Rapid-Onset Obesity With Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD) Syndrome May Have a Hypothalamus-Periaqueductal Gray Localization. Pediatr Neurol 2015; 52:521.</LI></OL></div><div id=\"graphicVersion\">Graphic 88393 Version 5.0</div></div></div>"},"88409":{"type":"graphic_diagnosticimage","displayName":"Supravalvar aortic stenosis catheter angiogram","title":"Supravalvar aortic stenosis catheter angiogram","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Supravalvar aortic stenosis catheter angiogram</div><div class=\"cntnt\"><img style=\"width:580px; height:590px;\" src=\"images/PEDS/88409_Supra_aortic_sten_cath_angi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Discrete supravalvar aortic stenosis in a patient with Williams syndrome. This catheter angiogram in an anteroposterior projection with contrast injection in the aortic root demonstrates the typical discrete narrowing of the ascending aorta at the sinotubular junction (arrow), just above the aortic sinuses of Valsalva. This angiogram is also clinically useful to exclude the more severe manifestations of the aortopathy seen with Williams syndrome, demonstrating no stenoses of the coronary artery origins, proximal brachiocephalic vessels, or hypoplasia/coarctation of the thoracic aorta.</div><div class=\"graphic_reference\">Reproduced with permission from: Brown DW, Fulton DR. Congenital heart disease in children and adolescents. In: Hurst's the Heart, 13th ed, Fuster V, Walsh RA, Harrington RA (Eds), McGraw-Hill, New York 2011. Copyright &copy; 2011 McGraw-Hill Education. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88409 Version 2.0</div></div></div>"},"88410":{"type":"graphic_diagnosticimage","displayName":"PCP x-ray and BAL","title":"Radiographic and bronchoalveolar lavage features of <em>Pneumocystis</em> pneumonia (PCP)","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Radiographic and bronchoalveolar lavage features of <em>Pneumocystis</em> pneumonia (PCP)</div><div class=\"cntnt\"><img style=\"width:455px; height:575px;\" src=\"images/ID/88410_PCP_x_ray_and_BAL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with acquired immunodeficiency syndrome (AIDS) who develop PCP typically present with a cough, fever, and exertional dyspnea. A chest radiograph (panel A) characteristically has interstitial and alveolar infiltrates in a perihilar distribution. In AIDS patients, BAL demonstrates the associated inflammatory cell burden, rich in lymphocytes (CD8+ T cells) and macrophages, with a relative paucity of neutrophils (see the Wright-Giemsa stained smear in panel B). A methenamine silver stained smear of BAL fluid from patients with AIDS (panel C) reveals abundant numbers of <em>Pneumocystis</em> cyst forms. In immunocompromised patients without AIDS, PCP has a more fulminant onset and can rapidly progress to respiratory failure. The chest radiograph from such patients (panel D) usually has diffuse lung infiltrates in a pattern that is consistent with severe lung injury, whereas the BAL fluid (see the Wright-Giemsa stained smear in panel E) has an abundance of inflammatory cells, particularly neutrophils. A methenamine silver stain of the BAL fluid (panel F) again demonstrates cyst forms, although usually significantly fewer than in patients with AIDS (compare with panel C).</div><div class=\"graphic_footnotes\">BAL: bronchoalveolar lavage.</div><div class=\"graphic_reference\">Adapted with permission from Macmillan Publishers Ltd: Nature Reviews Microbiology. Thomas CF Jr, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 2007; 5:298. Copyright &copy; 2007. <a href=\"http://www.nature.com/nrmicro\" target=\"_blank\">www.nature.com/nrmicro</a>.</div><div id=\"graphicVersion\">Graphic 88410 Version 4.0</div></div></div>"},"88411":{"type":"graphic_table","displayName":"daEPOCH-R for non-Hodgkin lymphoma","title":"Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (daEPOCH-R) for non-Hodgkin lymphoma<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (daEPOCH-R) for non-Hodgkin lymphoma<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Rituximab</td> <td>375 mg/m<sup>2</sup> IV</td> <td>Dilute in normal saline (NS) or 5% dextrose in water (D5W) to a final concentration of 1 to 4 mg/mL. Initial infusion: Start at 50 mg/hour; escalate in 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated.<sup>[2]</sup> In the absence of an initial infusion reaction, for subsequent infusions, administer 20% of the total dose over the first 30 minutes and the remaining 80% over 60 minutes, as tolerated. The 90-minute infusion schedule should NOT be used in patients who have clinically significant cardiovascular disease or have a circulating lymphocyte count &#8805;5000/microL.*</td> <td>Day 0 or 1</td> </tr> <tr> <td>Etoposide</td> <td>50 mg/m<sup>2</sup> per day IV</td> <td rowspan=\"3\">Dilute a 24-hour supply of etoposide, doxorubicin, and vincristine in 500 mL NS and administer as continuous infusion over 24 hours per day through central venous line. Solution must be protected from light to maintain stability.</td> <td rowspan=\"3\">Days 1 to 4 (96 hours)</td> </tr> <tr> <td>Doxorubicin</td> <td>10 mg/m<sup>2</sup> per day IV</td> </tr> <tr> <td>Vincristine</td> <td>0.4 mg/m<sup>2</sup> per day IV (dose not capped)</td> </tr> <tr> <td>Cyclophosphamide</td> <td>750 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL NS or D5W and administer over 30 minutes.</td> <td>Day 5</td> </tr> <tr> <td>Prednisone</td> <td>60 mg/m<sup>2</sup> orally twice daily</td> <td>Administer first dose 30 minutes prior to chemotherapy on day 1.</td> <td>Days 1 to 5</td> </tr> <tr class=\"divider_bottom\"> <td>Granulocyte colony-stimulating factor</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Start day 6</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE. </li> <li>Refer to UpToDate topics on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with acetaminophen and diphenhydramine, with or without an H2 receptor blocker, 30 minutes prior to at least the first and second infusions of rituximab.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin and vincristine are vesicants; avoid extravasation. Etoposide is an irritant. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with hematopoietic growth factors is an essential component of this regimen. Regular or pegylated granulocyte colony-stimulating factor may be used according to center policy. In addition, due to the risk of developing <em>Pneumocystis jiroveci</em> pneumonia and other opportunistic infections, consider the use of antimicrobial prophylaxis.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Adjustment of initial cyclophosphamide, doxorubicin, etoposide, and vincristine doses may be needed for preexisting liver dysfunction.<sup>[3-6]</sup> In addition, dose adjustment of etoposide and cyclophosphamide may be required for renal dysfunction. </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hepatitis screening</strong></td> <td colspan=\"3\"> <ul> <li>Patients should be screened for hepatitis B and C prior to starting rituximab, and, if positive, considered for antiviral prophylaxis. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cardiac screening</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin is associated with cardiomyopathy, the incidence of which is related to cumulative dose. Assess baseline LVEF prior to initiation of therapy. Dose alterations should be considered for LVEF &#60;50%, and doxorubicin therapy is contraindicated in patients with LVEF &#60;30% at initiation, those with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin or any other anthracyclines. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Central nervous system (CNS) prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>The need for CNS prophylaxis is determined based upon the aggressiveness of the tumor reflected in the histology, organ involvement, and presence or absence of high risk features. </li> <li>Refer to UpToDate topic on \"Secondary involvement of the CNS by non-Hodgkin lymphoma\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>HIV screening</strong></td> <td colspan=\"3\"> <ul> <li>Patients should be screened for HIV prior to starting therapy. Consider reducing the initial dose of cyclophosphamide to 187 mg/m<sup>2</sup> if CD4 &#60;100/microL at diagnosis.<sup>[7]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Vincristine may cause constipation, and in severe cases, paralytic ileus. A routine prophylactic regimen against constipation is recommended in all patients receiving vincristine. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count twice weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess basic metabolic panel (creatinine and electrolytes) and liver function prior to each subsequent treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor cumulative doxorubicin dose. Reassess LVEF periodically during daEPOCH-R therapy, as clinically indicated. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Carriers of hepatitis B or C should be monitored for clinical and laboratory signs of active infection during and following completion of therapy. Rituximab should be discontinued if reactivation occurs. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelosuppression</strong></td> <td colspan=\"3\"> <ul> <li>Each new cycle should be delayed until ANC is &#62;1000/microL and platelet count is &#62;100,000/microL. Doses of etoposide, doxorubicin, and cyclophosphamide are adjusted based upon the nadir ANC and platelet counts:<sup>[1]</sup> <ul> <li>If nadir ANC &#8805;500 cells/microL, increase doses by 20% over preceding cycle. </li> <li>If ANC &#60;500 cells/microL on one or two measurements, doses remain the same as preceding cycle. </li> <li>If ANC &#60;500 on &#8805;3 measurements or platelets &#60;25,000/microL on one measurement, doses reduced by 20% from preceding cycle. Doxorubicin and etoposide doses are not reduced below starting dose. </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neuropathy</strong></td> <td colspan=\"3\"> <ul> <li>Dose adjustment of vincristine may be necessary if the severity of neuropathy persists or worsens. No specific guidelines are available for dose adjustments. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Hepatic dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Dose adjustments of vincristine may be necessary in the setting of liver toxicity. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease for more information\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count; ANC: absolute neutrophil count.<br />* A subcutaneous formulation (rituximab-hyaluronidase) that uses a fixed dose and a shorter administration time is an acceptable alternative for patients who have tolerated at least one full dose of intravenous rituximab.<SUP>[8]</SUP> Dosing varies by histology and clinicians should refer to the US Prescribing Information for details.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Wilson WH, et al. Blood 2002; 99:2685.</LI>&#xD;&#xA;<LI>Rituximab injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed December 18, 2012).</LI>&#xD;&#xA;<LI>Cyclophosphamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed December 18, 2012).</LI>&#xD;&#xA;<LI>Doxorubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed December 18, 2012).</LI>&#xD;&#xA;<LI>Vincristine sulfate injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed December 18, 2012).</LI>&#xD;&#xA;<LI>Etoposide injection. United States Prescribing Information. US National Library of Medicine. (Available online at: www.dailymed.nlm.nih.gov, accessed December 18, 2012).</LI>&#xD;&#xA;<LI>Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 2010; 115:3008.</LI>&#xD;&#xA;<LI>Rituximab and hyaluronidase human injection for subcutaneous use. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed June 30, 2017).</LI></OL></div><div id=\"graphicVersion\">Graphic 88411 Version 14.0</div></div></div>"},"88412":{"type":"graphic_table","displayName":"Drugs causing erythroderma","title":"Drugs most frequently reported as cause of erythroderma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs most frequently reported as cause of erythroderma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>ACE inhibitors (enalapril, lisinopril)</td> </tr> <tr> <td>Allopurinol</td> </tr> <tr> <td>Bevacizumab</td> </tr> <tr> <td>Carbamazepine</td> </tr> <tr> <td>Chlorpromazine</td> </tr> <tr> <td>Dapsone</td> </tr> <tr> <td>Erythropoietin</td> </tr> <tr> <td>Gold salts</td> </tr> <tr> <td>Hydroxychloroquine</td> </tr> <tr> <td>Imatinib</td> </tr> <tr> <td>Isoniazid</td> </tr> <tr> <td>Penicillin</td> </tr> <tr> <td>Phenobarbital</td> </tr> <tr> <td>Phenytoin</td> </tr> <tr> <td>Piroxicam</td> </tr> <tr> <td>Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole)</td> </tr> <tr> <td>Retinoids (acitretin, isotretinoin)</td> </tr> <tr> <td>Streptomycin</td> </tr> <tr> <td>Sulfasalazine</td> </tr> <tr> <td>Terbinafine</td> </tr> <tr> <td>Thalidomide</td> </tr> <tr> <td>Trimethoprim/sulfamethoxazole</td> </tr> <tr> <td>Vancomycin</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme.</div><div class=\"graphic_reference\">Data from: Grant-Kels JM, Fedeles F, Rothe MJ. Exfoliative dermatitis. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith L, Katz S, Gilchrest B, et al (Eds), McGraw-Hill, 2012.</div><div id=\"graphicVersion\">Graphic 88412 Version 2.0</div></div></div>"},"88414":{"type":"graphic_diagnosticimage","displayName":"Ruptured abdominal aortic aneurysm laminated thrombus","title":"Ruptured abdominal aortic aneurysm laminated thrombus","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ruptured abdominal aortic aneurysm laminated thrombus</div><div class=\"cntnt\"><img style=\"width:598px; height:247px;\" src=\"images/RADIOL/88414_Rupt_abd_aort_aneu_thrombus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The non-contrast CT scan (A) shows contained rupture of a&nbsp;9 cm aortic aneurysm with layers of extraluminal high density acute hemorrhage (arrow) in the anterior pararenal space consistent with rupture. On the contrast study (B), the likely point of rupture is seen (arrow) adjacent to a small amount of extravasated contrast (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 88414 Version 1.0</div></div></div>"},"88419":{"type":"graphic_figure","displayName":"Invasive pneumococcal infections children 1994-2011","title":"Number of invasive pneumococcal infections, eight children's hospitals (United States), 1994-2011","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Number of invasive pneumococcal infections, eight children's hospitals (United States), 1994-2011</div><div class=\"cntnt\"><img style=\"width:522px; height:302px;\" src=\"images/PEDS/88419_Invpneuinfectchild9411.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Number of invasive pneumococcal infections in children among eight children's hospitals by study years, 1994-2011. PCV13 was introduced in 2010. The total annual admissions among the eight hospitals over the last three study years were 111,969 (2009), 114,615 (2010), and 118,077 (2011).</div><div class=\"graphic_footnotes\">PCV7: 7-valent pneumococcal conjugate vaccine; PCV13: 13-valent pneumococcal conjugate vaccine.</div><div class=\"graphic_reference\">Reproduced with permission from: Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32:203. DOI: <a href=\"http://journals.lww.com/pidj/Abstract/2013/03000/Early_Trends_for_Invasive_Pneumococcal_Infections.3.aspx\" target=\"_blank\">10.1097/INF.0b013e318275614b</a>. Copyright &copy; 2013 Wolters Kluwer Health, Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 88419 Version 6.0</div></div></div>"},"88420":{"type":"graphic_table","displayName":"Lymph node stations gastric cancer","title":"Lymph node stations gastric cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lymph node stations gastric cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Station</td> <td class=\"subtitle1\">Lymph node location</td> <td class=\"subtitle1\">Associated vessel</td> </tr> <tr> <td>1</td> <td>Right paracardial region of stomach</td> <td>First branch of ascending left gastric artery</td> </tr> <tr> <td>2</td> <td>Left paracardial region of stomach</td> <td>Esophagogastric branch of left subphrenic artery</td> </tr> <tr> <td>3a</td> <td>Lesser curvature</td> <td>Left gastric artery</td> </tr> <tr> <td>3b</td> <td>Lesser curvature</td> <td>2nd branch and distal part of the right gastric artery</td> </tr> <tr> <td>4sa</td> <td>Left greater curvature</td> <td>Short gastrics</td> </tr> <tr> <td>4sb</td> <td>Right greater curvature</td> <td>Left gastroepiploic artery</td> </tr> <tr> <td>4d</td> <td>Right greater curvature</td> <td>2nd branch and distal part of the right gastroepiploic artery</td> </tr> <tr> <td>5</td> <td>Suprapyloric</td> <td>1st branch and proximal part of the right gastric artery</td> </tr> <tr> <td>6</td> <td>Infrapyloric</td> <td>1st branch and proximal part of the right gastroepiploic artery</td> </tr> <tr> <td>7</td> <td>&nbsp;</td> <td>Left gastric artery</td> </tr> <tr> <td>8a</td> <td>Anteriosuperior</td> <td>Common hepatic artery</td> </tr> <tr> <td>8b</td> <td>Posterior</td> <td>Common hepatic artery</td> </tr> <tr> <td>9</td> <td>&nbsp;</td> <td>Celiac artery</td> </tr> <tr> <td>10</td> <td>Splenic hilum</td> <td>Splenic artery distal to pancreatic tail and at roots of short gastrics</td> </tr> <tr> <td>11p</td> <td>Along margin of pancreas</td> <td>Proximal splenic artery from origin to halfway from origin to pancreatic tail</td> </tr> <tr> <td>11d</td> <td>Along margin of pancreas</td> <td>Distal splenic artery from halfway from origin to pancreatic tail to end of pancreatic tail</td> </tr> <tr> <td>12a</td> <td>Hepatoduodenal ligament</td> <td>Proper hepatic artery from conflucence of the right and left hepatic ducts and upper border of the pancreas</td> </tr> <tr> <td>12b</td> <td>Hepatoduodenal ligament</td> <td>Along bile duct caudal half the conflucence of the right and left hepatic ducts and upper border of the pancreas</td> </tr> <tr> <td>12p</td> <td>Hepatoduodenal ligament</td> <td>Along portal vein caudal half the conflucence of the right and left hepatic ducts and upper border of the pancreas</td> </tr> <tr> <td>13</td> <td>Posterior surface of the head of the pancreas</td> <td>&nbsp;</td> </tr> <tr> <td>14V</td> <td>Root of the mesentery</td> <td>Superior mesenteric vein</td> </tr> <tr> <td>15</td> <td>Colonic</td> <td>Middle colic vessels</td> </tr> <tr> <td>16a1</td> <td>Paraaortic in diaphragmatic hiatus</td> <td>&nbsp;</td> </tr> <tr> <td>16a2</td> <td>Paraaortic</td> <td>Upper margin of the origin of the celiac artery and lower border of the left renal vein</td> </tr> <tr> <td>16b1</td> <td>Paraaortic</td> <td>Lower border of the left renal vein and upper border of the origin of the inferior mesenteric vein</td> </tr> <tr> <td>16b2</td> <td>Paraaortic</td> <td>Between the upper border of the origin of the inferior mesenteric artery and the aortic bifurcation</td> </tr> <tr> <td>17</td> <td>Anterior surface of the pancreatic head beneath the pancreatic sheath</td> <td>&nbsp;</td> </tr> <tr> <td>18</td> <td>Along the inferior border of the pancreatic body</td> <td>&nbsp;</td> </tr> <tr> <td>19</td> <td>Infradiaphragmatic</td> <td>Predominantly along the subphrenic artery</td> </tr> <tr> <td>20</td> <td>Paraesophageal in the diaphragmatic esophageal hiatus</td> <td>&nbsp;</td> </tr> <tr> <td>110</td> <td>Paraesophageal in the lower thorax</td> <td>&nbsp;</td> </tr> <tr> <td>111</td> <td>Supradiaphragmatic, separate from the esophagus</td> <td>&nbsp;</td> </tr> <tr> <td>112</td> <td>Posterior mediastinal, separate from the esophagus and the esophageal hiatus</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric cancer 2011 14:101. Copyright &copy; 2011; with kind permission from Springer Science + Business Media B.V.</div><div id=\"graphicVersion\">Graphic 88420 Version 4.0</div></div></div>"},"88421":{"type":"graphic_table","displayName":"Prev of palliative sed","title":"Prevalence of palliative sedation in the management of refractory symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of palliative sedation in the management of refractory symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Year</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">Place</td> <td class=\"subtitle1\">Percent sedated for refractory symptoms</td> <td class=\"subtitle1\">Reference</td> </tr> <tr> <td><strong>Ventafridda</strong></td> <td class=\"centered\">1990</td> <td class=\"centered\">120</td> <td>Home</td> <td class=\"centered\">52</td> <td class=\"centered\">1</td> </tr> <tr> <td><strong>Fainsinger</strong></td> <td class=\"centered\">1991</td> <td class=\"centered\">100</td> <td>Inpatient (IP)</td> <td class=\"centered\">16</td> <td class=\"centered\">2</td> </tr> <tr> <td><strong>Morita</strong></td> <td class=\"centered\">1996</td> <td class=\"centered\">143</td> <td>Hospice</td> <td class=\"centered\">43</td> <td class=\"centered\">3</td> </tr> <tr> <td><strong>Stone</strong></td> <td class=\"centered\">1997</td> <td class=\"centered\">115</td> <td>IP and home</td> <td class=\"centered\">26</td> <td class=\"centered\">4</td> </tr> <tr> <td><strong>Fainsinger</strong></td> <td class=\"centered\">1998</td> <td class=\"centered\">76</td> <td>IP hospice</td> <td class=\"centered\">30</td> <td class=\"centered\">5</td> </tr> <tr> <td><strong>Chiu</strong></td> <td class=\"centered\">2001</td> <td class=\"centered\">251</td> <td>IP palliative care</td> <td class=\"centered\">28</td> <td class=\"centered\">6</td> </tr> <tr> <td><strong>Muller Busch</strong></td> <td class=\"centered\">2002</td> <td class=\"centered\">548</td> <td>IP palliative care</td> <td class=\"centered\">14</td> <td class=\"centered\">7</td> </tr> <tr> <td><strong>Sykes</strong></td> <td class=\"centered\">2003</td> <td class=\"centered\">237</td> <td>Hospice</td> <td class=\"centered\">48</td> <td class=\"centered\">8</td> </tr> <tr> <td><strong>Morita</strong></td> <td class=\"centered\">2004</td> <td>&nbsp;</td> <td>Multicenter</td> <td class=\"centered\">&#60;10 to 50</td> <td class=\"centered\">9</td> </tr> <tr> <td><strong>Kohara</strong></td> <td class=\"centered\">2005</td> <td class=\"centered\">124</td> <td>IP palliative care</td> <td class=\"centered\">50</td> <td class=\"centered\">10</td> </tr> <tr> <td><strong>Vitetta</strong></td> <td class=\"centered\">2005</td> <td class=\"centered\">102</td> <td>Hospice</td> <td class=\"centered\">67</td> <td class=\"centered\">11</td> </tr> <tr> <td><strong>Rietjens</strong></td> <td class=\"centered\">2008</td> <td class=\"centered\">157</td> <td>IP palliative care</td> <td class=\"centered\">43</td> <td class=\"centered\">12</td> </tr> <tr> <td><strong>Maltoni</strong></td> <td class=\"centered\">2009</td> <td class=\"centered\">518</td> <td>Multicenter</td> <td class=\"centered\">25</td> <td class=\"centered\">13</td> </tr> <tr> <td><strong>Mercendante</strong></td> <td class=\"centered\">2009</td> <td class=\"centered\">77</td> <td>IP palliative care</td> <td class=\"centered\">54</td> <td class=\"centered\">14</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Ventafridda V, Ripamonti C, De Conno F, et al. Symptom prevalence and control during cancer patients' last days of life. J Palliat Care 1990; 6:7.</li>&#xD;&#xA;    <li>Fainsinger R, Miller MJ, Bruera E, et al. Symptom control during the last week of life on a palliative care unit. J Palliat Care 1991; 7:5.</li>&#xD;&#xA;    <li>Morita T, Inoue S, Chihara S. Sedation for symptom control in Japan: the importance of intermittent use and communication with family members. J Pain Symptom Manage 1996; 12:32.</li>&#xD;&#xA;    <li>Stone P, Phillips C, Spruyt O, Waight C. A comparison of the use of sedatives in a hospital support team and in a hospice. Palliat Med 1997; 11:140.</li>&#xD;&#xA;    <li>Fainsinger RL, Landman W, Hoskings M, Bruera E. Sedation for uncontrolled symptoms in a South African hospice. J Pain Symptom Manage 1998; 16:145.</li>&#xD;&#xA;    <li>Chiu TY, Hu WY, Lue BH, et al. Sedation for refractory symptoms of terminal cancer patients in Taiwan. J Pain Symptom Manage 2001; 21:467.</li>&#xD;&#xA;    <li>Muller-Busch HC, Andres I, Jehser T. Sedation in palliative care - a critical analysis of 7 years experience. BMC Palliat Care 2003; 2:2.</li>&#xD;&#xA;    <li>Sykes N, Thorns A. Sedative use in the last week of life and the implications for end-of-life decision making. Arch Intern Med 2003; 163:341.</li>&#xD;&#xA;    <li>Morita T. Differences in physician-reported practice in palliative sedation therapy. Support Care Cancer 2004; 12:584.</li>&#xD;&#xA;    <li>Kohara H, Ueoka H, Takeyama H, et al. Sedation for terminally ill patients with cancer with uncontrollable physical distress. J Palliat Med 2005; 8:20.</li>&#xD;&#xA;    <li>Vitetta L, Kenner D, Sali A. Sedation and analgesia-prescribing patterns in terminally ill patients at the end of life. Am J Hosp Palliat Care 2005; 22:465.</li>&#xD;&#xA;    <li>Rietjens JA, van Zuylen L, van Veluw H, et al. Palliative sedation in a specialized unit for acute palliative care in a cancer hospital: comparing patients dying with and without palliative sedation. J Pain Symptom Manage 2008; 36:228.</li>&#xD;&#xA;    <li>Maltoni M, Pittureri C, Scarpi E, et al. Palliative sedation therapy does not hasten death: results from a prospective multicenter study. Ann Oncol 2009; 20:1163.</li>&#xD;&#xA;    <li>Mercadante S, Intravaia G, Villari P, et al. Controlled sedation for refractory symptoms in dying patients. J Pain Symptom Manage 2009; 37:771.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 88421 Version 3.0</div></div></div>"},"88422":{"type":"graphic_figure","displayName":"Lymph node drainage of the stomach","title":"Lymph node drainage of the stomach","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Lymph node drainage of the stomach</div><div class=\"cntnt\"><img style=\"width:535px; height:640px;\" src=\"images/SURG/88422_Lymph_node_drainage_stomach.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lymph node drainage of the stomach is depicted in the figure. The labels correspond to the lymph node stations as classified by the&nbsp;Japanese Gastric Cancer Association.</div><div class=\"graphic_reference\">Japanese classification of gastric carcinoma: 3rd English edition. Gastric cancer 2011 14:101.</div><div id=\"graphicVersion\">Graphic 88422 Version 1.0</div></div></div>"},"88423":{"type":"graphic_table","displayName":"Meds for palliative sed","title":"Medications used for palliative sedation in patients with refractory symptoms at end of life*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications used for palliative sedation in patients with refractory symptoms at end of life*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Pharmacology</td> <td class=\"subtitle1\">Dosing (adult)</td> <td class=\"subtitle1\">Role in palliative sedation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Benzodiazepines</td> </tr> <tr> <td class=\"indent1\">Midazolam</td> <td> <p>Short-acting GABA<sub>A</sub> agonist</p> <p>Rapidly penetrates CNS</p> <p>Brief duration of action</p> Continuous infusion is generally required to maintain effect</td> <td> <p><strong>Acute:</strong> 1 to 5 mg IV every 5 to 15 minutes as needed until calm.<sup>&#182;</sup></p> <p><strong>Continuous infusion:</strong> Initially 1 mg/hour IV or SQ then 0.5 to 5 mg per hour titrated to calm. Doses of up to 20 mg/hour have been used.</p> A ceiling effect can occur.</td> <td> <p><strong>Role:</strong> First-line choice. Often given in combination with an antipsychotic to relieve accompanying symptoms of agitated delirium.</p> <p><strong>Advantages:</strong> Rapid onset. Water soluble and compatible with most drugs given by CSQI. Potent sedative and anxiolytic also useful for control of seizures, muscle spasms, nausea, vomiting, and intractable central pruritus. Reversal agent available (flumazenil).</p> <strong>Disadvantages:</strong> Risk of paradoxical agitation and delirium. Risk of apnea with large individual doses in combination with opioid or if low cardiac output. Accumulation, prolonged sedation, and tolerance can occur after several days of continuous use.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lorazepam</td> <td> <p>Intermediate-acting GABA<sub>A</sub> agonist</p> <p>Relatively slow onset</p> Longer duration of effect compared to midazolam</td> <td> <p><strong>Intermittent:</strong> 1 to 4 mg IV every two to six hours or 1 to 2 mg SQ every six to eight hours.</p> <p><strong>Continuous infusion:</strong> 0.01 to 0.1 mg/kg/hour IV or SQ. Doses of up to 10 mg/hour have been used.</p> A ceiling effect can occur.</td> <td> <p><strong>Role:</strong> An alternative to midazolam for patients likely to require a longer period of sedation or receiving care where midazolam continuous infusion is unavailable. Often given in combination with an antipsychotic.</p> <p><strong>Advantages:</strong> Potent sedative and anxiolytic also useful for control of seizures (IV/SQ but not orally), muscle spasms, nausea, and vomiting. Prolonged onset and duration of effect may permit management with intermittent IV or SQ injections in some patients. Reversal agent available (flumazenil).</p> <strong>Disadvantages:</strong> Relatively slow onset. Risk of oversedation when titrating due to delayed response. Risk of paradoxical agitation and delirium. IV and CSQI line incompatibilities, risk of line precipitate, tissue injury, and phlebitis. Accumulation of toxic propylene glycol solvent. Drug accumulation, prolonged sedation, and tolerance can occur after several days of continuous use.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">First-generation antipsychotics</td> </tr> <tr> <td class=\"indent1\">Levomepromazine (methotrimeprazine)</td> <td>Sedating dopamine D<sub>2</sub>, 5HT<sub>2A</sub>, H<sub>1</sub>, alpha<sub>1</sub>, alpha<sub>2</sub>, and muscarinic antagonist with analgesic and amnestic effects. Usual onset within 20 to 40 minutes.</td> <td> <p><strong>Initial loading dose:</strong> 12.5 to 25 mg SQ, IM or IV.</p> <p><strong>Continuous infusion:</strong> 2 to 3 mg/hour SQ; usual effective dose 50 to 300 mg daily.</p> <strong>Intermittent:</strong> 6.25 mg SQ every hour as needed with background dose of 12.5 to 25 mg daily in one or two divided doses (titrate based on as-needed dose requirements).</td> <td> <p><strong>Role:</strong> Sedating antipsychotic for control of delirium and/or agitation in imminently dying patient. Often given when large doses of benzodiazepine (eg, midazolam 30 mg daily) do not provide sufficient anxiolysis or calm. NOTE: Not available in the United States.</p> <p><strong>Advantages:</strong> Effective sedative, analgesic, and anxiolytic with rapid onset and useful for control of nausea, vomiting, delirium, and agitation. Flexible delivery options include CSQI that is compatible for delivery with analgesics and anticholinergics often used in palliative care.</p> <strong>Disadvantages:</strong> Anticholinergic effects, orthostatic hypotension with rapid IV administration, akathisia, acute dystonic reactions, seizures, and cardiotoxicity associated with QT prolongation.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Chlorpromazine</td> <td>See levomepromazine</td> <td> <p><strong>Intermittent:</strong> 12.5 to 25 mg IV or IM every 4 to 12 hours.</p> <p><strong>Continuous infusion:</strong> 3 to 5 mg/hour IV. Usual effective dose 37.5 to 150 mg daily (parenteral).</p> <strong>Rectal:</strong> 100 mg every 6 to 12 hours.</td> <td> <p><strong>Role:</strong> A sedating antipsychotic alternative in settings where levomepromazine is not available.</p> <p><strong>Advantages:</strong> Effective sedative and anxiolytic with rapid onset; also useful for control of delirium, agitation, nausea, vomiting, and intractable hiccups. Wide availability.</p> <strong>Disadvantages:</strong> SQ administration is not an option due to tissue damage and pain. Anticholinergic effects, orthostatic hypotension (which can be severe) with rapid IV administration, akathisia, acute dystonic reactions, seizures, and cardiotoxicity associated with QT prolongation.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Barbiturate</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Phenobarbital</td> <td>Enhances GABA and inhibits glutamate, providing long acting sedative, hypnotic, and anticonvulsant actions (higher doses)</td> <td> <p><strong>Initial loading dose:</strong> 1 to 3 mg/kg IV or IM (100 to 200 mg); repeat after 30 minutes if needed.</p> <strong>Continuous infusion:</strong> 0.5 mg/kg/hour IV or SQ (800 mg daily); may increase if needed up to 2400 mg daily.</td> <td> <p><strong>Role:</strong> A second-line option for refractory agitation in imminently dying patients who have not adequately responded to full doses of midazolam with either levomepromazine or chlorpromazine.</p> <p><strong>Advantages:</strong> Provides effective sedation to patients who have developed extreme tolerance to benzodiazepines and antipsychotics; controls refractory seizures. Maintenance dose may be administered by CSQI.</p> <strong>Disadvantages:</strong> Paradoxical excitement, especially among older adults. Other adverse effects include hypotension, bradycardia, nausea, vomiting, and serious cutaneous allergic reactions. Phenobarbital increases drug metabolism and can decrease serum concentrations of other drugs. It should not be abruptly discontinued due to occurrence of rebound seizures.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Short-acting anesthetic</td> </tr> <tr> <td class=\"indent1\">Propofol</td> <td>Ultra rapid-acting general anesthetic providing global CNS depression by GABA<sub>A</sub> potentiation and possibly inhibition of glutamate</td> <td>Initiate as continuous infusion at 5 micrograms/kg/minute IV and titrate every 5 to 10 minutes in increments of 5 to 10 micrograms/kg/minute. Effective dose range: 5 to 50 micrograms/kg/minute.</td> <td> <p><strong>Role:</strong> A second-line option for refractory intolerable agitation and delirium in imminently dying patient who has not adequately responded to full doses of benzodiazepines and antipsychotics receiving care in a specialty setting (ie, critical care unit) with access to necessary expertise and equipment.</p> <p><strong>Advantages:</strong> Produces reliable and rapid unconsciousness. Useful in patients who have developed extreme tolerance to benzodiazepines and antipsychotics; controls refractory nausea, vomiting, and seizures.</p> <strong>Disadvantages:</strong> Infusion site pain and phlebitis if given via peripheral vein. Delivered in an oil-in-water emulsion that can support bacterial growth, requiring strict adherence to aseptic technique and frequent bottle and tubing changes. Requires computer-controlled infusion pump. Other adverse effects: apnea with bolus injection, hypotension, allergic reactions, and bradycardia.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; IV: intravenous; SQ: subcutaneous;&nbsp;CIVI: continuous intravenous infusion; CSQI: continuous subcutaneous infusion; 5HT: serotonin; IM: intramuscular.<br />* The medications listed in this table for palliative sedation in general do NOT provide analgesia. Analgesia must be provided prior to and during use of palliative sedation with appropriate opioid and non-opioid options. For additional information, refer to UpToDate topic reviews of pain assessment and management at end of life.<br />¶ Immediate deep sedation is rarely needed, ie, for sudden massive hemorrhage.</div><div class=\"graphic_reference\">Courtesy of author with additional data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>De Graeff A, Dean M. Palliative sedation therapy in the last weeks of life: A literature review and recommendations for standards. J Pall Med 2007; 10:67.</li>&#xD;&#xA;    <li>Twycross R, Wilcock A (Eds). Palliative care formulary, 4th ed, Palliativedrugs.com Ltd, Nottingham, UK, 2012.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 88423 Version 4.0</div></div></div>"},"88429":{"type":"graphic_table","displayName":"EAPC ten item framework for palliative sed","title":"European Association of Palliative Care (EAPC) 10 item framework for guidelines in palliative sedation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">European Association of Palliative Care (EAPC) 10 item framework for guidelines in palliative sedation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Recommend preemptive discussion of potential role of sedation in end of life care and contingency planning.</td> </tr> <tr> <td>2. Describe the indications in which sedation may or should be considered.</td> </tr> <tr> <td>3. Describe the necessary evaluation and consultation procedures.</td> </tr> <tr> <td>4. Specify consent requirements.</td> </tr> <tr> <td>5. Indicate the need to discuss the decision making process with the patient's family.</td> </tr> <tr> <td>6. Present direction for selection of the sedation method.</td> </tr> <tr> <td>7. Present direction for dose titration, patient monitoring, and care.</td> </tr> <tr> <td>8. Guidance for decisions regarding hydration and nutrition and concomitant medications.</td> </tr> <tr> <td>9. The care and informational needs of the patient's family.</td> </tr> <tr> <td>10. Care for the medical professionals.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Cherny NI, Radbruch L. European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. Palliat Med 2009; 23:581.</div><div id=\"graphicVersion\">Graphic 88429 Version 1.0</div></div></div>"},"88430":{"type":"graphic_diagnosticimage","displayName":"CT scan acute interstitial edematous pancreatitis","title":"CT scan of acute interstitial edematous pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">CT scan of acute interstitial edematous pancreatitis</div><div class=\"cntnt\"><img style=\"width:490px; height:426px;\" src=\"images/RADIOL/88430_CT_scan_acu_panc_edema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;computed tomography (CT)&nbsp;scan in a 75-year-old man with acute interstitial pancreatitis reveals heterogeneous appearance of the&nbsp;pancreas&nbsp;(arrow) and peripancreatic fat stranding (arrowhead).</div><div id=\"graphicVersion\">Graphic 88430 Version 1.0</div></div></div>"},"88431":{"type":"graphic_diagnosticimage","displayName":"CT scan acute peripancreatic fluid collections","title":"CT scan of acute interstitial pancreatitis with acute peripancreatic fluid collections","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">CT scan of acute interstitial pancreatitis with acute peripancreatic fluid collections</div><div class=\"cntnt\"><img style=\"width:590px; height:466px;\" src=\"images/RADIOL/88431_CT_scan_pancreatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan&nbsp;reveals acute interstitial pancreatitis with an acute peripancreatic fluid&nbsp;collections (APFC)&nbsp;around the body and tail of the pancreas (arrowheads). There is mild heterogeneity of the enhanced pancreas (arrow).</div><div id=\"graphicVersion\">Graphic 88431 Version 2.0</div></div></div>"},"88432":{"type":"graphic_diagnosticimage","displayName":"CT scan necrotizing pancreatitis","title":"CT scan of necrotizing pancreatitis with peripancreatic necrosis","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">CT scan of necrotizing pancreatitis with peripancreatic necrosis</div><div class=\"cntnt\"><img style=\"width:590px; height:401px;\" src=\"images/RADIOL/88432_CT_scan_acut_int_panc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan of a 34-year-old male with acute pancreatitis reveals&nbsp;the pancreas enhances homogeneously (arrow) but there is evidence of peripancreatic necrosis (arrowhead).</div><div id=\"graphicVersion\">Graphic 88432 Version 1.0</div></div></div>"},"88434":{"type":"graphic_diagnosticimage","displayName":"CT scan acute necrotic collection","title":"CT scan of acute necrotic collection","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">CT scan of acute necrotic collection</div><div class=\"cntnt\"><img style=\"width:590px; height:490px;\" src=\"images/RADIOL/88434_CT_acut_pan_necr_panc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan reveals an acute necrotic collection in a 20-year-old female with acute pancreatitis. The axial CT image shows&nbsp;pancreatic necrosis with a&nbsp;nonenhancing region in the neck and the body of the pancreas (between arrowheads). In the surrounding anterior pararenal space, there is a large fluid accumulation that contains islands of&nbsp;necrosis (arrow).</div><div id=\"graphicVersion\">Graphic 88434 Version 1.0</div></div></div>"},"88436":{"type":"graphic_diagnosticimage","displayName":"CT scan infected pancreatic necrosis","title":"CT scan of acute necrotizing pancreatitis complicated by infected pancreatic necrosis","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">CT scan of acute necrotizing pancreatitis complicated by infected pancreatic necrosis</div><div class=\"cntnt\"><img style=\"width:570px; height:499px;\" src=\"images/RADIOL/88436_CT_necrot_inf_pancreat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan reveals&nbsp;gas bubbles&nbsp;(arrow)&nbsp;within an area of pancreatic necrosis. The presence of&nbsp;gas bubbles is a pathognomonic sign of infection of the necrosis.</div><div id=\"graphicVersion\">Graphic 88436 Version 1.0</div></div></div>"},"88447":{"type":"graphic_figure","displayName":"Pathogenetic mechanisms in schistosomal glomerulonephritis","title":"Pathogenetic mechanisms in schistosomal glomerulonephritis","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Pathogenetic mechanisms in schistosomal glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:628px; height:461px;\" src=\"images/NEPH/88447_Path_mech_schistosomal_glom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Glomeruli are eventually exposed to adult worm gut antigens that escape hepatic clearance and to Schistosoma-specific antibodies generated by immunocompetent cells in the liver, systemic lymphoid tissues, and spleen. This process is activated by concomitant salmonellosis via&nbsp;toll-like receptor&nbsp;4 (TLR4)&nbsp;and&nbsp;by hepatitis C virus infection&nbsp;via TLR2. The predominant immunoglobulin is IgM in class I schistosomal glomerular disease, IgG in class II, and IgA in classes III and IV. Note that glomerular exposure to serum amyloid A (SAA) generated by the hepatocytes under the influence of interleukin-1 (IL-1)&nbsp;and IL-6 may produce&nbsp;class V lesions. Autoimmune mechanisms may also be involved&nbsp;in propagating glomerular lesions.</div><div class=\"graphic_footnotes\">SEA: soluble egg antigens; G: schistosomal granuloma; IICC: intestinal immunocompetent cells; Sm-PEPCK: S. mansoni phosphoenolpyruvate carboxykinase; MSA: major serologic antigen; HCV: hepatitis C virus; TLR: toll-like receptor; IL-n: interleukin #; TH1: T-helper 1 cell products; HICC: hepatic immunocompetent cells; H: hepatocyte; SAA: serum amyloid A protein; X: impaired macrophage clearance of SAA; SICC: systemic immunocompetent cells; CSA: circulating schistosomal antigens.</div><div class=\"graphic_reference\">Adapted from: Barsoum R. The changing face of schistosomal glomerulopathy. Kidney Int 2004; 66:2472.</div><div id=\"graphicVersion\">Graphic 88447 Version 1.0</div></div></div>"},"88448":{"type":"graphic_picture","displayName":"Glomerular lesions in schistosomiasis","title":"Glomerular lesions in schistosomiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glomerular lesions in schistosomiasis</div><div class=\"cntnt\"><img style=\"width:423px; height:516px;\" src=\"images/NEPH/88448_Glomer_lesion_schistos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A-D are stained with H&amp;E. F is stained with Masson's trichrome.<BR>(A) Class I: Axial mesangial proliferation.<BR>(B) Class II: Salmonella-associated exudative glomerulonephritis (GN).<BR>(C) Class III: Membranoproliferative (mesangiocapillary) GN.<BR>(D) Class IV: Focal segmental sclerosis.<BR>(E) Class V: Amyloidosis.<BR>(F) Class VI: HCV-associated mixed lesion including mesangial proliferation amidst amyloid and cryoglobulin deposits.</div><div class=\"graphic_reference\">(A) Reprinted by permission from: Macmillan Publishers Ltd: Kidney International. Barsoum RS. Schistosomal glomerulopathies. Kidney Int 1993; 44:1. Copyright &copy; 1993. <a href=\"http://www.nature.com/ki\" style=\"font-style: italic;\" target=\"_blank\">www.nature.com/ki</a>.<br />(B-E) Courtesy of Wesam M Ismail, MD.<br />(F) Reprinted by permission from: Macmillan Publishers Ltd: Kidney International. Barsoum R. The changing face of schistosomal glomerulopathy. Kidney Int 2004; 66:2472. Copyright &copy; 2004. <a href=\"http://www.nature.com/ki\" style=\"font-style: italic;\" target=\"_blank\">www.nature.com/ki</a>.</div><div id=\"graphicVersion\">Graphic 88448 Version 1.0</div></div></div>"},"88449":{"type":"graphic_picture","displayName":"Calcified schistosomal ova in a rectal biopsy","title":"Calcified schistosomal ova in a rectal biopsy","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Calcified schistosomal ova in a rectal biopsy</div><div class=\"cntnt\"><img style=\"width:572px; height:427px;\" src=\"images/NEPH/88449_SRC-Clcfd_schstsml_ov_rctl_bpsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal mucosa overlying a&nbsp;submucosal layer containing numerous calcified Schistosoma japonicum eggs.</div><div class=\"graphic_reference\">Reproduced with permission of The American Society of Tropical Medicine and Hygiene, from Chronic Schistosomiasis in a Patient with Rectal Cancer. Bharti AR, Weidner N, Ramamoorthy S. Am J Trop Med Hyg 2009; 80:1. Copyright © 2009; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 88449 Version 2.0</div></div></div>"},"88458":{"type":"graphic_table","displayName":"Classification of nerve injury","title":"Classification of nerve injury and potential recovery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of nerve injury and potential recovery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Sunderland<br /> (1990)</td> <td class=\"subtitle1\">Seddon<br /> (1943)</td> <td class=\"subtitle1\">Grade of lesion</td> <td class=\"subtitle1\">Pathology</td> <td class=\"subtitle1\">Electro-diagnostic studies</td> <td class=\"subtitle1\">Prognosis*</td> </tr> <tr> <td class=\"centered\">I</td> <td>Neurapraxia</td> <td>Mild</td> <td>Demyelination</td> <td>Conduction block</td> <td>Excellent (up to 3 months)</td> </tr> <tr> <td class=\"centered\">II</td> <td>Axonotmesis</td> <td>Mild-moderate</td> <td>Demyelination and axon loss</td> <td>Axon loss<sup>&#182;</sup></td> <td>Good, limited by \"time-distance\" factor</td> </tr> <tr> <td class=\"centered\">III</td> <td>Neurotmesis</td> <td>Moderate</td> <td>II + involvement of endoneurium</td> <td>Axon loss<sup>&#182;</sup></td> <td>Good-fair</td> </tr> <tr> <td class=\"centered\">IV</td> <td>Neurotmesis</td> <td>Severe</td> <td>III + involvement of perineurium</td> <td>Axon loss<sup>&#182;</sup></td> <td>Poor-nil</td> </tr> <tr> <td class=\"centered\">V</td> <td>Neurotmesis</td> <td>Severe</td> <td>IV + involvement of epineurium</td> <td>Axon loss<sup>&#182;</sup></td> <td>Nil</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* As the lesion is commonly mixed (demyelinating and axonal) the recovery is usually biphasic: the neurapraxic component resolves quickly, followed by a slower recovery of the axonal component, which is dependent upon distal axonal sprouting, axonal regeneration, and the level of injury (proximal versus distal).<br />&para; Most nerve lesions are mixed, consisting of a combination of neurapraxia and axonotmesis/neurotmesis, and therefore presenting as a mix of conduction block and partial axonal loss.</div><div class=\"graphic_reference\">Original figure modified for this publication. Sunderland S. Nerve Injuries and their Repair: a Critical Appraisal. Churchill Livingstone, Edinburgh 1991. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88458 Version 2.0</div></div></div>"},"88465":{"type":"graphic_table","displayName":"Trade names of antithrombotic drugs","title":"Trade names of antithrombotic drugs ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Trade names of antithrombotic drugs </div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">US trade name</td> <td class=\"subtitle1\">Common European<br /> trade name(s)</td> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">Category</td> </tr> <tr> <td>Acova*</td> <td>Argatra, Novastan</td> <td>Argatroban </td> <td>Thrombin inhibitor</td> </tr> <tr> <td>Aggrastat</td> <td>Aggrastat</td> <td>Tirofiban </td> <td>Glycoprotein IIb/IIIa inhibitor</td> </tr> <tr> <td>Aggrenox</td> <td>Agrenox, Asasantin</td> <td>Dipyridamole and aspirin</td> <td>Antiplatelet agents (other and NSAID)</td> </tr> <tr> <td>Angiomax</td> <td>Angiox</td> <td>Bivalirudin</td> <td>Thrombin inhibitor</td> </tr> <tr> <td>Arixtra</td> <td>Arixtra</td> <td>Fondaparinux</td> <td>Factor Xa inhibitor</td> </tr> <tr> <td>Brilinta</td> <td>Brilique</td> <td>Ticagrelor</td> <td>Antiplatelet agent (P2Y12 blocker)</td> </tr> <tr> <td>Coumadin</td> <td>Coumadin, Marevan</td> <td>Warfarin </td> <td>Vitamin K antagonist</td> </tr> <tr> <td>Effient</td> <td>Effient</td> <td>Prasugrel</td> <td>Antiplatelet agent (P2Y12 blocker)</td> </tr> <tr> <td>Eliquis</td> <td>Eliquis</td> <td>Apixaban </td> <td>Factor Xa inhibitor</td> </tr> <tr> <td>Fragmin</td> <td>Fragmin</td> <td>Dalteparin</td> <td>LMWH</td> </tr> <tr> <td>&nbsp;</td> <td>Fraxiparine, Fraxodi</td> <td>Nadroparin</td> <td>LMWH</td> </tr> <tr> <td>&nbsp;</td> <td>Innohep, Logiparin</td> <td>Tinzaparin</td> <td>LMWH</td> </tr> <tr> <td>Integrilin</td> <td>Integrilin</td> <td>Eptifibatide</td> <td>Glycoprotein IIb/IIIa inhibitor</td> </tr> <tr> <td>Iprivask</td> <td>Revasc</td> <td>Desirudin </td> <td>Thrombin inhibitor</td> </tr> <tr> <td>Jantoven</td> <td>Coumadin, Marevan</td> <td>Warfarin</td> <td>Vitamin K antagonist</td> </tr> <tr> <td>Lovenox</td> <td>Clexane, Klexane</td> <td>Enoxaparin</td> <td>LMWH</td> </tr> <tr> <td>&nbsp;</td> <td>Orgaran</td> <td>Danaparoid</td> <td>LMWH</td> </tr> <tr> <td>Plavix</td> <td>Grepid, Plavix, Iscover (numerous)</td> <td>Clopidogrel</td> <td>Antiplatelet agent (P2Y12 blocker)</td> </tr> <tr> <td>Persantine</td> <td>Persantin</td> <td>Dipyridamole</td> <td>Antiplatelet agent (other)</td> </tr> <tr> <td>Pletal</td> <td>Pletal</td> <td>Cilostazol</td> <td>Antiplatelet agent (other)</td> </tr> <tr> <td>Pradaxa</td> <td>Pradaxa</td> <td>Dabigatran</td> <td>Thrombin inhibitor</td> </tr> <tr> <td>ReoPro</td> <td>ReoPro</td> <td>Abciximab </td> <td>Glycoprotein IIb/IIIa inhibitor</td> </tr> <tr> <td>&nbsp;</td> <td>Sintrom</td> <td>Acenocoumarol</td> <td>Vitamin k antagonist</td> </tr> <tr> <td>Ticlid*</td> <td>Ticlid</td> <td>Ticlopidine</td> <td>Antiplatelet agent (P2Y12 blocker)</td> </tr> <tr> <td>Xarelto</td> <td>Xarelto</td> <td>Rivaroxaban</td> <td>Factor Xa inhibitor</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Numerous names exists for aspirin and unfractionated heparin, including:</td> </tr> <tr> <td class=\"indent1\">Ascriptin, Bayer, Bufferin, Ecotrin (others)</td> <td>&nbsp;</td> <td>Aspirin</td> <td>Antiplatelet agent (NSAID)</td> </tr> <tr> <td class=\"indent1\">Hep-Lock, HepFlush</td> <td>Calciparine, Hepalean (numerous)</td> <td>Heparin</td> <td>Unfractionated heparin</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAID: nonsteroidal antiinflammatory drug; LMWH: low molecular weight heparin.<br />* Inactive US trade name(s). Marketed in US under generic name.</div><div id=\"graphicVersion\">Graphic 88465 Version 1.0</div></div></div>"},"88466":{"type":"graphic_table","displayName":"Trimodality studies in pleural MPM","title":"Trimodality studies in pleural malignant pleural pneumonectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Trimodality studies in pleural malignant pleural pneumonectomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Ref</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">Chemotherapy RR<br /> (percent)</td> <td class=\"subtitle1\">EPP done<br /> (percent)</td> <td class=\"subtitle1\">Mortality<br /> (percent)</td> <td class=\"subtitle1\">Completed trimodal<br /> (percent)</td> <td class=\"subtitle1\">OS (ITT) months</td> <td class=\"subtitle1\">OS: Subsets months</td> <td class=\"subtitle1\">PFS months</td> </tr> <tr> <td><strong>Weder<sup>[1]</sup></strong></td> <td class=\"centered\">19</td> <td class=\"centered\">32</td> <td class=\"centered\">84</td> <td class=\"centered\">0</td> <td class=\"centered\">68</td> <td class=\"centered\">23</td> <td class=\"centered\">NR</td> <td class=\"centered\">CT + EPP: 16.5</td> </tr> <tr> <td><strong>Weder<sup>[2]</sup></strong></td> <td class=\"centered\">61</td> <td class=\"centered\">NR</td> <td class=\"centered\">74</td> <td class=\"centered\">2.2</td> <td class=\"centered\">59</td> <td class=\"centered\">19.8</td> <td class=\"centered\">CT + EPP: 23</td> <td class=\"centered\">CT + EPP: 13.5</td> </tr> <tr> <td><strong>Rea<sup>[3]</sup></strong></td> <td class=\"centered\">21</td> <td class=\"centered\">33</td> <td class=\"centered\">81</td> <td class=\"centered\">0</td> <td class=\"centered\">71</td> <td class=\"centered\">25.5</td> <td class=\"centered\">27.5</td> <td class=\"centered\">CT + EPP: 16.3</td> </tr> <tr> <td><strong>Flores<sup>[4]</sup></strong></td> <td class=\"centered\">21</td> <td class=\"centered\">26</td> <td class=\"centered\">42</td> <td class=\"centered\">0</td> <td class=\"centered\">42</td> <td class=\"centered\">19</td> <td class=\"centered\">CT + EPP + RT: 33.5</td> <td class=\"centered\">NR</td> </tr> <tr> <td><strong>Opitz<sup>[5]</sup></strong></td> <td class=\"centered\">63</td> <td class=\"centered\">32</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">3.2</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">NR</td> <td class=\"centered\">NR</td> <td class=\"centered\">NR</td> </tr> <tr> <td><strong>Buduhan<sup>[6]</sup></strong></td> <td class=\"centered\">55</td> <td class=\"centered\">NR</td> <td class=\"centered\">84</td> <td class=\"centered\">4.3</td> <td class=\"centered\">69</td> <td class=\"centered\">NR</td> <td class=\"centered\">CT + EPP: 24<br /> TMT: 25</td> <td class=\"centered\">NR</td> </tr> <tr> <td><strong>de Perrot<sup>[7]</sup></strong></td> <td class=\"centered\">60</td> <td class=\"centered\">NR</td> <td class=\"centered\">75</td> <td class=\"centered\">6.7</td> <td class=\"centered\">50</td> <td class=\"centered\">14</td> <td class=\"centered\">NR</td> <td class=\"centered\">NR</td> </tr> <tr> <td><strong>Krug<sup>[8]</sup></strong></td> <td class=\"centered\">77</td> <td class=\"centered\">32</td> <td class=\"centered\">70</td> <td class=\"centered\">4</td> <td class=\"centered\">52</td> <td class=\"centered\">16.8</td> <td class=\"centered\">CT + EPP: 21.9<br /> TMT: 29.1</td> <td class=\"centered\">ITT: 10.1<br /> CT + EPP: 18.3</td> </tr> <tr> <td><strong>Van Schil<sup>[9]</sup></strong></td> <td class=\"centered\">58</td> <td class=\"centered\">43</td> <td class=\"centered\">72</td> <td class=\"centered\">6.5</td> <td class=\"centered\">65</td> <td class=\"centered\">18.4</td> <td class=\"centered\">TMT: 33</td> <td class=\"centered\">ITT: 13.9</td> </tr> <tr> <td><strong>Rea<sup>[10]</sup></strong></td> <td class=\"centered\">54</td> <td class=\"centered\">29</td> <td class=\"centered\">83</td> <td class=\"centered\">NR</td> <td class=\"centered\">41</td> <td class=\"centered\">15.5</td> <td class=\"centered\">NR</td> <td class=\"centered\">ITT PFS: 8.6</td> </tr> <tr> <td><strong>Bille<sup>[11]</sup></strong></td> <td class=\"centered\">25</td> <td class=\"centered\">NR</td> <td class=\"centered\">88</td> <td class=\"centered\">4</td> <td class=\"centered\">71</td> <td class=\"centered\">12.8</td> <td class=\"centered\">NR</td> <td class=\"centered\">NR</td> </tr> <tr> <td><strong>Okada<sup>[12]</sup></strong></td> <td class=\"centered\">27</td> <td class=\"centered\">NR</td> <td class=\"centered\">100</td> <td class=\"centered\">3.7</td> <td class=\"centered\">63</td> <td class=\"centered\">13</td> <td class=\"centered\">23 (chemoRT after EPP)</td> <td class=\"centered\">NR</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RR: response rate; EPP: extrapleural pneumonectomy; OS: overall survival; PFS: progression free survival; CT: chemotherapy; TMT: trimodality therapy; ITT: intent to treat; NR: not recorded.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Weder W, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22(17):3451, 2004.</LI>&#xD;&#xA;<LI>Weder W, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 18(7):1196, 2007.</LI>&#xD;&#xA;<LI>Rea F, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results. Lung Cancer 57(1):89, 2007.</LI>&#xD;&#xA;<LI>Flores RM, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 1(4):289, 2006.</LI>&#xD;&#xA;<LI>Opitz I, et al. Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg 29(4):579, 2006.</LI>&#xD;&#xA;<LI>Buduhan G, et al. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 88(3):870, 2009.</LI>&#xD;&#xA;<LI>de Perrot M, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 27(9):1413, 2009.</LI>&#xD;&#xA;<LI>Krug LM, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27(18):3007, 2009.</LI>&#xD;&#xA;<LI>Van Schil PE, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 36(6):1362, 2010.</LI>&#xD;&#xA;<LI>Pasello G, et al. Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM). Anticancer Res 32(12):5393, 2012.</LI>&#xD;&#xA;<LI>Bille A, et al: Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals. Gen Thorac Cardiovasc Surg 60(5):289, 2012.</LI>&#xD;&#xA;<LI>Okada K: Trimodality Therapy With Extrapleural Pneumonectomy, Radiation Therapy, And Chemotherapy For Malignant Pleural Mesothelioma. 11th International Conference of the International Mesothelioma Interest Group. 2012.</LI></OL></div><div id=\"graphicVersion\">Graphic 88466 Version 3.0</div></div></div>"},"88467":{"type":"graphic_table","displayName":"Pleurectomy decortication and MCR","title":"Pleurectomy decortication as maximal cytoreductive surgery of pleural mesothelioma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pleurectomy decortication as maximal cytoreductive surgery of pleural mesothelioma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Ref</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">Rx</td> <td class=\"subtitle1\">MCR P/D done<br /> (percent)</td> <td class=\"subtitle1\">Mortality<br /> (percent)</td> <td class=\"subtitle1\">Completed trimodal<br /> (percent)</td> <td class=\"subtitle1\">OS (ITT) months</td> <td class=\"subtitle1\">OS: Subsets months</td> <td class=\"subtitle1\">PFS months</td> </tr> <tr> <td rowspan=\"2\"><strong>Sugarbaker<sup>[1]</sup></strong></td> <td class=\"centered\" rowspan=\"2\">64</td> <td class=\"centered\" rowspan=\"2\">Palliative P/D</td> <td class=\"centered\" rowspan=\"2\">&ndash;</td> <td class=\"centered\" rowspan=\"2\">3.1</td> <td class=\"centered\" rowspan=\"2\">&ndash;</td> <td class=\"centered\" rowspan=\"2\">9.4</td> <td class=\"centered\">Epith: 21.7</td> <td class=\"centered\" rowspan=\"2\">&ndash;</td> </tr> <tr> <td class=\"centered\">Non-epith: 5.8</td> </tr> <tr> <td rowspan=\"2\"><strong>Waller<sup>[2]</sup></strong></td> <td class=\"centered\" rowspan=\"2\">102</td> <td class=\"centered\">P/D, radical</td> <td class=\"centered\">51</td> <td class=\"centered\">5.9</td> <td class=\"centered\">65</td> <td class=\"centered\">15.3</td> <td class=\"centered\">25.4 Epith</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"centered\">Non-radical</td> <td class=\"centered\">51</td> <td class=\"centered\">9.8</td> <td class=\"centered\">26</td> <td class=\"centered\">7.1</td> <td class=\"centered\">10.2 Epith</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td><strong>Butchart<sup>[3]</sup></strong></td> <td class=\"centered\">24</td> <td class=\"centered\">P/D CT + RT</td> <td class=\"centered\">24</td> <td class=\"centered\">1.1</td> <td class=\"centered\">24</td> <td class=\"centered\">26</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td rowspan=\"2\"><strong>Shahin<sup>[4]</sup></strong></td> <td class=\"centered\" rowspan=\"2\">26</td> <td class=\"centered\">P/D, radical</td> <td class=\"centered\">13</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">CT: 54<br /> RT: 46</td> <td class=\"centered\">16.9</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"centered\">Non-radical</td> <td class=\"centered\">13</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">CT: 54<br /> RT: 15</td> <td class=\"centered\">6.8</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td><strong>Bolukbas<sup>[5]</sup></strong></td> <td class=\"centered\">88</td> <td class=\"centered\">P/D, RT, CT</td> <td class=\"centered\">NR</td> <td class=\"centered\">2.3</td> <td class=\"centered\">84</td> <td class=\"centered\">26</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">13</td> </tr> <tr> <td><strong>Cameron<sup>[6]</sup></strong></td> <td class=\"centered\">121</td> <td class=\"centered\">P/D, RT &#177; CT</td> <td class=\"centered\">100</td> <td class=\"centered\">NR</td> <td class=\"centered\">NR</td> <td class=\"centered\">13.8</td> <td class=\"centered\">19.7 P/D and RT</td> <td class=\"centered\">NR</td> </tr> <tr> <td rowspan=\"2\"><strong>Friedberg<sup>[7]</sup></strong></td> <td class=\"centered\" rowspan=\"2\">44</td> <td class=\"centered\" rowspan=\"2\">P/D, PDT, CT</td> <td class=\"centered\" rowspan=\"2\">97</td> <td class=\"centered\" rowspan=\"2\">2.3</td> <td class=\"centered\" rowspan=\"2\">100</td> <td class=\"centered\" rowspan=\"2\">~33</td> <td class=\"centered\">Epith: 37-57</td> <td class=\"centered\" rowspan=\"2\">9.6</td> </tr> <tr> <td class=\"centered\">Non-epith: 6.8</td> </tr> <tr> <td><strong>Lang-Lazdunski<sup>[8]</sup></strong></td> <td class=\"centered\">65</td> <td class=\"centered\">P/D, HPov, RT, CT</td> <td class=\"centered\">NR</td> <td class=\"centered\">0</td> <td class=\"centered\">100</td> <td class=\"centered\">5 y: 33.4</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">9</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Rx: treatment protocol; MCR: maximal cytoreductive surgery; OS: overall survival; P/D: pleurectomy decortication; PFS: progression free survival; RT: radiation therapy; CT: chemotherapy; PDT: photodynamic therapy; HPov: hyperthermic povidone; NR: not reported.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Sugarbaker DJ, et al: Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma. Int J Surg 6(4):293, 2008.</li>&#xD;&#xA;    <li>Waller DA, et al: Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. Eur J Cardiothorac Surg 34(4):88, 2008.</li>&#xD;&#xA;    <li>Butchart EG, et al: Three decades of experience in the surgical multi-modality management of pleural mesothelioma. Eur J Cardiothorac Surg 37(3):552, 2010.</li>&#xD;&#xA;    <li>Shahin Y, et al: How successful is lung-preserving radical surgery in the mesothelioma and radical surgery-trial environment? A case-controlled analysis. Eur J Cardiothorac Surg 39(3):360, 2011.</li>&#xD;&#xA;    <li>Bolukbas S. Long-Term Outcome After Radical Pleurectomy Followed By Chemoradiation For Malignant Pleural Mesothelioma: A 10-Year Single Center Experience. 11th International Conference of the International Mesothelioma Interest Group. 2012. 9-12-2012. Ref Type: Abstract.</li>&#xD;&#xA;    <li>Cameron RB, et al: The Timing of Chemotherapy in the Multimodality Therapy of Pleural Mesothelioma. 11th International Conference of the International Mesothelioma Interest Group. 2013. 9-12-2012. Ref Type: Abstract.</li>&#xD;&#xA;    <li>Friedberg J, et al: Radical Pleurectomy And Intraoperative Porfimer Sodium Photodynamic Therapy For Malignant. 11th International Conference of the International Mesothelioma Interest Group. 2013. 9-12-2012. Ref Type: Abstract.</li>&#xD;&#xA;    <li>Lang-Lazdunski L, et al: Pleurectomy/Decortication, Hyperthermic Pleural Lavage With Povidone-Iodine Followed By Adjuvant Chemotherapy: Survival Analysis In 65 Consecutive Patients. 11th International Conference of the International Mesothelioma Interest Group. 2013. Ref Type: Abstract.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 88467 Version 2.0</div></div></div>"},"88468":{"type":"graphic_table","displayName":"Multimodality data comparing PD and E","title":"Multimodality data comparing pleurectomy/decortication and extrapleural pneumonectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Multimodality data comparing pleurectomy/decortication and extrapleural pneumonectomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Ref</td> <td class=\"subtitle1\">Procedure</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">30 d mortality<br /> (percent)</td> <td class=\"subtitle1\">Morbidity<br /> (percent)</td> <td class=\"subtitle1\">Median fu (months)</td> <td class=\"subtitle1\"> <p>Median OS (months)</p> </td> <td class=\"subtitle1\">2 year<br /> (percent)</td> <td class=\"subtitle1\">5 year<br /> (percent)</td> </tr> <tr> <td rowspan=\"2\"><strong>Lang-Lazdunski<sup>[1]</sup></strong></td> <td class=\"centered\">P/D<br /> (V/P/dgm/peri)</td> <td class=\"centered\">54</td> <td class=\"centered\">0</td> <td class=\"centered\">28</td> <td class=\"centered\">15.7</td> <td class=\"centered\">23</td> <td class=\"centered\">49</td> <td class=\"centered\">30.1</td> </tr> <tr> <td class=\"centered\">EPP</td> <td class=\"centered\">22</td> <td class=\"centered\">4.5</td> <td class=\"centered\">68</td> <td class=\"centered\">12.9</td> <td class=\"centered\">12.8</td> <td class=\"centered\">18.2</td> <td class=\"centered\">9</td> </tr> <tr> <td rowspan=\"2\"><strong>Rena<sup>[2]</sup></strong></td> <td class=\"centered\">P/D<br /> (? extended)</td> <td class=\"centered\">37</td> <td class=\"centered\">0</td> <td class=\"centered\">24</td> <td class=\"centered\">2-45</td> <td class=\"centered\">25</td> <td class=\"centered\">55</td> <td class=\"centered\">NA</td> </tr> <tr> <td class=\"centered\">EPP</td> <td class=\"centered\">40</td> <td class=\"centered\">5</td> <td class=\"centered\">62</td> <td class=\"centered\">10-41</td> <td class=\"centered\">20</td> <td class=\"centered\">35</td> <td class=\"centered\">NA</td> </tr> <tr> <td rowspan=\"2\"><strong>Sorensen<sup>[3]</sup></strong></td> <td class=\"centered\">P/D</td> <td class=\"centered\">34</td> <td class=\"centered\">0</td> <td class=\"centered\">NR</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">28.4</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">27</td> </tr> <tr> <td class=\"centered\">EPP</td> <td class=\"centered\">28</td> <td class=\"centered\">0</td> <td class=\"centered\">NR</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">31.9</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">16</td> </tr> <tr> <td rowspan=\"2\"><strong>Pass<sup>[4]</sup></strong></td> <td class=\"centered\">P/D<br /> (all stages, 24 extended)</td> <td class=\"centered\">78</td> <td class=\"centered\">1.3</td> <td class=\"centered\">22</td> <td class=\"centered\">22<br /> (0-204)</td> <td class=\"centered\">23</td> <td class=\"centered\">46</td> <td class=\"centered\">19</td> </tr> <tr> <td class=\"centered\">EPP</td> <td class=\"centered\">102</td> <td class=\"centered\">4.9</td> <td class=\"centered\">57</td> <td class=\"centered\">12<br /> (0-118)</td> <td class=\"centered\">12</td> <td class=\"centered\">23</td> <td class=\"centered\">5</td> </tr> <tr> <td rowspan=\"2\"><strong>&nbsp;</strong></td> <td class=\"centered\">P/D Stage I/II<br /> (11 extended)</td> <td class=\"centered\">38</td> <td class=\"centered\">2</td> <td class=\"centered\">20</td> <td class=\"centered\">35<br /> (0-204)</td> <td class=\"centered\">44</td> <td class=\"centered\">66</td> <td class=\"centered\">35</td> </tr> <tr> <td class=\"centered\">EPP Stage I/II</td> <td class=\"centered\">20</td> <td class=\"centered\">5</td> <td class=\"centered\">30</td> <td class=\"centered\">27.5<br /> (0-105)</td> <td class=\"centered\">25</td> <td class=\"centered\">55</td> <td class=\"centered\">29</td> </tr> <tr> <td rowspan=\"2\"><strong>&nbsp;Bovolato<sup>[5]</sup></strong><br /> <strong>&nbsp;</strong></td> <td class=\"centered\">P/D</td> <td class=\"centered\">204</td> <td class=\"centered\">2.6</td> <td class=\"centered\">10</td> <td class=\"centered\">80</td> <td class=\"centered\">20.5</td> <td class=\"centered\">40</td> <td class=\"centered\">10</td> </tr> <tr> <td class=\"centered\">EPP</td> <td class=\"centered\">301</td> <td class=\"centered\">4.1</td> <td class=\"centered\">22</td> <td class=\"centered\">80</td> <td class=\"centered\">18.8</td> <td class=\"centered\">37</td> <td class=\"centered\">12</td> </tr> <tr> <td rowspan=\"2\">&nbsp;<strong>Flores<sup>[6]</sup></strong></td> <td class=\"centered\">P/D</td> <td class=\"centered\"> <p>278</p> </td> <td class=\"centered\">4</td> <td class=\"centered\">-</td> <td class=\"centered\">17</td> <td class=\"centered\">16</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> </tr> <tr> <td class=\"centered\">EPP</td> <td class=\"centered\">&nbsp;385</td> <td class=\"centered\">7</td> <td class=\"centered\">-</td> <td class=\"centered\">17</td> <td class=\"centered\">12</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> </tr> <tr> <td rowspan=\"2\">&nbsp;<strong>Burt<sup>[7]</sup></strong></td> <td class=\"centered\">P/D</td> <td class=\"centered\">130</td> <td class=\"centered\">3.1</td> <td class=\"centered\">4</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> </tr> <tr> <td class=\"centered\">EPP</td> <td class=\"centered\">95</td> <td class=\"centered\">10.5</td> <td class=\"centered\">24</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OS: overall survival; P/D: pleurectomy decortication; V/P: visceral/parietal; dgm: diaphragm; peri: pericardium; fu: followup.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Lang-Lazdunski L, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol 7(4):737, 2012.</LI>&#xD;&#xA;<LI>Rena O, et al. Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure. Lung Cancer 77(1):151, 2012.</LI>&#xD;&#xA;<LI>Two Simultaneous Consecutive Non-Randomized Cohorts of Operable Patients with MPM Receiving Induction Therapy Followed either by EPP and Postoperative Radiotherapy or Pleurectomy Decortication Alone. 11th International Conference of the International Mesothelioma Interest Group. 2012; 2012.</LI>&#xD;&#xA;<LI>Pass H. Mesothelioma Revisited: A Multidisciplinary Approach. Third ESMO European Lung Cancer Conference; 12 Apr 19; 2012.</LI>&#xD;&#xA;<LI>Bovolato P, et al. Does surgery improve survival of patients with malignant pleural mesothelioma? A multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol 2014;&nbsp;9(3):390.</LI>&#xD;&#xA;<LI>Flores RM, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008; 135:620.</LI>&#xD;&#xA;<LI>Burt BM, et al. Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality. J Thorac Cardiovasc Surg 2014; 148:30.&nbsp;</LI></OL></div><div id=\"graphicVersion\">Graphic 88468 Version 4.0</div></div></div>"},"88480":{"type":"graphic_algorithm","displayName":"Management of open nerve injury","title":"Management of open nerve injury","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Management of open nerve injury</div><div class=\"cntnt\"><img style=\"width:472px; height:274px;\" src=\"images/NEURO/88480_Manage_open_nerve_injury.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified with permission from: Grant GA, Goodkin R, Kliot M. Evaluation and surgical management of peripheral nerve problems. Neurosurgery 1999; 44:825. Copyright &copy; 1999 Congress of Neurological Surgeons. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 88480 Version 2.0</div></div></div>"},"88481":{"type":"graphic_algorithm","displayName":"Management of closed nerve injury","title":"Management of closed nerve injury","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Management of closed nerve injury</div><div class=\"cntnt\"><img style=\"width:593px; height:527px;\" src=\"images/NEURO/88481_Manage_closed_nerve_injury.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">EDX: electrodiagnostic studies, EMG: electromyography; MRI: magnetic resonance imaging; MRN: magnetic resonance neurography; NCS: nerve conduction studies; SSEP: somatosensory evoked potentials; US: ultrasonography.</div><div class=\"graphic_reference\">Modified from: Grant GA, Goodkin R, Kliot M. Evaluation and surgical management of peripheral nerve problems. Neurosurgery 1999; 44:825.</div><div id=\"graphicVersion\">Graphic 88481 Version 1.0</div></div></div>"},"88483":{"type":"graphic_diagnosticimage","displayName":"SLE CT scan showing ground glass","title":"Ground glass pulmonary changes on computerized tomography imaging in systemic lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Ground glass pulmonary changes on computerized tomography imaging in systemic lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:590px; height:489px;\" src=\"images/RADIOL/88483_SLE_CT_scn_grnd_glass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The axial CT image from a 40-year-old female with systemic lupus erythematosus shows a subsegmental region of ground glass change (arrow) in the posterior segment of the right lower lobe. In the posterior segment of the left lower lobe, there is a focal parenchymal infiltrate with an air bronchogram (arrowhead).</div><div class=\"graphic_footnotes\">CT: computerized tomography.</div><div id=\"graphicVersion\">Graphic 88483 Version 1.0</div></div></div>"},"88484":{"type":"graphic_diagnosticimage","displayName":"Acute pneumonitis SLE chest x-ray and CT scan","title":"Acute pneumonitis on chest radiography and computerized tomography imaging in systemic lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Acute pneumonitis on chest radiography and computerized tomography imaging in systemic lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:599px; height:240px;\" src=\"images/RADIOL/88484_Acut_pneumon_SLE_x_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The chest x-ray performed on this 41-year-old female shows a diffuse interstitial pattern, and the CT scan through the chest shows multicentric ground glass changes centered around the bronchovascular bundle compatible with acute lupus pneumonitis.</div><div class=\"graphic_footnotes\">CT: computerized tomography.</div><div id=\"graphicVersion\">Graphic 88484 Version 1.0</div></div></div>"},"88485":{"type":"graphic_diagnosticimage","displayName":"SLE with interstitial lung disease on chest radiograph","title":"Chest radiograph showing interstitial lung disease in a patient with systemic lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Chest radiograph showing interstitial lung disease in a patient with systemic lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:599px; height:332px;\" src=\"images/RADIOL/88485_SLE_end_interst_fib_x.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;frontal and lateral&nbsp;chest radiographs&nbsp;show bibasilar&nbsp;reticular markings&nbsp;and honeycombing in a 39-year-old female patient with a&nbsp;longstanding diagnosis of SLE.</div><div class=\"graphic_footnotes\">AP: anteroposterior; SLE: systemic lupus erythematosus.</div><div class=\"graphic_reference\">Courtesy of Joseph Farnam, MD.</div><div id=\"graphicVersion\">Graphic 88485 Version 2.0</div></div></div>"},"88486":{"type":"graphic_diagnosticimage","displayName":"SLE with interstitial lung disease on CT scan","title":"Computerized tomography scan showing interstitial lung disease with honeycombing in systemic lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Computerized tomography scan showing interstitial&nbsp;lung disease with honeycombing in systemic lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:597px; height:223px;\" src=\"images/RADIOL/88486_SLE_end_interst_fib_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A:&nbsp;A small segmental region of honeycombing is demonstrated in the anterior segment of the right upper lobe (arrow)&nbsp;in this 39-year-old&nbsp;female with systemic lupus erythematosus. Panel B: Extensive honeycombing and reticular markings&nbsp;are demonstrated in the lower lobes (arrows).</div><div class=\"graphic_reference\">Courtesy of Joseph Farnam, MD.</div><div id=\"graphicVersion\">Graphic 88486 Version 2.0</div></div></div>"},"88489":{"type":"graphic_algorithm","displayName":"Management of type 2 diabetes in children and adolescents","title":"Management of type 2 diabetes in children and adolescents","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Management of type 2 diabetes in children and adolescents</div><div class=\"cntnt\"><img style=\"width:500px; height:386px;\" src=\"images/PEDS/88489_Manage_type_2_diab_adolesc.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BG: blood glucose; A1C: hemoglobin A1c.<BR>* Type 2 diabetes mellitus (T2DM) is typically characterized by overweight or obesity (BMI ≥85 percentile), a strong family history of T2DM, normal or elevated insulin and C-peptide concentrations, gradual onset of disease, evidence of insulin resistance (eg, acanthosis nigricans), and no evidence of diabetic autoimmunity (negative tests for islet autoantibodies such as IAA, ICA, GAD, IA2, and ZnT8). If all or most of these characteristics are present, the patient probably has type 2 diabetes. Some patients have mixed features, and will be difficult to classify. Refer to UpToDate topic review on presentation and diagnosis of type 2 diabetes in children.<BR><FONT class=bullet>•</FONT> In patients beginning insulin therapy, metformin should only be started after ketosis is cleared and blood glucose is improved. In those patients with A1C &gt;13 percent prior to insulin therapy, we suggest beginning metformin only after A1C has been reduced to &lt;12 percent with insulin therapy.<BR>Δ Lifestyle changes include dietary counseling as outlined by the Academy of Nutrition and Dietetics, physical activity (moderate to vigorous for at least 1 hour daily), and restricting nonacademic \"screen time\" to less than 2 hours daily.<BR><FONT class=lozenge>◊</FONT> Intensification of treatment consists of more frequent blood glucose monitoring and adjustment of the dose and type of medication to meet goals for blood glucose and A1C.</div><div class=\"graphic_reference\">Based on recommendations from: Copeland KC, Silverstein J, Moore KR, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. Pediatrics 2013; 131(2):364.</div><div id=\"graphicVersion\">Graphic 88489 Version 2.0</div></div></div>"},"88490":{"type":"graphic_table","displayName":"Summary of pediatric weight management guidelines from AND","title":"Summary of pediatric weight management guidelines from the Academy of Nutrition and Dietetics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of pediatric weight management guidelines from the Academy of Nutrition and Dietetics</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td><strong>A multi-component intervention is recommended, focusing on modifying diet and physical activity. This is implemented through nutrition counseling, with family participation.</strong></td> </tr> <tr> <td><strong>Assessment and intervention should focus on the following:</strong></td> </tr> <tr> <td class=\"indent1\">Eating habits:</td> </tr> <tr> <td class=\"indent2\">Reduce total dietary fat and calorically sweetened beverages</td> </tr> <tr> <td class=\"indent2\">Promote intake of vegetables and fruits</td> </tr> <tr> <td class=\"indent2\">Reduce consumption of food away from home</td> </tr> <tr> <td class=\"indent2\">Reduce portion sizes</td> </tr> <tr> <td class=\"indent2\">Do not skip breakfast</td> </tr> <tr> <td class=\"indent1\">Parental guidance:</td> </tr> <tr> <td class=\"indent2\">Do not strictly restrict highly-palatable foods, because this is predicted to lead to covert consumption</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Do not pressure the child to eat or use food as a reward</td> </tr> <tr> <td><strong>Energy intake goals:</strong></td> </tr> <tr> <td class=\"indent1\">Children 6 to 12 years: balanced macro-nutrient diet, no fewer than 900 kcal per day</td> </tr> <tr> <td class=\"indent1\">Adolescents 13 years and older: balanced macro-nutrient diet, no fewer than 1200 kcal per day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">For children and adolescents who are &#62;120 percent of ideal body weight with serious medical complications that require rapid weight loss, a medically supervised Protein Sparing Modified Fast Diet (PSMF) may be utilized in a short-term intervention (typically 10 weeks)</td> </tr> <tr> <td><strong>Physical activity goals:</strong></td> </tr> <tr> <td class=\"indent1\">Moderate to vigorous physical activity for at least one hour daily</td> </tr> <tr> <td class=\"indent1\">Restrict non-academic screen time (eg, television use) to less than two hours daily</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Recommendations from: the Academy of Nutrition and Dietetics, Pediatric weight management evidence-based nutrition practice guideline. Available at: http://andevidencelibrary.com/topic.cfm?cat=2721 (Accessed on February 25, 2013).</div><div id=\"graphicVersion\">Graphic 88490 Version 2.0</div></div></div>"},"88493":{"type":"graphic_picture","displayName":"Palmar-plantar rash human parechovirus type 3","title":"Palmar-plantar rash in children with human parechovirus type 3","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Palmar-plantar rash in children with human parechovirus type 3</div><div class=\"cntnt\"><img style=\"width:584px; height:436px;\" src=\"images/PEDS/88493_Palplantrashparechovirus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Erythematous palmar-plantar rash (39-day-old boy; day 4 after fever onset).<br />(C) Erythematous palmar rash (25-day-old boy; day 5 after fever onset).<br />(D) Erythematous plantar rash (84-day-old girl; day 3 after fever onset).</div><div class=\"graphic_reference\">Reproduced with permission from: Shoji K, Komuro H, Miyata I, et al. Dermatologic manifestations of human parechovirus type 3 infection in neonates and infants. Pediatr Infect Dis J 2013; 32:233. DOI: <a href=\"http://journals.lww.com/pidj/Abstract/2013/03000/Dermatologic_Manifestations_of_Human_Parechovirus.9.aspx\" target=\"_blank\">10.1097/INF.0b013e31827b1fd0</a>. Copyright &copy; 2013 Wolters Kluwer Health, Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 88493 Version 6.0</div></div></div>"},"88511":{"type":"graphic_diagnosticimage","displayName":"Infant coarctation of the aorta and heart failure","title":"Chest radiography of an infant with critical coarctation of the aorta and heart failure","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Chest radiography of an infant with critical coarctation of the aorta and heart failure</div><div class=\"cntnt\"><img style=\"width:599px; height:241px;\" src=\"images/RADIOL/88511_Infant_coarc_aort_fail.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a chest radiograph of a newborn infant who presented with respiratory distress. Image A is a frontal radiograph of the chest demonstrating pulmonary edema caused by critical coarctation of the descending aorta, which was diagnosed by echocardiography. Image B is the lateral chest radiograph from the same patient.</div><div class=\"graphic_reference\">Courtesy of Lachlan Smith, MD.</div><div id=\"graphicVersion\">Graphic 88511 Version 1.0</div></div></div>"},"88515":{"type":"graphic_table","displayName":"Interpretation of sweat chloride","title":"Interpretation of sweat chloride test results for diagnosis of cystic fibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpretation of sweat chloride test results for diagnosis of cystic fibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Sweat chloride concentration</td> <td class=\"subtitle1\">Result</td> <td class=\"subtitle1\">Interpretation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Newborn to 6 months</td> </tr> <tr> <td class=\"indent1\">&#8804;29 mmol/L</td> <td>Normal</td> <td>CF very unlikely</td> </tr> <tr> <td class=\"indent1\">30 to 59 mmol/L</td> <td>Intermediate</td> <td>Possible CF, additional testing recommended*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;60 mmol/L</td> <td>Abnormal</td> <td>Diagnosis of CF, if confirmed by a second test and if clinical symptoms consistent with CF are present<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Infants &#8805;6 months, children and adults</td> </tr> <tr> <td class=\"indent1\">&#8804;39 mmol/L</td> <td>Normal</td> <td>CF very unlikely</td> </tr> <tr> <td class=\"indent1\">40 to 59 mmol/L</td> <td>Intermediate</td> <td>Possible CF, additional testing recommended*</td> </tr> <tr> <td class=\"indent1\">&#8805;60 mmol/L</td> <td>Abnormal</td> <td>Diagnosis of CF, if confirmed by a second test and if clinical symptoms consistent with CF are present<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CF: cystic fibrosis.<br />* Additional testing usually consists of molecular diagnosis (DNA analysis) and a second sweat test.<br />¶ Clinical symptoms of CF are not required among newborns identified through a screening program, or among siblings of patients with CF who are diagnosed by shared genotype.</div><div class=\"graphic_reference\">Data from: Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008; 153:S4.</div><div id=\"graphicVersion\">Graphic 88515 Version 2.0</div></div></div>"},"88517":{"type":"graphic_algorithm","displayName":"Immobile arm in children","title":"Immobile arm in children","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Immobile arm in children</div><div class=\"cntnt\"><img style=\"width:588px; height:558px;\" src=\"images/EM/88517_Immobile_arm_children.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* More than one attempt or manuever may be needed for successful reduction.</div><div id=\"graphicVersion\">Graphic 88517 Version 2.0</div></div></div>"},"88518":{"type":"graphic_algorithm","displayName":"Immobile arm in children with neurologic deficits","title":"Immobile arm in children with neurologic deficits","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Immobile arm in children with neurologic deficits</div><div class=\"cntnt\"><img style=\"width:548px; height:278px;\" src=\"images/EM/88518_Immob_arm_child_neuro_def.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Erb or Klumpke palsy.<br />&#182; In some patients with rapid return of normal function, the diagnosis of Todd paralysis may be made without neuroimaging, especially those with a history of prior episodes.</div><div id=\"graphicVersion\">Graphic 88518 Version 2.0</div></div></div>"},"88519":{"type":"graphic_algorithm","displayName":"Immobile arm in children with fever inflammation systemic signs","title":"Immobile arm in children with fever, localized inflammation, or systemic illness ","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Immobile arm in children with fever, localized inflammation, or systemic illness </div><div class=\"cntnt\"><img style=\"width:473px; height:420px;\" src=\"images/EM/88519_Imm_arm_child_fev_inflamm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">* More than one attempt or manuever may be needed for successful reduction.<br /><span class=\"bullet\">&bull;</span> For example, leukocytosis in blood or joint fluid, elevated C-reactive protein or erythrocyte sedimentation rate, or, in young infants, positive serology for syphillis.</div><div id=\"graphicVersion\">Graphic 88519 Version 1.0</div></div></div>"},"88520":{"type":"graphic_table","displayName":"Identifying the actively dying patient","title":"Identifying the actively dying patient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Identifying the actively dying patient</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Profound progressive weakness</td> </tr> <tr> <td>Bed-bound state</td> </tr> <tr> <td>Sleeping much of the time</td> </tr> <tr> <td>Indifference to food and fluids</td> </tr> <tr> <td>Difficulty swallowing</td> </tr> <tr> <td>Disorientation to time, with increasingly short attention span</td> </tr> <tr> <td>Low or lower blood pressure not related to hypovolemia</td> </tr> <tr> <td>Urinary incontinence or retention caused by weakness</td> </tr> <tr> <td>Oliguria</td> </tr> <tr> <td>Loss of ability to close eyes</td> </tr> <tr> <td>Hallucinations involving previously deceased important individuals</td> </tr> <tr> <td>References to going home or similar themes</td> </tr> <tr> <td>Changes in respiratory rate and pattern (Cheyne-Stokes breathing, apneas)</td> </tr> <tr> <td>Noisy breathing, pooling of airway secretions</td> </tr> <tr> <td>Mottling and cooling of the skin due to vasomotor instability with venous pooling, particularly tibial</td> </tr> <tr> <td>Dropping blood pressure with rising, weak pulse</td> </tr> <tr> <td>Mental status changes (delirium, restlessness, agitation, coma)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Bicanovsky L. Comfort Care: Symptom Control in the Dying. In: Palliative Medicine, Walsh D, Caraceni AT, Fainsinger R, et al (Eds), Saunders, Philadelphia 2009. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88520 Version 2.0</div></div></div>"},"88521":{"type":"graphic_table","displayName":"Elements of quality end of life care","title":"Elements of quality end of life care from the SUPPORT study","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Elements of quality end of life care from the SUPPORT study</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">1. Care related to symptoms and personal care</td> </tr> <tr> <td class=\"indent2\">Pain and symptom management</td> </tr> <tr> <td class=\"indent2\">Being clean</td> </tr> <tr> <td class=\"indent2\">Having physical touch</td> </tr> <tr> <td class=\"subtitle1_single\">2. Being prepared for death</td> </tr> <tr> <td class=\"indent2\">Having affairs in order</td> </tr> <tr> <td class=\"indent2\">Believing family is prepared</td> </tr> <tr> <td class=\"indent2\">Knowing what to expect</td> </tr> <tr> <td class=\"indent2\">Communicating treatment preferences and naming a proxy decision maker</td> </tr> <tr> <td class=\"subtitle1_single\">3. Achieving a sense of completion</td> </tr> <tr> <td class=\"indent2\">Saying good bye to important people</td> </tr> <tr> <td class=\"indent2\">Recognizing one's own accomplishments</td> </tr> <tr> <td class=\"indent2\">Resolving unfinished business</td> </tr> <tr> <td class=\"subtitle1_single\">4. Being treated as a whole person</td> </tr> <tr> <td class=\"indent2\">Maintaining dignity</td> </tr> <tr> <td class=\"indent2\">Maintaining a sense of humor</td> </tr> <tr> <td class=\"indent2\">Not dying alone</td> </tr> <tr> <td class=\"indent2\">Having someone who will listen</td> </tr> <tr> <td class=\"subtitle1_single\">5. Relating to family, society, care providers, and transcendent</td> </tr> <tr> <td class=\"indent2\">Trust in and comfort with physician and nurses</td> </tr> <tr> <td class=\"indent2\">Being able to discuss personal fears, including dying and death</td> </tr> <tr> <td class=\"indent2\">Not being a burden to family or society</td> </tr> <tr> <td class=\"indent2\">Being able to help others</td> </tr> <tr> <td class=\"indent2\">Coming to peace with God</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Wilson DM, Cable-Williams BE. Death in Modern Society. In: Palliative Medicine, Walsh D, Caraceni AT, Fainsinger R, et al (Eds), Saunders, Philadelphia 2009. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88521 Version 1.0</div></div></div>"},"88522":{"type":"graphic_table","displayName":"Genetic testing in retinoblastoma","title":"Summary of molecular genetic testing used in retinoblastoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of molecular genetic testing used in retinoblastoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gene symbol</td> <td class=\"subtitle1\" colspan=\"2\">Test method</td> <td class=\"subtitle1\">Mutations detected</td> <td class=\"subtitle1\">Mutation detection frequency by test method*<sup>&#182;</sup></td> <td class=\"subtitle1\">Test availability<sup>&#916;</sup></td> </tr> <tr> <td rowspan=\"8\"><em>RB1</em></td> <td rowspan=\"3\">Gross deletion/duplication analysis<sup>&#9674;</sup></td> <td>FISH</td> <td rowspan=\"2\">Submicroscopic deletions and translocations</td> <td>&#62;8%</td> <td class=\"centered\" rowspan=\"7\">For a list of available laboratories, please see <a href=\"http://www.ncbi.nlm.nih.gov/gtr/tests/?term=C0035335%5BDISCUI%5D&#38;condition=C0035335&amp;#38;compare_labs=1\" target=\"_blank\">the Genetic Testing Registry</a></td> </tr> <tr> <td>Heterozygosity testing</td> <td>8%</td> </tr> <tr> <td>MLPA, quantitative multiplex PCR, other methods<sup>&#9674;</sup></td> <td>Submicroscopic whole exon(s) deletions, insertions, and rearrangements</td> <td>16%</td> </tr> <tr> <td colspan=\"2\">Mutation scanning</td> <td rowspan=\"2\">Single-base substitutions, small length mutations</td> <td rowspan=\"2\">70 to 75%</td> </tr> <tr> <td colspan=\"2\">Sequence analysis (genomic)</td> </tr> <tr> <td colspan=\"2\">Targeted mutation analysis</td> <td>Specific panel of recurrent point mutations</td> <td>25%</td> </tr> <tr> <td colspan=\"2\">Methylation analysis</td> <td>Hypermethylation of the promoter region</td> <td>10 to 12%<sup>&#167;</sup></td> </tr> <tr> <td colspan=\"2\">Sequence analysis of RNA from blood</td> <td>(Deep intronic) splice mutations, gross rearrangements</td> <td>&#60;5%<sup>&#165;</sup></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FISH: fluorescence in situ hybridization; MLPA: multiplex ligation-dependent probe amplification; PCR: polymerase chain reaction; GH: genomic hybridization; CLIA: Clinical Laboratory Improvement Amendments.<br />* The ability of the test method used to detect a mutation that is present in the indicated gene.<br />¶ In individuals with normal chromosome studies; refers to the ability to detect a&nbsp;heritable mutation if one is present.<br />Δ Test availability refers to availability in the GeneTests Laboratory Directory. <EM>GeneReviews</EM> designates a molecular genetic test as clinically available only if the test is listed in the GeneTests Laboratory Directory by either a US CLIA-licensed laboratory or a non-US clinical laboratory. GeneTests does not verify laboratory-submitted information or warrant any aspect of a laboratory's licensure or performance. Clinicians must communicate directly with the laboratories to verify information.<br /><FONT class=lozenge>◊</FONT> Testing that identifies whole-exon deletions/duplications not readily detectable by sequence analysis of genomic DNA; a variety of methods including quantitative PCR, long-range PCR, MLPA, or targeted array GH (gene/segment-specific) may be used. A full array GH analysis that detects deletions/duplications across the genome may also include this gene/segment.<br />§ In retinoblastoma tumor tissue.<br />¥ In individuals without a mutation identified by DNA-based analyses.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Lohmann D, Scheffer H, Gaille B. Best practice guidelines for molecular analysis of retinoblastoma. European Molecular Genetics Quality Network 2002.</li>&#xD;&#xA;    <li>Rushlow D, Piovesan B, Zhang K, et al. Detection of mosaic RB1 mutations in families with retinoblastoma. Hum Mutat 2009; 30:842.</li>&#xD;&#xA;    <li>Zhang K, Nowak I, Rushlow D, et al. Patterns of missplicing caused by RB1 gene mutations in patients with retinoblastoma and association with phenotypic expression. Hum Mutat 2008; 29:475.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Lohmann DR, Gallie BL. Retinoblastoma. GeneReviews. Pagon RA, Bird TD, Dolan CR, et al (Eds). Copyright &copy; University of Washington, Seattle, 1993-2013. Available at: <a href=\"http://www.ncbi.nlm.nih.gov/books/NBK1452/\" target=\"_blank\">http://www.ncbi.nlm.nih.gov/books/NBK1452/</a>. Accessed on March 5, 2013.</div><div id=\"graphicVersion\">Graphic 88522 Version 5.0</div></div></div>"},"88523":{"type":"graphic_figure","displayName":"Breast anatomy","title":"Anatomy of the breast","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Anatomy of the breast</div><div class=\"cntnt\"><img style=\"width:538px; height:509px;\" src=\"images/PEDS/88523_Breast_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 88523 Version 4.0</div></div></div>"},"88524":{"type":"graphic_diagnosticimage","displayName":"Abdominal x-ray small bowel obstruction","title":"Small bowel obstruction on x-ray of the abdomen","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Small bowel obstruction on x-ray of the abdomen</div><div class=\"cntnt\"><img style=\"width:587px; height:341px;\" src=\"images/RADIOL/88524_Sm_bow_obstruct_abdom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A supine examination of the abdomen (A) shows a dilated loop of small bowel on the left side of the abdomen (arrow). The upright examination (B) shows an air fluid level in the stomach (arrow) and in the small bowel (arrowhead).</div><div id=\"graphicVersion\">Graphic 88524 Version 2.0</div></div></div>"},"88525":{"type":"graphic_diagnosticimage","displayName":"CT small bowel obstruction","title":"Small bowel obstruction and small bowel feces sign on a CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Small bowel obstruction and small bowel feces sign on a CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:354px;\" src=\"images/RADIOL/88525_CT_sm_bowel_obstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of the abdomen at the level of the umbilicus (A) shows a transition zone defining the level of a small bowel obstruction (dashed arrow). The upstream small bowel (short arrow) is dilated and the downstream small bowel is decompressed (arrow). The descending colon is also decompressed (arrowhead). Image B is a sagittal reconstruction of the CT and shows the zone of transition (dashed arrow) and a small bowel feces sign (arrow) in the adjacent upstream small bowel. The rectum is empty (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 88525 Version 1.0</div></div></div>"},"88526":{"type":"graphic_picture","displayName":"Wax injection model of the mammary duct tree","title":"Wax injection model of the mammary duct tree","html":"<div class=\"graphic\"><div style=\"width: 802px\" class=\"figure\"><div class=\"ttl\">Wax injection model of the mammary duct tree</div><div class=\"cntnt\"><img style=\"width:782px; height:674px;\" src=\"images/SURG/88526_Wax_injct_mdl_mamm_dct_tree.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On the Anatomy of the Breast, Plate V, Fig. 1. Cooper's caption reads \"Lactiferous tubes, injected with red wax, in a woman who died during the period of lactation. Twelve ducts have been filled and ligatures are placed on their orifices. The ducts are seen forming large reservoirs at the roots of the mamillary tubes; these reservoirs are seen to be produced by the union of numerous branches from the ducts. The ducts are perceived to terminate at the margin of the gland in branches, but in some parts, in glandules.\" Glandular tissue is most obvious at 3 to 5 o'clock and 10 to 11 o'clock. This may be the first published suggestion of significant biological variation between human mammary gland lobes.</div><div class=\"graphic_reference\">Reproduced from: Cooper AP. Plate V: Ducts, reservoirs, and glandules. In: The Anatomy of the Breast, Longman, Orme, Green, Brown, and Longmans, London 1840.</div><div id=\"graphicVersion\">Graphic 88526 Version 1.0</div></div></div>"},"88531":{"type":"graphic_table","displayName":"Classification of tricuspid valve atresia","title":"Classification of tricuspid valve (TV) atresia based on associated anatomic lesions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of tricuspid valve (TV) atresia based on associated anatomic lesions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type I</td> <td class=\"subtitle1\">Type II</td> <td class=\"subtitle1\">Type III</td> </tr> <tr> <td>TV atresia with normally related great arteries <ul> <li>Type a - intact ventricular septum with pulmonary atresia</li> <li>Type b - small VSD with pulmonary stenosis/hypoplasia</li> <li>Type c - large VSD without pulmonary stenosis</li> </ul> </td> <td>TV atresia with D-loop transposition of great arteries <ul> <li>Type a - VSD with pulmonary atresia</li> <li>Type b - VSD with pulmonary stenosis/hypoplasia</li> <li>Type c - VSD without pulmonary stenosis</li> </ul> </td> <td>TV atresia with malposition of the great arteries other than D-loop transposition of the great arteries, associated complex lesions (eg, truncus arteriosus, atriventricular septal defects, double outlet right ventricle)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TV atresia: tricuspid valve atresia; VSD: ventricular septal defect.</div><div class=\"graphic_reference\">Reproduced with permission from: Epstein ML. Tricuspid atresia, stenosis, regurgitation. In: Moss and Adams Heart Disease in Infants, Children, and Adolescents. Allen HD, Driscoll DJ, Shaddy RE, Feltes TF (Eds), Lippincott Williams &amp; Wilkins 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 88531 Version 4.0</div></div></div>"},"88532":{"type":"graphic_waveform","displayName":"ECG tricuspid valve atresia","title":"Electrocardiograph in an infant with tricuspid valve atresia","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Electrocardiograph in an infant with tricuspid valve atresia</div><div class=\"cntnt\"><img style=\"width:600px; height:466px;\" src=\"images/PEDS/88532_ECG_tricuspid_valve_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 12-lead electrocardiogram demonstrates some typical findings noted in infants with tricuspid valve atresia. Tall P-waves in lead II indicate right atrial enlargement, and ventricular forces are notable for left axis deviation and diminished right ventricular forces (small or absent R-waves in precordial leads V1&ndash;V3).</div><div id=\"graphicVersion\">Graphic 88532 Version 1.0</div></div></div>"},"88533":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray tricuspid valve atresia","title":"Chest radiograph of an infant with tricuspid valve atresia","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of an infant with tricuspid valve atresia</div><div class=\"cntnt\"><img style=\"width:481px; height:487px;\" src=\"images/PEDS/88533_Cxray_tricuspid_val_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a chest x-ray of an infant with tricuspid valve atresia, with ventricular septal defect (VSD) and mild pulmonary stenosis (tricuspid atresia Type 1b with normal anatomy of the great arteries and a small VSD). Radiographic findings in tricuspid valve atresia are dependent on associated cardiac conditions, which vary from patient to patient. In this patient, there is mild cardiomegaly and increased pulmonary vascular markings, consistent with moderately increased pulmonary blood flow due to the VSD.</div><div id=\"graphicVersion\">Graphic 88533 Version 1.0</div></div></div>"},"88534":{"type":"graphic_diagnosticimage","displayName":"Echocardiography tricuspid valve atresia","title":"Echocardiograph in an infant with tricuspid valve atresia","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Echocardiograph in an infant with tricuspid valve atresia</div><div class=\"cntnt\"><img style=\"width:590px; height:448px;\" src=\"images/PEDS/88534_Echocard_tricus_val_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an apical four-chamber view of the heart taken from an echocardiogram performed in an infant with tricuspid valve&nbsp;atresia Type 1b (normal anatomy of the great arteries and a small ventricular septal defect [VSD]). The enlarged atria and left ventricle, an interatrial communication, and a small slit-like right ventricle (*)&nbsp;with absence of the tricuspid valve are appreciated. The VSD and pulmonary stenosis associated with subtype 1b of tricuspid valve atresia are not demonstrated in this frame.</div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium; LV: left ventricle.<br />* Hypoplastic right ventricle.</div><div id=\"graphicVersion\">Graphic 88534 Version 1.0</div></div></div>"},"88535":{"type":"graphic_figure","displayName":"Birth control effectiveness PI","title":"How effective are the different forms of birth control?","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">How effective are the different forms of birth control?</div><div class=\"cntnt\"><img style=\"width:620px; height:504px;\" src=\"images/PI/88535_Birth_control_effective_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LAM: lactational amenorrhea method.</div><div class=\"graphic_reference\">Reproduced with permission from: the World Health Organization.</div><div id=\"graphicVersion\">Graphic 88535 Version 2.0</div></div></div>"},"88537":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray pulmonary atresia with intact VS","title":"Chest radiograph of an infant with pulmonary atresia with intact ventricular septum","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of an infant with pulmonary atresia with intact ventricular septum</div><div class=\"cntnt\"><img style=\"width:590px; height:512px;\" src=\"images/PEDS/88537_Chest_xray_pulm_atresia_VS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anteroposterior (AP) chest radiograph of a cyanotic neonate with pulmonary atresia with an intact ventricular septum, demonstrating right atrial enlargement and cardiomegaly due to significant tricuspid regurgitation. There is also a relative paucity of pulmonary vascularity.</div><div id=\"graphicVersion\">Graphic 88537 Version 1.0</div></div></div>"},"88538":{"type":"graphic_picture","displayName":"Embedded earring","title":"Embedded earring","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Embedded earring</div><div class=\"cntnt\"><img style=\"width:598px; height:285px;\" src=\"images/EM/88538_Embedded_ear_ring.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Ear ring embedded in the lobule of the ear.<br />(B) The lobule is infiltrated with local anesthetic and posterior surface incised with a #11 blade.<br />(C) The embedded earring is removed.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 88538 Version 1.0</div></div></div>"},"88539":{"type":"graphic_waveform","displayName":"ECG pulmonary atresia with intact VS","title":"Electrocardiograph of an infant with pulmonary atresia with intact ventricular septum","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Electrocardiograph of an infant with pulmonary atresia with intact ventricular septum</div><div class=\"cntnt\"><img style=\"width:610px; height:358px;\" src=\"images/PEDS/88539_ECG_pulm_atresia_intact_VS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This electrocardiogram (ECG) of a neonate demonstrates several features consistent with pulmonary atresia with an intact ventricular septum (PA/IVS), including right atrial enlargement based on tall p waves in leads I, II, and aVF, and abnormal relative left axis deviation (QRS axis +30 degrees) due to a decrease of right-sided forces from RV hypoplasia. Cyanosis in a neonate with left axis deviation on ECG should prompt the clinician to consider PA/IVS. Although the ECG does not demonstrate significant myocardial ischemia, ST and T wave abnormalities should be ruled out on all patients with PA/IVS due to the possibility of coronary abnormalities.</div><div id=\"graphicVersion\">Graphic 88539 Version 3.0</div></div></div>"},"88540":{"type":"graphic_diagnosticimage","displayName":"Echo pulmonary atresia with intact VS","title":"Echocardiographic images of pulmonary atresia with intact ventricular septum","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Echocardiographic images of pulmonary atresia with intact ventricular septum</div><div class=\"cntnt\"><img style=\"width:595px; height:490px;\" src=\"images/PEDS/88540_Echo_pulm_atresia_intact_VS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Echocardiogram in a fetus at 32 weeks gestation with pulmonary atresia and intact ventricular septum (PA/IVS) demonstrates the normally formed aortic arch with a vertical ductus arteriosus (*). In the normal fetus, the ductus arteriosus lies in a more horizontal plane as it carries blood from the main pulmonary artery to the descending aorta. In the fetus with PA/IVS, the ductus arteriosus provides retrograde pulmonary blood flow and it lies in a more vertical position.<br />(B) Four-chamber view in a fetus at 32 weeks gestation with PA/IVS demonstrating a severely hypoplastic RV and shunting of blood from the RA through the foramen ovale (*) to the LA and LV.<br />(C) Four-chamber view in a neonate with PA/IVS demonstrating a small tricuspid valve and RV compared with the normally sized mitral valve and LV.<br />(D) Four-chamber view in a neonate with PA/IVS with measurements of the tricuspid and mitral valves. Note the small tricuspid valve (measurement 1) and RV compared with the normally sized mitral valve (measurement 2) and LV; the tricuspid valve measures 0.3 centimeters, which correlates to a Z-score of approximately &ndash;4.</div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium; RV: right ventricle; LV: left ventricle.</div><div class=\"graphic_reference\">Courtesy of Rajesh Punn, MD.</div><div id=\"graphicVersion\">Graphic 88540 Version 3.0</div></div></div>"},"88541":{"type":"graphic_diagnosticimage","displayName":"Cath pulmonary atresia with intact VS","title":"Cardiac catheterization images of pulmonary atresia with intact ventricular septum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cardiac catheterization images of pulmonary atresia with intact ventricular septum</div><div class=\"cntnt\"><img style=\"width:442px; height:656px;\" src=\"images/PEDS/88541_Cath_pulm_atresia_intact_VS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Posteroanterior and lateral angiograms demonstrating an atretic PV in a neonate. There is a well formed infundibulum (right ventricular outflow tract [RVOT]), and multiple connections between the RV and the coronary arteries are evident. (* denotes coronary connections filled from the right ventricle).<br />(B) Posteroanterior angiogram in a neonate after surgery for PA/intact ventricular septum [IVS]. There is a hypoplastic RV, and multiple connections between the RV and coronary arteries are evident. (* denotes coronary connections filled from the RV).<br />(C) Posteroanterior and lateral angiograms of a patient with a tripartite RV after surgery for PA/IVS. The pulmonary valve leaflets are evident and there is a well-formed inlet, body, and infundibulum of the RV. Coronary connections from the RV are present, but less prominent than in angiograms A and B. (* denotes coronary connections filled from the RV).</div><div class=\"graphic_footnotes\">PA: posteroanterior; PV: pulmonary valve; RV: right ventricle.</div><div id=\"graphicVersion\">Graphic 88541 Version 2.0</div></div></div>"},"88543":{"type":"graphic_table","displayName":"Second-line TB drugs for children","title":"Dosing of second-line antituberculosis drugs in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing of second-line antituberculosis drugs in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Daily pediatric dose</td> <td class=\"subtitle1\">Usual maximum daily dose</td> <td class=\"subtitle1\">Main and rare but serious adverse effects</td> </tr> <tr> <td>Levofloxacin*</td> <td>15 to 20 mg/kg orally or IV in two divided doses*</td> <td>750 mg* (may increase to 1000 mg per day if tolerated)</td> <td rowspan=\"2\">GI toxicity, arthralgias, tendonitis, tendon rupture, CNS effects (including sleep disturbance and headache), peripheral neuropathy, QT prolongation, dysglycemia, rash, hepatotoxicity</td> </tr> <tr> <td>Moxifloxacin*</td> <td>10 mg/kg orally or IV*</td> <td>400 mg*</td> </tr> <tr> <td>Amikacin<sup><span style=\"font-size: 13px;\">&#182;&#916;</span></sup></td> <td>15 to&nbsp;20 mg/kg IM or IV adjusted according to serum concentrations</td> <td>1 g</td> <td>Ototoxicity, vestibular toxicity, nephrotoxicity, electrolyte disturbances, local pain with IM injections</td> </tr> <tr> <td>Kanamycin<sup>&#182;&#916;</sup></td> <td>15 to 20 mg/kg IM or IV adjusted according to serum concentrations</td> <td>1 g</td> <td>Ototoxicity, vestibular toxicity, nephrotoxicity, electrolyte disturbances, local pain with IM injections</td> </tr> <tr> <td>Capreomycin<sup>&#182;&#916;</sup></td> <td>15 to 20 mg/kg IM or IV adjusted according to serum concentrations</td> <td>1 g</td> <td>Ototoxicity, vestibular toxicity, nephrotoxicity, electrolyte disturbances, local pain with IM injections</td> </tr> <tr> <td>Streptomycin<sup>&#182;</sup><sup>&#916;</sup></td> <td>15 to 20 mg/kg IM or IV</td> <td>1 g</td> <td>Ototoxicity, vestibular toxicity, nephrotoxicity, electrolyte disturbances, local pain with IM injections </td> </tr> <tr> <td>Ethionamide</td> <td>15 to 20 mg/kg orally in one dose or two divided doses</td> <td>1 g</td> <td>GI toxicity (antiemetic premedication is often helpful), hepatic toxicity, metallic taste, endocrine effects including hypothyroidism (treat with thyroid replacement), neurotoxicity; pyridoxine 50 to 100 mg per day (scaled to body weight) may be useful in preventing or reducing peripheral neuropathy</td> </tr> <tr> <td>Cycloserine<sup>&#9674;</sup></td> <td>15 to 20 mg/kg orally in one dose or&nbsp;two divided doses</td> <td>1 g</td> <td> <p>CNS toxicity (psychiatric symptoms, seizures usually occur at peak concentrations &#62;35 mcg/mL but may occur in the normal therapeutic range), peripheral neuropathy, dermatologic effects</p> <p>Administration of pyridoxine 50 mg (oral once per day scaled to body weight) for every 250 mg of cycloserine may be useful in preventing or reducing neurotoxicity</p> </td> </tr> <tr> <td>Linezolid</td> <td> <p>&#60;12&nbsp; years old: 20 mg kg orally or IV in two divided doses</p> <p>&#8805;12&nbsp; years old:&nbsp; 600 mg orally or IV once per day</p> </td> <td>600 mg</td> <td>Myelosuppression, GI toxicity, neuropathy (optic and peripheral); pyridoxine 50 to 100 mg per day (scaled to body weight) may be useful in preventing or reducing peripheral neuropathy </td> </tr> <tr> <td>Clofazimine (not commercially available in the United States; requires application to FDA Division of Special Pathogen and Immunologic Drug Products; telephone <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">301-796-1600</span>)</td> <td>1 to 5 mg/kg orally (optimal dose in children is unknown)</td> <td>300 mg</td> <td>Red-grey discoloration of skin, eyes, body fluids, GI toxicity, photosensitivity, others</td> </tr> <tr> <td>High-dose isoniazid</td> <td>15 to 20 mg/kg orally, IM, or IV </td> <td>400 mg</td> <td>Hepatitis, peripheral neuropathy (administer with pyridoxine), hypersensitivity, others </td> </tr> <tr> <td>Bedaquiline</td> <td>Not recommended for use in children (data lacking, optimal dose is unknown)</td> <td>&nbsp;</td> <td>QT prolongation, hepatitis, GI toxicity, others</td> </tr> <tr> <td>Delamanid</td> <td>Not recommended for use in children (data lacking, studies are ongoing)</td> <td>&nbsp;</td> <td>GI toxicity, QT prolongation</td> </tr> <tr> <td>Para-aminosalicylic acid</td> <td> <p>200 to 300 mg/kg orally (usually divided 100 mg/kg in two or three divided doses)</p> </td> <td>12 g</td> <td>GI toxicity, hepatotoxicity, hypothyroidism (treat with thyroid replacement)</td> </tr> <tr> <td>Imipenem-cilastatin</td> <td>&#167;</td> <td>&#167;</td> <td>GI toxicity, seizures</td> </tr> <tr> <td>Meropenem<sup>&#165;</sup></td> <td>60 mg/kg IV in three divided doses; must be given with oral clavulanate (see amoxicillin-clavulanate below)</td> <td>3 g</td> <td>GI toxicity, seizures</td> </tr> <tr> <td>Amoxicillin-clavulanate</td> <td>45 mg/kg amoxicillin component orally in three divided doses</td> <td>2&nbsp;g (amoxicillin component), 375 mg (clavulanate component)</td> <td>GI toxicity</td> </tr> <tr> <td>Thiacetazone<sup>&#135;</sup> (not available in United States)</td> <td>3 to 4 mg/kg orally</td> <td>150 mg</td> <td>GI toxicity, myelosuppression, hepatitis, peripheral neuropathy, cutaneous hypersensitivity reactions</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Antituberculous agents are used in multidrug combination regimens of varying duration, which are described in detail in a separate table (refer to the UpToDate table on regimens for treatment of drug-susceptible tuberculosis) and in the accompanying text. The optimal dosing of many second-line drugs used to treat drug-resistant tuberculosis in children is not known.<br />Dosing of oral medications for treatment of multidrug-resistant or extensively drug-resistant tuberculosis should be daily, not intermittent.<br />Doses listed in this table are for patients with normal renal function; dose adjustment of many of these agents is needed in altered renal function. </div><div class=\"graphic_footnotes\">TB: tuberculosis; IV: intravenous; GI: gastrointestinal; CNS: central nervous system; IM: intramuscular.<br />* According to the American Academy of Pediatrics, although fluoroquinolones are not routinely first-line therapy in children &lt;18 years old, their use may be justified in certain circumstances, such as multidrug-resistant tuberculosis. The optimal dose is not known.<br />¶ Generally given five to seven times per week (15 mg/kg or a maximum of 1 g per dose) for an initial two to four months and then (if needed) two to three times per week (20 to 30 mg/kg or a maximum of 1.5 g per dose). Dose should be decreased if renal function is diminished. Amikacin is preferred to kanamycin in children. Since IM injection of amikacin is very painful, IV infusion is preferred.<br />Δ For patients who are overweight or obese, dose is based on adjusted dosing weight (refer to the&nbsp;UpToDate calculator). When available, serum drug monitoring is advised to establish optimal dosing.<br /><FONT class=lozenge>◊</FONT> When available, serum drug monitoring is advised to establish optimal dosing. Recommended peak (two to four hours post-dose) level is not higher than 30 microg/mL.<br />§&nbsp;Experience with imipenem-cilastatin in children with drug-resistant TB is very limited.<br />¥&nbsp;Dosing of meropenem in the setting of meningitis (in the absence of specific data for tuberculous meningitis) consists of 120 mg/kg in three divided doses.<br />‡&nbsp;Should not be used in patients with HIV because of the serious risk of life-threatening adverse effects.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Seddon JA, Furn JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med 2012; 186:953.</LI>&#xD;&#xA;<LI>World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO, Geneva 2008.</LI>&#xD;&#xA;<LI>World Health Organization.&nbsp;WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. WHO, Geneva 2016.</LI>&#xD;&#xA;<LI>World Health Organization.&nbsp;Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2nd ed. WHO, Geneva 2014.</LI>&#xD;&#xA;<LI>Treatment Guidelines from The Medical Letter. The Medical Letter 2012; 10:29.</LI>&#xD;&#xA;<LI>Curry International Tuberculosis Center and California Department of Public Health, 2016: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition.</LI></OL></div><div id=\"graphicVersion\">Graphic 88543 Version 6.0</div></div></div>"},"88545":{"type":"graphic_movie","displayName":"2D TTE short axis LA appendage","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal short axis view at the level of the aortic valve showing the left atrial (LA) appendage","html":"<div class=\"graphic normal\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal short axis view at the level of the aortic valve showing the left atrial (LA) appendage</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/88545_2DTTEshortaxisLAmovie.mp4\" style=\"width:528px;height:368px\"></div><img style=\"width:576px; height:398px;\" src=\"images/CARD/88545_2DTTEshortaxisLAimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left atrial appendage is seen on the right.</div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium; LAA: left atrial appendage; AoV: aortic valve.</div><div id=\"graphicVersion\">Graphic 88545 Version 1.0</div></div></div>"},"88547":{"type":"graphic_picture","displayName":"Chronic eosinophilic leukemia with FIP1L1-PDGFRA","title":"Chronic eosinophilic leukemia with FIP1L1-PDGFRA","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic eosinophilic leukemia with FIP1L1-PDGFRA</div><div class=\"cntnt\"><img style=\"width:419px; height:514px;\" src=\"images/ALLRG/88547_Chron_eosin_leuk_FIPL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood (panels A and B) and bone marrow aspirate (panel C) samples from a patient with myeloproliferative neoplasm with eosinophilia and abnormalities of PDGFRA.&nbsp;The peripheral blood film shows eosinophils with abnormal size, granulation, and nuclear lobulation. Red blood cells and platelets are normal and there are no circulating blast cells. The bone marrow exhibits eosinophilic hyperplasia and increased myeloid blast cells (panel C;&nbsp;white arrows show blast cells). Abnormal eosinophils with dysplastic granules are present.<br /></div><div class=\"graphic_footnotes\">FIP1L1-PDGFRA: Fip1-like1-platelet-derived growth factor receptor alpha.</div><div class=\"graphic_reference\">This research was originally published in Blood. Verdu J, de Paz F. Chronic eosinophilic leukemia with FIP1L1-PDGFRA. Blood 2013; 121:1254. Copyright © 2013 The American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 88547 Version 5.0</div></div></div>"},"88548":{"type":"graphic_picture","displayName":"TB granuloma and immune recovery","title":"Iris granuloma due to tuberculosis followed by immune recovery tuberculous uveitis","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Iris granuloma due to tuberculosis followed by immune recovery tuberculous uveitis</div><div class=\"cntnt\"><img style=\"width:605px; height:382px;\" src=\"images/ID/88548_TB_granuloma_immune_recov.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Right eye of an HIV patient with coexisting tubercular uveitis showing iris granuloma and hypopyon. Anterior chamber aspiration revealed acid-fast bacilli, confirming the diagnosis of tuberculosis. (B) Severe form of immune recovery uveitis resulting in perforation of the right eye following antiretroviral therapy and antitubercular treatment. Iris is seen prolapsed through the perforation site at the limbus.</div><div id=\"graphicVersion\">Graphic 88548 Version 4.0</div></div></div>"},"88571":{"type":"graphic_picture","displayName":"Pathology of endometrial stromal sarcoma","title":"Pathology of endometrial stromal sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathology of endometrial stromal sarcoma</div><div class=\"cntnt\"><img style=\"width:349px; height:262px;\" src=\"images/ONC/88571_Path_endometri_strom_sarc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">H&E stain, 400x.</div><div class=\"graphic_reference\">Courtesy of Rex Bentley, MD.</div><div id=\"graphicVersion\">Graphic 88571 Version 2.0</div></div></div>"},"88588":{"type":"graphic_table","displayName":"Terminology developmental dysplasia of the hip","title":"Terminology for developmental dysplasia of the hip","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Terminology for developmental dysplasia of the hip</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Term</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td>Dysplasia</td> <td>Abnormality of the shape of the hip joint (usually shallowness of the acetabulum, involving the superior and anterior margins).</td> </tr> <tr> <td>Subluxatable/subluxable</td> <td>The femoral head is reduced (ie, within the acetabulum) at rest but can be partially dislocated or subluxated with examination maneuvers. This is a hip with <strong>mild instability or laxity</strong>.</td> </tr> <tr> <td>Dislocatable</td> <td>The femoral head is reduced at rest but can&nbsp;dislocate in other positions or with examination maneuvers. This is a hip with<strong> instabi</strong><strong>lity</strong>.&nbsp;</td> </tr> <tr> <td>Subluxation</td> <td>The femoral head is partially outside of the acetabulum but remains in contact with it.&nbsp;</td> </tr> <tr> <td>Reducible</td> <td>The&nbsp;hip dislocated at rest, but the femoral head can be positioned into the acetabulum with manipulation (generally flexion and abduction).</td> </tr> <tr> <td>Dislocation&nbsp;</td> <td>Complete loss of contact between the femoral head and the acetabulum. </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 88588 Version 2.0</div></div></div>"},"88589":{"type":"graphic_figure","displayName":"Anatomy developmental dysplasia of the hip","title":"Anatomy of developmental dysplasia of the hip","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Anatomy of developmental dysplasia of the hip</div><div class=\"cntnt\"><img style=\"width:475px; height:571px;\" src=\"images/PEDS/88589_Anat_devel_dysplasia_hip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Obstacles to reduction of a dislocated hip include medial capsular constriction, inverted labrum, neolimbus, pulvinar, hypertrophied ligamentum teres and transverse acetabular ligament, and tight iliopsoas tendon.</div><div id=\"graphicVersion\">Graphic 88589 Version 1.0</div></div></div>"},"88595":{"type":"graphic_diagnosticimage","displayName":"Bilateral inguinal hernias","title":"Bilateral inguinal hernias","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Bilateral inguinal hernias</div><div class=\"cntnt\"><img style=\"width:548px; height:321px;\" src=\"images/RADIOL/88595_Bilat_femoral_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan of the pelvis through the femoral heads show bilateral fat containing inguinal hernias (arrows) extending medial to the pubic tubercle (arrowheads) and&nbsp;associated with non-compressed femoral veins (dashed arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 88595 Version 3.0</div></div></div>"},"88596":{"type":"graphic_diagnosticimage","displayName":"Nonobstructing left inguinal hernia on CT","title":"Nonobstructing left inguinal hernia on CT","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Nonobstructing left inguinal hernia on CT</div><div class=\"cntnt\"><img style=\"width:565px; height:510px;\" src=\"images/RADIOL/88596_Non_left_inguin_hern_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The axial CT images of the lower pelvis (A, B) reveal a left-sided inguinal mass containing contrast-filled small bowel (arrow), which is consistent with an inguinal hernia. A coronal reconstruction (C) and sagittal reconstruction (C) demonstrate nondilated small bowel within the hernia sac (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 88596 Version 2.0</div></div></div>"},"88597":{"type":"graphic_diagnosticimage","displayName":"Incarcerated left inguinal hernia on CT","title":"Incarcerated left inguinal hernia on CT","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Incarcerated left inguinal hernia on CT</div><div class=\"cntnt\"><img style=\"width:592px; height:482px;\" src=\"images/RADIOL/88597_Obstr_l_inguin_hern_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;preliminary scout film (A) demonstrates dilated ascending colon (arrow) with a focal narrowing of the distal descending colon in the left inguinal region (arrowhead). There is an air fluid level in the dilated ascending colon (B arrow). The descending colon is normal in caliber (B arrowhead). A knuckle of incarcerated bowel in a left inguinal hernia can be seen&nbsp;(arrows in C and D).</div><div id=\"graphicVersion\">Graphic 88597 Version 1.0</div></div></div>"},"88598":{"type":"graphic_picture","displayName":"Primary cholesteatoma 1","title":"Primary cholesteatoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary cholesteatoma</div><div class=\"cntnt\"><img style=\"width:306px; height:309px;\" src=\"images/PC/88598_Primary_cholesteatoma_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left ear. Small epitympanic erosion with cholesteatoma. The skin surrounding the erosion is hyperemic and everted.</div><div class=\"graphic_reference\">Reproduced with permission from: Sanna M, Russo A, DeDonato G, et al. Color Atlas of Otoscopy: From Diagnosis to Surgery, 2nd ed, Thieme, New York 2002. Copyright &copy; 2002 Thieme Publishers.</div><div id=\"graphicVersion\">Graphic 88598 Version 1.0</div></div></div>"},"88599":{"type":"graphic_picture","displayName":"Primary cholesteatoma 2","title":"Primary cholesteatoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary cholesteatoma</div><div class=\"cntnt\"><img style=\"width:309px; height:306px;\" src=\"images/PC/88599_Primary_cholesteatoma_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left ear. Epitympanic erosion with cholesteatoma. Extension of the cholesteatoma into the mesotympanum (visible through the transparent pars tensa).</div><div class=\"graphic_reference\">Reproduced with permission from: Sanna M, Russo A, DeDonato G, et al. Color Atlas of Otoscopy: From Diagnosis to Surgery, 2nd ed, Thieme, New York 2002. Copyright &copy; 2002 Thieme Publishers.</div><div id=\"graphicVersion\">Graphic 88599 Version 1.0</div></div></div>"},"88600":{"type":"graphic_picture","displayName":"Primary cholesteatoma 3","title":"Primary cholesteatoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary cholesteatoma</div><div class=\"cntnt\"><img style=\"width:308px; height:301px;\" src=\"images/PC/88600_Primary_cholesteatoma_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left ear. The epitympanic area is occupied by a cholesteatoma mass protruding into the external auditor canal. The skin is hypervascularized.</div><div class=\"graphic_reference\">Reproduced with permission from: Sanna M, Russo A, DeDonato G, et al. Color Atlas of Otoscopy: From Diagnosis to Surgery, 2nd ed, Thieme, New York 2002. Copyright &copy; 2002 Thieme Publishers.</div><div id=\"graphicVersion\">Graphic 88600 Version 1.0</div></div></div>"},"88601":{"type":"graphic_picture","displayName":"Immunohistochemistry showing fibronectin staining in glomerulus","title":"Immunohistochemistry showing fibronectin staining in the glomerulus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunohistochemistry showing fibronectin staining in the glomerulus</div><div class=\"cntnt\"><img style=\"width:382px; height:296px;\" src=\"images/NEPH/88601_Imm_fibrone_stain_glom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunohistochemical staining of a glomerulus for fibronectin&nbsp;in a patient with fibronectin glomerulopathy. Fibronectin is deposited in the mesangium and along the capillary walls.</div><div id=\"graphicVersion\">Graphic 88601 Version 1.0</div></div></div>"},"88603":{"type":"graphic_table","displayName":"Drugs that can be associated with symptoms of RLS","title":"Drugs that can be associated with symptoms of restless legs syndrome (RLS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs that can be associated with symptoms of restless legs syndrome (RLS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Caffeine</td> </tr> <tr> <td>Antidepressants (except bupropion)</td> </tr> <tr> <td>Antipsychotics</td> </tr> <tr> <td>Dopamine-blocking antiemetics (eg, metoclopramide)</td> </tr> <tr> <td>Centrally-acting antihistamines</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 88603 Version 4.0</div></div></div>"},"88604":{"type":"graphic_table","displayName":"International Neuroblastoma Risk Group staging system","title":"International Neuroblastoma Risk Group staging system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International Neuroblastoma Risk Group staging system</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10\"></colgroup><colgroup width=\"90\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td class=\"centered\">L1</td> <td>Localized tumor not involving vital structures as defined by the list of image-defined risk factors and confined to one body compartment</td> </tr> <tr> <td class=\"centered\">L2</td> <td>Locoregional tumor with presence of one or more image-defined risk factors</td> </tr> <tr> <td class=\"centered\">M</td> <td>Distant metastatic disease (except stage MS)</td> </tr> <tr> <td class=\"centered\">MS</td> <td>Metastatic disease in children younger than 18 months with metastases confined to skin, liver, and/or bone marrow</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Patients with multifocal primary tumors should be staged according to the greatest extent of disease as defined in the table.</div><div class=\"graphic_reference\">From: Monclair T, et al: J Clin Oncol 27(2), 2009:298-303. Reprinted with permission. Copyright &copy; 2009 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88604 Version 1.0</div></div></div>"},"88605":{"type":"graphic_figure","displayName":"Tricuspid valve atresia","title":"Schematic diagram of type Ib or Ic and type II tricuspid valve atresia ","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Schematic diagram of type Ib or Ic and type II tricuspid valve atresia </div><div class=\"cntnt\"><img style=\"width:539px; height:350px;\" src=\"images/PEDS/88605_Tricupid_valve_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram demonstrating the anatomical and physiologic features of TV atresia type Ib or Ic (normally related great arteries and VSD), and TV atresia type IIc (d-loop transposition of the great arteries with no pulmonary stenosis). TV atresia with normally related great arteries and <STRONG>no</STRONG> VSD is classified as type Ia. In all types of TV atresia, the obligate atrial level shunt results in mixing of systemic and pulmonary venous blood in the left atrium. In types Ib and&nbsp;Ic, there is a left-to-right shunting at the level of the VSD, which serves as the source of pulmonary blood. In type II, the VSD is critical for systemic output, as the right ventricle, which provides the systemic circulation through the aorta, is dependent on blood flowing from the left ventricle through the VSD. In TV atresia type II, blood flow to the pulmonary artery is derived directly from the left ventricle.</div><div class=\"graphic_footnotes\">TV: tricuspid valve; VSD: ventricular septal defect; RA: right atrium; RV: right ventricle; LA: left atrium; LV: left ventricle; PA: pulmonary artery; Ao: aorta.</div><div id=\"graphicVersion\">Graphic 88605 Version 1.0</div></div></div>"},"88606":{"type":"graphic_table","displayName":"Physiologic changes in geriatric trauma patients","title":"Physiologic changes in geriatric trauma patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physiologic changes in geriatric trauma patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organ system</td> <td class=\"subtitle1\">Changes</td> <td class=\"subtitle1\">Implications</td> </tr> <tr> <td>Pulmonary</td> <td> <p>Decreased vital capacity</p> <p>Decreased forced expiratory volume</p> <p>Smaller alveolar surface area</p> Decreased chest wall compliance</td> <td>Reduced respiratory reserve</td> </tr> <tr> <td>Cardiac</td> <td> <p>Decreased cardiac output</p> Decreased sensitivity to catecholamines</td> <td> <p>Reduced cardiac reserve</p> Vital signs may not reflect severity of injury</td> </tr> <tr> <td>Renal</td> <td> <p>Decreased glomerular filtration rate</p> Decreased renal mass</td> <td> <p>Increased risk of traumatic injury</p> <p>Increased risk of contrast-induced nephropathy</p> <p>Increased susceptibility to fluid overload</p> Reduced clearance of certain medications</td> </tr> <tr> <td>Hepatic</td> <td>Decreased hepatic function</td> <td>Decreased clearance of certain medications</td> </tr> <tr> <td>Gastrointestinal</td> <td> <p>Diminished pain sensation</p> Increased laxity of abdominal wall musculature</td> <td>Potential for significant abdominal injury without peritoneal signs</td> </tr> <tr> <td>Immune</td> <td>Impaired immune response</td> <td>Increased risk of infection</td> </tr> <tr> <td>Musculoskeletal</td> <td> <p>Loss of muscle mass</p> Osteoporosis</td> <td>Increased risk of fracture</td> </tr> <tr> <td>Neurologic</td> <td> <p>Decreased autoregulatory capability</p> Brain atrophy</td> <td> <p>Increased susceptibility to injury from decreased cerebral perfusion</p> Increased risk for occult injury</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 88606 Version 1.0</div></div></div>"},"88609":{"type":"graphic_diagnosticimage","displayName":"Fetal echo tricuspid valve atresia","title":"Fetal echocardiography of tricuspid valve atresia with a ventricular septal defect","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Fetal echocardiography of tricuspid valve atresia with a ventricular septal defect</div><div class=\"cntnt\"><img style=\"width:590px; height:446px;\" src=\"images/PEDS/88609_Fetal_echo_tric_val_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fetal echocardiography showing a typical four-chamber view in a fetus with tricuspid valve atresia (TV) demonstrating muscular atresia with a hypoplastic right ventricle (RV) and a ventricular septal defect (VSD). The interarterial communication is through the patent foramen ovale (*).</div><div class=\"graphic_footnotes\">LV: left ventricle.</div><div id=\"graphicVersion\">Graphic 88609 Version 1.0</div></div></div>"},"88620":{"type":"graphic_table","displayName":"Snellen visual acuity conversion","title":"Snellen visual acuity conversions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Snellen visual acuity conversions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">20 feet</td> <td class=\"subtitle1\">4 meters</td> <td class=\"subtitle1\">6 meters</td> </tr> <tr> <td class=\"centered\">20/200</td> <td class=\"centered\">4/40</td> <td class=\"centered\">6/60</td> </tr> <tr> <td class=\"centered\">20/160</td> <td class=\"centered\">4/32</td> <td class=\"centered\">6/48</td> </tr> <tr> <td class=\"centered\">20/125</td> <td class=\"centered\">4/25</td> <td class=\"centered\">6/38</td> </tr> <tr> <td class=\"centered\">20/100</td> <td class=\"centered\">4/20</td> <td class=\"centered\">6/30</td> </tr> <tr> <td class=\"centered\">20/80</td> <td class=\"centered\">4/16</td> <td class=\"centered\">6/24</td> </tr> <tr> <td class=\"centered\">20/63</td> <td class=\"centered\">4/12.6</td> <td class=\"centered\">6/20</td> </tr> <tr> <td class=\"centered\">20/50</td> <td class=\"centered\">4/10</td> <td class=\"centered\">6/15</td> </tr> <tr> <td class=\"centered\">20/40</td> <td class=\"centered\">4/8</td> <td class=\"centered\">6/12</td> </tr> <tr> <td class=\"centered\">20/32</td> <td class=\"centered\">4/6.3</td> <td class=\"centered\">6/10</td> </tr> <tr> <td class=\"centered\">20/25</td> <td class=\"centered\">4/5</td> <td class=\"centered\">6/7.5</td> </tr> <tr> <td class=\"centered\">20/20</td> <td class=\"centered\">4/4</td> <td class=\"centered\">6/6</td> </tr> <tr> <td class=\"centered\">20/16</td> <td class=\"centered\">4/3.2</td> <td class=\"centered\">6/5</td> </tr> <tr> <td class=\"centered\">20/12.5</td> <td class=\"centered\">4/2.5</td> <td class=\"centered\">6/3.75</td> </tr> <tr> <td class=\"centered\">20/10</td> <td class=\"centered\">4/2</td> <td class=\"centered\">6/3</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Ferris FL III, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982; 94:91.</div><div id=\"graphicVersion\">Graphic 88620 Version 2.0</div></div></div>"},"88622":{"type":"graphic_diagnosticimage","displayName":"Normal thoracic aortogram","title":"Normal thoracic aortogram","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Normal thoracic aortogram</div><div class=\"cntnt\"><img style=\"width:590px; height:458px;\" src=\"images/RADIOL/88622_Normal_thor_aortogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An aortogram in the left anterior oblique (LAO) projection (A) and the right anterior oblique (RAO) projection demonstrates normal contours of the thoracic aorta (B).</div><div id=\"graphicVersion\">Graphic 88622 Version 1.0</div></div></div>"},"88623":{"type":"graphic_diagnosticimage","displayName":"Low grade blunt thoracic aortic injury","title":"Low grade blunt thoracic aortic injury","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Low grade blunt thoracic aortic injury</div><div class=\"cntnt\"><img style=\"width:598px; height:413px;\" src=\"images/RADIOL/88623_Low_gr_blunt_thor_aort_inj.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan (A) is limited by artifact but suggests an intramural hematoma (arrow). An aortogram in the left anterior oblique projection (B) demonstrates a focal deformity of the aortic knob caused by a subadventitial hematoma (arrow). There is mild narrowing of the aortic lumen.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 88623 Version 2.0</div></div></div>"},"88624":{"type":"graphic_diagnosticimage","displayName":"Blunt thoracic aortic tear and pseudoaneurysm","title":"Blunt thoracic aortic tear and pseudoaneurysm","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Blunt thoracic aortic tear and pseudoaneurysm</div><div class=\"cntnt\"><img style=\"width:599px; height:313px;\" src=\"images/RADIOL/88624_Blunt_thor_aor_psuedo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;chest x-ray (A) demonstrates a widened mediastinum following blunt injury to the chest (arrows). The aortogram in an anteroposterior projection (B) demonstrates a circumferential tear of the isthmus (arrow). A small pseudoaneurysm at the insertion site of the ligamentum arteriosum is noted (arrowhead).</div><div id=\"graphicVersion\">Graphic 88624 Version 1.0</div></div></div>"},"88625":{"type":"graphic_diagnosticimage","displayName":"Blunt thoracic aortic injury with hemothorax","title":"Blunt thoracic aortic injury with hemothorax","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Blunt thoracic aortic injury with hemothorax</div><div class=\"cntnt\"><img style=\"width:598px; height:479px;\" src=\"images/RADIOL/88625_Blthoraortinjhemothorax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;CT scan of the proximal descending aorta demonstrates a focal traumatic tear. The site of the tear can be seen (arrow in A). There is a large left hemothorax (arrow in&nbsp;B). A magnified view of the CT scan demonstrates the site of the rupture (dashed arrow in&nbsp;C) with the associated mediastinal hematoma (arrow in&nbsp;C) and hemothorax (arrowhead in&nbsp;C). An overlay (D) demonstrates the findings, highlighting the pseudoaneurysm (light red), hematoma (maroon), and hemothorax (bright red).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 88625 Version 2.0</div></div></div>"},"88626":{"type":"graphic_diagnosticimage","displayName":"Blunt thoracic aortic injury with mediastinal hematoma","title":"Blunt thoracic aortic injury with mediastinal hematoma","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Blunt thoracic aortic injury with mediastinal hematoma</div><div class=\"cntnt\"><img style=\"width:597px; height:505px;\" src=\"images/RADIOL/88626_Bl_thor_aort_inj_med_hemato.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan at the level of the aortic arch demonstrates a traumatic tear associated with a mediastinal hematoma (arrow in A). The site of the tear can be seen (arrows in B and C). A small left hemothorax is also present (arrow in D). Steatosis of the liver is also present (arrowhead in D).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 88626 Version 2.0</div></div></div>"},"88627":{"type":"graphic_diagnosticimage","displayName":"Aortogram with traumatic intimal tear","title":"Aortogram with traumatic intimal tear","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Aortogram with traumatic intimal tear</div><div class=\"cntnt\"><img style=\"width:598px; height:487px;\" src=\"images/RADIOL/88627_Aortog_traum_intim_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The aortogram demonstrates a circumferential tear in the proximal descending thoracic aorta (arrows) in the left anterior oblique projection (A) and in the right anterior oblique projection (B).</div><div id=\"graphicVersion\">Graphic 88627 Version 1.0</div></div></div>"},"88628":{"type":"graphic_table","displayName":"Accuracy of imaging for preoperative parathyroid localization","title":"Diagnostic accuracy of imaging modalities for preoperative parathyroid localization","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic accuracy of imaging modalities for preoperative parathyroid localization</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Imaging modality</td> <td class=\"subtitle1\">Sensitivity<br /> (percent)</td> <td class=\"subtitle1\">Positive predictive value<br /> (percent)</td> </tr> <tr> <td>Sestamibi</td> <td class=\"centered\">71-79</td> <td class=\"centered\">72-95</td> </tr> <tr> <td>Sestamibi-SPECT</td> <td class=\"centered\">70-81</td> <td class=\"centered\">91-95</td> </tr> <tr> <td>Ultrasound</td> <td class=\"centered\">64-91</td> <td class=\"centered\">83-96</td> </tr> <tr> <td>4D-CT</td> <td class=\"centered\">83-95</td> <td class=\"centered\">88-99</td> </tr> <tr> <td>MRI</td> <td class=\"centered\">40-85</td> <td class=\"centered\">N/A</td> </tr> <tr> <td>MET-PET-CT scan</td> <td class=\"centered\">79-90</td> <td class=\"centered\">93-94</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SPECT: sestamibi-single photon emission computed tomography; CT: computed tomography; MRI: magnetic resonance imaging; N/A: not applicable; MET-PET-CT scan: 11C-methionine positron emission tomography and computed tomography.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Cheung K, Wang TS, Farrokhyar F, et al. A meta-analysis of preoperative localization techniques for patients with primary hyperparathyroidism. Ann Surg Oncol 2012; 19:577.</LI>&#xD;&#xA;<LI>Mihai R, Simon D, Hellman P. Imaging for primary hyperparathyroidism--an evidence-based analysis. Langenbecks Arch Surg 2009; 394:765.</LI>&#xD;&#xA;<LI>Weber T, Maier-Funk C, Ohlhauser D, et al. Accurate Preoperative Localization of Parathyroid Adenomas With C-11 Methionine PET/CT. Ann Surg 2013; 257:1124.</LI></OL></div><div id=\"graphicVersion\">Graphic 88628 Version 4.0</div></div></div>"},"88629":{"type":"graphic_diagnosticimage","displayName":"Blunt thoracic aortic injury ascending aorta","title":"Blunt thoracic aortic injury ascending aorta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blunt thoracic aortic injury ascending aorta</div><div class=\"cntnt\"><img style=\"width:449px; height:590px;\" src=\"images/RADIOL/88629_Bl_thor_aort_inj_ascen_aort.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An aortogram in the left anterior oblique projection following blunt thoracic injury demonstrates a pseudoaneurysm of the ascending aorta (arrow).</div><div id=\"graphicVersion\">Graphic 88629 Version 1.0</div></div></div>"},"88630":{"type":"graphic_diagnosticimage","displayName":"Blunt thoracic aortic injury descending aorta","title":"Blunt thoracic aortic injury descending aorta","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Blunt thoracic aortic injury descending aorta</div><div class=\"cntnt\"><img style=\"width:598px; height:444px;\" src=\"images/RADIOL/88630_Bl_thor_aort_inj_desc_aorta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;aortogram demonstrates a normal appearing descending thoracic aorta in the left anterior oblique projection (A). A traumatic aortic tear is demonstrated in the right anterior oblique projection (arrow in B).</div><div id=\"graphicVersion\">Graphic 88630 Version 1.0</div></div></div>"},"88643":{"type":"graphic_table","displayName":"Dietary intervention options for EoE","title":"Advantages and disadvantages of different dietary interventions for eosinophilic esophagitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of different dietary interventions for eosinophilic esophagitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Consideration</td> <td class=\"subtitle1\" colspan=\"3\">Dietary intervention</td> </tr> <tr> <td class=\"subtitle2\">Testing-directed elimination</td> <td class=\"subtitle2\">Empiric elimination</td> <td class=\"subtitle2\">Elemental formula</td> </tr> <tr> <td>Therapeutic success rate</td> <td>50 to 70%</td> <td>50 to 70%</td> <td>&#62;90%</td> </tr> <tr> <td>Number of foods avoided</td> <td>Typically &#60;6 foods eliminated</td> <td>Typically six foods/food groups eliminated from diet</td> <td>All food eliminated</td> </tr> <tr> <td>Available data</td> <td> <p>Multiple centers</p> <p>Retrospective</p> Pediatric</td> <td> <p>Multiple centers</p> <p>Prospective and retrospective</p> Pediatric and adult</td> <td> <p>Multiple centers</p> <p>Prospective and retrospective</p> Pediatric and adult</td> </tr> <tr> <td>Cost</td> <td>Requires purchase of specific specialty foods</td> <td>Requires purchase of specific specialty foods</td> <td> <p>USD &#8805;$50 per can</p> Not always covered by insurance unless via tube feeding</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 88643 Version 3.0</div></div></div>"},"88644":{"type":"graphic_waveform","displayName":"Typical absence status epilepticus","title":"Typical absence status epilepticus","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Typical absence status epilepticus</div><div class=\"cntnt\"><img style=\"width:541px; height:304px;\" src=\"images/NEURO/88644_Prim_gen_nonconv_epil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electroencephalogram (EEG) in a 51-year-old man with primary generalized epilepsy presenting with subacute confusion and ataxia,&nbsp;showing irregular generalized spike and wave or polyspike and wave at 2.5-3.5 Hz, consistent with typical absence status epilepticus.</div><div id=\"graphicVersion\">Graphic 88644 Version 2.0</div></div></div>"},"88651":{"type":"graphic_table","displayName":"Antibiotic treatment Shigella children","title":"Antibiotic regimens for Shigella in children <18 years of age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotic regimens for Shigella in children &lt;18 years of age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"35%\"></colgroup><colgroup width=\"30%\"></colgroup><colgroup width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibiotic</td> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Maximum daily dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Parenteral agents</td> </tr> <tr> <td class=\"indent1\">Ceftriaxone (preferred)</td> <td>50 mg/kg IV or IM once daily for five days*</td> <td>1.5 g/day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ciprofloxacin<sup>&#182;</sup></td> <td>20 mg/kg per day IV divided in two doses for five days</td> <td>800 mg/day</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Oral agents</td> </tr> <tr> <td class=\"indent1\">Ampicillin<sup>&#916;</sup></td> <td>100 mg/kg per day in four divided doses for five days</td> <td>4 g/day</td> </tr> <tr> <td class=\"indent1\">Azithromycin (preferred<sup>&#9674;</sup>)</td> <td> <p>12 mg/kg orally once daily day one;</p> 6 mg/kg orally once daily on days two through five</td> <td> <p>500 mg/day on the first day;</p> 250 mg/day on days two through five</td> </tr> <tr> <td class=\"indent1\">Cefixime<sup>&#9674;</sup></td> <td>8 mg/kg per day orally in one or two divided doses for five days</td> <td>400 mg/day</td> </tr> <tr> <td class=\"indent1\">Ceftibuten<sup>&#9674;</sup></td> <td>9 mg/kg orally once daily for five days</td> <td>400 mg/day</td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin<sup>&#182;</sup></td> <td>20 mg/kg per day orally in two divided doses for five days</td> <td>1 g/day</td> </tr> <tr> <td class=\"indent1\">Nalidixic acid<sup>&#182;</sup><sup>&#916;&#167;</sup></td> <td>55 mg/kg per day orally divided in four doses for five days</td> <td>4 g/day</td> </tr> <tr> <td class=\"indent1\">Norfloxacin<sup>&#182;&#167;</sup></td> <td>10 to 15 mg/kg per day orally in two divided doses for five days</td> <td>800 mg/day</td> </tr> <tr> <td class=\"indent1\">Pivmecillinam<sup>&#167;</sup></td> <td>45 to 60 mg/kg per day orally in three or four divided doses for five days</td> <td>900 mg/day</td> </tr> <tr> <td class=\"indent1\">Trimethoprim-sulfamethoxazole (Co-trimoxazole, TMP-SMX)<sup>&#916;</sup></td> <td>10 mg/kg (based upon TMP component) orally in two divided doses for five days</td> <td>320 mg TMP/day</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; IM: intramuscular.<br />* Patients who do not have immune deficiency or bacteremia and are afebrile after two days may be treated with two doses.<br />¶ For children &lt;18 years, should be used only if no other safe and effective alternative is available. Fluoroquinolone doses need to be adjusted in setting of renal insufficiency.<br />Δ Should be used only if the isolated strain is susceptible or current local microbiologic data suggest susceptibility.<br />◊ Azithromycin&nbsp;generally is preferred unless<EM> Shigella</EM> was acquired in South&nbsp;Asia&nbsp;(eg, India, Pakistan, Bangladesh). Cefixime or ceftibuten are preferred for<EM> Shigella</EM> acquired in South&nbsp;Asia.&nbsp;<br />§ Not available in United States.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>American Academy of Pediatrics. Shigella infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th, Kimberlin DW, Brady MT, Jackson MA, Long SS. (Eds), American Academy of Pediatrics 2015, p. 706.</LI>&#xD;&#xA;<LI>Eidlitz-Marcus T, Cohen YH, Nussinovitch M, et al. Comparative efficacy of two- and five-day courses of ceftriaxone for treatment of severe shigellosis in children. J Pediatr 1993; 123:822.</LI>&#xD;&#xA;<LI>Jackson MA, Schutze GE, Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. Pediatrics 2016; 138.</LI>&#xD;&#xA;<LI>Martin JM, Pitetti R, Maffei F, et al. Treatment of shigellosis with cefixime: Two days vs. five days. Pediatr Infect Dis J 2000; 19:522.</LI>&#xD;&#xA;<LI>Salam MA, Dhar U, Khan WA, Bennish ML. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet 1998; 352:522.</LI></OL></div><div id=\"graphicVersion\">Graphic 88651 Version 9.0</div></div></div>"},"88652":{"type":"graphic_table","displayName":"Semiological spectrum of nonconvulsive seizures","title":"Semiological spectrum of nonconvulsive seizures and nonconvulsive status epilepticus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Semiological spectrum of nonconvulsive seizures and nonconvulsive status epilepticus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Negative symptoms</td> <td class=\"subtitle1\">Positive symptoms</td> </tr> <tr> <td> <p>Anorexia</p> <p>Aphasia/mutism</p> <p>Amnesia</p> <p>Catatonia</p> <p><strong>Coma</strong></p> <p><strong>Confusion</strong></p> <p><strong>Lethargy</strong></p> Staring</td> <td> <p>Agitation/aggression</p> <p>Automatisms</p> <p>Blinking</p> <p>Crying</p> <p>Delirium</p> <p>Delusions</p> <p>Echolalia</p> <p>Facial twitching</p> <p>Laughter</p> <p>Nausea/vomiting</p> <p>Nystagmus/eye deviation</p> <p>Perseveration</p> <p>Psychosis</p> Tremulousness</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original figure modified for this publication. Jirsch J and Hirsch LJ. Nonconvulsive Seizures: Developing a Rational Approach to the Diagnosis and Management in the Critically Ill Population. Clin Neurophysiol 2007; 118:1660. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88652 Version 1.0</div></div></div>"},"88654":{"type":"graphic_table","displayName":"IV antiseizure drug trial for NCSE","title":"Intravenous antiseizure drug trial for the diagnosis of nonconvulsive status epilepticus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intravenous antiseizure drug trial for the diagnosis of nonconvulsive status epilepticus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Applies to:</strong> Patients with rhythmic or periodic focal or generalized epileptiform discharges on EEG with neurological impairment</td> </tr> <tr> <td><strong>Monitoring:</strong> EEG, pulse oximetry, blood pressure, ECG, respiratory rate with dedicated nurse</td> </tr> <tr> <td><strong>Antiseizure drug trial:</strong></td> </tr> <tr> <td class=\"indent1\">Sequential small doses of a rapidly-acting IV&nbsp;antiseizure drug&nbsp;(eg, fosphenytoin 10 mg/kg, valproate 20 mg/kg, levetiracetam 20 mg/kg, or lacosamide 200 mg) or a short-duration benzodiazepine (eg, midazolam at 1 mg/dose)</td> </tr> <tr> <td class=\"indent1\">Between doses, repeated clinical and EEG assessment</td> </tr> <tr> <td class=\"indent1\">Trial is stopped after any of the following: <ul> <li>Persistent resolution of the EEG pattern (and exam repeated) </li> <li>Definite clinical improvement </li> <li>Respiratory depression, hypotension, or other adverse effect </li> <li>A maximum dose is reached (such as 0.2 mg/kg midazolam, although higher doses&nbsp;may be needed if the&nbsp;patient is on chronic benzodiazepines) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Test is considered positive if there is resolution of the potentially ictal EEG pattern AND either an improvement in the clinical state or the appearance of previously-absent normal EEG patterns (eg, posterior dominant \"alpha\" rhythm). If EEG improves but patient does not, the result is equivocal. A negative test does not rule out NCSE.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">ECG: electrocardiogram; EEG: electroencephalogram;&nbsp;IV: intravenous;&nbsp;NCSE: nonconvulsive status epilepticus.</div><div class=\"graphic_reference\">Original figure modified for this publication. Jirsch J and Hirsch LJ. Nonconvulsive Seizures: Developing a Rational Approach to the Diagnosis and Management in the Critically Ill Population. Clin Neurophysiol 2007; 118:1660. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88654 Version 3.0</div></div></div>"},"88672":{"type":"graphic_diagnosticimage","displayName":"Acromioclavicular injury Type V   ","title":"Acromioclavicular injury Type V","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Acromioclavicular injury Type V</div><div class=\"cntnt\"><img style=\"width:599px; height:182px;\" src=\"images/RADIOL/88672_X_ray_V_acromiocl_inju.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiographs of both clavicles (A) reveal superior displacement of the left clavicle with marked widening of the acromioclavicular distance (arrowhead) and coracoclavicular distance (arrow). The acromioclavicular distance is more than twice the distance when compared to the contralateral normal side. Dislocation of the sternoclavicular joint (dashed arrow) is also noted. Image B focuses on the widening of the coracoclavicular distance (arrow) and the approximately 2.2 cm widening of the coracoclavicular distance (arrowhead). These findings are consistent with&nbsp;a Type&nbsp;V acromioclavicular injury.</div><div class=\"graphic_reference\">Courtesy of Joseph Farnam, MD.</div><div id=\"graphicVersion\">Graphic 88672 Version 2.0</div></div></div>"},"88673":{"type":"graphic_picture","displayName":"Sacrococcygeal teratoma at 30 weeks gestation","title":"Predominately cystic exophytic sacrococcygeal teratoma at 30 weeks gestation","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Predominately cystic exophytic sacrococcygeal teratoma at 30 weeks gestation</div><div class=\"cntnt\"><img style=\"width:515px; height:417px;\" src=\"images/ONC/88673_Pre_cys_exo_sac_ter_30.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Ultrasound image of the distal spine shows a mass (arrow) extending off the caudal end of the fetus.<br />(B) Color Doppler image shows predominantly cystic nature of the tumor with very little flow.<br />(C) Fetal magnetic resonance image shows a small portion of intrapelvic extent (arrows).</div><div id=\"graphicVersion\">Graphic 88673 Version 3.0</div></div></div>"},"88674":{"type":"graphic_picture","displayName":"Utrasound of a sacrococcygeal teratoma at 23 weeks gestation","title":"Predominately solid large sacrococcygeal teratoma at 23 weeks gestation","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Predominately solid large sacrococcygeal teratoma at 23 weeks gestation</div><div class=\"cntnt\"><img style=\"width:513px; height:193px;\" src=\"images/ONC/88674_Predom_soli_sacr_terat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Sagittal view of the distal spine shows a large solid tumor (arrow) off the caudal end of the fetus.<br />(B) Due to mass effect on the bladder, there is bilateral hydronephrosis. Given the large size and solid nature of this tumor (arrow), the fetus needs to be carefully monitored for development of hydrops.</div><div class=\"graphic_footnotes\">RK: right kidney; LK: left kidney</div><div id=\"graphicVersion\">Graphic 88674 Version 2.0</div></div></div>"},"88675":{"type":"graphic_picture","displayName":"Fetal MRI of a sacrococcygeal teratoma","title":"Fetal MRI of a sacrococcygeal teratoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fetal MRI of a sacrococcygeal teratoma</div><div class=\"cntnt\"><img style=\"width:504px; height:468px;\" src=\"images/ONC/88675_MR_predo_intra_sacr_ter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fetal&nbsp;magnetic resonance image showing a predominantly intrapelvic sacrococcygeal&nbsp;teratoma (arrows)</div><div id=\"graphicVersion\">Graphic 88675 Version 2.0</div></div></div>"},"88676":{"type":"graphic_figure","displayName":"Right double lumen tube","title":"Right double lumen tube","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Right double lumen tube</div><div class=\"cntnt\"><img style=\"width:537px; height:706px;\" src=\"images/ANEST/88676_R_DLT.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 88676 Version 1.0</div></div></div>"},"88677":{"type":"graphic_figure","displayName":"Left double lumen tube","title":"Left double lumen tube","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Left double lumen tube</div><div class=\"cntnt\"><img style=\"width:511px; height:676px;\" src=\"images/ANEST/88677_L_DLT.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 88677 Version 1.0</div></div></div>"},"88678":{"type":"graphic_figure","displayName":"Well positioned left double lumen tube","title":"Well positioned left double lumen tube","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Well positioned left double lumen tube</div><div class=\"cntnt\"><img style=\"width:480px; height:513px;\" src=\"images/ANEST/88678_Well_positioned_L_DLT.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Photos reproduced from: Campos J. Lung Isolation. In: Principles and Practice of Anesthesia for Thoracic Surgery, Slinger P (Ed), New York, Springer 2011. Copyright © 2011, with kind permission from Springer Science + Business Media B.V.</div><div id=\"graphicVersion\">Graphic 88678 Version 1.0</div></div></div>"},"88679":{"type":"graphic_figure","displayName":"Well positioned right double lumen tube","title":"Well positioned right double lumen tube","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Well positioned right double lumen tube</div><div class=\"cntnt\"><img style=\"width:485px; height:413px;\" src=\"images/ANEST/88679_Well_positioned_R_DLT.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Photos reproduced from: Campos J. Lung Isolation. In: Principles and Practice of Anesthesia for Thoracic Surgery, Slinger P (Ed), New York, Springer 2011. Copyright © 2011, with kind permission from Springer Science + Business Media B.V.</div><div id=\"graphicVersion\">Graphic 88679 Version 1.0</div></div></div>"},"88680":{"type":"graphic_figure","displayName":"Too distal left double lumen tube","title":"Too distal left double lumen tube","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Too distal left double lumen tube</div><div class=\"cntnt\"><img style=\"width:464px; height:410px;\" src=\"images/ANEST/88680_Too_distal_L_DLT.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 88680 Version 2.0</div></div></div>"},"88681":{"type":"graphic_figure","displayName":"Tracheal view of herniating left double lumen tube cuff","title":"Tracheal view of herniating left double lumen tube cuff","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Tracheal view of herniating left double lumen tube cuff</div><div class=\"cntnt\"><img style=\"width:475px; height:418px;\" src=\"images/ANEST/88681_Herniating_L_DLT.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 88681 Version 1.0</div></div></div>"},"88693":{"type":"graphic_table","displayName":"CL treatment","title":"Drug regimens for treatment of cutaneous leishmaniasis in adults<sup>[1-3]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug regimens for treatment of cutaneous leishmaniasis in adults<sup>[1-3]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Local therapy</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Pentavalent antimonials</td> <td>Sodium stibogluconate*</td> <td>0.5 to 2 mL of 100 mg/mL pentavalent antimony (Sb<sup>5+</sup>) intralesionally every three to seven days until healed (treat up to 3 weeks)</td> </tr> <tr> <td>Meglumine antimoniate<sup>&#182;</sup></td> <td>0.5 to 2 mL of 81 mg/mL pentavalent antimony (Sb<sup>5+</sup>) intralesionally every three to seven days until healed (treat up to 3 weeks)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Paromomycin</td> <td>Paromomycin ointment<sup>&#916;</sup></td> <td>Apply topically to lesions twice daily for 10 days, rest for 10 days, then reapply for 10 days</td> </tr> <tr> <td> <p>Paromomycin cream (15%)<sup>&#9674;</sup></p> <p>WR 279396 cream<sup>&#167;</sup></p> </td> <td>Apply topically to lesions once daily for 20 days</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Oral systemic therapy</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Azoles</td> <td>Fluconazole</td> <td>200 mg orally once daily for six weeks</td> </tr> <tr> <td>Ketoconazole</td> <td>600 mg orally once daily for 28 days</td> </tr> <tr> <td class=\"indent1\">Miltefosine</td> <td>Miltefosine<sup>&#165;</sup></td> <td>2.5 mg/kg (maximum 150 mg) orally in three divided doses for 28 days; if weight is 30 to 44 kg, use 50 mg orally twice daily</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Parenteral systemic therapy</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Pentavalent antimonials</td> <td>Sodium stibogluconate</td> <td>20 mg Sb<sup>V</sup>/kg/day intravenously or intramuscularly for 10 to 20 days<sup>&#135;</sup></td> </tr> <tr> <td>Meglumine antimoniate</td> <td>20 mg Sb<sup>V</sup>/kg/day intravenously or intramuscularly for 10 to 20 days<sup>&#135;</sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Amphotericin</td> <td>Amphotericin B deoxycholate</td> <td>0.5 to 1 mg/kg intravenously dosed daily or&nbsp;every other day for a cumulative total dose of 15 to 30 mg/kg</td> </tr> <tr> <td>Liposomal amphotericin B (AmBisome)</td> <td>3 mg/kg intravenously daily for five to seven doses, such as days 1 to 5, 10</td> </tr> <tr> <td class=\"indent1\">Pentamidine</td> <td>Pentamidine isethionate</td> <td>3&nbsp;to 4 mg/kg intravenously or intramuscularly every other day for four to seven doses or until healed</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Agents listed, dose regimens, and combinations are effective only against certain <EM>Leishmania</EM> species/strains and only in certain areas of the world. Refer to the UpToDate topic on treatment of cutaneous leishmaniasis for the therapeutic approach to cutaneous leishmaniasis. Pediatric dosing is summarized separately<SUP>[3]</SUP>.</div><div class=\"graphic_footnotes\">Sb<SUP>V</SUP>: pentavalent antimony.<br />* In the United States,&nbsp;it may be obtained from the Centers for Drug Control and Prevention Drug Services telephone <FONT class=baec5a81-e4d6-4674-97f3-e9220f0136c1 style=\"WHITE-SPACE: nowrap\">404-639-3670<A title=\"Call: 404-639-3670\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" href=\"#\"><IMG title=\"Call: 404-639-3670\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" src=\"data:image/png;base64,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\"></A></FONT> or <FONT class=baec5a81-e4d6-4674-97f3-e9220f0136c1 style=\"WHITE-SPACE: nowrap\">404-639-2888<A title=\"Call: 404-639-2888\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" href=\"#\"><IMG title=\"Call: 404-639-2888\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" src=\"data:image/png;base64,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\"></A></FONT> (nights, weekends) or email <A href=\"mailto:drugservice@cdc.gov\">drugservice@cdc.gov</A>. <br />¶ Effective dose for weight &gt;75 kg may require higher dose off-label (with attendant gastrointestinal effects), aiming for &gt;2.5 mg/kg dose.<br />Δ Compounding instructions and additional information is summarized separately.<SUP>[3]</SUP><br /><FONT class=lozenge>◊</FONT> For treatment of CL among military healthcare beneficiaries in the United States,&nbsp;it may be obtained from US Army Medical Materiel Development Activity at <FONT class=baec5a81-e4d6-4674-97f3-e9220f0136c1 style=\"WHITE-SPACE: nowrap\">301-401-2768<A title=\"Call: 301-401-2768\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" href=\"#\"><IMG title=\"Call: 301-401-2768\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" src=\"data:image/png;base64,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\"></A></FONT> .<br />§ WR279396 (a topical cream containing 15% paromomycin and 0.5% gentamicin) is no longer available; it has been replaced by 15% paromomycin cream.<br />¥&nbsp;Miltefosine is US Food and Drug Administration approved and commercially available in the United States. Miltefosine should not be used in women of childbearing age unless a validated contraceptive method is used during treatment and for at least six months following treatment.<br />‡&nbsp;Doses are expressed as mg of pentavalent antimony content. Duration of 10 days is appropriate for treatment of relatively mild disease with evidence of clinical response by day 10; otherwise, the duration should be extended. Duration of 20 days is appropriate for treatment of CL due to species known to cause mucosal disease. Meglumine antimoniate has 81 mg Sb<SUP>V</SUP>/mL, while sodium stibogluconate (SSG) contains 100 mg Sb<SUP>V</SUP>/mL. Intravenous treatment is usually diluted at least 10-fold with 5% dextrose in water and SSG is filtered.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Goto H, Laulett Lindoso JA. Cutaneous and mucocutaneous leishmaniasis. Inf Dis Clin N Am 2012; 26:293.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. Parasites - Leishmaniasis Available at: <A href=\"http://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx\" target=_blank>http://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx</A> (Accessed March 25, 2013).</LI>&#xD;&#xA;<LI>Drugs for parasitic infections, 2nd ed. The Medical Letter, New Rochelle, NY 2010. p.26.</LI></OL></div><div id=\"graphicVersion\">Graphic 88693 Version 18.0</div></div></div>"},"88694":{"type":"graphic_table","displayName":"ML treatment","title":"Drug regimens for treatment of mucosal leishmaniasis in adults<sup>[1-3]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug regimens for treatment of mucosal leishmaniasis in adults<sup>[1-3]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td rowspan=\"2\">Pentavalent antimonials*</td> <td>Sodium stibogluconate<sup>&#182;</sup></td> <td>20 mg Sb<sup>V</sup>/kg<sup>&#916;</sup> intravenously or intramuscularly per day for 28 days</td> </tr> <tr> <td>Meglumine antimoniate<sup>&#9674;</sup><sup>&#167;</sup></td> <td>20 mg Sb<sup>V</sup>/kg<sup>&#916;</sup> intravenously or intramuscularly per day for 30 days</td> </tr> <tr> <td rowspan=\"2\">Amphotericin</td> <td>Amphotericin B deoxycholate</td> <td>0.5 to 1 mg/kg intravenously per day or every other day, up to total cumulative dose of 20 to 45 mg/kg</td> </tr> <tr> <td>Liposomal amphotericin B (AmBisome)</td> <td>3 mg/kg intravenously once daily up to total cumulative dose of&nbsp;20 to&nbsp;60&nbsp;mg/kg</td> </tr> <tr> <td>Miltefosine</td> <td>Miltefosine<sup>&#165;</sup></td> <td>2.5 mg/kg orally (maximum 150 mg) in three divided doses for 28 days; if weight is 30 to 44 kg, give 50 mg orally in divided doses twice daily for 28 days</td> </tr> <tr> <td>Pentamidine</td> <td>Pentamidine isethionate</td> <td>2 to 4 mg/kg intravenously or intramuscularly every other day or three times per week, for 15 or more doses until healed (this is considered a lesser alternative)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Agents listed, dose regimens, and combinations are effective only against certain <em>Leishmania</em> species/strains and only in certain areas of the world. The therapeutic approach to mucosal leishmaniasis is discussed in the topic 'Treatment of cutaneous leishmaniasis.' Pediatric dosing is summarized separately<sup>[3]</sup>.</div><div class=\"graphic_footnotes\">SbV: pentavalent antimony.<br />* Pentavalent antimonials may be administered with pentoxifylline (400 mg orally three times a day) for synergistic activity.<br />¶ In the United States, it may be obtained from the Centers for Disease Control and Prevention Drug Services telephone <SPAN class=baec5a81-e4d6-4674-97f3-e9220f0136c1 style=\"WHITE-SPACE: nowrap\">404-639-3670<A title=\"Call: 404-639-3670\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" href=\"#\"><IMG title=\"Call: 404-639-3670\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" src=\"data:image/png;base64,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\"></A></SPAN> or <SPAN class=baec5a81-e4d6-4674-97f3-e9220f0136c1 style=\"WHITE-SPACE: nowrap\">404-639-2888<A title=\"Call: 404-639-2888\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" href=\"#\"><IMG title=\"Call: 404-639-2888\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" src=\"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABAAAAAQCAYAAAAf8/9hAAAACXBIWXMAAA7EAAAOxAGVKw4bAAAKT2lDQ1BQaG90b3Nob3AgSUNDIHByb2ZpbGUAAHjanVNnVFPpFj333vRCS4iAlEtvUhUIIFJCi4AUkSYqIQkQSoghodkVUcERRUUEG8igiAOOjoCMFVEsDIoK2AfkIaKOg6OIisr74Xuja9a89+bN/rXXPues852zzwfACAyWSDNRNYAMqUIeEeCDx8TG4eQuQIEKJHAAEAizZCFz/SMBAPh+PDwrIsAHvgABeNMLCADATZvAMByH/w/qQplcAYCEAcB0kThLCIAUAEB6jkKmAEBGAYCdmCZTAKAEAGDLY2LjAFAtAGAnf+bTAICd+Jl7AQBblCEVAaCRACATZYhEAGg7AKzPVopFAFgwABRmS8Q5ANgtADBJV2ZIALC3AMDOEAuyAAgMADBRiIUpAAR7AGDIIyN4AISZABRG8lc88SuuEOcqAAB4mbI8uSQ5RYFbCC1xB1dXLh4ozkkXKxQ2YQJhmkAuwnmZGTKBNA/g88wAAKCRFRHgg/P9eM4Ors7ONo62Dl8t6r8G/yJiYuP+5c+rcEAAAOF0ftH+LC+zGoA7BoBt/qIl7gRoXgugdfeLZrIPQLUAoOnaV/Nw+H48PEWhkLnZ2eXk5NhKxEJbYcpXff5nwl/AV/1s+X48/Pf14L7iJIEyXYFHBPjgwsz0TKUcz5IJhGLc5o9H/LcL//wd0yLESWK5WCoU41EScY5EmozzMqUiiUKSKcUl0v9k4t8s+wM+3zUAsGo+AXuRLahdYwP2SycQWHTA4vcAAPK7b8HUKAgDgGiD4c93/+8//UegJQCAZkmScQAAXkQkLlTKsz/HCAAARKCBKrBBG/TBGCzABhzBBdzBC/xgNoRCJMTCQhBCCmSAHHJgKayCQiiGzbAdKmAv1EAdNMBRaIaTcA4uwlW4Dj1wD/phCJ7BKLyBCQRByAgTYSHaiAFiilgjjggXmYX4IcFIBBKLJCDJiBRRIkuRNUgxUopUIFVIHfI9cgI5h1xGupE7yAAygvyGvEcxlIGyUT3UDLVDuag3GoRGogvQZHQxmo8WoJvQcrQaPYw2oefQq2gP2o8+Q8cwwOgYBzPEbDAuxsNCsTgsCZNjy7EirAyrxhqwVqwDu4n1Y8+xdwQSgUXACTYEd0IgYR5BSFhMWE7YSKggHCQ0EdoJNwkDhFHCJyKTqEu0JroR+cQYYjIxh1hILCPWEo8TLxB7iEPENyQSiUMyJ7mQAkmxpFTSEtJG0m5SI+ksqZs0SBojk8naZGuyBzmULCAryIXkneTD5DPkG+Qh8lsKnWJAcaT4U+IoUspqShnlEOU05QZlmDJBVaOaUt2ooVQRNY9aQq2htlKvUYeoEzR1mjnNgxZJS6WtopXTGmgXaPdpr+h0uhHdlR5Ol9BX0svpR+iX6AP0dwwNhhWDx4hnKBmbGAcYZxl3GK+YTKYZ04sZx1QwNzHrmOeZD5lvVVgqtip8FZHKCpVKlSaVGyovVKmqpqreqgtV81XLVI+pXlN9rkZVM1PjqQnUlqtVqp1Q61MbU2epO6iHqmeob1Q/pH5Z/YkGWcNMw09DpFGgsV/jvMYgC2MZs3gsIWsNq4Z1gTXEJrHN2Xx2KruY/R27iz2qqaE5QzNKM1ezUvOUZj8H45hx+Jx0TgnnKKeX836K3hTvKeIpG6Y0TLkxZVxrqpaXllirSKtRq0frvTau7aedpr1Fu1n7gQ5Bx0onXCdHZ4/OBZ3nU9lT3acKpxZNPTr1ri6qa6UbobtEd79up+6Ynr5egJ5Mb6feeb3n+hx9L/1U/W36p/VHDFgGswwkBtsMzhg8xTVxbzwdL8fb8VFDXcNAQ6VhlWGX4YSRudE8o9VGjUYPjGnGXOMk423GbcajJgYmISZLTepN7ppSTbmmKaY7TDtMx83MzaLN1pk1mz0x1zLnm+eb15vft2BaeFostqi2uGVJsuRaplnutrxuhVo5WaVYVVpds0atna0l1rutu6cRp7lOk06rntZnw7Dxtsm2qbcZsOXYBtuutm22fWFnYhdnt8Wuw+6TvZN9un2N/T0HDYfZDqsdWh1+c7RyFDpWOt6azpzuP33F9JbpL2dYzxDP2DPjthPLKcRpnVOb00dnF2e5c4PziIuJS4LLLpc+Lpsbxt3IveRKdPVxXeF60vWdm7Obwu2o26/uNu5p7ofcn8w0nymeWTNz0MPIQ+BR5dE/C5+VMGvfrH5PQ0+BZ7XnIy9jL5FXrdewt6V3qvdh7xc+9j5yn+M+4zw33jLeWV/MN8C3yLfLT8Nvnl+F30N/I/9k/3r/0QCngCUBZwOJgUGBWwL7+Hp8Ib+OPzrbZfay2e1BjKC5QRVBj4KtguXBrSFoyOyQrSH355jOkc5pDoVQfujW0Adh5mGLw34MJ4WHhVeGP45wiFga0TGXNXfR3ENz30T6RJZE3ptnMU85ry1KNSo+qi5qPNo3ujS6P8YuZlnM1VidWElsSxw5LiquNm5svt/87fOH4p3iC+N7F5gvyF1weaHOwvSFpxapLhIsOpZATIhOOJTwQRAqqBaMJfITdyWOCnnCHcJnIi/RNtGI2ENcKh5O8kgqTXqS7JG8NXkkxTOlLOW5hCepkLxMDUzdmzqeFpp2IG0yPTq9MYOSkZBxQqohTZO2Z+pn5mZ2y6xlhbL+xW6Lty8elQfJa7OQrAVZLQq2QqboVFoo1yoHsmdlV2a/zYnKOZarnivN7cyzytuQN5zvn//tEsIS4ZK2pYZLVy0dWOa9rGo5sjxxedsK4xUFK4ZWBqw8uIq2Km3VT6vtV5eufr0mek1rgV7ByoLBtQFr6wtVCuWFfevc1+1dT1gvWd+1YfqGnRs+FYmKrhTbF5cVf9go3HjlG4dvyr+Z3JS0qavEuWTPZtJm6ebeLZ5bDpaql+aXDm4N2dq0Dd9WtO319kXbL5fNKNu7g7ZDuaO/PLi8ZafJzs07P1SkVPRU+lQ27tLdtWHX+G7R7ht7vPY07NXbW7z3/T7JvttVAVVN1WbVZftJ+7P3P66Jqun4lvttXa1ObXHtxwPSA/0HIw6217nU1R3SPVRSj9Yr60cOxx++/p3vdy0NNg1VjZzG4iNwRHnk6fcJ3/ceDTradox7rOEH0x92HWcdL2pCmvKaRptTmvtbYlu6T8w+0dbq3nr8R9sfD5w0PFl5SvNUyWna6YLTk2fyz4ydlZ19fi753GDborZ752PO32oPb++6EHTh0kX/i+c7vDvOXPK4dPKy2+UTV7hXmq86X23qdOo8/pPTT8e7nLuarrlca7nuer21e2b36RueN87d9L158Rb/1tWeOT3dvfN6b/fF9/XfFt1+cif9zsu72Xcn7q28T7xf9EDtQdlD3YfVP1v+3Njv3H9qwHeg89HcR/cGhYPP/pH1jw9DBY+Zj8uGDYbrnjg+OTniP3L96fynQ89kzyaeF/6i/suuFxYvfvjV69fO0ZjRoZfyl5O/bXyl/erA6xmv28bCxh6+yXgzMV70VvvtwXfcdx3vo98PT+R8IH8o/2j5sfVT0Kf7kxmTk/8EA5jz/GMzLdsAAAAgY0hSTQAAeiUAAICDAAD5/wAAgOkAAHUwAADqYAAAOpgAABdvkl/FRgAAAaNJREFUeNqk009oz3Ecx/HH9/P9/YQRWSi2MGmNrebkpJgSLluKEw5Kk5zUsgMOTrO42MUVxUWRg+LgaPWbUGq7rRk7sExKNPt9vx8H32l921z2vrw+n3fvz/Pz/vP5JDFGy7HKwk1/fz/sR09VNjAZG6fv1buQHcZm3P8vAMfwCKswncoHCn8nbuAratiEUQglwLXiMJz/FhvWYC9OFb4htBV6B9VyBtsKzRJxbDhvbSS5i1kcQo736MNrjJcBeaG3MuFyInagA0fwckHcGzzGiXIJU38bk1U+x3W+x7U/yOvYU4prwG5MlAHPoS4925TMNDeHLxNUh0gGcRC9eFqk34TBMuAhfmL9b5Vz3elIbAmfLq02d4HQhbc4gBYcxUgZMFrcIJecrsgaT6avdl6sPqu1hw9XSWs4U5Q6udgYFfP+he25MEysVWQvutORLcfTYax4gn3z/VoM8A7Xi/WuKNmQCRujpLc1TGkP46hOI1sKADdxG3PzjkzoTNCT1rSFiX+PuLIEoI4rGC+6/xEPMsFKs7YmM8bsAMlyf2OwTPszAMZMeayGCpJVAAAAAElFTkSuQmCC\"></A></SPAN> (nights, weekends) or&nbsp;email <A href=\"mailto:drugservice@cdc.gov\">drugservice@cdc.gov</A>.&nbsp;For military patients only,&nbsp;it&nbsp;may be obtained from Force Health Protection Division at&nbsp;<SPAN class=baec5a81-e4d6-4674-97f3-e9220f0136c1 style=\"WHITE-SPACE: nowrap\">301-401-2768<A title=\"Call: (301) 401-2768\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" href=\"#\"><IMG title=\"Call: (301) 401-2768\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" src=\"data:image/png;base64,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\"></A></SPAN><br />Δ Doses are expressed as mg of pentavalent antimony content.<br /><FONT class=lozenge>◊</FONT> Effective dose for weight &gt;75 kg may require higher dose off-label (with attendant gastrointestinal effects), aiming for &gt;2.5 mg/kg dose.<br />§ Not commercially available in the United States. It may be possible to obtain via investigational new drug (IND) application to the US Food and Drug Administration (FDA). Meglumine antimoniate contains 81 mg Sb<SUP>V</SUP>/mL versus sodium stibogluconate, which has 100 mg Sb<SUP>V</SUP>/mL.<br />¥ Miltefosine is FDA approved and commercially available in the United States.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Goto H, Laulett Lindoso JA. Cutaneous and mucocutaneous leishmaniasis. Inf Dis Clin N Am 2012; 26:293.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. Parasites - Leishmaniasis. Available at: <A href=\"http://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx\" target=_blank>http://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx</A> (Accessed on&nbsp;March 25, 2013).</LI>&#xD;&#xA;<LI>Drugs for parasitic infections, 2nd ed. The Medical Letter, New Rochelle, NY 2010. p.26.</LI></OL></div><div id=\"graphicVersion\">Graphic 88694 Version 11.0</div></div></div>"},"88695":{"type":"graphic_table","displayName":"Types of birth control PI","title":"Types of birth control","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of birth control</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Methods included</td> <td class=\"subtitle1\">Some information</td> </tr> <tr class=\"divider_bottom\"> <td>Barrier methods</td> <td> <ul> <li>Male condom </li> <li>Female condom </li> <li>Diaphragm </li> <li>Cervical cap </li> </ul> </td> <td>These methods must be used during each sex act. They block sperm from getting into the uterus and reaching a woman's egg. Sometimes a cream or gel that kills sperm must be used along with this type of birth control. Only condoms can reduce the chance of catching a disease from sex.</td> </tr> <tr class=\"divider_bottom\"> <td>Short-acting hormonal methods</td> <td> <ul> <li>Shot/injection </li> <li>Progestin-only pill </li> <li>Estrogen-progestin pill </li> <li>Patch </li> <li>Vaginal ring </li> </ul> </td> <td>These methods all use hormones to cause changes in a woman's body that reduce the chance of pregnancy. The different options require a different amount of attention. For example, women having shots must see their doctor every 3 months for a shot. Women taking pills must take a pill every day. Women using the patch or the ring must change it once a week.</td> </tr> <tr class=\"divider_bottom\"> <td>Long-acting methods</td> <td> <ul> <li>Implantable rod </li> <li>Intrauterine device (IUD) with progestin </li> <li>IUD with copper </li> </ul> </td> <td>The implantable rod and the IUD with progestin both use hormones to prevent pregnancy. The IUD with copper releases copper to prevent pregnancy. These stay in the body and keep working for 3 to 10 years, depending on the method chosen.</td> </tr> <tr> <td>Sterilization</td> <td> <ul> <li>Vasectomy (for men) </li> <li>Tubal occlusion or ligation (for women) </li> </ul> </td> <td>These methods involve procedures or surgery and are permanent.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 88695 Version 2.0</div></div></div>"},"88699":{"type":"graphic_table","displayName":"Causes of weight loss in infants six months of age and younger","title":"Causes of weight loss in infants six months of age and younger","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of weight loss in infants six months of age and younger</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Life-threatening conditions</td> </tr> <tr> <td class=\"indent1\">Dehydration</td> </tr> <tr> <td class=\"indent1\">Intestinal malrotation with volvulus</td> </tr> <tr> <td class=\"indent1\">Congenital heart disease</td> </tr> <tr> <td class=\"indent1\">Congenital adrenal hyperplasia</td> </tr> <tr> <td class=\"indent1\">Inborn error of metabolism</td> </tr> <tr> <td class=\"subtitle1_single\">Common conditions</td> </tr> <tr> <td class=\"indent1\">Acute infection (eg, viral or bacterial gastroenteritis, urinary tract infection, pneumonia)</td> </tr> <tr> <td class=\"indent1\">Feeding disorder (eg, developmental immature sucking, anatomical defect [eg, cleft lip and palate], neuromuscular weakness)</td> </tr> <tr> <td class=\"indent1\">Gastroesophageal reflux disease</td> </tr> <tr> <td class=\"indent1\">Pyloric stenosis</td> </tr> <tr> <td class=\"indent1\">Child abuse and neglect</td> </tr> <tr> <td class=\"indent1\">Milk protein allergy</td> </tr> <tr> <td class=\"indent1\">Malnutrition (food insecurity or improper mixing of formula) and failure to thrive</td> </tr> <tr> <td class=\"subtitle1_single\">Other conditions</td> </tr> <tr> <td class=\"indent1\">Congenital human immunodeficiency virus infection</td> </tr> <tr> <td class=\"indent1\">Primary immunodeficiency</td> </tr> <tr> <td class=\"indent1\">Intestinal malabsorption (eg, enterokinase deficiency, abetalipoproteinemia, hypobetalipoproteinemia, cystic fibrosis)</td> </tr> <tr> <td class=\"indent1\">Kidney disease (eg, renal tubular acidosis, renal dysplasia)</td> </tr> <tr> <td class=\"indent1\">Liver disease (eg, biliary atresia, or congenital infection with hepatitis)</td> </tr> <tr> <td class=\"indent1\">Chronic lung disease (eg, bronchopulmonary dysplasia, cystic fibrosis)</td> </tr> <tr> <td class=\"indent1\">Malignancy</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 88699 Version 4.0</div></div></div>"},"88700":{"type":"graphic_algorithm","displayName":"Approach to weight loss in young infants","title":"Approach to weight loss in young infants six months of age and younger","html":"<div class=\"graphic\"><div style=\"width: 1218px\" class=\"figure\"><div class=\"ttl\">Approach to weight loss in young infants six months of age and younger</div><div class=\"cntnt\"><img style=\"width:1198px; height:978px;\" src=\"images/EM/88700_App_wght_loss_young_infant.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* In patients with early presentations of some diseases that usually cause significant illness, such as malrotation or congenital adrenal hyperplasia, appearance may be normal.<br />¶ These conditions typically present within the first one or two months of life.<br />Δ Not all patients with malignancy may have fever.<br /><FONT class=lozenge>◊</FONT> Poor feeding, pyloric stenosis or gastroenteritis are common conditions causing dehydration. In some patients, dehydration may be severe and cause ill appearance.<br />§ Conditions listed as causing critical illness may occasionally have less severe presentations.</div><div id=\"graphicVersion\">Graphic 88700 Version 3.0</div></div></div>"},"88701":{"type":"graphic_table","displayName":"IPD incidence and mortality","title":"Incidence and mortality rates of invasive pneumococcal disease in the United States, 2010 — Active Bacterial Core Surveillance (ABCs) report, Emerging Infections Program Network","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence and mortality rates of invasive pneumococcal disease in the United States, 2010 — Active Bacterial Core Surveillance (ABCs) report, Emerging Infections Program Network</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age (years)</td> <td class=\"subtitle1\" colspan=\"2\">Cases</td> <td class=\"subtitle1\" colspan=\"2\">Deaths</td> </tr> <tr> <td class=\"subtitle2\">Number</td> <td class=\"subtitle2\">(Rate*)</td> <td class=\"subtitle2\">Number</td> <td class=\"subtitle2\">(Rate*)</td> </tr> <tr> <td>&#60;1</td> <td class=\"centered\">142</td> <td class=\"centered\">(34.2)</td> <td class=\"centered\">1</td> <td class=\"centered\">(0.24)</td> </tr> <tr> <td>1</td> <td class=\"centered\">112</td> <td class=\"centered\">(26.6)</td> <td class=\"centered\">1</td> <td class=\"centered\">(0.24)</td> </tr> <tr> <td>2 to 4</td> <td class=\"centered\">171</td> <td class=\"centered\">(13.1)</td> <td class=\"centered\">1</td> <td class=\"centered\">(0.08)</td> </tr> <tr> <td>5 to 17</td> <td class=\"centered\">111</td> <td class=\"centered\">(2.2)</td> <td class=\"centered\">1</td> <td class=\"centered\">(0.02)</td> </tr> <tr> <td>18 to 34</td> <td class=\"centered\">260</td> <td class=\"centered\">(3.8)</td> <td class=\"centered\">18</td> <td class=\"centered\">(0.26)</td> </tr> <tr> <td>35 to 49</td> <td class=\"centered\">670</td> <td class=\"centered\">(10.5)</td> <td class=\"centered\">43</td> <td class=\"centered\">(0.68)</td> </tr> <tr> <td>50 to 64</td> <td class=\"centered\">1064</td> <td class=\"centered\">(18.8)</td> <td class=\"centered\">103</td> <td class=\"centered\">(1.82)</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;65</td> <td class=\"centered\">1292</td> <td class=\"centered\">(36.4)</td> <td class=\"centered\">199</td> <td class=\"centered\">(5.61)</td> </tr> <tr> <td><strong>Total:</strong></td> <td class=\"centered\"><strong>3822</strong></td> <td class=\"centered\"><strong>(12.8)</strong></td> <td class=\"centered\"><strong>367</strong></td> <td class=\"centered\"><strong>(1.23)</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Cases or deaths per 100,000 population for ABCs areas, which represent nearly 30,000,000 persons in certain counties in 10 states in the United States.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) report, Emerging Infections Program Network Streptococcus pneumoniae, 2010. Available at: <a href=\"http://www.cdc.gov/abcs/reports-findings/survreports/spneu10-orig.pdf\" target=\"_blank\">http://www.cdc.gov/abcs/reports-findings/survreports/spneu10-orig.pdf</a> (Accessed March 21, 2013).</div><div id=\"graphicVersion\">Graphic 88701 Version 3.0</div></div></div>"},"88702":{"type":"graphic_picture","displayName":"Balance error scoring system","title":"Balance error scoring system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Balance error scoring system</div><div class=\"cntnt\"><img style=\"width:413px; height:808px;\" src=\"images/EM/88702_Balanc_error_scoring_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinical test battery:<br /><UL class=decimal_heading>&#xD;&#xA;<LI>Perform a total of six 20 second trials using&nbsp;three different stances (double, single, tandem), each one used&nbsp;with&nbsp;two different surfaces (firm, foam)</LI></UL>Recorded errors:<br /><UL class=decimal_heading>&#xD;&#xA;<LI>Hands lifted off iliac crests</LI>&#xD;&#xA;<LI>Opening eyes</LI>&#xD;&#xA;<LI>Step, stumble, or fall</LI>&#xD;&#xA;<LI>Moving into &gt;30 degrees hip flexion or abduction</LI>&#xD;&#xA;<LI>Remaining out of testing position for &gt;5 seconds</LI></UL></div><div class=\"graphic_reference\">Credit: Mathew Gfeller Sport-Related TBI Research Center, UNC-Chapel Hill. Reproduced with permission from Kevin M. Guskiewicz, PhD, ATC, FACSM, FNATA.</div><div id=\"graphicVersion\">Graphic 88702 Version 1.0</div></div></div>"},"88734":{"type":"graphic_table","displayName":"Symptoms associated with colorectal cancer","title":"Symptoms associated with colorectal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms associated with colorectal cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">DOR*<br /> (95% CI*)</td> <td class=\"subtitle1\">AUC<sup>&#182;</sup></td> <td class=\"subtitle1\">Sensitivity<br /> (95% CI)</td> <td class=\"subtitle1\">1-specificity<br /> (95% CI)</td> <td class=\"subtitle1\">LR+<br /> (95% CI)</td> <td class=\"subtitle1\">LR&ndash;<br /> (95% CI)</td> </tr> <tr> <td>Rectal bleeding<sup>&#916;</sup></td> <td>2.6<br /> <p>(1.9-3.6)</p> p&#60;0.001</td> <td class=\"centered\">0.66</td> <td>0.46<br /> (0.38-0.55)</td> <td>0.25<br /> (0.19-0.31)</td> <td>1.9<br /> (1.5-2.3)</td> <td>0.7<br /> (0.6-0.8)</td> </tr> <tr> <td>Blood mixed with stool</td> <td>3.1<br /> <p>(2.0-4.8)</p> p&#60;0.001</td> <td class=\"centered\">0.68</td> <td>0.49<br /> (0.30-0.69)</td> <td>0.24<br /> (0.13-0.40)</td> <td>2.1<br /> (1.5-2.8)</td> <td>0.7<br /> (0.5-0.9)</td> </tr> <tr> <td>Blood: dark red</td> <td>3.9<br /> <p>(1.7-9.2)</p> p = 0.004</td> <td class=\"centered\">0.71</td> <td>0.29<br /> (0.09-0.65)</td> <td>0.10<br /> (0.03-0.28)</td> <td>3.1<br /> (1.6-6.0)</td> <td>0.8<br /> (0.6-1.1)</td> </tr> <tr> <td>Change in bowel habit</td> <td>1.5<br /> <p>(0.8-2.8)</p> p = 0.16</td> <td class=\"centered\">0.57</td> <td>0.32<br /> (0.21-0.46)</td> <td>0.24<br /> (0.15-0.35)</td> <td>1.4<br /> (0.9-2.1)</td> <td>0.9<br /> (0.7-1.1)</td> </tr> <tr> <td>Constipation</td> <td>1.1<br /> <p>(0.8-1.5)</p> p = 0.48</td> <td class=\"centered\">0.52</td> <td>0.12<br /> (0.08-0.18)</td> <td>0.11<br /> (0.07-0.16)</td> <td>1.1<br /> (0.8-1.5)</td> <td>1.0<br /> (1.0-1.0)</td> </tr> <tr> <td>Diarrhea</td> <td>0.9<br /> <p>(0.4-1.7)</p> p = 0.65</td> <td class=\"centered\">0.47</td> <td>0.15<br /> (0.07-0.28)</td> <td>0.17<br /> (0.09-0.29)</td> <td>0.9<br /> (0.5-1.6)</td> <td>1.0<br /> (0.9-1.1)</td> </tr> <tr> <td>Abdominal pain</td> <td>0.7<br /> <p>(0.5-1.1)</p> p = 0.12</td> <td class=\"centered\">0.45</td> <td>0.19<br /> (0.13-0.28)</td> <td>0.24<br /> (0.17-0.33)</td> <td>0.8<br /> (0.6-1.1)</td> <td>1.1<br /> (1.0-1.2)</td> </tr> <tr> <td>Weight loss</td> <td>2.9<br /> <p>(1.6-5.0)</p> p = 0.001</td> <td class=\"centered\">0.67</td> <td>0.20<br /> (0.12-0.31)</td> <td>0.08<br /> (0.05-0.13)</td> <td>2.5<br /> (1.5-4.0)</td> <td>0.9<br /> (0.8-1.0)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LR+: the likelihood ratio of having colorectal cancer in the presence of the symptom; LR–: the likelihood ratio of having colorectal cancer in the absence of the symptom.<br />* DOR: diagnostic odds ratio. No association between symptom and cancer if DOR = 1.<br />¶ AUC: Area Under the receiver operating characteristic Curve. No association between symptom and cancer if AUC = 0.5.<br />Δ Bleeding of any type.</div><div class=\"graphic_reference\">Reproduced from: Adelstein B, Macaskill P, Chan SF, et al. Most bowel cancer symptoms do not indicate colorectal cancer and polyps: a systematic review. BMC Gastroenterology 2011; 11:65. Copyright &copy; 2011 Adelstein et al.</div><div id=\"graphicVersion\">Graphic 88734 Version 4.0</div></div></div>"},"88737":{"type":"graphic_diagnosticimage","displayName":"X-ray and CT of knee lipohemarthrosis","title":"Lipohemarthrosis of the knee: Imaging on plain radiography and computerized tomography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lipohemarthrosis of the knee: Imaging on plain radiography and computerized tomography</div><div class=\"cntnt\"><img style=\"width:447px; height:452px;\" src=\"images/RADIOL/88737_X_CT_lipohemarthr_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An anteroposterior view of the left knee (A) shows a depressed fracture of the lateral tibial plateau (arrow). A tunnel view of the left knee (B), shows a vertical component of the fracture (arrow). A cross table lateral view (C) shows a fat-fluid level (arrow). An axial image from a CT scan (D) at a level above the knee confirms a fat-fluid level (arrow) with a low-density fat containing supernatant and blood layering posteriorly. These findings are consistent with a lipohemarthrosis secondary to a tibial fracture.</div><div class=\"graphic_footnotes\">CT: Computed tomography</div><div id=\"graphicVersion\">Graphic 88737 Version 3.0</div></div></div>"},"88738":{"type":"graphic_diagnosticimage","displayName":"CT carcinoid of the tricuspid valve","title":"Carcinoid involvement of the tricuspid valve on CT scan","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Carcinoid involvement of the tricuspid valve on CT scan</div><div class=\"cntnt\"><img style=\"width:590px; height:427px;\" src=\"images/RADIOL/88738_CT_carcin_tricusp_valv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT image through the heart shows thickened leaflets of the tricuspid valve (arrowheads) and an enlarged right atrium with a bulging interatrial septum (arrow) reflecting elevated right atrial pressures. The patient was a 63-year-old woman with metastatic carcinoid disease with tricuspid valve involvement.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 88738 Version 1.0</div></div></div>"},"88742":{"type":"graphic_diagnosticimage","displayName":"Richters hernia on computed tomography","title":"Richters hernia on computed tomography","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Richters hernia on computed tomography</div><div class=\"cntnt\"><img style=\"width:529px; height:440px;\" src=\"images/RADIOL/88742_CT_richters_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;CT scan shows a Richter's hernia with a knuckle of part of the small bowel protruding into a hernia of the anterior abdominal wall.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 88742 Version 2.0</div></div></div>"},"88743":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph lymphangitic carcinomatosis ovarian cancer","title":"Chest radiograph showing lymphangitic carcinomatosis in a patient with ovarian cancer","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Chest radiograph showing lymphangitic carcinomatosis in a patient with ovarian cancer</div><div class=\"cntnt\"><img style=\"width:466px; height:521px;\" src=\"images/RADIOL/88743_Chest_x_lymp_carc_pat_ovar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest&nbsp;radiograph shows diffuse bilateral, fine linear and nodular opacities that correspond to thickened interlobular septa of the lung parenchyma in a patient with metastatic ovarian cancer. This appearance is consistent with lymphangitic carcinomatosis.</div><div id=\"graphicVersion\">Graphic 88743 Version 3.0</div></div></div>"},"88744":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph of lymphangitic carcinomatosis","title":"Lymphangitic carcinomatosis on chest radiograph in a patient with lung cancer","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Lymphangitic carcinomatosis on chest radiograph in a patient with lung cancer</div><div class=\"cntnt\"><img style=\"width:725px; height:800px;\" src=\"images/RADIOL/88744_ChstxCTlymphcarcin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows diffuse unilateral, fine linear opacities with Kerley B lines that correspond to thickened interlobular septa of the lung. This appearance is consistent with lymphangitic carcinomatosis.</div><div id=\"graphicVersion\">Graphic 88744 Version 3.0</div></div></div>"},"88745":{"type":"graphic_diagnosticimage","displayName":"X-ray cervical rib","title":"Bilateral cervical ribs on x-ray in a patient with thoracic outlet syndrome","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Bilateral cervical ribs on x-ray in a patient with thoracic outlet syndrome</div><div class=\"cntnt\"><img style=\"width:599px; height:121px;\" src=\"images/RADIOL/88745_X_ray_cervical_rib.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 27-year-old female patient presented with loss of the right radial pulse and right hand ischemia. A chest x-ray (A) shows bilateral asymmetric cervical ribs. A magnified view (B) shows a shorter right cervical rib compared with the left. Angiography confirmed arterial compression by the cervical rib as the source of embolic disease to the right hand.</div><div id=\"graphicVersion\">Graphic 88745 Version 2.0</div></div></div>"},"88746":{"type":"graphic_diagnosticimage","displayName":"CT scan thoracic outlet syndrome","title":"CT scan thoracic outlet syndrome","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">CT scan thoracic outlet syndrome</div><div class=\"cntnt\"><img style=\"width:505px; height:481px;\" src=\"images/RADIOL/88746_CT_thoracic_out_syndr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 25-year-old female presented with a pulsatile left supraclavicular mass. A CT scan reformatted in the coronal view&nbsp;shows an oblique band of tissue (arrow) impinging on and compressing the subclavian artery resulting in post-stenotic dilation of the artery (arrowhead). The dilated segment of the subclavian artery correlated with the pulsatile mass noted clinically.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 88746 Version 2.0</div></div></div>"},"88747":{"type":"graphic_diagnosticimage","displayName":"Arteriogram demonstrating arterial thoracic outlet syndrome","title":"Arteriogram demonstrating arterial thoracic outlet syndrome","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Arteriogram demonstrating arterial thoracic outlet syndrome</div><div class=\"cntnt\"><img style=\"width:598px; height:192px;\" src=\"images/RADIOL/88747_Angiogr_thor_out_synd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An 18-year-old paratrooper complained of tingling in his fingers when he elevated his arms to deploy his parachute. A subclavian arteriogram with the left arm in neutral position (A) shows a patent left subclavian artery. Repeat arteriogram with the arm elevated (B) shows an abrupt cutoff of the subclavian artery (arrowhead) with delayed distal filling of the axillary artery (arrow) via multiple small collateral arteries. His symptoms were reproduced with arm elevation.</div><div id=\"graphicVersion\">Graphic 88747 Version 2.0</div></div></div>"},"88748":{"type":"graphic_diagnosticimage","displayName":"CT scan and x-ray abdomen pseudomyxoma peritonei with scalloping","title":"Pseudomyxoma peritonei with scalloping on CT scan and KUB x-ray","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Pseudomyxoma peritonei with scalloping on CT scan and KUB x-ray</div><div class=\"cntnt\"><img style=\"width:598px; height:263px;\" src=\"images/RADIOL/88748_CT_x_abd_pseud_scallop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A plain film of the abdomen (A) of a 49-year-old man with pseudomyxoma peritonei demonstrates multicentric curvilinear calcifications in the right upper quadrant (arrows). A CT scan (B) of the same case demonstrates scalloping of the liver surface (arrow) and splenic surface (dashed arrow) caused by loculated accumulations of mucin with extensive peritoneal calcifications (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography; KUB: kidney, ureter, and bladder.</div><div id=\"graphicVersion\">Graphic 88748 Version 3.0</div></div></div>"},"88749":{"type":"graphic_diagnosticimage","displayName":"CT scan pseudomyxoma peritonei","title":"Pseudomyxoma peritonei on CT scan","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Pseudomyxoma peritonei on CT scan</div><div class=\"cntnt\"><img style=\"width:597px; height:244px;\" src=\"images/RADIOL/88749_CT_pseudomyxoma_perit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan (A) of an 85-year-old patient with pseudomyxoma peritonei shows large cystic accumulations of mucus (arrows) surrounded by calcified rims. A coronal reconstruction (B) shows that the cystic accumulations in the upper abdomen impinge on the diaphragm (arrowhead) and the liver (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 88749 Version 1.0</div></div></div>"},"88751":{"type":"graphic_diagnosticimage","displayName":"CT scan non Hodgkin B cell lymphoma","title":"Lymphadenopathy and splenomegaly on CT scan in a patient with non-Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Lymphadenopathy and splenomegaly on CT scan in a patient with non-Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:590px; height:491px;\" src=\"images/RADIOL/88751_CT_non_hodgkin_b_lymp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan of the abdomen at the level of the kidneys in a patient with extensive B-cell non-Hodgkin lymphoma. There is massive enlargement of the retroperitoneal nodes (arrows) as well as enlarged nodes at the base of the small bowel mesentery. The spleen is also enlarged (dashed arrow).</div><div id=\"graphicVersion\">Graphic 88751 Version 3.0</div></div></div>"},"88752":{"type":"graphic_table","displayName":"Rapid desensitization protocol for insulin","title":"Rapid desensitization protocol for insulin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid desensitization protocol for insulin</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Doses of insulin/insulin analogue injected subcutaneously (international units)*</td> <td class=\"subtitle1\">Time</td> <td class=\"subtitle1\">Monitoring</td> </tr> <tr> <td class=\"centered\">0.00001</td> <td rowspan=\"12\">Intervals between injections 15 to 30 minutes</td> <td rowspan=\"12\">Monitor glucose levels and allergic symptoms; prepare for emergency intervention</td> </tr> <tr> <td class=\"centered\">0.0001</td> </tr> <tr> <td class=\"centered\">0.001</td> </tr> <tr> <td class=\"centered\">0.01</td> </tr> <tr> <td class=\"centered\">0.1</td> </tr> <tr> <td class=\"centered\">1</td> </tr> <tr> <td class=\"centered\">2</td> </tr> <tr> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">8</td> </tr> <tr> <td class=\"centered\">12</td> </tr> <tr> <td class=\"centered\">16</td> </tr> <tr> <td class=\"centered\">20</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In case of local allergic reactions, the last dose is repeated until no reaction occurs, and then the dose increases are continued. If a systemic reaction occurs, the reaction is treated as required. Once the symptoms have resolved, the protocol is resumed, starting with one-half of the dose that caused the reaction.</div><div id=\"graphicVersion\">Graphic 88752 Version 3.0</div></div></div>"},"88754":{"type":"graphic_figure","displayName":"Annual snake envenomations by world regions","title":"Number of snake envenomations by world regions","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Number of snake envenomations by world regions</div><div class=\"cntnt\"><img style=\"width:605px; height:617px;\" src=\"images/EM/88754_Ann_snake_envenoma_regions.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Global Burden of Disease regions are defined according to regions that are epidemiologically homogeneous so that estimates in one country within a region can be reasonably used by other countries within that region. However, this method may produce some inaccuracies in regions, (eg, the Carribean) where land masses are discreet (eg, islands) or are separated by geographical barriers such as mountain ranges or large bodies of water.</div><div class=\"graphic_footnotes\">GBD: global burden of disease.</div><div class=\"graphic_reference\">Reproduced from: Kasturiratne A, Wickremasinghe AR, de Silva N, et al. The Global Burden of Snakebite: A Literature Analysis and Modelling Based on Regional Estimates of Envenoming and Deaths. PLoS Med 2008; 5:e218. Copyright © 2008 Kasturiratne et al.</div><div id=\"graphicVersion\">Graphic 88754 Version 1.0</div></div></div>"},"88755":{"type":"graphic_table","displayName":"Eligibility criteria allo-HCT","title":"General eligibility criteria for allogeneic hematopoietic cell transplantation (allo-HCT)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">General eligibility criteria for allogeneic hematopoietic cell transplantation (allo-HCT)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Disease-related indication</td> </tr> <tr> <td>Suitable donor available</td> </tr> <tr> <td>Karnofsky performance status &#8805;70 for a myeloablative HCT or &#8805;50 for a nonmyeloablative HCT</td> </tr> <tr> <td>Renal function:<br /> <ul> <li>While no specific cutoff is universally used, many centers limit allo-HCT to those with a serum creatinine &#60;2 mg/dL (177 micromol/L) or CrCl &#62;50 </li> </ul> </td> </tr> <tr> <td>Cardiac reserve:<br /> <ul> <li>LVEF &#62;35 </li> </ul> </td> </tr> <tr> <td>Pulmonary function:<br /> <ul> <li>A corrected DLCO &#62;35 percent </li> </ul> </td> </tr> <tr> <td>Liver function:<br /> <ul> <li>No frank cirrhosis of the liver </li> </ul> </td> </tr> <tr> <td>Adequate psychosocial and financial support</td> </tr> <tr> <td>While no specific age cutoff is universally used, many centers limit myeloablative allo-HCT to patients &#60;55 years and reduced intensity allo-HCT to patients &#60;75 years</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LVEF: left ventricular ejection fraction; DLCO: diffusing capacity of the lungs for carbon monoxide.</div><div id=\"graphicVersion\">Graphic 88755 Version 2.0</div></div></div>"},"88760":{"type":"graphic_table","displayName":"Epidemiology treponematoses","title":"Distribution of endemic treponematosis (1987 to 2015)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distribution of endemic treponematosis (1987 to 2015)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">World Health Organization region</td> <td class=\"subtitle1\">Yaws</td> <td class=\"subtitle1\">Bejel</td> <td class=\"subtitle1\">Pinta</td> </tr> <tr> <td>Africa</td> <td> <p>Benin (2012)</p> <p>Cameroon (2015)</p> <p>Central African Republic (2012)</p> <p>Congo (2012)</p> <p>Democratic Republic of Congo (2009)</p> <p>C&#244;te d'Ivoire (2013)</p> <p>Ghana (2015)</p> Togo (2015)</td> <td> <p>Senegal (2012)</p> <p>Burkina Faso (1988)</p> <p>Mali (1999)</p> Niger (1998)</td> <td>None</td> </tr> <tr> <td>Eastern Mediterranean</td> <td>Unknown</td> <td> <p>Saudi Arabia (1985)</p> <p>Iraq (2012)</p> <p>Turkey (1995)</p> <p>Syria (NA)</p> <p>Pakistan (2017)</p> </td> <td>None</td> </tr> <tr> <td>Americas</td> <td>Last report was on the elimination of yaws from Ecuador in 2003</td> <td>None</td> <td> <p>Mexico (1981)</p> <p>Brasil (1988)</p> <p>Colombia (1977)</p> <p>Panama (1988)</p> <p>Peru (NA)</p> <p>Venezuela (1992)</p> </td> </tr> <tr> <td>Southeast Asia*</td> <td> <p>Indonesia (2015)</p> Timor Leste (2010)</td> <td>None</td> <td>None</td> </tr> <tr> <td>Western Pacific</td> <td> <p>Papua New Guinea (2015)</p> <p>Solomon Islands (2015)</p> <p>Vanuatu (2015)</p> <p>Philippines (2017)<sup>&#182;</sup></p> Wallis and Futuna (2011)</td> <td>None</td> <td>None</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Indicated in brackets is the year of the most recent published report from each country.</div><div class=\"graphic_footnotes\">* India interrupted transmission in 2004 and declared elimination in 2006. Since 2004, no new cases have been reported. India was certified free of yaws by the World Health Organization in May 2016.<br />¶ The Philippines confirmed cases of yaws in a survey in 2017.</div><div id=\"graphicVersion\">Graphic 88760 Version 2.0</div></div></div>"},"88761":{"type":"graphic_table","displayName":"Characteristics treponematoses","title":"Epidemiologic and clinical characteristics of treponemal diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epidemiologic and clinical characteristics of treponemal diseases</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\"> <p>Syphilis<br /> (<em>Treponema pallidum pallidum</em>)</p> </td> <td class=\"subtitle1\"> <p>Yaws<br /> (<em>Treponema pallidum</em><em> pertenue</em>)</p> </td> <td class=\"subtitle1\"> <p>Bejel<br /> (<em>Treponema pallidum</em><em> endemicum</em>)</p> </td> <td class=\"subtitle1\"> <p>Pinta<br /> (<em>Treponema carateum</em>)</p> </td> </tr> <tr> <td><strong>Geographical distribution (climate)</strong></td> <td>Worldwide</td> <td>Tropics (hot, humid areas)</td> <td>Deserts of Africa and Saudi Arabia (hot, dry areas)</td> <td>Central and South America (hot, humid areas)</td> </tr> <tr> <td><strong>Age group (peak incidence)</strong></td> <td>Adults (18 to 30)</td> <td>Children (2 to 10)</td> <td>Children (2 to 10)</td> <td>Adults (15 to 50)</td> </tr> <tr> <td><strong>Transmission</strong></td> <td>Sexual and congenital</td> <td>Skin-to-skin contact</td> <td>Mouth to mouth or utensils</td> <td>Skin-to-skin contact</td> </tr> <tr> <td><strong>Initial lesion (frequency)</strong></td> <td>Common</td> <td>Common</td> <td>Rare</td> <td>Common</td> </tr> <tr> <td><strong>Initial lesion (location)</strong></td> <td>Genitals</td> <td>Lower extremities</td> <td>Oral mucosa</td> <td>Extremities</td> </tr> <tr> <td><strong>Dissemination</strong></td> <td>Widespread and systemic</td> <td>Widespread to skin and bone</td> <td>Limited to intertriginous areas and facial bone</td> <td>Limited to skin</td> </tr> <tr> <td><strong>Late complications without treatment</strong></td> <td>Ulcers (10 percent), neurological (10 percent), cardiovascular (10 to 15 percent)</td> <td>Destructive lesions of skin and bones (10 percent)</td> <td>Destruction of nose/palate</td> <td>Local skin hypoacromia</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Perine PL, Hopkins DR. Handbook of Endemic Treponematoses: Yaws, Endemic Syphilis, and Pinta, World Health Organization, Geneva 1984.</div><div id=\"graphicVersion\">Graphic 88761 Version 4.0</div></div></div>"},"88782":{"type":"graphic_table","displayName":"GRACE risk score","title":"GRACE risk score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">GRACE risk score</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk category<br /> (tertile)</td> <td class=\"subtitle1\">GRACE risk score</td> <td class=\"subtitle1\">In-hospital death<br /> (percent)</td> </tr> <tr> <td>Low</td> <td class=\"centered\">&#8804;108</td> <td class=\"centered\">&#60;1</td> </tr> <tr> <td>Intermediate</td> <td class=\"centered\">109-140</td> <td class=\"centered\">1-3</td> </tr> <tr class=\"divider_bottom\"> <td>High</td> <td class=\"centered\">&#62;140</td> <td class=\"centered\">&#62;3</td> </tr> <tr> <td class=\"subtitle1\">Risk category<br /> (tertile)</td> <td class=\"subtitle1\">GRACE risk score</td> <td class=\"subtitle1\">Post-discharge to six-month death<br /> (percent)</td> </tr> <tr> <td>Low</td> <td class=\"centered\">&#8804;88</td> <td class=\"centered\">&#60;3</td> </tr> <tr> <td>Intermediate</td> <td class=\"centered\">89-118</td> <td class=\"centered\">3-8</td> </tr> <tr> <td>High</td> <td class=\"centered\">&#62;118</td> <td class=\"centered\">&#62;8</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:2999. By permission of the European Society of Cardiology. Copyright &copy; 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 88782 Version 2.0</div></div></div>"},"88800":{"type":"graphic_picture","displayName":"Rapidly involuting congenital hemangioma","title":"Rapidly involuting congenital hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rapidly involuting congenital hemangioma</div><div class=\"cntnt\"><img style=\"width:373px; height:563px;\" src=\"images/DERM/88800_Rpdly_invltng_cngntl_hemngm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large scalp vascular mass was present at birth in this infant.</div><div id=\"graphicVersion\">Graphic 88800 Version 1.0</div></div></div>"},"88802":{"type":"graphic_table","displayName":"Complications of PPROM","title":"Pregnancy complications associated with preterm premature rupture of membranes (PPROM)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pregnancy complications associated with preterm premature rupture of membranes (PPROM)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pregnancy complication</td> <td class=\"subtitle1\">Potential consequences for offspring</td> <td class=\"subtitle1\">Potential maternal consequences</td> </tr> <tr> <td>Intrauterine infection</td> <td> <p>Neonatal sepsis</p> Long-term neurodevelopmental abnormalities, particularly cerebral palsy</td> <td>Postpartum endometritis</td> </tr> <tr> <td>Umbilical cord compression</td> <td>Fetal asphyxia</td> <td>Cesarean delivery</td> </tr> <tr> <td>Oligohydramnios</td> <td>Limb restriction deformities and pulmonary hypoplasia (primarily with severe oligohydramnios in the early to mid second trimester). These complications are rare when membrane rupture occurs after 23 weeks.</td> <td>&nbsp;</td> </tr> <tr> <td>Fetal malpresentation</td> <td>&nbsp;</td> <td>Cesarean delivery</td> </tr> <tr> <td>Umbilical cord prolapse</td> <td>Fetal asphyxia</td> <td>Cesarean delivery</td> </tr> <tr> <td>Abruptio placentae</td> <td>Fetal asphyxia</td> <td> <p>Cesarean delivery</p> Coagulopathy</td> </tr> <tr> <td>Preterm birth</td> <td>Morbidity of prematurity, including respiratory abnormalities, intraventricular hemorrhage, necrotizing enterocolitis, retinopathy of prematurity, patent ductus arteriosus</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 88802 Version 3.0</div></div></div>"},"88803":{"type":"graphic_picture","displayName":"Rapidly involuting congenital hemangioma 2","title":"Rapidly involuting congenital hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rapidly involuting congenital hemangioma</div><div class=\"cntnt\"><img style=\"width:345px; height:485px;\" src=\"images/DERM/88803_RICH_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This healthy newborn had a congenital 4 cm subcutaneous purplish-blue rubbery tumor on the left leg, just below the knee. Note the surrounding pallor and overlying telangiectasias.</div><div class=\"graphic_reference\">Copyright © Jennifer Sawyer-Butler, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 88803 Version 4.0</div></div></div>"},"88804":{"type":"graphic_table","displayName":"Laboratory evaluation for thrombophilias","title":"Laboratory evaluation for thrombophilias in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory evaluation for thrombophilias in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"50%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Thrombophilia</td> <td class=\"subtitle1\">Laboratory studies</td> <td class=\"subtitle1\">Strength of association between IT and risk of VTE</td> </tr> <tr> <td><strong>Factor V Leiden mutation</strong></td> <td>DNA-based PCR assay (or screen with activated protein C resistance)</td> <td> <p>Weak (heterozygous)</p> Strong (homozygous)</td> </tr> <tr> <td><strong>Prothrombin 20210 mutation</strong></td> <td>DNA-based PCR assay</td> <td>Weak</td> </tr> <tr> <td><strong>Antithrombin deficiency</strong></td> <td>Antithrombin activity via chromogenic or clotting assay</td> <td>Strong</td> </tr> <tr> <td><strong>Protein C deficiency</strong></td> <td>Protein C activity via chromogenic or clotting assay</td> <td>Strong</td> </tr> <tr> <td><strong>Protein S deficiency</strong></td> <td>Protein S activity via assay or immunologic assay of free and total protein S antigen</td> <td>Strong</td> </tr> <tr> <td>Hyperhomocysteinemia*</td> <td>Fasting homocysteine</td> <td>Weak</td> </tr> <tr> <td>Antiphospholipid antibodies<sup>&#182;</sup></td> <td>Phospholipid-based clotting assays, (PTT, DRVVT or Staclot LA) with confirmatory assay using exogenous phospholipid, ELISA assays for IgG and IgM antibodies directed against cardiolipin and &#946;2 glycoprotein</td> <td>Strong</td> </tr> <tr> <td>Elevated factor VIII<sup>&#916;</sup></td> <td>Factor VIII activity via one-stage clotting or chromogenic assay</td> <td>Weak</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The most common thrombophilias and accompanying diagnostic laboratory studies. Established genetic factors shown in <strong>bold</strong>.</div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction; PTT: partial thromboplastin time; DRVVT: dilute Russell viper venom time (a test for lupus anticoagulant); Staclot LA: Staclot lupus anticoagulant; ELISA: enzyme-linked immunosorbent assay; IT: inherited thrombophilia; VTE: venous thromboembolism.<br />* Hyperhomocysteinemia can be inherited or acquired (eg, nutritional deficiencies).<br />¶ Antiphospholipid antibodies are generally acquired rather than inherited.<br />Δ Elevated factor VIII can be inherited or acquired (eg, inflammation).</div><div class=\"graphic_reference\">Courtesy of Leslie Raffini, MD.</div><div id=\"graphicVersion\">Graphic 88804 Version 4.0</div></div></div>"},"88805":{"type":"graphic_table","displayName":"Conditions acquired thrombophilic lab abnormalities","title":"Conditions associated with acquired thrombophilic laboratory abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with acquired thrombophilic laboratory abnormalities</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Acute thrombosis<br /> <ul> <li>Decreased protein C </li> <li>Decreased protein S </li> <li>Decreased antithrombin III </li> </ul> </td> </tr> <tr> <td>Asparaginase therapy (eg, acute lymphoblastic leukemia)<br /> <ul> <li>Decreased antithrombin III </li> </ul> </td> </tr> <tr> <td>Complex congenital heart disease (single ventricle)<br /> <ul> <li>Decreased protein C </li> <li>Decreased protein S </li> <li>Decreased antithrombin III </li> </ul> </td> </tr> <tr> <td>Heparin therapy<br /> <ul> <li>Decreased antithrombin III </li> </ul> </td> </tr> <tr> <td>Infection<br /> <ul> <li>Transient antiphospholipid antibodies </li> </ul> </td> </tr> <tr> <td>Inflammation<br /> <ul> <li>Elevated factor VIII </li> <li>Decreased protein S </li> </ul> </td> </tr> <tr> <td>Liver disease<br /> <ul> <li>Decreased protein C </li> <li>Decreased protein S </li> <li>Decreased antithrombin III </li> </ul> </td> </tr> <tr> <td>Nephrotic syndrome<br /> <ul> <li>Decreased protein C </li> <li>Decreased protein S </li> </ul> </td> </tr> <tr> <td>Nutritional deficiency*<br /> <ul> <li>Elevated homocysteine </li> </ul> </td> </tr> <tr> <td>Pregnancy<br /> <ul> <li>Low protein S </li> </ul> </td> </tr> <tr> <td>Warfarin therapy<br /> <ul> <li>Decreased protein C </li> <li>Decreased protein S </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Elevated homocysteine levels are associated with deficiencies of vitamin B12, folate, or pyridoxine (vitamin B6).</div><div class=\"graphic_reference\">Courtesy of Dr. Leslie Raffini.</div><div id=\"graphicVersion\">Graphic 88805 Version 2.0</div></div></div>"},"88806":{"type":"graphic_table","displayName":"Evaluation of patients with PPROM","title":"Evaluation of pregnancies with preterm premature rupture of membranes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of pregnancies with preterm premature rupture of membranes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diagnostic tests (one of the following):</td> </tr> <tr> <td class=\"indent1\">Nitrazine and fern</td> </tr> <tr> <td class=\"indent1\">Commercial&nbsp;assay (eg, AmniSure, Actim PROM, ROM Plus)</td> </tr> <tr> <td class=\"subtitle1_single\">Assessments to consider after confirmation of membrane rupture:</td> </tr> <tr> <td class=\"indent1\">Complete blood count</td> </tr> <tr> <td class=\"indent1\">Test for fetal lung maturity (eg, lamellar body count in amniotic fluid, lecithin sphingomyelin ratio)</td> </tr> <tr> <td class=\"indent1\">Rectovaginal culture for group B <em>Streptococcus</em></td> </tr> <tr> <td class=\"indent1\">Ultrasound examination for fetal growth, position, residual amniotic fluid volume, fetal anatomy, and biophysical profile</td> </tr> <tr> <td class=\"indent1\">Cardiotocography to monitor fetal heart rate (including a nonstress test) and frequency of uterine contractions</td> </tr> <tr> <td class=\"indent1\">Nucleic acid amplification test or culture for <em>Neisseria gonorrhoeae</em> and <em>Chlamydia trachomatis</em></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 88806 Version 3.0</div></div></div>"},"88807":{"type":"graphic_picture","displayName":"RICH-involuted","title":"Rapidly involuting congenital hemangiomas","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Rapidly involuting congenital hemangiomas</div><div class=\"cntnt\"><img style=\"width:504px; height:307px;\" src=\"images/DERM/88807_RICH_involuted.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This healthy 13-month-old boy had a firm bluish-purple plaque on his left leg at birth. The lesion flattened and lightened in color within six months and continued to regress without therapy, leaving a slightly atrophic 5 cm pale purple plaque with overlying telangiectasias.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 88807 Version 3.0</div></div></div>"},"88814":{"type":"graphic_figure","displayName":"Endemic treponematoses map","title":"Geographic distribution of yaws, bejel, and pinta","html":"<div class=\"graphic\"><div style=\"width: 834px\" class=\"figure\"><div class=\"ttl\">Geographic distribution of yaws, bejel, and pinta</div><div class=\"cntnt\"><img style=\"width:814px; height:415px;\" src=\"images/ID/88814_Endemic_treponematoses_map.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Countries where endemic treponemal diseases have recently been reported.</div><div class=\"graphic_reference\">Reproduced from: Marks M, Solomon AW, Mabey DC. Endemic treponemal diseases. Trans R Soc Trop Med Hyg 2014; 108:601, by permission of Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. Copyright &copy; 2014.</div><div id=\"graphicVersion\">Graphic 88814 Version 2.0</div></div></div>"},"88818":{"type":"graphic_algorithm","displayName":"Evaluation of pediatric hypernatremia - Uosm and Posm","title":"Utility of urine and plasma osmolality in the evaluation of pediatric hypernatremia ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Utility of urine and plasma osmolality in the evaluation of pediatric hypernatremia </div><div class=\"cntnt\"><img style=\"width:418px; height:204px;\" src=\"images/PEDS/88818_Evaluat_hypernat_Uosm_Posm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In cases when the cause of pediatric hypernatremia remains uncertain, comparing the urine osmolality (Uosm) with the plasma osmolality (Posm) may be helpful in establishing the underlying etiology. Uosm that is less than Posm suggests that the&nbsp;child has a concentrating defect, which increases the likelihood of excess urinary water loss. In contrast,&nbsp;children with Uosm greater than Posm have an intact urinary concentrating mechanism and are more likely to have hypernatremia due to excess gastrointestinal or skin water loss, or excess salt intake.</div><div id=\"graphicVersion\">Graphic 88818 Version 1.0</div></div></div>"},"88819":{"type":"graphic_table","displayName":"Ped causes of hypernatremia due to urine loss","title":"Pediatric causes of hypernatremia due to free urinary water losses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric causes of hypernatremia due to free urinary water losses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Conditions with urinary concentration defects</td> </tr> <tr> <td class=\"subtitle2_left\">Central diabetes insipidus</td> </tr> <tr> <td class=\"sublist2_start\">Congenital</td> </tr> <tr> <td class=\"sublist2\">Central nervous system malformations (eg, holoprosencephaly)</td> </tr> <tr> <td class=\"sublist2\">Genetic causes</td> </tr> <tr> <td class=\"sublist2_start\">Acquired</td> </tr> <tr> <td class=\"sublist2\">Central nervous system tumors (eg, craniopharyngioma)</td> </tr> <tr> <td class=\"sublist2\">Infiltrative processes</td> </tr> <tr> <td class=\"sublist2\">Postneurosurgery</td> </tr> <tr> <td class=\"sublist2\">Trauma</td> </tr> <tr> <td class=\"subtitle2_left\">Nephrogenetic diabetes insipidus</td> </tr> <tr> <td class=\"sublist2_start\">Congenital</td> </tr> <tr> <td class=\"sublist2\">X-linked (Xp28)</td> </tr> <tr> <td class=\"sublist2\">Autosomal (12q13)</td> </tr> <tr> <td class=\"sublist2\">Other inherited disorders or syndromes</td> </tr> <tr> <td class=\"sublist3\">Bardet-Biedl syndrome</td> </tr> <tr> <td class=\"sublist3\">Bartter syndrome</td> </tr> <tr> <td class=\"sublist3\">Familial hypomagnesemia with hypercalciuria and nephrocalcinosis</td> </tr> <tr> <td class=\"sublist2_start\">Acquired</td> </tr> <tr> <td class=\"sublist2\">Drug induced</td> </tr> <tr> <td class=\"sublist3\">Lithium</td> </tr> <tr> <td class=\"sublist3\">Amphotericin</td> </tr> <tr> <td class=\"sublist3\">Demeclocycline</td> </tr> <tr> <td class=\"sublist3\">Ifosfamide</td> </tr> <tr> <td class=\"sublist3\">Foscarnet</td> </tr> <tr> <td class=\"sublist3\">Cidofovir</td> </tr> <tr> <td class=\"sublist2_start\">Electrolyte abnormalities</td> </tr> <tr> <td class=\"sublist2\">Hypercalcemia</td> </tr> <tr> <td class=\"sublist2\">Hypokalemia</td> </tr> <tr> <td class=\"sublist2_start\">Renal disease</td> </tr> <tr> <td class=\"sublist2\">Obstructive uropathy</td> </tr> <tr> <td class=\"sublist2\">Sickle cell nephropathy</td> </tr> <tr> <td class=\"sublist2\">Nephronophthisis</td> </tr> <tr> <td class=\"sublist2\">Cystinosis</td> </tr> <tr> <td class=\"subtitle1_single\">Osmotic diuresis</td> </tr> <tr> <td>Mannitol use</td> </tr> <tr> <td>Hyperglycemia</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 88819 Version 2.0</div></div></div>"},"88820":{"type":"graphic_figure","displayName":"Tricuspid valve atresia - Fetal circulation","title":"Fetal circulation for tricuspid valve atresia","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Fetal circulation for tricuspid valve atresia</div><div class=\"cntnt\"><img style=\"width:499px; height:626px;\" src=\"images/PEDS/88820_TVA-Fetal_circulation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In fetuses with tricuspid valve atresia, there is obligate right-to-left flow of the entire systemic venous return across the foramen ovale because there is no direct communication between the right atrium and ventricle. As a result, the left ventricle, which receives all the systemic venous return, becomes the dominant ventricle. In this illustration of types 1b and 1c tricuspid valve atresia, left-to-right flow across the ventricular septal defect is the source of pulmonary blood flow.<br />The presence of reverse (left-to-right flow) blood flow in the ductus arteriosus (DA) suggests inadequate pulmonary outflow, which in turn indicates the need for postnatal initiation of prostaglandin therapy to maintain ductal patency. In contrast, in normal fetal circulation, the majority of the systemic venous return flows from the right atrium into the right ventricle (the dominant fetal ventricle) and through the DA into the aorta.</div><div id=\"graphicVersion\">Graphic 88820 Version 2.0</div></div></div>"},"88821":{"type":"graphic_figure","displayName":"Nomogram for survival intrahepatic cholangiocarcinoma","title":"Nomogram to predict survival after resection of an intrahepatic cholangiocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 638px\" class=\"figure\"><div class=\"ttl\">Nomogram to predict survival after resection of an intrahepatic cholangiocarcinoma</div><div class=\"cntnt\"><img style=\"width:618px; height:600px;\" src=\"images/ONC/88821_Nomo_surv_intrahepat_chola.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To use the nomogram, an individual patient's value is located on each variable axis, and a line is drawn upward to determine the number of points received for each variable value. The sum of these numbers is located on the total points axis, and a line is drawn downward to the survival axes to determine the likelihood of three- or five-year survival.</div><div class=\"graphic_footnotes\">CEA: preoperative level of serum carcinoembryonic antigen; CA 19-9: preoperative level of carbohydrate antigen 19-9; LN metastasis: regional lymph node metastasis; Direct invasion and local metastasis: direct invasion of adjacent structures and local extrahepatic metastasis; PI: periductal infiltrating type.</div><div class=\"graphic_reference\">From: Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol 2013; 31:1188. Reprinted with permission. Copyright &copy; 2013 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88821 Version 3.0</div></div></div>"},"88828":{"type":"graphic_diagnosticimage","displayName":"Incidental detection of DDH","title":"Developmental dysplasia of the hip detected incidentally","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Developmental dysplasia of the hip detected incidentally</div><div class=\"cntnt\"><img style=\"width:436px; height:590px;\" src=\"images/PEDS/88828_Incidental_detection_DDH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Routine cystogram in this 2.2-year-old girl revealed disruption of Shenton line (dashed lines) and acetabular dysplasia (arrow) of the right hip. Note normal Shenton line on the left.</div><div id=\"graphicVersion\">Graphic 88828 Version 2.0</div></div></div>"},"88831":{"type":"graphic_diagnosticimage","displayName":"Pre and post-stent aortogram coarctation of aorta","title":"Pre and post-stent aortogram of a patient with coarctation of the aorta","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Pre and post-stent aortogram of a patient with coarctation of the aorta</div><div class=\"cntnt\"><img style=\"width:582px; height:353px;\" src=\"images/PEDS/88831_Pr_pst-stn_artgrm_corct_art.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Aortogram demonstrating coarctation of the aorta prior to stent placement in a 16-year-old patient. The arrow indicates the discrete narrowing of the aorta.<BR>(B)&nbsp;The arrow shows that the area of narrowing has disappeared after stent placement.</div><div id=\"graphicVersion\">Graphic 88831 Version 1.0</div></div></div>"},"88832":{"type":"graphic_picture","displayName":"Anaplastic thyroid cancer 2","title":"Anaplastic thyroid cancer: Findings on histology (pleomorphism, mitosis)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Anaplastic thyroid cancer: Findings on histology (pleomorphism, mitosis)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ENDO/88832_Anapla_thyroid_canc_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anaplastic thyroid cancer demonstrating pleomorphism, mitosis (arrowhead), and neutrophilic infiltration (arrow).</div><div class=\"graphic_reference\">Courtesy of Ronald A Ghossein, MD.</div><div id=\"graphicVersion\">Graphic 88832 Version 2.0</div></div></div>"},"88833":{"type":"graphic_picture","displayName":"Anaplastic thyroid cancer 1","title":"Anaplastic thyroid cancer: Findings on histology (giant cells, spindle cells)","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Anaplastic thyroid cancer: Findings on histology (giant cells, spindle cells)</div><div class=\"cntnt\"><img style=\"width:514px; height:196px;\" src=\"images/ENDO/88833_Anapl_thyroid_canc_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anaplastic thyroid cancer demonstrating giant cells (A) and spindle cells (B).</div><div class=\"graphic_reference\">Courtesy of Ronald A Ghossein, MD.</div><div id=\"graphicVersion\">Graphic 88833 Version 2.0</div></div></div>"},"88834":{"type":"graphic_diagnosticimage","displayName":"Angiograms coarctation of the aorta","title":"Angiograms of coarctations of the aorta","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Angiograms of coarctations of the aorta</div><div class=\"cntnt\"><img style=\"width:582px; height:322px;\" src=\"images/PEDS/88834_Angiogram_coarctation_aorta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Angiogram of a two-month female infant with Turner syndrome. Arrow showing discrete area of narrowing. Arrowhead is showing hypoplastic aortic arch. Dashed arrow is showing a very small patent ductus arteriosus (PDA).<br />(B) Transverse aortic arch angiogram image in a 31-year-old male patient who presented with hypertension and was found to have severe coarctation. The angiogram reveals presence of severe narrowing distal to the left subclavian artery (arrow).</div><div id=\"graphicVersion\">Graphic 88834 Version 3.0</div></div></div>"},"88835":{"type":"graphic_figure","displayName":"Parts of a rigid laparoscope","title":"Parts of a rigid laparoscope","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Parts of a rigid laparoscope</div><div class=\"cntnt\"><img style=\"width:518px; height:693px;\" src=\"images/SURG/88835_Parts_of_an_endoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>Light post &ndash; Fiberoptic light cords attach to the scope here.</li>&#xD;&#xA;    <li>Light fibers &ndash; Glass fibers that carry light from the light post to the distal end of the scope.</li>&#xD;&#xA;    <li>Objective lens system &ndash; A collection of lenses, windows, and/or prisms located at the distal end of the scope. The distal objective can be manufactured at angles ranging from 0&deg; to 120&deg;, which enables the operator to see areas that might otherwise be out of view.</li>&#xD;&#xA;    <li>Lens train &ndash; A series of glass rod lenses and spacers that transfer the image through the shaft.</li>&#xD;&#xA;    <li>Shaft &ndash; Stainless steel tube that houses the lens train.</li>&#xD;&#xA;    <li>Ocular lens assembly &ndash; The focusing lens of the scope located near the proximal end of the scope.</li>&#xD;&#xA;    <li>Eyepiece &ndash; The eyepiece is located at the proximal end of the scope. The image can be viewed through the scope, or the eyepiece can be attached to a camera coupler to view the image on an external monitor.</li>&#xD;&#xA;</ul></div><div id=\"graphicVersion\">Graphic 88835 Version 2.0</div></div></div>"},"88837":{"type":"graphic_diagnosticimage","displayName":"CT coarctation of the aorta","title":"Computed tomographic three dimensional reconstruction of coarctation of the aorta","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Computed tomographic three dimensional reconstruction of coarctation of the aorta</div><div class=\"cntnt\"><img style=\"width:571px; height:304px;\" src=\"images/PEDS/88837_CT_coarctation_of_the_aorta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic three-dimensional volume rendered reconstruction of the thoracic aorta demonstrating:<br />(A) Severe aortic coarctation (arrow) in a 22-year-old patient with hypertension and a new diagnosis of aortic coarctation.<br />(B) Demonstrates extensive collateral vessels in the same patient.</div><div id=\"graphicVersion\">Graphic 88837 Version 1.0</div></div></div>"},"88871":{"type":"graphic_figure","displayName":"RDT schematic","title":"Mode of action of antigen-detecting malaria rapid diagnostic tests","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Mode of action of antigen-detecting malaria rapid diagnostic tests</div><div class=\"cntnt\"><img style=\"width:574px; height:548px;\" src=\"images/ID/88871_RDT_schematic.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A malaria rapid diagnostic test (RDT) is a lateral flow immunochromatographic device that detects protein (antigen [Ag]) derived from the blood stage of malaria parasites. Blood is usually obtained from a finger prick, in a similar way to that usually used for malaria microscopy. A small sample of blood, usually 5 to 20 microL, is placed on the RDT strip, or in a well of the cassette or card test device, and lysed to release the Ag from within red blood cells and parasites from within these cells (a variable amount of Ag is also present in the serum). After several minutes, the test produces a series of visible lines to signal the presence or absence of Ag in the blood sample by the mechanism outlined below:<br />(A) Dye-labeled antibody (Ab), specific for the target Ag, is present on the lower end of the nitrocellulose strip or in a well provided by a casing covering the strip. Ab, specific for another epitope on the target Ag, is bound to the strip in a thin (test) line, and Ab specific for the labeled Ab is bound at the control line.<br />(B) Blood and buffer, which have been placed on the strip or in the well, are mixed with labeled Ab and are drawn up the strip across the lines of bound Ab.<br />(C) If Ag is present, labeled Ab will be trapped on the test line. Other labeled Ab is trapped on the control line. If sufficient labeled Ab accumulates, the dye labels will become visible to the naked eye as a narrow line.</div><div class=\"graphic_footnotes\">* Not normally visible.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Nature Reviews Microbiology. Bell D, Wongsrichanalai C, Barnwell JW. Ensuring quality and access for malaria diagnosis: how can it be achieved? Nat Rev Microbiol 2006; 4:682. Copyright &copy; 2006. <a href=\"http://www.nature.com/nrmicro\" style=\"font-style: italic;\" target=\"_blank\">www.nature.com/nrmicro</a>.</div><div id=\"graphicVersion\">Graphic 88871 Version 1.0</div></div></div>"},"88872":{"type":"graphic_table","displayName":"Available RDTs","title":"Target antigens of commercially available RDTs*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Target antigens of commercially available RDTs*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">RDT type</td> <td class=\"subtitle1\">Target antigens of test</td> <td class=\"subtitle1\">Possible results</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">I</td> <td>1. HRP2 (<em>P. falciparum </em>specific)</td> <td> <p>No Pf</p> <p>Pf<sup>&#182;</sup></p> Invalid</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">II</td> <td> <p>1. HRP2 (<em>P. falciparum </em>specific)</p> 2. Aldolase (pan-specific)</td> <td> <p>No malaria</p> <p>Pf or mixed<sup>&#916;</sup></p> <p>Pv, Po, and/or Pm<sup>&#9674;</sup></p> Invalid</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">III</td> <td> <p>1. HRP2 (<em>P. falciparum </em>specific)</p> 2. pLDH (pan-specific)</td> <td> <p>No malaria</p> <p>Pf or mixed<sup>&#916;</sup></p> <p>Pv, Po, and/or Pm<sup>&#9674;</sup></p> Invalid</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">IV</td> <td> <p>1. pLDH (<em>P. falciparum </em>specific)</p> 2. pLDH (pan-specific)</td> <td> <p>No malaria</p> <p>Pf or mixed<sup>&#916;</sup></p> Invalid</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">V</td> <td> <p>1. pLDH (<em>P. falciparum </em>specific)</p> 2. pLDH (<em>P. vivax </em>specific)</td> <td> <p>No malaria</p> <p>Pf<sup>&#182;</sup></p> <p>Pv</p> <p>Pf and Pv</p> Invalid</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">VI</td> <td> <p>1. HRP2 (<em>P. falciparum </em>specific)</p> <p>2. pLDH (pan-specific)</p> 3. pLDH (<em>P. vivax </em>specific)</td> <td> <p>No malaria</p> <p>Pf and Pv +/&ndash; Po and/or Pm<sup>&#916;</sup></p> <p>Pf +/&ndash; Po and/or Pm</p> <p>Pv +/&ndash; Po and/or Pm<sup>&#9674;</sup></p> <p>Po and/or Pm</p> Invalid</td> </tr> <tr> <td class=\"centered\">VII</td> <td>1. Aldolase</td> <td> <p>No malaria</p> <p>Pf, Pv, Po, and/or Pm<sup>&#9674;</sup></p> Invalid</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RDT: rapid diagnostic test; HRP2: histidine-rich protein 2; pLDH: <EM>Plasmodium</EM> lactate dehydrogenase; Pf: <EM>Plasmodium falciparum</EM>; Pm: <EM>Plasmodium malariae</EM>; Po: <EM>Plasmodium ovale</EM>; Pv: <EM>Plasmodium vivax</EM>; invalid: an absent control line.<br />* Most combinations are available in cassette or dipstick format. All RDTs include a control line in addition to test line(s).<br />¶ Indicates that Pf is present. There could be other species present as coinfection.<br />Δ RDT cannot distinguish Pf from mixed infections (Pf with Pv, Po, or Pm). A positive HRP2 line alone could be present in low-density Pf infection, as an anti-aldolase test line is commonly less sensitive than an anti-HRP2 line, but low-density non-falciparum coinfection can equally be missed.<br /><FONT class=lozenge>◊</FONT> Pf is excluded, other species are present as single species or as a coinfection.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Microbiology. Bell D, Wongsrichanalai C, Barnwell JW. Ensuring quality and access for malaria diagnosis: how can it be achieved? Nat Rev Microbiol 2006; 4:682. Copyright &copy; 2006. <a href=\"http://www.nature.com/nrmicro\" target=\"_blank\">www.nature.com/nrmicro</a>.</div><div id=\"graphicVersion\">Graphic 88872 Version 5.0</div></div></div>"},"88876":{"type":"graphic_figure","displayName":"Balance tests for older adults","title":"Balance tests for older adults","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Balance tests for older adults</div><div class=\"cntnt\"><img style=\"width:496px; height:670px;\" src=\"images/PC/88876_Balance_tests_for_older_adults.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 88876 Version 1.0</div></div></div>"},"88877":{"type":"graphic_diagnosticimage","displayName":"Cranial nerve enhancement secondary to leptomeningeal metastases","title":"Cranial nerve enhancement secondary to leptomeningeal metastases","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Cranial nerve enhancement secondary to leptomeningeal metastases</div><div class=\"cntnt\"><img style=\"width:598px; height:492px;\" src=\"images/RADIOL/88877_Cranial_nerv_metas_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain magnetic resonance imaging (MRI)&nbsp;in a 57-year-old female with small cell lung cancer and a history of brain metastases, presenting with new leptomeningeal disease. Pre-contrast axial (A-C) and&nbsp;post-contrast axial (D-F) T1-weighted MR imaging demonstrates abnormal enhancement of cranial nerve V (arrow), VII (arrowhead), and VIII (dashed arrow).</div><div id=\"graphicVersion\">Graphic 88877 Version 1.0</div></div></div>"},"88879":{"type":"graphic_diagnosticimage","displayName":"CT intralobar sequestration","title":"Intralobar sequestration on CT scan","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Intralobar sequestration on CT scan</div><div class=\"cntnt\"><img style=\"width:599px; height:227px;\" src=\"images/RADIOL/88879_CT_intralobar_sequest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) An axial CT scan of a 26-year-old man with an intralobar sequestration shows a heterogeneous subsegmental soft tissue density in the left lobe (arrow). <BR>(B) An artery arising from the descending aorta (arrowhead) supplies the sequestration (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 88879 Version 2.0</div></div></div>"},"88880":{"type":"graphic_diagnosticimage","displayName":"CT intralobar sequestration and pneumonia","title":"Intralobar sequestration with pneumonia on CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Intralobar sequestration with pneumonia on CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:227px;\" src=\"images/RADIOL/88880_CT_intra_sequest_pneum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan (A) of a 31-year-old woman with an intralobar sequestration shows a left lower pneumonia (arrowhead) with a surrounding region of emphysema (arrow). A reformatted coronal image (B) shows a systemic artery arising from the descending aorta (arrow) that supplies the sequestration.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 88880 Version 1.0</div></div></div>"},"88881":{"type":"graphic_diagnosticimage","displayName":"CT scan cecum B cell lymphoma","title":"Polypoid form of colorectal B cell lymphoma on CT scan","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Polypoid form of colorectal B cell lymphoma on CT scan</div><div class=\"cntnt\"><img style=\"width:590px; height:452px;\" src=\"images/RADIOL/88881_CT_cecum_B_cell_lymph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan of the abdomen at the level of the iliac crests in a patient with colorectal B cell lymphoma. There is a polypoid enhancing mass of the cecum (arrowhead) as well as enhancement and thickening of the ileum (arrow) suggesting involvement with lymphoma.</div><div id=\"graphicVersion\">Graphic 88881 Version 3.0</div></div></div>"},"88883":{"type":"graphic_diagnosticimage","displayName":"CT colon non Hodgkin lymphoma","title":"Non Hodgkin lymphoma of the descending colon on CT scan","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Non Hodgkin lymphoma of the descending colon on CT scan</div><div class=\"cntnt\"><img style=\"width:590px; height:392px;\" src=\"images/RADIOL/88883_CT_col_non_Hodg_lymph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan of the abdomen and pelvis at the level of the mid-descending colon in a patient with non Hodgkin lymphoma. There is well defined, bulky, circumferential thickening of the colonic wall (arrow), without significant induration or obstruction despite the unusually large size of the tumor.</div><div id=\"graphicVersion\">Graphic 88883 Version 3.0</div></div></div>"},"88884":{"type":"graphic_diagnosticimage","displayName":"CT scan rectum B cell lymphoma","title":"B cell lymphoma of the rectum on CT","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">B cell lymphoma of the rectum on CT</div><div class=\"cntnt\"><img style=\"width:590px; height:427px;\" src=\"images/RADIOL/88884_CT_rectum_B_lymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A computed tomography (CT) scan of the abdomen and pelvis at the level of the acetabuli in a patient with rectal B cell lymphoma. There is diffuse irregular, circumferential thickening of the rectum (arrowhead) with mild perirectal induration (arrow).</div><div id=\"graphicVersion\">Graphic 88884 Version 3.0</div></div></div>"},"88885":{"type":"graphic_form","displayName":"UAB study of aging life-space assessment","title":"UAB study of aging life-space assessment","html":"<div class=\"graphic\"><div style=\"width: 638px\" class=\"figure\"><div class=\"ttl\">UAB study of aging life-space assessment</div><div class=\"cntnt\"><img style=\"width:618px; height:799px;\" src=\"images/PC/88885_UAB_aging_life_assessment.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Life-space assessments can be used clinically to assess current status, set goals, and monitor improvement, stability, or deterioration in mobility by assessing baseline and follow-up scores.</div><div class=\"graphic_reference\">Reprinted from Peel C, Sawyer Baker P, Roth DL, et al. Assessing mobility in older adults: the UAB Study of Aging Life-Space Assessment. Physical Therapy Oct 2005, vol. 85, no. 10, pages 1008-1019, with permission of the American Physical Therapy Association. This material is copyrighted, and any further reproduction or distribution requires written permission from APTA (<a href=\"http://www.apta.org/\" target=\"_blank\">www.apta.org</a>).</div><div id=\"graphicVersion\">Graphic 88885 Version 1.0</div></div></div>"},"88886":{"type":"graphic_table","displayName":"VR-12 survey","title":"The Veterans Rand 12-Item Health Survey (VR-12)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Veterans Rand 12-Item Health Survey (VR-12)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>The following questions ask for your views about your health - how you feel and how well you are able to do your usual activities. All kinds of people across the country are being asked these same questions. Their answers and yours will help to improve health care for everyone. There are no right or wrong answers; please choose the answer that best fits your life right now.</td> </tr> <tr> <td><strong>Answer each question by marking an \"X\" next to the best response. For example:</strong></td> </tr> <tr> <td class=\"sublist1_start\">What is your gender?</td> </tr> <tr> <td class=\"sublist2\">___ Male</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">_X_ Female</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Q1.</strong> In general, would you say your health is:</td> </tr> <tr> <td class=\"sublist2\">___ Excellent</td> </tr> <tr> <td class=\"sublist2\">___ Very good</td> </tr> <tr> <td class=\"sublist2\">___ Fair</td> </tr> <tr> <td class=\"sublist2\">___ Poor</td> </tr> <tr> <td><strong>Q2.</strong> The following questions are about activities you might do during a typical day. Does <strong>your health now limit you</strong> in these activities? If so, how much?</td> </tr> <tr> <td class=\"sublist2_start\">a. <strong>Moderate activities</strong>, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf?</td> </tr> <tr> <td class=\"sublist2\">___ Yes, limited a lot</td> </tr> <tr> <td class=\"sublist2\">___ Yes, limited a little</td> </tr> <tr> <td class=\"sublist2\">___ No, not limited at all</td> </tr> <tr> <td class=\"sublist2_start\">b. Climbing <strong>several</strong> flights of stairs?</td> </tr> <tr> <td class=\"sublist2\">___ Yes, limited a lot</td> </tr> <tr> <td class=\"sublist2\">___ Yes, limited a little</td> </tr> <tr> <td class=\"sublist2\">___ No, not limited at all</td> </tr> <tr> <td><strong>Q3.</strong> During the past&nbsp;four weeks, have you had any of the following problems with your work or other regular daily activities <strong>as a result of your physical health</strong>?</td> </tr> <tr> <td class=\"sublist2_start\">a. <strong>Accomplished less</strong> than you would like</td> </tr> <tr> <td class=\"sublist2\">___ No, none of time</td> </tr> <tr> <td class=\"sublist2\">___ Yes, a little of the time</td> </tr> <tr> <td class=\"sublist2\">___ Yes, some of the time</td> </tr> <tr> <td class=\"sublist2\">___ Yes, most of the time</td> </tr> <tr> <td class=\"sublist2\">___ Yes, all of the time</td> </tr> <tr> <td class=\"sublist2_start\">b. Were limited in the <strong>kind</strong> of work or other activities</td> </tr> <tr> <td class=\"sublist2\">___ No, none of the time</td> </tr> <tr> <td class=\"sublist2\">___ Yes, a little of the time</td> </tr> <tr> <td class=\"sublist2\">___ Yes, some of the time</td> </tr> <tr> <td class=\"sublist2\">___ Yes, most of the time</td> </tr> <tr> <td class=\"sublist2\">___ Yes, all of the time</td> </tr> <tr> <td><strong>Q4.</strong> During the past&nbsp;four weeks, have you had any of the following problems with your work or other regular daily activities <strong>as a result of any emotional problems</strong> (such as feeling depressed or anxious)?</td> </tr> <tr> <td class=\"sublist2_start\">a. <strong>Accomplished less</strong> than you would like</td> </tr> <tr> <td class=\"sublist2\">___ No, none of the time</td> </tr> <tr> <td class=\"sublist2\">___ Yes, a little of the time</td> </tr> <tr> <td class=\"sublist2\">___ Yes, some of the time</td> </tr> <tr> <td class=\"sublist2\">___ Yes, most of the time</td> </tr> <tr> <td class=\"sublist2\">___ Yes, all of the time</td> </tr> <tr> <td class=\"sublist2_start\">b. Didn't do work or other activities as <strong>carefully</strong> as usual</td> </tr> <tr> <td class=\"sublist2\">___ No, none of the time</td> </tr> <tr> <td class=\"sublist2\">___ Yes, a little of the time</td> </tr> <tr> <td class=\"sublist2\">___ Yes, some of the time</td> </tr> <tr> <td class=\"sublist2\">___ Yes, most of the time</td> </tr> <tr> <td class=\"sublist2\">___ Yes, all of the time</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Q5.</strong> During the past&nbsp;four weeks, how much did <strong>pain</strong> interfere with your normal work (including both work outside the home and housework)?</td> </tr> <tr> <td class=\"sublist2\">___ Not at all</td> </tr> <tr> <td class=\"sublist2\">___ A little bit</td> </tr> <tr> <td class=\"sublist2\">___ Moderately</td> </tr> <tr> <td class=\"sublist2\">___ Quite a bit</td> </tr> <tr> <td class=\"sublist2\">___ Extremely</td> </tr> <tr> <td><strong>These questions are about how you feel and how things have been with you during the past&nbsp;four weeks. For each question, please give the one answer that comes closest to the way you have been feeling.</strong></td> </tr> <tr> <td><strong>Q6a.</strong> How much of the time during the past&nbsp;four weeks:</td> </tr> <tr> <td class=\"sublist2_start\">Have you felt calm and peaceful?</td> </tr> <tr> <td class=\"sublist2\">___ All of the time</td> </tr> <tr> <td class=\"sublist2\">___ Most of the time</td> </tr> <tr> <td class=\"sublist2\">___ A good bit of the time</td> </tr> <tr> <td class=\"sublist2\">___ Some of the time</td> </tr> <tr> <td class=\"sublist2\">___ A little of the time</td> </tr> <tr> <td class=\"sublist2\">___ None of the time</td> </tr> <tr> <td><strong>Q6b.</strong> How much of the time during the past&nbsp;four weeks:</td> </tr> <tr> <td class=\"sublist2_start\">Did you have a lot of energy?</td> </tr> <tr> <td class=\"sublist2\">___ All of the time</td> </tr> <tr> <td class=\"sublist2\">___ Most of the time</td> </tr> <tr> <td class=\"sublist2\">___ A good bit of the time</td> </tr> <tr> <td class=\"sublist2\">___ Some of the time</td> </tr> <tr> <td class=\"sublist2\">___ A little of the time</td> </tr> <tr> <td class=\"sublist2\">___ None of the time</td> </tr> <tr> <td><strong>Q6c.</strong> How much of the time during the past&nbsp;four weeks:</td> </tr> <tr> <td class=\"sublist2_start\">Have you felt downhearted and blue?</td> </tr> <tr> <td class=\"sublist2\">___ All of the time</td> </tr> <tr> <td class=\"sublist2\">___ Most of the time</td> </tr> <tr> <td class=\"sublist2\">___ A good bit of the time</td> </tr> <tr> <td class=\"sublist2\">___ Some of the time</td> </tr> <tr> <td class=\"sublist2\">___ A little of the time</td> </tr> <tr> <td class=\"sublist2\">___ None of the time</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Q7.</strong> During the past&nbsp;four weeks, how much of the time has your <strong>physical health or emotional problems</strong> interfered with your social activities (like visiting with friends, relatives, etc)?</td> </tr> <tr> <td class=\"sublist2\">___ All of the time</td> </tr> <tr> <td class=\"sublist2\">___ Most of the time</td> </tr> <tr> <td class=\"sublist2\">___ Some of the time</td> </tr> <tr> <td class=\"sublist2\">___ A little of the time</td> </tr> <tr> <td class=\"sublist2\">___ None of the time</td> </tr> <tr> <td><strong>Now, we'd like to ask you some questions about how your health may have changed</strong></td> </tr> <tr> <td class=\"sublist1_start\"><strong>Q8.</strong> Compared&nbsp;with one year ago, how would you rate your physical health in general <strong>now</strong>?</td> </tr> <tr> <td class=\"sublist2\">___ Much better</td> </tr> <tr> <td class=\"sublist2\">___ Slightly better</td> </tr> <tr> <td class=\"sublist2\">___ About the same</td> </tr> <tr> <td class=\"sublist2\">___ Slightly worse</td> </tr> <tr> <td class=\"sublist2\">___ Much worse</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Q8.</strong> Compared&nbsp;with one year ago, how would you rate your <strong>emotional problems</strong> (such as feeling anxious, depressed or irritable) <strong>now</strong>?</td> </tr> <tr> <td class=\"sublist2\">___ Much better</td> </tr> <tr> <td class=\"sublist2\">___ Slightly better</td> </tr> <tr> <td class=\"sublist2\">___ About the same</td> </tr> <tr> <td class=\"sublist2\">___ Slightly worse</td> </tr> <tr> <td class=\"sublist2\">___ Much worse</td> </tr> </tbody></table></div><div class=\"graphic_reference\">The items in this questionnaire were obtained from the Medicare Health Outcomes Survey (HOS) with the express permission of NCQA and the Centers for Medicare &amp; Medicaid Services (CMS). However, this survey is not being used as part of the Medicare HOS program and is not recognized as such by NCQA or CMS.<br />© 2013 by the National Committee for Quality Assurance (NCQA). This survey instrument may not be reproduced or transmitted in any form, electronic or mechanical, without the express written permission of NCQA. All rights reserved. Items 1-9: The VR-12 Health Survey item content was developed and modified from a 36-item health survey. This survey was developed at RAND as part of the Medical Outcomes Study. It was developed with support from the US Department of Veterans Affairs. Permission received April 2013. HEDIS® 2013 © 2013 by NCQA. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88886 Version 4.0</div></div></div>"},"88887":{"type":"graphic_table","displayName":"Life expectancy in states of functional health","title":"Life expectancy (years) in various states of functional health according to age, gender, and initial functioning status","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Life expectancy (years) in various states of functional health according to age, gender, and initial functioning status</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Age</td> <td class=\"subtitle1\" rowspan=\"3\">Initial functional category</td> <td class=\"subtitle1\" colspan=\"8\">Life expectancy in years in each functional status</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"4\">Women</td> <td class=\"subtitle2\" colspan=\"4\">Men</td> </tr> <tr> <td class=\"subtitle3\">Independent years</td> <td class=\"subtitle3\">Mobility-disabled years</td> <td class=\"subtitle3\">ADL-disabled years</td> <td class=\"subtitle3\">Total years</td> <td class=\"subtitle3\">Independent years</td> <td class=\"subtitle3\">Mobility-disabled years</td> <td class=\"subtitle3\">ADL-disabled years</td> <td class=\"subtitle3\">Total years</td> </tr> <tr> <td class=\"centered\" rowspan=\"3\">70</td> <td>Independent</td> <td class=\"centered\">10.0</td> <td class=\"centered\">4.0</td> <td class=\"centered\">2.7</td> <td class=\"centered\">16.7</td> <td class=\"centered\">8.5</td> <td class=\"centered\">2.6</td> <td class=\"centered\">1.0</td> <td class=\"centered\">12.1</td> </tr> <tr> <td>Mobility-disabled</td> <td class=\"centered\">7.3</td> <td class=\"centered\">5.6</td> <td class=\"centered\">2.8</td> <td class=\"centered\">15.7</td> <td class=\"centered\">5.6</td> <td class=\"centered\">4.1</td> <td class=\"centered\">1.1</td> <td class=\"centered\">10.7</td> </tr> <tr> <td>ADL-disabled</td> <td class=\"centered\">3.0</td> <td class=\"centered\">2.9</td> <td class=\"centered\">5.6</td> <td class=\"centered\">11.5</td> <td class=\"centered\">1.6</td> <td class=\"centered\">1.5</td> <td class=\"centered\">3.4</td> <td class=\"centered\">6.5</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\" rowspan=\"3\">75</td> <td>Independent</td> <td class=\"centered\">7.0</td> <td class=\"centered\">3.6</td> <td class=\"centered\">2.6</td> <td class=\"centered\">13.2</td> <td class=\"centered\">6.0</td> <td class=\"centered\">2.4</td> <td class=\"centered\">1.0</td> <td class=\"centered\">9.4</td> </tr> <tr> <td>Mobility-disabled</td> <td class=\"centered\">4.0</td> <td class=\"centered\">5.2</td> <td class=\"centered\">2.8</td> <td class=\"centered\">12.0</td> <td class=\"centered\">2.9</td> <td class=\"centered\">3.8</td> <td class=\"centered\">1.1</td> <td class=\"centered\">7.9</td> </tr> <tr> <td>ADL-disabled</td> <td class=\"centered\">1.1</td> <td class=\"centered\">1.8</td> <td class=\"centered\">5.3</td> <td class=\"centered\">8.2</td> <td class=\"centered\">0.5</td> <td class=\"centered\">0.8</td> <td class=\"centered\">3.1</td> <td class=\"centered\">4.4</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\" rowspan=\"3\">80</td> <td>Independent</td> <td class=\"centered\">4.7</td> <td class=\"centered\">3.2</td> <td class=\"centered\">2.4</td> <td class=\"centered\">10.3</td> <td class=\"centered\">4.1</td> <td class=\"centered\">2.2</td> <td class=\"centered\">0.9</td> <td class=\"centered\">7.2</td> </tr> <tr> <td>Mobility-disabled</td> <td class=\"centered\">2.0</td> <td class=\"centered\">4.4</td> <td class=\"centered\">2.7</td> <td class=\"centered\">9.0</td> <td class=\"centered\">1.4</td> <td class=\"centered\">3.3</td> <td class=\"centered\">1.0</td> <td class=\"centered\">5.7</td> </tr> <tr> <td>ADL-disabled</td> <td class=\"centered\">0.4</td> <td class=\"centered\">1.0</td> <td class=\"centered\">4.7</td> <td class=\"centered\">6.0</td> <td class=\"centered\">0.2</td> <td class=\"centered\">0.4</td> <td class=\"centered\">2.6</td> <td class=\"centered\">3.1</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\" rowspan=\"3\">85</td> <td>Independent</td> <td class=\"centered\">3.3</td> <td class=\"centered\">2.9</td> <td class=\"centered\">1.8</td> <td class=\"centered\">8.0</td> <td class=\"centered\">2.9</td> <td class=\"centered\">2.1</td> <td class=\"centered\">0.7</td> <td class=\"centered\">5.8</td> </tr> <tr> <td>Mobility-disabled</td> <td class=\"centered\">1.0</td> <td class=\"centered\">3.6</td> <td class=\"centered\">2.3</td> <td class=\"centered\">6.9</td> <td class=\"centered\">0.7</td> <td class=\"centered\">2.8</td> <td class=\"centered\">0.9</td> <td class=\"centered\">4.4</td> </tr> <tr> <td>ADL-disabled</td> <td class=\"centered\">0.1</td> <td class=\"centered\">0.5</td> <td class=\"centered\">4.0</td> <td class=\"centered\">4.6</td> <td class=\"centered\">0.0</td> <td class=\"centered\">0.2</td> <td class=\"centered\">2.1</td> <td class=\"centered\">2.3</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Life expectancy (years) in various states of functional health according to age, gender, and initial functioning status using 1988 to 1990 established populations for epidemiologic studies of the elderly data.</div><div class=\"graphic_footnotes\">ADL: activities of daily living.</div><div class=\"graphic_reference\">From: Keeler E, Guralnik JM, Tian H, et al. The impact of functional status on life expectancy in older persons. J Gerontol A Biol Sci Med Sci 2010; 65:727. By permission of The Gerontological Society of America. Copyright &copy; 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 88887 Version 9.0</div></div></div>"},"88891":{"type":"graphic_table","displayName":"Clinical findings of ciguatera fish poisoning","title":"Clinical findings of ciguatera fish poisoning by geographical region","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical findings of ciguatera fish poisoning by geographical region</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Clinical features</td> <td class=\"subtitle1\" colspan=\"4\">Relative frequency</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"4\">Geographical region (Ocean)</td> </tr> <tr> <td class=\"subtitle3\">Caribbean</td> <td class=\"subtitle3\">Atlantic</td> <td class=\"subtitle3\">Pacific</td> <td class=\"subtitle3\">Indian</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Gastrointestinal</td> </tr> <tr> <td class=\"indent1\">Diarrhea</td> <td>+++</td> <td>+++</td> <td>++</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Vomiting</td> <td>++</td> <td>+++</td> <td>++</td> <td>++</td> </tr> <tr> <td class=\"indent1\">Abdominal pain</td> <td>++</td> <td>Not reported</td> <td>++</td> <td>+</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Neurologic</td> </tr> <tr> <td class=\"indent1\">Extremity paresthesia</td> <td>++</td> <td>++</td> <td>+++</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Circumoral paresthesia</td> <td>++</td> <td>++</td> <td>+++</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Temperature dysesthesia</td> <td>++</td> <td>Not reported</td> <td>+++</td> <td>++</td> </tr> <tr> <td class=\"indent1\">Pruritus</td> <td>++</td> <td>++</td> <td>+++</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Dental pain or teeth feeling loose</td> <td>+</td> <td>Not reported</td> <td>+</td> <td>Not reported</td> </tr> <tr> <td class=\"indent1\">Headache</td> <td>++</td> <td>++</td> <td>++</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Vertigo</td> <td>++</td> <td>++</td> <td>++</td> <td>Not reported</td> </tr> <tr> <td class=\"indent1\">Myalgia or arthralgia</td> <td>++</td> <td>+++</td> <td>+++</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Weakness</td> <td>+++</td> <td>+</td> <td>++</td> <td>+++</td> </tr> <tr> <td class=\"indent1\">Hallucinations</td> <td>Not reported</td> <td>Not reported</td> <td>0/+</td> <td>+</td> </tr> <tr> <td class=\"indent1\">Giddiness</td> <td>Not reported</td> <td>Not reported</td> <td>+</td> <td>+</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Cardiovascular</td> </tr> <tr> <td class=\"indent1\">Bradycardia</td> <td>Not reported</td> <td>Not reported</td> <td>+</td> <td>Not reported</td> </tr> <tr> <td class=\"indent1\">Hypertension</td> <td>Not reported</td> <td>Not reported</td> <td>+</td> <td>Not reported</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Estimates of relative frequencies are based upon reports from series with at least 100 patients.</div><div class=\"graphic_reference\">Data from: Friedman MA, Fleming LE, Fernandez M, et al. Ciguatera fish poisoning: treatment, prevention and management. Mar Drugs 2008; 6:456.</div><div id=\"graphicVersion\">Graphic 88891 Version 1.0</div></div></div>"},"88892":{"type":"graphic_picture","displayName":"Pruritus ani","title":"Pruritus ani","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pruritus ani</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/GAST/88892_Pruritus_ani.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perianal erythema with mild lichenification.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 88892 Version 3.0</div></div></div>"},"88897":{"type":"graphic_picture","displayName":"Yaws ulcerative lesion","title":"Yaws ulcerative lesion","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Yaws ulcerative lesion</div><div class=\"cntnt\"><img style=\"width:476px; height:717px;\" src=\"images/ID/88897_Primaryyawsonface.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulcer in a patient in the primary or secondary stage, round in shape with raised margins and reddish bed.</div><div class=\"graphic_reference\">Courtesy of Oriol Mitj&agrave;, MD.</div><div id=\"graphicVersion\">Graphic 88897 Version 3.0</div></div></div>"},"88902":{"type":"graphic_table","displayName":"Order of appearance of clinical signs of malignant hyperthermia","title":"Typical order of appearance of clinical signs of malignant hyperthermia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical order of appearance of clinical signs of malignant hyperthermia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Masseter spasm (in some cases)</td> </tr> <tr> <td>Hypercarbia</td> </tr> <tr> <td>Sinus tachycardia</td> </tr> <tr> <td>Generalized muscular rigidity</td> </tr> <tr> <td>Tachypnea</td> </tr> <tr> <td>Cyanosis</td> </tr> <tr> <td>Rapidly increasing temperature</td> </tr> <tr> <td>Elevated temperature</td> </tr> <tr> <td>Sweating</td> </tr> <tr> <td>Ventricular tachycardia</td> </tr> <tr> <td>Cola-colored urine</td> </tr> <tr> <td>Ventricular fibrillation</td> </tr> <tr> <td>Excessive bleeding</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Clinical signs of MH are variable between patients, but those that occur tend to present in a similar order. In a series of 224 patients with MH, signs occured in the order listed, from earliest to latest.</div><div class=\"graphic_footnotes\">MH: malignant hyperthermia.</div><div class=\"graphic_reference\">Source: Larach MG, Gronert GA, Allen GC, et al. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010; 110:498.</div><div id=\"graphicVersion\">Graphic 88902 Version 4.0</div></div></div>"},"88903":{"type":"graphic_diagnosticimage","displayName":"Bilateral popliteal artery aneurysms on CT","title":"Bilateral popliteal artery aneurysms on CT","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Bilateral popliteal artery aneurysms on CT</div><div class=\"cntnt\"><img style=\"width:596px; height:239px;\" src=\"images/RADIOL/88903_Bilat_popliteal_sms_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT angiogram demonstrates a 1.2 cm aneurysm of the right popliteal artery and a 2 cm aneurysm of the left popliteal artery. &#xD;&#xA;<UL>&#xD;&#xA;<LI>Proximal to the aneurysms,&nbsp;a patent but narrowed distal segment of a right-sided femoral-popliteal artery bypass (arrowhead in A) and&nbsp;a normal left distal SFA (arrow in A) can be seen. </LI>&#xD;&#xA;<LI>The&nbsp;left popliteal artery aneurysm (arrowhead in B) is poorly opacified.The right-sided aneurysm is small (arrow in D) and the distal right popliteal artery is normal (arrow in E).</LI>&#xD;&#xA;<LI>The 3D reconstruction of the peripheral arteries (C) shows a right-sided popliteal artery aneurysm (arrowhead in C). The left-sided popliteal artery aneurysm starts at the distal superficial artery (dashed arrow in C) and extends into the proximal popliteal artery (arrow). </LI></UL></div><div class=\"graphic_footnotes\">CT: computed tomography<BR>SFA: superficial femoral artery<BR>3D: three-dimensional</div><div id=\"graphicVersion\">Graphic 88903 Version 1.0</div></div></div>"},"88904":{"type":"graphic_diagnosticimage","displayName":"Ruptured popliteal artery aneurysm on CT","title":"Ruptured popliteal artery aneurysm on CT","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Ruptured popliteal artery aneurysm on CT</div><div class=\"cntnt\"><img style=\"width:525px; height:505px;\" src=\"images/RADIOL/88904_Rupt_popli_art_aneu_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;noncontrast CT scan shows bilateral popliteal artery&nbsp;aneurysms (right: A and C; left: B and D). The right-sided aneurysm (arrow in A)&nbsp;is ruptured with extravasation into the soft tissues (arrowhead in A).&nbsp;A fluid collection containing high density blood (arrow in C) can also be seen&nbsp;more proximally in the right popliteal fossa. The left-sided popliteal aneurysm (arrow in B) is smaller and complex, but unruptured.</div><div class=\"graphic_footnotes\">CT: computed tomography</div><div id=\"graphicVersion\">Graphic 88904 Version 1.0</div></div></div>"},"88906":{"type":"graphic_table","displayName":"Prevalence of clinical signs in malignant hyperthermia","title":"Prevalence of clinical signs during malignant hyperthermia episode","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of clinical signs during malignant hyperthermia episode</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical sign</td> <td class=\"subtitle1\">Percentage with sign</td> </tr> <tr> <td>Hypercarbia</td> <td class=\"centered\">92.2</td> </tr> <tr> <td>Sinus tachycardia</td> <td class=\"centered\">72.9</td> </tr> <tr> <td>Rapidly increasing temperature</td> <td class=\"centered\">64.7</td> </tr> <tr> <td>Elevated temperature</td> <td class=\"centered\">52.2</td> </tr> <tr> <td>Generalized muscular rigidity</td> <td class=\"centered\">40.8</td> </tr> <tr> <td>Tachypnea</td> <td class=\"centered\">27.1</td> </tr> <tr> <td>Masseter spasm</td> <td class=\"centered\">26.7</td> </tr> <tr> <td>Sweating</td> <td class=\"centered\">17.6</td> </tr> <tr> <td>Cola-colored urine</td> <td class=\"centered\">13.7</td> </tr> <tr> <td>Cyanosis</td> <td class=\"centered\">9.4</td> </tr> <tr> <td>Ventricular tachycardia</td> <td class=\"centered\">3.5</td> </tr> <tr> <td>Excessive bleeding</td> <td class=\"centered\">2.7</td> </tr> <tr> <td>Ventricular fibrillation</td> <td class=\"centered\">2.4</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Clinical signs of malignant hyperthermia, listed with the prevalence with which each was noted in 255 patients reported to the North American MH Registry from 1987 to 2006. Signs such as hypercarbia and tachycardia were defined as being inappropriate to the clinical situation. Notably, 79.6 percent had one or more signs indicative of muscular involvement (masseter spasm, generalized muscular rigidity, cola-colored urine, peak creatinine kinase &gt;10,000 units/L, or peak potassium &gt;6.0 mEq/L).</div><div class=\"graphic_reference\">Data from: Larach MG, Gronert GA, Allen GC, et al. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010; 110:498.</div><div id=\"graphicVersion\">Graphic 88906 Version 3.0</div></div></div>"},"88907":{"type":"graphic_picture","displayName":"Noninvoluting congenital hemangioma 1","title":"Noninvoluting congenital hemangioma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Noninvoluting congenital hemangioma</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/88907_NICH_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 40 x 55 mm bluish patch on the right clavicular area with an overlying red telangiectatic vascular mass in a two-year-old boy. The child was born with a vascular nodule on the right clavicular area. Contrary to expectations, this asymptomatic lesion has continued to slowly increase in size in proportion to the growth of the patient.</div><div class=\"graphic_reference\">Copyright © Albert Yan, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 88907 Version 5.0</div></div></div>"},"88908":{"type":"graphic_picture","displayName":"NICH 2","title":"Noninvoluting congenital hemangioma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Noninvoluting congenital hemangioma</div><div class=\"cntnt\"><img style=\"width:504px; height:364px;\" src=\"images/DERM/88908_NICH_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 6 x 8 cm partially compressible bluish tumor with overlying red and purple papules and telangiectasias and surrounding pallor in a 10-month-old boy. The lesion was present at birth and showed no signs of growth or regression.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 88908 Version 3.0</div></div></div>"},"88910":{"type":"graphic_table","displayName":"Clinical features of acute myelopathies","title":"Clinical features suggestive of acute myelopathies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features suggestive of acute myelopathies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Potential diagnosis</td> </tr> <tr> <td>Acute paraparesis with sensory level and/or autonomic involvement</td> <td>Acute myelopathy</td> </tr> <tr> <td>History of thrombosis</td> <td>Arterial or venous ischemic infarct</td> </tr> <tr> <td>Male, &#62;40 years old with stuttering or downhill myelopathy over months</td> <td>Venous hypertension, dural arteriovenous fistula</td> </tr> <tr> <td>Known tuberculosis</td> <td>Vertebral compression fracture or central nervous system tuberculosis</td> </tr> <tr> <td>History of or concurrent optic neuritis</td> <td>Neuromyelitis optica</td> </tr> <tr> <td>History of or concurrent systemic rheumatologic disorder</td> <td>Transverse myelitis associated with rheumatologic disorder</td> </tr> <tr> <td>Prior history of demyelination and mild, mainly sensory symptoms</td> <td>Transverse myelitis associated with multiple sclerosis</td> </tr> <tr> <td>Antecedent trauma (eg, hyperextension)</td> <td>Consider congenital or acquired spinal column stenosis and compression</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 88910 Version 1.0</div></div></div>"},"88911":{"type":"graphic_table","displayName":"MRI findings of acute myelopathies","title":"Suggestive MRI findings of acute myelopathies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggestive MRI findings of acute myelopathies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">MRI findings</td> <td class=\"subtitle1\">Potential diagnosis</td> </tr> <tr> <td>Blood within the spinal cord (bright and dark T1 and T2 signal)</td> <td>Vascular malformation such as cavernous angioma or dural arteriovenous fistula</td> </tr> <tr> <td>Flow voids within spinal cord</td> <td>Dural arteriovenous fistula or arteriovenous malformation</td> </tr> <tr> <td>Central T2 signal abnormality</td> <td>Venous hypertension</td> </tr> <tr> <td>Ring-enhancing lesion</td> <td>Infection or tumor (but consider course of intravenous glucocorticoids to rule out inflammatory process before progressing to biopsy)</td> </tr> <tr> <td>Acute loss of vertical intervertebral disc height and corresponding T2 signal abnormality</td> <td>Consider fibrocartilaginous embolism</td> </tr> <tr> <td>Fusiform lesion extending over &#62;3 spinal cord segments</td> <td>Consider neuromyelitis optica or disease-associated transverse myelitis</td> </tr> <tr> <td>T2 bright lesion in white matter occupying less than 2 spinal cord segments in rostral-caudal extent and less than 50 percent of the cord diameter</td> <td>Consider multiple sclerosis</td> </tr> <tr> <td>T2 spinal cord lesion adjacent to disk herniation or spondylitic ridge, but lack of spinal cord compression</td> <td>Consider dynamic spinal cord compression only during flexion or extension (flexion-extension x-ray to determine the presence of abnormal spinal column mobility; MRI in flexion or extended position instead of in neutral position)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 88911 Version 1.0</div></div></div>"},"88912":{"type":"graphic_table","displayName":"Distinguishing GBS from transverse myelitis","title":"Distinguishing features between acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome) and transverse myelitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing features between acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome) and transverse myelitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Characteristics</td> <td class=\"subtitle1\">Acute myelitis</td> <td class=\"subtitle1\">Guillain-Barr&#233; syndrome</td> <td class=\"subtitle1\">Distinguishing features</td> </tr> <tr class=\"divider_bottom\"> <td>Motor findings</td> <td>Paraparesis or quadriparesis</td> <td>Ascending weakness LE&#62;UE in the early stages</td> <td> <p>Myelopathy: if UE involvement, often as severe as LE; often no UE involvement</p> GBS: there usually is UE involvement and it is less severe than LE involvement early in the disease</td> </tr> <tr class=\"divider_bottom\"> <td>Sensory findings</td> <td>Usually can diagnosis a spinal cord level</td> <td>Ascending sensory loss LE&#62;UE in the early stages</td> <td> <p>Myelopathy: sensory level usually identified; often no arm involvement</p> GBS: no sensory level; usually UE less affected than LE early in the disease</td> </tr> <tr class=\"divider_bottom\"> <td>Autonomic findings</td> <td>Early loss of bowel and bladder control</td> <td>Autonomic dysfunction of the cardiovascular system</td> <td> <p>Myelopathy: urinary urgency or retention early and prominent; cardiovascular instability only in severe cases higher than T6 spinal level</p> GBS: urinary urgency or retention less common; cardiovascular instability is more common</td> </tr> <tr class=\"divider_bottom\"> <td>Cranial nerve findings</td> <td>None</td> <td>Extra-ocular muscle palsies or facial weakness</td> <td>GBS: cranial neuropathies are more common than in acute myelopathy</td> </tr> <tr class=\"divider_bottom\"> <td>Electrophysiologic findings</td> <td> <p>EMG/NCV findings may be normal or may implicate the spinal cord</p> Prolonged central conduction on somatosensory evoked potential (SEP) latencies or missing SEP in conjunction with normal sensory nerve action potentials</td> <td>EMG/NCV findings confined to the peripheral nervous system: motor and/or sensory nerve conduction velocity reduced, distal latencies prolonged; conduction block; reduced H reflex usually present</td> <td> <p>The lack of peripheral nerve abnormalities in a patient with progressive weakness and sensory loss should suggest evaluation of the spinal cord for pathology</p> Conversely, patients with suspected acute myelopathy but equivocal clinical, laboratory, or radiologic findings may warrant peripheral nerve examination</td> </tr> <tr class=\"divider_bottom\"> <td>MRI findings</td> <td>Usually a focal area of increased T2 signal with or without gadolinium enhancement</td> <td>Normal</td> <td>MRI abnormalities may be helpful in diagnosing a patient who is suspected of having GBS from acute myelopathy</td> </tr> <tr> <td>CSF</td> <td>Usually, CSF pleocytosis and/or increased IgG index</td> <td>Usually, elevated protein in the absence of CSF pleocytosis</td> <td>CSF pleocytosis and elevated IgG index may be helpful in diagnosing a patient who is suspected of having GBS from acute myelopathy</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 88912 Version 1.0</div></div></div>"},"88913":{"type":"graphic_table","displayName":"Indications for PT and aPTT testing","title":"Indications for obtaining PT testing alone, aPTT testing alone, or PT and aPTT testing combined","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for obtaining PT testing alone, aPTT testing alone, or PT and aPTT testing combined</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical circumstance(s)</td> <td class=\"subtitle1\">PT<br /> testing alone</td> <td class=\"subtitle1\">aPTT<br /> testing alone</td> <td class=\"subtitle1\">PT and aPTT<br /> testing combined</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Monitoring anticoagulation</td> </tr> <tr> <td class=\"indent1\">Warfarin only (without heparin)</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Therapeutic unfractionated heparin (without warfarin)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Transitions between heparin and warfarin therapy</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&#8730;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Patient assessment</td> </tr> <tr> <td class=\"indent1\">Assessment of patients with signs or symptoms of hemorrhage or thrombosis</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&#8730;</td> </tr> <tr> <td class=\"indent1\">Assessment of patients with history of condition known to be associated with risk of bleeding or thrombosis due to <strong>extrinsic</strong> coagulation pathway abnormalities, either genetic or acquired</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Assessment of patients with history of condition known to be associated with risk of bleeding or thrombosis due to <strong>intrinsic</strong> coagulation pathway abnormalities, either genetic or acquired</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&#8730;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Assessment of risk of hemorrhage or thrombosis in patients who are going to have a medical intervention known to be associated with increased risk of bleeding or thrombosis</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&#8730;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PT: prothrombin time; aPTT: activated partial thromboplastin time.</div><div id=\"graphicVersion\">Graphic 88913 Version 1.0</div></div></div>"},"88914":{"type":"graphic_table","displayName":"Diagnostic criteria for transverse myelitis","title":"Diagnostic criteria for transverse myelitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for transverse myelitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li> <p>Sensory, motor or autonomic dysfunction attributable to the spinal cord</p> </li> <li> <p>Bilateral signs and/or symptoms</p> </li> <li> <p>Clearly defined sensory level</p> </li> <li> <p>No evidence of compressive cord lesion</p> </li> <li> <p>Inflammation defined by cerebrospinal fluid pleocytosis <em><strong>or</strong></em> elevated IgG index <em><strong>or</strong></em> gadolinium enhancement</p> </li> <li>Progression to nadir between four hours and 21 days </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 88914 Version 2.0</div></div></div>"},"88917":{"type":"graphic_table","displayName":"Advantages and disadvantages of DMPA contraception","title":"Advantages and disadvantages of DMPA contraception","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of DMPA contraception</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Advantages</td> </tr> <tr> <td class=\"indent1\">Reversible</td> </tr> <tr> <td class=\"indent1\">Private</td> </tr> <tr> <td class=\"indent1\">Lasts 12 weeks</td> </tr> <tr> <td class=\"indent1\">Effective in obese women</td> </tr> <tr> <td class=\"indent1\">Reduces the risk of ectopic pregnancy</td> </tr> <tr> <td class=\"indent1\">Periods become light and may cease</td> </tr> <tr> <td class=\"indent1\">Reduces dysmenorrhea and other menstrual symptoms</td> </tr> <tr> <td class=\"indent1\">Few drug interactions</td> </tr> <tr> <td class=\"indent1\">Fewer seizures in epileptics</td> </tr> <tr> <td class=\"indent1\">Fewer sickle cell crises in women with sickle cell disease</td> </tr> <tr> <td class=\"indent1\">Reduces pelvic pain in women with endometriosis</td> </tr> <tr> <td class=\"indent1\">Reduces uterine bleeding in women with heavy bleeding due to uterine fibroids</td> </tr> <tr> <td class=\"indent1\">May reduce risk of pelvic inflammatory disease</td> </tr> <tr> <td class=\"subtitle1_single\">Disadvantages</td> </tr> <tr> <td class=\"indent1\">Increase in unscheduled bleeding</td> </tr> <tr> <td class=\"indent1\">Possible increased weight gain</td> </tr> <tr> <td class=\"indent1\">Possible increase in depressed mood</td> </tr> <tr> <td class=\"indent1\">Decrease in bone density that is usually reversible</td> </tr> <tr> <td class=\"indent1\">Small risk of severe allergic reaction</td> </tr> <tr> <td class=\"indent1\">Return to fertility is not immediate</td> </tr> <tr> <td class=\"indent1\">Return clinic visits needed every 12 weeks</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Goldberg AB, Grimes DA. Injectable contraceptives. In: Contraceptive Technology, 19th ed, Hatcher RA, Trussell J, Nelson AL, et al (Eds), Ardent Media, New York 2007.</div><div id=\"graphicVersion\">Graphic 88917 Version 2.0</div></div></div>"},"88919":{"type":"graphic_table","displayName":"Features that predict recurrent transverse myelitis","title":"Features that predict recurrent transverse myelitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features that predict recurrent transverse myelitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tests</td> <td class=\"subtitle1\">Monophasic</td> <td class=\"subtitle1\">Recurrent</td> </tr> <tr> <td>Spinal MRI</td> <td>Single T2 lesion</td> <td>Multiple distinct lesions or fusiform lesion extending over three or more spinal cord segments</td> </tr> <tr> <td>Brain MRI</td> <td>Normal</td> <td>T2/FLAIR abnormalities</td> </tr> <tr> <td>Blood serology</td> <td>Normal</td> <td>One or more autoantibodies (ANA, dsDNA, phospholipid, c-ANCA)</td> </tr> <tr> <td>SS-A</td> <td>Negative</td> <td>Positive</td> </tr> <tr> <td>NMO-IgG</td> <td>Negative</td> <td>Positive</td> </tr> <tr> <td>Oligoclonal bands (CSF)</td> <td>Negative</td> <td>Positive</td> </tr> <tr> <td>Systemic disease</td> <td>None</td> <td>Connective tissue disorder</td> </tr> <tr> <td>Optic nerve involvement</td> <td>No</td> <td>Likely</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 88919 Version 1.0</div></div></div>"},"88920":{"type":"graphic_algorithm","displayName":"Evaluation of suspected acute myelopathy","title":"Evaluation of suspected acute myelopathy","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">Evaluation of suspected acute myelopathy</div><div class=\"cntnt\"><img style=\"width:603px; height:774px;\" src=\"images/NEURO/88920_Evalsuspacutemyelopathy.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified with permission from: Berger JR, Cambi F, Di Rocco A, Farace J. Overview to approach to the patient with noncompressive myelopathy. Continuum (Minneap Minn) 2005; 11:13. DOI: <a href=\"http://journals.lww.com/continuum/Fulltext/2005/06000/Overview_to_Approach_to_the_Patient_With.3.aspx\" target=\"_blank\">10.1212/01.CON.0000293718.40497.96</a>. Copyright &copy; 2013 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 88920 Version 6.0</div></div></div>"},"88921":{"type":"graphic_table","displayName":"SIRs for second sarcomas based on time since first CA diagnosis","title":"Standardized Incidence Ratios (SIRs) for subsequent sarcoma after any first cancer in adulthood according to RT versus no RT, and time since first cancer diagnosis, SEER 9 (1973-2008)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Standardized Incidence Ratios (SIRs) for subsequent sarcoma after any first cancer in adulthood according to RT versus no RT, and time since first cancer diagnosis, SEER 9 (1973-2008)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"8\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Time since first cancer diagnosis</td> <td class=\"subtitle1\" colspan=\"4\">Bone sarcoma</td> <td class=\"subtitle1\" colspan=\"4\">Soft tissue sarcoma</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">RT</td> <td class=\"subtitle2\" colspan=\"2\">No RT</td> <td class=\"subtitle2\" colspan=\"2\">RT</td> <td class=\"subtitle2\" colspan=\"2\">No RT</td> </tr> <tr> <td class=\"subtitle3\">Obs</td> <td class=\"subtitle3\">SIR</td> <td class=\"subtitle3\">Obs</td> <td class=\"subtitle3\">SIR</td> <td class=\"subtitle3\">Obs</td> <td class=\"subtitle3\">SIR</td> <td class=\"subtitle3\">Obs</td> <td class=\"subtitle3\">SIR</td> </tr> <tr> <td>1 to 4 years</td> <td class=\"centered\">34</td> <td class=\"centered\">1.49*</td> <td class=\"centered\">77</td> <td class=\"centered\">1.32*</td> <td class=\"centered\">135</td> <td class=\"centered\">1.22*</td> <td class=\"centered\">311</td> <td class=\"centered\">1.15*</td> </tr> <tr> <td>5 to 9 years</td> <td class=\"centered\">43</td> <td class=\"centered\">2.74*</td> <td class=\"centered\">56</td> <td class=\"centered\">1.24</td> <td class=\"centered\">185</td> <td class=\"centered\">2.22*</td> <td class=\"centered\">271</td> <td class=\"centered\">1.21*</td> </tr> <tr> <td>10 to 14 years</td> <td class=\"centered\">23</td> <td class=\"centered\">3.23*</td> <td class=\"centered\">34</td> <td class=\"centered\">1.31</td> <td class=\"centered\">78</td> <td class=\"centered\">2.04*</td> <td class=\"centered\">141</td> <td class=\"centered\">1.06</td> </tr> <tr class=\"divider_bottom\"> <td>15+ years</td> <td class=\"centered\">23</td> <td class=\"centered\">4.35*</td> <td class=\"centered\">24</td> <td class=\"centered\">0.94</td> <td class=\"centered\">62</td> <td class=\"centered\">2.20*</td> <td class=\"centered\">159</td> <td class=\"centered\">1.21*</td> </tr> <tr> <td><strong>Total</strong></td> <td class=\"centered\"><strong>123</strong></td> <td class=\"centered\"><strong>2.42</strong>*</td> <td class=\"centered\"><strong>191</strong></td> <td class=\"centered\"><strong>1.23</strong>*</td> <td class=\"centered\"><strong>460</strong></td> <td class=\"centered\"><strong>1.77</strong>*</td> <td class=\"centered\"><strong>882</strong></td> <td class=\"centered\"><strong>1.16</strong>*</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Analysis includes adulthood (age 20 to 79 years at diagnosis) greater than one year survivors of any first cancer (excluding bone sarcoma or soft tissue sarcoma, respectively). Follow-up for second primary bone or soft tissue sarcoma continued to age 85 years. Patients with unknown radiotherapy were excluded.</div><div class=\"graphic_footnotes\">Obs: observed number of subsequent primary sarcomas; RT: radiotherapy.<br />* p&lt;0.05.</div><div class=\"graphic_reference\">Reproduced from: Berrington de Gonzalez A, Kutsenko A, Rajaraman P. Sarcoma risk after radiation exposure. Clin Sarcoma Res 2012; 2:18. Copyright &copy; 2012 Berrington de Gonzalez et al and BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 88921 Version 3.0</div></div></div>"},"88922":{"type":"graphic_table","displayName":"SIRs for second sarcoma based on RT and age at first cancer","title":"Standardized Incidence Ratios (SIRs) for secondary sarcoma after any first cancer according to RT and age at first cancer diagnosis, SEER 9 (1973-2008)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Standardized Incidence Ratios (SIRs) for secondary sarcoma after any first cancer according to RT and age at first cancer diagnosis, SEER 9 (1973-2008)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"8\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Age at first cancer diagnosis</td> <td class=\"subtitle1\" colspan=\"4\">Bone sarcoma</td> <td class=\"subtitle1\" colspan=\"4\">Soft tissue sarcoma</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">RT</td> <td class=\"subtitle2\" colspan=\"2\">No RT</td> <td class=\"subtitle2\" colspan=\"2\">RT</td> <td class=\"subtitle2\" colspan=\"2\">No RT</td> </tr> <tr> <td class=\"subtitle3\">Obs</td> <td class=\"subtitle3\">SIR</td> <td class=\"subtitle3\">Obs</td> <td class=\"subtitle3\">SIR</td> <td class=\"subtitle3\">Obs</td> <td class=\"subtitle3\">SIR</td> <td class=\"subtitle3\">Obs</td> <td class=\"subtitle3\">SIR</td> </tr> <tr> <td>20 to 39 years</td> <td class=\"centered\">13</td> <td class=\"centered\">4.40*</td> <td class=\"centered\">10</td> <td class=\"centered\">1.31</td> <td class=\"centered\">52</td> <td class=\"centered\">5.32*</td> <td class=\"centered\">58</td> <td class=\"centered\">2.25*</td> </tr> <tr> <td>40 to 59 years</td> <td class=\"centered\">42</td> <td class=\"centered\">3.71*</td> <td class=\"centered\">40</td> <td class=\"centered\">1.23</td> <td class=\"centered\">129</td> <td class=\"centered\">2.41*</td> <td class=\"centered\">219</td> <td class=\"centered\">1.37*</td> </tr> <tr> <td>60 to 79 years</td> <td class=\"centered\">40</td> <td class=\"centered\">2.60*</td> <td class=\"centered\">57</td> <td class=\"centered\">1.31</td> <td class=\"centered\">177</td> <td class=\"centered\">1.83*</td> <td class=\"centered\">302</td> <td class=\"centered\">1.15*</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Analysis includes adulthood (age 20 to 79 years at diagnosis) greater than one year survivors of any first cancer (excluding bone sarcoma or soft tissue sarcoma, respectively). Follow-up for second primary bone or soft tissue sarcoma continued to age 85 years. Patients with unknown radiotherapy were excluded.</div><div class=\"graphic_footnotes\">Obs: observed number of subsequent primary sarcomas; RT: radiotherapy.<BR>* p&lt;0.05.</div><div class=\"graphic_reference\">Reproduced from: Berrington de Gonzalez A, Kutsenko A, Rajaraman P. Sarcoma risk after radiation exposure. Clin Sarcoma Res 2012; 2:18. Copyright © 2012 Berrington de Gonzalez et al and BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 88922 Version 2.0</div></div></div>"},"88924":{"type":"graphic_picture","displayName":"Pinta primary skin lesion","title":"Pinta","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pinta</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/88924_Pinta_primary_skin_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Primary skin lesion in pinta.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 88924 Version 1.0</div></div></div>"},"88926":{"type":"graphic_picture","displayName":"Pinta skin hypopigmentation","title":"Pinta","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Pinta</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/88926_Pinta_skin_hypopigmentat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pigment changes in the skin in late pinta.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 88926 Version 1.0</div></div></div>"},"88927":{"type":"graphic_picture","displayName":"Yaws multiple papillomatous lesions","title":"Yaws multiple papillomatous lesions","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Yaws multiple papillomatous lesions</div><div class=\"cntnt\"><img style=\"width:478px; height:718px;\" src=\"images/DERM/88927_Yawssecondarysknlesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple papules consistent with secondary stage lesions of yaws after lymphatic dissemination.</div><div class=\"graphic_reference\">Courtesy of Oriol Mitj&agrave;, MD.</div><div id=\"graphicVersion\">Graphic 88927 Version 2.0</div></div></div>"},"88929":{"type":"graphic_picture","displayName":"Yaws plantar hyperkeratotic plaques","title":"Plantar hyperkeratotic plaques in yaws","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plantar hyperkeratotic plaques in yaws</div><div class=\"cntnt\"><img style=\"width:298px; height:511px;\" src=\"images/ID/88929_Yawsplntrhyprkrtotcplqus.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 88929 Version 3.0</div></div></div>"},"88930":{"type":"graphic_figure","displayName":"Suture closure of auricular hematoma drainage site","title":"Suture closure of auricular hematoma drainage site","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Suture closure of auricular hematoma drainage site</div><div class=\"cntnt\"><img style=\"width:365px; height:369px;\" src=\"images/EM/88930_Suture_closure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Appose the skin and perichondrial flap to the underlying cartilage using 5-0 absorbable (eg, Monocryl or fast-absorbing gut) or nonabsorbable (eg, nylon) suture by placing mattress stitches through and through the cartilage. leave a small area open to drain.</div><div id=\"graphicVersion\">Graphic 88930 Version 1.0</div></div></div>"},"88931":{"type":"graphic_figure","displayName":"Bolster placement after auricular hematoma drainage","title":"Bolster placement after auricular hematoma drainage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bolster placement after auricular hematoma drainage</div><div class=\"cntnt\"><img style=\"width:365px; height:369px;\" src=\"images/EM/88931_Bolster_placement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After the auricular hematoma is drained, a thermoplast bolster is molded to the ear and sutured into place with 3-0 or 4-0 nonabsorbable suture.</div><div id=\"graphicVersion\">Graphic 88931 Version 1.0</div></div></div>"},"88932":{"type":"graphic_picture","displayName":"Severe pretibial myxedema","title":"Pretibial myxedema (severe)","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Pretibial myxedema (severe)</div><div class=\"cntnt\"><img style=\"width:572px; height:428px;\" src=\"images/ENDO/88932_Severe_pretibial_myxedema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe pretibial myxedema reminiscent of elephantiasis.</div><div class=\"graphic_reference\">Courtesy of Terry Davies, MD, FRCP, FACE.</div><div id=\"graphicVersion\">Graphic 88932 Version 2.0</div></div></div>"},"88933":{"type":"graphic_table","displayName":"Pediatric bacterial arthritis history","title":"Important aspects of the history in a child with suspected bacterial arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the history in a child with suspected bacterial arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical feature</td> <td class=\"subtitle1\">Potential significance</td> </tr> <tr class=\"divider_bottom\"> <td>Progression of symptoms</td> <td>The pain of bacterial arthritis does not wax and wane over time</td> </tr> <tr class=\"divider_bottom\"> <td>Joint trauma</td> <td>May provide a point of entry for direct inoculation, which is associated with unusual pathogens (eg, sporotrichosis, <em>Pasteurella</em>, anaerobes)</td> </tr> <tr class=\"divider_bottom\"> <td>Rash</td> <td> <p>May help to determine etiology (eg, <em>Neisseria gonorrhoeae</em>, <em>N. meningitidis</em>, Lyme disease)</p> Varicella zoster virus may cause primary arthritis</td> </tr> <tr class=\"divider_bottom\"> <td>Skin or soft tissue infection</td> <td>May provide a portal of entry for <em>Staphylococcus aureus</em> or group A streptococcal bacteremia</td> </tr> <tr class=\"divider_bottom\"> <td>Recent use of antibiotics</td> <td> <p>May attenuate symptoms in bacterial arthritis</p> <p>May be associated with antecedent infection associated with postinfectious arthritis</p> May be associated with serum-sickness-like reaction</td> </tr> <tr class=\"divider_bottom\"> <td>Recent or concurrent illness</td> <td> <p>Upper respiratory tract infection may precede bacterial arthritis or transient synovitis</p> <p>Enteric, genitourinary, and respiratory infections may precede postinfectious reactive arthritis</p> Concurrent varicella zoster virus infection may provide a portal of entry for <em>S. aureus</em> or group A streptococcus, leading to bacteremia</td> </tr> <tr class=\"divider_bottom\"> <td>Onset of most recent menses (for postpubertal females)</td> <td>Disseminated gonococcal infection usually occurs in the first seven days of the menstrual cycle</td> </tr> <tr class=\"divider_bottom\"> <td>Exposure and travel history</td> <td>May suggest a particular pathogen or other condition (eg, <em>Mycobacteria tuberculosis</em>, Lyme disease, coccidioidomycosis, hepatitis B, histoplasmosis, chikungunya virus)</td> </tr> <tr class=\"divider_bottom\"> <td>Immunization status</td> <td> <p>Arthritis caused by <em>Haemophilus influenzae</em> type B, <em>S. pneumoniae</em>, hepatitis B virus, measles, and mumps may occur in unimmunized children</p> Receipt of rubella vaccine virus is associated with joint symptoms two weeks after immunization</td> </tr> <tr> <td>Family history of rheumatologic disease or inflammatory bowel disease</td> <td>May provide an alternative explanation for signs and symptoms</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 88933 Version 1.0</div></div></div>"},"88934":{"type":"graphic_picture","displayName":"Bacterial arthritis wrist","title":"Bacterial arthritis of the wrist","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bacterial arthritis of the wrist</div><div class=\"cntnt\"><img style=\"width:376px; height:504px;\" src=\"images/PEDS/88934_Bacterial_arthritis_wrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Septic arthritis of the wrist. This 8-day-old infant presented with multiple foci of infection, including his wrist, which is quite swollen. Purulent fluid obtained from the joint grew group B streptococci.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig W, Baskin MN. Atlas of Pediatric Emergency Medicine. Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 88934 Version 2.0</div></div></div>"},"88939":{"type":"graphic_table","displayName":"Dutch Lipid Clinic Network FH criteria","title":"Dutch Lipid Clinic Network diagnostic criteria for familial hypercholesterolaemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dutch Lipid Clinic Network diagnostic criteria for familial hypercholesterolaemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Criteria</td> <td class=\"subtitle1\">Points</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">1) Family history</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>First-degree relative with known premature (men: &#60;55 years; women: &#60;60 years) coronary or vascular disease, or </li> <li>First-degree relative with known LDL-C above the 95<sup>th</sup> percentile </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>First-degree relative with tendinous xanthomata and/or arcus cornealis, or </li> <li>Children &#60;18 years of age with LDL-C above the 95<sup>th</sup> percentile </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">2) Clinical history</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Patient with premature (men: &#60;55 years; women: &#60;60 years) coronary artery disease </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Patient with premature (men: &#60;55 years; women: &#60;60 years) cerebral or peripheral vascular disease </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">3) Physical examination</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Tendinous xanthomata </li> </ul> </td> <td class=\"centered\">6</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Arcus cornealis before age 45 years </li> </ul> </td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">4) LDL-C levels</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>LDL-C &#8805;8.5 mmol/L (325 mg/dL) </li> </ul> </td> <td class=\"centered\">8</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>LDL-C 6.5-8.4 mmol/L (251-325 mg/dL) </li> </ul> </td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>LDL-C 5.0-6.4 mmol/L (191-250 mg/dL) </li> </ul> </td> <td class=\"centered\">3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>LDL-C 4.0-4.9 mmol/L (155-190 mg/dL) </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">5) DNA analysis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Functional mutation in the LDLR, apoB, or PCSK9 gene </li> </ul> </td> <td class=\"centered\">8</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\">Choose only one score per group, the highest applicable diagnosis (diagnosis is based on the total number of points obtained) <ul class=\"decimal_heading\"> <li>A \"definite\" FH diagnosis requires &#62;8 points </li> <li>A \"probable\" FH diagnosis requires 6-8 points </li> <li>A \"possible\" FH diagnosis requires 3-5 points </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FH: familial hypercholesterolaemia; LDL-C: low-density lipoprotein-cholesterol.<br />* Exclusive of each other (ie, maximum six points if both are present).</div><div class=\"graphic_reference\">Reproduced from: Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37(39):2999-3058. By permission of Oxford University Press on behalf of the European Society of Cardiology. Copyright © 2016 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.escardio.org/\" target=_blank>www.escardio.org/</A>.</div><div id=\"graphicVersion\">Graphic 88939 Version 13.0</div></div></div>"},"88941":{"type":"graphic_diagnosticimage","displayName":"Triradiate cartilage child pelvis","title":"Triradiate cartilage in a child's pelvis","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Triradiate cartilage in a child's pelvis</div><div class=\"cntnt\"><img style=\"width:572px; height:418px;\" src=\"images/EM/88941_Triradit_cartlge_chld_pelvs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Triradiate cartilage (arrow) typically fuses when a child is between the ages of 14 and 16 years. During childhood the Triradiate cartilage complicates the interpretation of pelvic radiographs. Note that the cartilage is present bilaterally and appears symmetric.</div><div class=\"graphic_reference\">Courtesy of James Fiechtl, MD.</div><div id=\"graphicVersion\">Graphic 88941 Version 1.0</div></div></div>"},"88943":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph of hydropneumothorax","title":"Chest radiograph of hydropneumothorax","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of hydropneumothorax</div><div class=\"cntnt\"><img style=\"width:504px; height:447px;\" src=\"images/PULM/88943_Chst_radio_hydropneumotho.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows left-sided hydropneumothorax due to a bronchopleural fistula in a patient with a chronic empyema and&nbsp;prior known semi-invasive aspergillosis.</div><div id=\"graphicVersion\">Graphic 88943 Version 1.0</div></div></div>"},"88944":{"type":"graphic_diagnosticimage","displayName":"Hydropneumothorax in rheumatoid arthritis","title":"Hydropneumothorax with irregular pleural thickening in a patient with rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Hydropneumothorax with irregular pleural thickening in a patient with rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:513px; height:191px;\" src=\"images/PULM/88944_Hydropneu_rheum_arthri.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph (A) shows an atypical loculated right pneumothorax with two separate collections of pleural gas in a patient with known rheumatoid arthritis. CT thorax image (B) shows chronic right hydropneumothorax with gas-liquid level due to bronchopleural fistula and irregular visceral and parietal pleural thickening.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 88944 Version 2.0</div></div></div>"},"88945":{"type":"graphic_diagnosticimage","displayName":"Bullous lung disease and pneumothorax","title":"Bullous lung disease and spontaneous pneumothorax","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bullous lung disease and spontaneous pneumothorax</div><div class=\"cntnt\"><img style=\"width:504px; height:363px;\" src=\"images/PULM/88945_Bull_lung_dis_pneumothorax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT thorax in a patient with severe bullous lung disease and a spontaneous right-sided pneumothorax.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 88945 Version 3.0</div></div></div>"},"88946":{"type":"graphic_diagnosticimage","displayName":"Gallbladder sludge ultrasonography","title":"Gallbladder sludge on ultrasonography","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Gallbladder sludge on ultrasonography</div><div class=\"cntnt\"><img style=\"width:579px; height:250px;\" src=\"images/GAST/88946_Gallblddr_sludg_ultrsngrphy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasonography images in a patient with gallbladder sludge.<br />(Panel A) A large amorphous collection of sludge within the gallbladder (arrow) that does not cast an acoustic shadow.<br />(Panel B) When the patient was turned onto one side, the gallbladder sludge formed a layer along the dependent portion of the gallbladder (arrows).</div><div id=\"graphicVersion\">Graphic 88946 Version 1.0</div></div></div>"},"88947":{"type":"graphic_algorithm","displayName":"Approach to the evaluation of early pregnancy bleeding","title":"Approach to the evaluation of early pregnancy bleeding","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Approach to the evaluation of early pregnancy bleeding</div><div class=\"cntnt\"><img style=\"width:609px; height:618px;\" src=\"images/OBGYN/88947_Appr_eval_early_preg_bleed.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When evaluating early pregnancy bleeding, it is important to also consider the possibility of heterotopic pregnancy and the loss of one gestation from a multiple gestation.</div><div class=\"graphic_footnotes\">* An ectopic pregnancy can be excluded using a combination of serial human chorionic gonadotropin (hCG) levels and ultrasound examinations.</div><div id=\"graphicVersion\">Graphic 88947 Version 1.0</div></div></div>"},"88948":{"type":"graphic_picture","displayName":"RICH-NICH overlap","title":"Noninvoluting congenital hemangioma (NICH)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Noninvoluting congenital hemangioma (NICH)</div><div class=\"cntnt\"><img style=\"width:504px; height:481px;\" src=\"images/DERM/88948_RICH_NICH_overlap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 10 cm soft partially compressible subcutaneous mass with central overlying scar and telangiectasias at the border. This three-year-old girl was thought to have a rapidly involuting congenital hemangioma. However, after some apparent regression following ulceration of the center of the lesion in early infancy, it changed little over the ensuing 2.5 years.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 88948 Version 3.0</div></div></div>"},"88949":{"type":"graphic_figure","displayName":"Venous drainage of the small intestine","title":"Venous drainage of the small intestine","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Venous drainage of the small intestine</div><div class=\"cntnt\"><img style=\"width:514px; height:571px;\" src=\"images/SURG/88949_Venous_drain_small_intest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mesenteric veins parallel their corresponding arteries. The SMV drains the small intestine, cecum, ascending, and transverse colon via the jejunal, ileal, ileocolic, right colic, and middle colic veins. The SMV joins the splenic vein to drain into the portal vein.</div><div class=\"graphic_footnotes\">SMV: superior mesenteric vein</div><div id=\"graphicVersion\">Graphic 88949 Version 3.0</div></div></div>"},"88950":{"type":"graphic_picture","displayName":"Periumbilical ecchymosis","title":"Periumbilical ecchymosis","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Periumbilical ecchymosis</div><div class=\"cntnt\"><img style=\"width:598px; height:218px;\" src=\"images/SURG/88950_Periumbilicalecchymosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Reddish discoloration, the so-called Cullen's sign, was seen around the patient's umbilicus.<br />(B) Intraoperative findings: marked hemorrhage in the mesocolon was seen.</div><div class=\"graphic_reference\">Reproduced with permission from: Sugimoto H, Inoue S, Okochi O, et al. Cullen's Sign in Pancreatic Trauma. Pancreas 2002; 24:408. Copyright &copy; 2002 Wolters Kluwer Health, Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 88950 Version 6.0</div></div></div>"},"88953":{"type":"graphic_table","displayName":"Pregnancy testing","title":"Pregnancy testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pregnancy testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Urine pregnancy test</td> <td class=\"subtitle1\">Serum pregnancy test</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Minimum hCG level for a positive test</strong></td> <td>Qualitative test: 20 to 50 milli-int. units/mL, depending on test</td> <td> <p>Qualitative test: 5 to 10 milli-int. units/mL, depending on test</p> Quantitative test: 1 to 2 milli-int. units/mL for an ultrasensitive test</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Causes of a false-negative test</strong></td> <td colspan=\"2\"> <ol> <li>Performed too soon after conception; hCG concentration is below threshold for a positive test </li> <li>The hCG isoform measured is different from the hCG isoform in the sample (pertains mostly to urine tests) </li> <li>Hook effect due to extremely high hCG concentration (&#62;500,000 milli-int. units/mL, these levels are most commonly seen in gestational trophoblastic neoplasia) </li> </ol> </td> </tr> <tr> <td><strong>Causes of a false-positive test</strong></td> <td colspan=\"2\"> <ol> <li>Recent first-trimester pregnancy loss (induced or spontaneous) in which hCG levels, though declining, are still elevated&nbsp; </li> <li>Pregnancy loss very soon after implantation (\"biochemical pregnancy\") </li> <li>hCG secretion from a tumor </li> <li>Pituitary hCG secretion </li> <li>Interference from human antibodies against animal antibodies or heterophilic antibodies (serum test positive but urine hCG will be negative) </li> <li>Patient has received a medication containing hCG or certain antibodies </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">hCG: human chorionic gonadotropin.</div><div id=\"graphicVersion\">Graphic 88953 Version 5.0</div></div></div>"},"88955":{"type":"graphic_table","displayName":"The contribution of C1INH to protease inhibition in plasma","title":"The contribution of C1INH to protease inhibition in plasma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The contribution of C1INH to protease inhibition in plasma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Protease</td> <td class=\"subtitle1\">%&nbsp;of plasma inhibitory capacity provided by C1INH</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Complement system</td> </tr> <tr> <td class=\"indent1\">C1r</td> <td class=\"centered\">100</td> </tr> <tr> <td class=\"indent1\">C1s</td> <td class=\"centered\">100</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">MASP2</td> <td class=\"centered\">*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Contact system</td> </tr> <tr> <td class=\"indent1\">Plasma kallikrein</td> <td class=\"centered\">42 to 84</td> </tr> <tr> <td class=\"indent1\">Coagulation factor XIa</td> <td class=\"centered\">47</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Coagulation factor XIIa</td> <td class=\"centered\">90</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Fibrinolytic system</td> </tr> <tr> <td class=\"indent1\">Tissue plasminogen activator</td> <td class=\"centered\">&#182;</td> </tr> <tr> <td class=\"indent1\">Plasmin</td> <td class=\"centered\">&#182;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">C1INH: C1 inhibitor; MASP2: mannose-associated serine protease 2.<br />* Undetermined; probably the primary inhibitor; alpha<SUB>2</SUB>-macroglobulin may play some role.<br />¶ C1INH plays little (if any) role under normal circumstances, but small amounts of complexes with tissue plasminogen activator and plasmin may be observed in some situations (angioedema attacks, endotoxin shock, and exhaustive exercise).</div><div class=\"graphic_reference\">Reproduced from: Davis AE III. Hereditary angioedema: a current state-of-the art review, III: Mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 2008; 100 (Suppl 2):S7. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88955 Version 6.0</div></div></div>"},"88968":{"type":"graphic_algorithm","displayName":"Sequence of malignant hyperthermia susceptibility testing","title":"Sequence of malignant hyperthermia susceptibility testing ","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Sequence of malignant hyperthermia susceptibility testing </div><div class=\"cntnt\"><img style=\"width:562px; height:511px;\" src=\"images/ANEST/88968_Sequmalignhyperthersus.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Once a proband has been determined to be susceptible to MH by a clinical episode plus either a positive contracture test or a mutation found on a RYR1 genetic analysis, first-degree relatives may be tested. Those with the mutation are considered MHS without having to undergo contracture test. Relatives without the mutation should undergo contracture testing.</div><div class=\"graphic_footnotes\">MH: malignant hyperthermia; MHS: susceptible to malignant hyperthermia; RYR1: ryanodine receptor; CT: contracture test (either caffeine-halothane contracture test, or in vitro contracture test).<br />* Since contracture testing requires muscle biopsy, some patients may initially elect mutation screening, which involves only blood testing. However, because of its relatively low sensitivity (up to 25 percent), a negative mutation screen does not rule out MH susceptibility, and contracture testing is then recommended for final diagnosis. The sensitivity of RYR1 genetic analysis is higher if the patient selection criteria are based on contracture test rather than clinical episode. If a mutation analysis is performed based on only a clinically suspected MH episode, the clinical episode should be evaluated by one or more MH experts to evaluate the likelihood of the episode being MH.<br />&#916; Probands and their relatives with a positive contracture test and negative mutation analysis should undergo repeat mutation analysis when additional mutations are identified and gene screens become more comprehensive.</div><div class=\"graphic_reference\">Reproduced with permission from: Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. JAMA 2005; 293:2918. Copyright © 2005 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 88968 Version 7.0</div></div></div>"},"88980":{"type":"graphic_diagnosticimage","displayName":"Sulcal leptomeningeal metastases","title":"Sulcal leptomeningeal metastases","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Sulcal leptomeningeal metastases</div><div class=\"cntnt\"><img style=\"width:519px; height:260px;\" src=\"images/ONC/88980_Sulcl_tumr_leptmngl_metast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial (A) and sagittal (B) post-contrast T1-weighted brain MRI highlighting left frontal and parietal sulcal metastases (arrows) in a patient with leptomeningeal disease.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 88980 Version 3.0</div></div></div>"},"88981":{"type":"graphic_diagnosticimage","displayName":"Cerebellar MRI findings in leptomeningeal metastases","title":"Cerebellar MRI findings in leptomeningeal metastases","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Cerebellar MRI findings in leptomeningeal metastases</div><div class=\"cntnt\"><img style=\"width:487px; height:233px;\" src=\"images/ONC/88981_Sulcl_T2_hyprnt_lptmgl_mtst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial post-contrast T1-weighted (A) and fluid-attenuated inversion recovery (B) brain MRI sequences demonstrating abnormal leptomeningeal enhancement and T2 hyperintensity in the left cerebellum in a patient with leptomeningeal metastases.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 88981 Version 3.0</div></div></div>"},"88983":{"type":"graphic_table","displayName":"Laboratory values in acute malignant hyperthermia","title":"Laboratory values in acute malignant hyperthermia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory values in acute malignant hyperthermia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Laboratory study</td> <td class=\"subtitle1\">Typical value in MH</td> <td class=\"subtitle1\">Patient conditions</td> </tr> <tr> <td rowspan=\"2\">Creatine kinase</td> <td>&#62;20,000 international units</td> <td>With succinylcholine</td> </tr> <tr> <td>&#62;10,000 international units</td> <td>Without succinylcholine</td> </tr> <tr class=\"divider_top\"> <td>Urine myoglobin</td> <td>&#62;60 mcg/L</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td>Serum myoglobin</td> <td>&#62;170 mcg/L</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td>Serum K</td> <td>&#62;6 mEq/L</td> <td>Without renal failure</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">PaCO<sub>2</sub></td> <td>&#62;60 mmHg</td> <td>During controlled ventilation</td> </tr> <tr> <td>&#62;65 mmHg</td> <td>During spontaneous ventilation</td> </tr> <tr class=\"divider_top\"> <td>Arterial pH</td> <td>&#60;7.25</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td>Base excess</td> <td>Below &ndash;8 mEq/L</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Typical laboratory values used to confirm the diagnosis of acute malignant hyperthermia.</div><div class=\"graphic_reference\">Source: Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80:771.</div><div id=\"graphicVersion\">Graphic 88983 Version 3.0</div></div></div>"},"88989":{"type":"graphic_picture","displayName":"Schambergs disease extensive","title":"Schamberg's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schamberg's disease</div><div class=\"cntnt\"><img style=\"width:430px; height:574px;\" src=\"images/DERM/88989_Schambergs_diseas_extensive.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple petechiae and purpura on the lower extremities in Schamberg's disease (progressive pigmentary purpura).</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 88989 Version 1.0</div></div></div>"},"88990":{"type":"graphic_picture","displayName":"Schambergs disease nonblanching","title":"Schamberg's disease","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Schamberg's disease</div><div class=\"cntnt\"><img style=\"width:574px; height:430px;\" src=\"images/DERM/88990_Schambergs_disese_nonblanch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Compression with a glass slide reveals the nonblanchable nature of petechiae and purpura in Schamberg's disease (progressive pigmentary purpura), a type of pigmented purpuric dermatosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 88990 Version 1.0</div></div></div>"},"88991":{"type":"graphic_picture","displayName":"Purpura annularis telangiectodes large lesion","title":"Purpura annularis telangiectodes (Majocchi's disease)","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Purpura annularis telangiectodes (Majocchi's disease)</div><div class=\"cntnt\"><img style=\"width:574px; height:430px;\" src=\"images/DERM/88991_Purpu_anular_telng_lrg_lesn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large purpuric patch on the lower extremity with an annular configuration.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 88991 Version 1.0</div></div></div>"},"88992":{"type":"graphic_picture","displayName":"Pigmented purpuric lichenoid dermatosis of Gougerot and Blum","title":"Pigmented purpuric lichenoid dermatosis of Gougerot and Blum","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Pigmented purpuric lichenoid dermatosis of Gougerot and Blum</div><div class=\"cntnt\"><img style=\"width:574px; height:430px;\" src=\"images/DERM/88992_Pgmt_purp_lich_der_Goug_Blm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Violaceous papules and small plaques as well as yellow-brown macules on the lower extremities.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 88992 Version 1.0</div></div></div>"},"88993":{"type":"graphic_picture","displayName":"Lichen aureus","title":"Lichen aureus","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Lichen aureus</div><div class=\"cntnt\"><img style=\"width:574px; height:430px;\" src=\"images/DERM/88993_Lichen_aureus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Purpuric gold-brown plaques on the distal leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 88993 Version 1.0</div></div></div>"},"88994":{"type":"graphic_picture","displayName":"Granulomatous pigmented purpura","title":"Granulomatous pigmented purpura","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Granulomatous pigmented purpura</div><div class=\"cntnt\"><img style=\"width:502px; height:316px;\" src=\"images/DERM/88994_Granulomatouspigmentpurp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brown purpuric papules on the lower legs and dorsum of the feet.</div><div class=\"graphic_reference\">Reproduced with permission from: Tato BP, Marinero Escobedo S, Pérez González YC, et al. Granulomatous variant of pigmented purpuric dermatosis. Am J Dermatopathol 2012; 34:746. DOI: <A href=\"http://journals.lww.com/amjdermatopathology/Abstract/2012/10000/Granulomatous_Variant_of_Pigmented_Purpuric.10.aspx\" target=_blank>10.1097/DAD.0b013e31823f616a</A>. Copyright © 2012 Wolters Kluwer Health, Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 88994 Version 6.0</div></div></div>"},"88995":{"type":"graphic_picture","displayName":"Granulomatous pigmented purpura pathology","title":"Granulomatous pigmented purpura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granulomatous pigmented purpura</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/88995_Granupigmpurpurpathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">View of granulomatous infiltrate in superficial dermis with extravasation of red blood cells and siderophages.</div><div class=\"graphic_reference\">Reproduced with permission from: Tato BP, Marinero Escobedo S, P&eacute;rez Gonz&aacute;lez YC, et al. Granulomatous variant of pigmented purpuric dermatosis. Am J Dermatopathol 2012; 34:746. DOI: <a href=\"http://journals.lww.com/amjdermatopathology/Abstract/2012/10000/Granulomatous_Variant_of_Pigmented_Purpuric.10.aspx\" target=\"_blank\">10.1097/DAD.0b013e31823f616a</a>. Copyright &copy; 2012 Wolters Kluwer Health, Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 88995 Version 6.0</div></div></div>"},"88997":{"type":"graphic_picture","displayName":"Unilateral linear capillaritis","title":"Unilateral linear capillaritis","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Unilateral linear capillaritis</div><div class=\"cntnt\"><img style=\"width:592px; height:469px;\" src=\"images/DERM/88997_Unilateral_linear_capillaritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brown and purpuric patches in a linear distribution on the lower extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: Abdullah L, Abbas O. Dermacase. Can you identify this condition? Unilateral linear capillaritis. Can Fam Physician 2011; 57(5):563. Copyright &copy; 2011 The College of Family Physicians of Canada.</div><div id=\"graphicVersion\">Graphic 88997 Version 1.0</div></div></div>"}};